{"PMC3742715": [["IntroductionThe presence of certain environmental stress stimuli can cause the accumulation of translationally silenced mRNPs in cytoplasmic foci, termed stress granules, which are thought to represent temporary sites of mRNA sorting and storage (for reviews, see Anderson and Kedersha, 2002, Anderson and Kedersha, 2008, Kedersha and Anderson, 2002, Kedersha et al., 2005).", [["mRNPs", "ANATOMY", 120, 125], ["cytoplasmic foci", "ANATOMY", 129, 145], ["stress granules", "ANATOMY", 154, 169], ["mRNPs", "CELLULAR_COMPONENT", 120, 125], ["cytoplasmic foci", "CELLULAR_COMPONENT", 129, 145], ["stress granules", "CELLULAR_COMPONENT", 154, 169], ["mRNA", "RNA", 221, 225], ["certain environmental stress stimuli", "PROBLEM", 28, 64], ["translationally silenced mRNPs", "PROBLEM", 95, 125], ["cytoplasmic foci", "PROBLEM", 129, 145], ["termed stress granules", "PROBLEM", 147, 169], ["stress stimuli", "OBSERVATION", 50, 64], ["translationally silenced mRNPs", "OBSERVATION", 95, 125], ["cytoplasmic foci", "OBSERVATION", 129, 145], ["stress granules", "OBSERVATION", 154, 169], ["thought to represent", "UNCERTAINTY", 181, 201], ["temporary sites", "OBSERVATION", 202, 217]]], ["Stress granules are generated when conditions of cellular stress result in the inhibition of mRNA translation initiation, although the mechanism by which they form is still unknown.", [["Stress granules", "ANATOMY", 0, 15], ["cellular", "ANATOMY", 49, 57], ["granules", "ORGANISM_SUBSTANCE", 7, 15], ["cellular", "CELL", 49, 57], ["Stress granules", "PROBLEM", 0, 15], ["cellular stress", "PROBLEM", 49, 64], ["mRNA translation initiation", "TREATMENT", 93, 120]]], ["These foci contain stalled pre-initiation complexes consisting of small, but not large, ribosomal subunits, mRNA, and canonical translation initiation factors such as eIF4E, eIF4G, eIF4A, eIF4B, and eIF3.", [["foci", "ANATOMY", 6, 10], ["ribosomal", "CELLULAR_COMPONENT", 88, 97], ["eIF4E", "GENE_OR_GENE_PRODUCT", 167, 172], ["eIF4G", "GENE_OR_GENE_PRODUCT", 174, 179], ["eIF4A", "GENE_OR_GENE_PRODUCT", 181, 186], ["eIF4B", "GENE_OR_GENE_PRODUCT", 188, 193], ["eIF3", "GENE_OR_GENE_PRODUCT", 199, 203], ["pre-initiation complexes", "PROTEIN", 27, 51], ["ribosomal subunits", "PROTEIN", 88, 106], ["mRNA", "RNA", 108, 112], ["canonical translation initiation factors", "PROTEIN", 118, 158], ["eIF4E", "PROTEIN", 167, 172], ["eIF4G", "PROTEIN", 174, 179], ["eIF4A", "PROTEIN", 181, 186], ["eIF4B", "PROTEIN", 188, 193], ["eIF3", "PROTEIN", 199, 203], ["These foci", "PROBLEM", 0, 10], ["stalled pre-initiation complexes", "PROBLEM", 19, 51], ["large, ribosomal subunits, mRNA", "PROBLEM", 81, 112], ["eIF4A", "TREATMENT", 181, 186], ["eIF4B", "TREATMENT", 188, 193], ["eIF3", "TREATMENT", 199, 203], ["foci", "OBSERVATION", 6, 10], ["stalled", "OBSERVATION_MODIFIER", 19, 26], ["pre-initiation complexes", "OBSERVATION", 27, 51], ["small", "OBSERVATION_MODIFIER", 66, 71], ["not", "UNCERTAINTY", 77, 80], ["large", "OBSERVATION_MODIFIER", 81, 86], ["ribosomal subunits", "OBSERVATION", 88, 106], ["canonical translation", "OBSERVATION", 118, 139]]], ["While stress granule assembly has not been completely defined, it has been shown to involve the motor proteins dynein and kinesin, and movement along microtubules (Chernov et al., 2009, Ivanov et al., 2003, Loschi et al., 2009, Tsai et al., 2009, Zurla et al., 2011).", [["stress granule", "ANATOMY", 6, 20], ["microtubules", "ANATOMY", 150, 162], ["stress granule", "CELLULAR_COMPONENT", 6, 20], ["dynein", "GENE_OR_GENE_PRODUCT", 111, 117], ["kinesin", "GENE_OR_GENE_PRODUCT", 122, 129], ["microtubules", "CELLULAR_COMPONENT", 150, 162], ["motor proteins", "PROTEIN", 96, 110], ["dynein", "PROTEIN", 111, 117], ["kinesin", "PROTEIN", 122, 129], ["stress granule", "PROBLEM", 6, 20], ["stress granule", "OBSERVATION", 6, 20]]], ["RNA binding proteins have been proposed to be required for the formation of stress granules, including T-cell restricted intracellular antigen 1 (TIA-1), TIA-1-related protein (TIAR), and RasGAP-SH3 domain binding protein (G3BP) (Kedersha et al., 1999, Tourriere et al., 2003).", [["stress granules", "ANATOMY", 76, 91], ["T-cell", "ANATOMY", 103, 109], ["intracellular", "ANATOMY", 121, 134], ["stress granules", "CELLULAR_COMPONENT", 76, 91], ["T-cell restricted intracellular antigen 1", "GENE_OR_GENE_PRODUCT", 103, 144], ["TIA-1", "GENE_OR_GENE_PRODUCT", 146, 151], ["TIA-1-related protein", "GENE_OR_GENE_PRODUCT", 154, 175], ["TIAR", "GENE_OR_GENE_PRODUCT", 177, 181], ["RasGAP-SH3 domain binding protein", "GENE_OR_GENE_PRODUCT", 188, 221], ["G3BP", "GENE_OR_GENE_PRODUCT", 223, 227], ["RNA binding proteins", "PROTEIN", 0, 20], ["T-cell restricted intracellular antigen 1", "PROTEIN", 103, 144], ["TIA", "PROTEIN", 146, 149], ["TIA-1-related protein", "PROTEIN", 154, 175], ["TIAR", "PROTEIN", 177, 181], ["RasGAP", "PROTEIN", 188, 194], ["SH3 domain binding protein", "PROTEIN", 195, 221], ["G3BP", "PROTEIN", 223, 227], ["RNA binding proteins", "PROBLEM", 0, 20], ["stress granules", "PROBLEM", 76, 91], ["intracellular antigen", "TEST", 121, 142], ["TIA", "TEST", 146, 149], ["TIA", "TEST", 154, 157], ["protein", "TEST", 168, 175], ["TIAR", "TEST", 177, 181], ["RasGAP", "TEST", 188, 194], ["stress granules", "OBSERVATION", 76, 91]]], ["The self-oligomerization properties of these proteins contribute to their assembly of cytoplasmic aggregates under conditions of stress.", [["cytoplasmic aggregates", "ANATOMY", 86, 108], ["cytoplasmic", "ORGANISM_SUBSTANCE", 86, 97], ["The self-oligomerization properties", "TREATMENT", 0, 35], ["these proteins", "PROBLEM", 39, 53], ["cytoplasmic aggregates", "PROBLEM", 86, 108], ["stress", "PROBLEM", 129, 135], ["cytoplasmic aggregates", "OBSERVATION", 86, 108]]], ["A truncated form of TIA-1 (TIA-1-PRD) containing only the C-terminal domain of the protein has been shown to be a dominant negative inhibitor of stress granule assembly (Gilks et al., 2004).", [["stress granule", "ANATOMY", 145, 159], ["TIA", "DISEASE", 20, 23], ["C", "CHEMICAL", 58, 59], ["TIA-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 27, 36], ["stress granule", "CELLULAR_COMPONENT", 145, 159], ["TIA", "PROTEIN", 20, 23], ["TIA", "PROTEIN", 27, 30], ["PRD", "PROTEIN", 33, 36], ["C-terminal domain", "PROTEIN", 58, 75], ["TIA", "PROBLEM", 20, 23], ["TIA", "TEST", 27, 30], ["the C-terminal domain of the protein", "PROBLEM", 54, 90], ["stress granule assembly", "PROBLEM", 145, 168], ["TIA", "OBSERVATION", 20, 23], ["terminal", "ANATOMY_MODIFIER", 60, 68], ["dominant", "OBSERVATION_MODIFIER", 114, 122], ["negative", "OBSERVATION", 123, 131], ["stress granule", "OBSERVATION", 145, 159]]], ["Expressing only the central domain of G3BP also prevents stress granule formation (Tourriere et al., 2003).IntroductionIn addition to conditions such as hypoxia, nutrient deprivation, and oxidative stress, some viruses are also known to induce the formation of stress granules (for review, see White and Lloyd, 2012).", [["stress granule", "ANATOMY", 57, 71], ["stress granules", "ANATOMY", 261, 276], ["hypoxia", "DISEASE", 153, 160], ["G3BP", "GENE_OR_GENE_PRODUCT", 38, 42], ["stress granule", "CELLULAR_COMPONENT", 57, 71], ["stress granules", "CELLULAR_COMPONENT", 261, 276], ["central domain", "PROTEIN", 20, 34], ["G3BP", "PROTEIN", 38, 42], ["stress granule formation", "PROBLEM", 57, 81], ["hypoxia", "PROBLEM", 153, 160], ["nutrient deprivation", "TREATMENT", 162, 182], ["oxidative stress", "PROBLEM", 188, 204], ["some viruses", "PROBLEM", 206, 218], ["stress granules", "PROBLEM", 261, 276], ["prevents", "UNCERTAINTY", 48, 56], ["stress granule formation", "OBSERVATION", 57, 81], ["stress granules", "OBSERVATION", 261, 276]]], ["Respiratory syncytial virus, coronaviruses, and reovirus induce stress granule formation as a way to down-regulate host cell translation (Lindquist et al., 2010, Raaben et al., 2007, Smith et al., 2006, Sola et al., 2011).", [["stress granule", "ANATOMY", 64, 78], ["cell", "ANATOMY", 120, 124], ["Respiratory syncytial virus", "DISEASE", 0, 27], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["coronaviruses", "ORGANISM", 29, 42], ["reovirus", "ORGANISM", 48, 56], ["stress granule", "CELLULAR_COMPONENT", 64, 78], ["cell", "CELL", 120, 124], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["coronaviruses", "PROBLEM", 29, 42], ["reovirus", "PROBLEM", 48, 56], ["stress granule formation", "PROBLEM", 64, 88], ["syncytial virus", "OBSERVATION", 12, 27], ["stress granule formation", "OBSERVATION", 64, 88], ["host cell", "OBSERVATION", 115, 124]]], ["Semliki Forest virus and hepatitis C virus initially induce the formation of stress granules upon infection, but then subsequently inhibit their formation over the course of infection (Ariumi et al., 2011, McInerney et al., 2005).", [["stress granules", "ANATOMY", 77, 92], ["hepatitis C", "DISEASE", 25, 36], ["infection", "DISEASE", 98, 107], ["infection", "DISEASE", 174, 183], ["Semliki Forest virus", "ORGANISM", 0, 20], ["hepatitis C virus", "ORGANISM", 25, 42], ["stress granules", "CELLULAR_COMPONENT", 77, 92], ["Semliki", "SPECIES", 0, 7], ["hepatitis C virus", "SPECIES", 25, 42], ["Semliki Forest virus", "SPECIES", 0, 20], ["hepatitis C virus", "SPECIES", 25, 42], ["Semliki Forest virus", "PROBLEM", 0, 20], ["hepatitis C virus", "PROBLEM", 25, 42], ["stress granules", "PROBLEM", 77, 92], ["infection", "PROBLEM", 98, 107], ["infection", "PROBLEM", 174, 183], ["Forest virus", "OBSERVATION", 8, 20], ["stress granules", "OBSERVATION", 77, 92], ["infection", "OBSERVATION", 98, 107], ["infection", "OBSERVATION", 174, 183]]], ["Rotavirus and cardioviruses induce eIF2\u03b1 phosphorylation (a canonical pathway for translation inhibition) but additionally inhibit stress granule formation (Borghese and Michiels, 2011, Montero et al., 2008).", [["stress granule", "ANATOMY", 131, 145], ["Rotavirus", "DISEASE", 0, 9], ["Rotavirus", "ORGANISM", 0, 9], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["stress granule", "CELLULAR_COMPONENT", 131, 145], ["eIF2\u03b1", "PROTEIN", 35, 40], ["Rotavirus", "TREATMENT", 0, 9], ["cardioviruses", "TREATMENT", 14, 27], ["eIF2\u03b1 phosphorylation", "TREATMENT", 35, 56], ["a canonical pathway", "TREATMENT", 58, 77], ["translation inhibition", "TREATMENT", 82, 104], ["stress granule formation", "PROBLEM", 131, 155], ["granule formation", "OBSERVATION", 138, 155]]], ["Infection with poliovirus, a positive-strand RNA virus, also induces the formation of stress granules (Mazroui et al., 2006).", [["stress granules", "ANATOMY", 86, 101], ["poliovirus", "ORGANISM", 15, 25], ["stress granules", "CELLULAR_COMPONENT", 86, 101], ["poliovirus", "SPECIES", 15, 25], ["Infection", "PROBLEM", 0, 9], ["poliovirus", "PROBLEM", 15, 25], ["a positive-strand RNA virus", "PROBLEM", 27, 54], ["stress granules", "PROBLEM", 86, 101], ["poliovirus", "OBSERVATION", 15, 25], ["strand RNA virus", "OBSERVATION", 38, 54], ["stress granules", "OBSERVATION", 86, 101]]], ["One study reported that poliovirus infection initially induced the formation of stress granules, but disrupted their formation as infection progressed (White et al., 2007).", [["stress granules", "ANATOMY", 80, 95], ["poliovirus infection", "DISEASE", 24, 44], ["infection", "DISEASE", 130, 139], ["poliovirus", "ORGANISM", 24, 34], ["stress granules", "CELLULAR_COMPONENT", 80, 95], ["poliovirus", "SPECIES", 24, 34], ["One study", "TEST", 0, 9], ["poliovirus infection", "PROBLEM", 24, 44], ["stress granules", "PROBLEM", 80, 95], ["infection", "PROBLEM", 130, 139], ["poliovirus", "OBSERVATION_MODIFIER", 24, 34], ["infection", "OBSERVATION", 35, 44], ["stress granules", "OBSERVATION", 80, 95], ["infection", "OBSERVATION_MODIFIER", 130, 139]]], ["G3BP was cleaved by the viral proteinase 3C, and it was proposed that this cleavage led to the dissociation of stress granules during infection.", [["stress granules", "ANATOMY", 111, 126], ["infection", "DISEASE", 134, 143], ["G3BP", "GENE_OR_GENE_PRODUCT", 0, 4], ["viral proteinase 3C", "GENE_OR_GENE_PRODUCT", 24, 43], ["stress granules", "CELLULAR_COMPONENT", 111, 126], ["G3BP", "PROTEIN", 0, 4], ["viral proteinase 3C", "PROTEIN", 24, 43], ["the viral proteinase 3C", "TREATMENT", 20, 43], ["this cleavage", "PROBLEM", 70, 83], ["stress granules", "PROBLEM", 111, 126], ["infection", "PROBLEM", 134, 143], ["stress granules", "OBSERVATION", 111, 126], ["infection", "OBSERVATION", 134, 143]]], ["A subsequent report was published suggesting that stress granules form and persist even at later times of poliovirus infection (Piotrowska et al., 2010).", [["stress granules", "ANATOMY", 50, 65], ["poliovirus infection", "DISEASE", 106, 126], ["granules", "ORGANISM_SUBSTANCE", 57, 65], ["poliovirus", "SPECIES", 106, 116], ["stress granules", "PROBLEM", 50, 65], ["poliovirus infection", "PROBLEM", 106, 126], ["stress granules", "OBSERVATION", 50, 65]]], ["This latter study examined the stress granule marker protein TIA-1 and found that TIA-1 positive foci could still be observed over the course of infection, despite lacking G3BP and eIF4G.", [["stress granule", "ANATOMY", 31, 45], ["foci", "ANATOMY", 97, 101], ["infection", "DISEASE", 145, 154], ["stress granule", "CELLULAR_COMPONENT", 31, 45], ["TIA-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["TIA-1", "GENE_OR_GENE_PRODUCT", 82, 87], ["G3BP", "GENE_OR_GENE_PRODUCT", 172, 176], ["eIF4G", "GENE_OR_GENE_PRODUCT", 181, 186], ["stress granule marker protein", "PROTEIN", 31, 60], ["TIA-1", "PROTEIN", 61, 66], ["TIA", "PROTEIN", 82, 85], ["G3BP", "PROTEIN", 172, 176], ["eIF4G", "PROTEIN", 181, 186], ["This latter study", "TEST", 0, 17], ["the stress granule marker protein TIA", "PROBLEM", 27, 64], ["TIA", "PROBLEM", 82, 85], ["1 positive foci", "PROBLEM", 86, 101], ["infection", "PROBLEM", 145, 154], ["eIF4G", "TREATMENT", 181, 186], ["TIA", "OBSERVATION", 82, 85], ["foci", "OBSERVATION", 97, 101], ["infection", "OBSERVATION", 145, 154]]], ["Sam68, an RNA binding protein that has been shown to interact with the poliovirus RNA-dependent RNA polymerase 3D (Lukong and Richard, 2003, McBride et al., 1996), was also found to be a unique component of poliovirus-induced stress granules.", [["stress granules", "ANATOMY", 226, 241], ["Sam68", "GENE_OR_GENE_PRODUCT", 0, 5], ["poliovirus", "ORGANISM", 207, 217], ["stress granules", "CELLULAR_COMPONENT", 226, 241], ["Sam68", "PROTEIN", 0, 5], ["RNA binding protein", "PROTEIN", 10, 29], ["poliovirus RNA-dependent RNA polymerase 3D", "PROTEIN", 71, 113], ["an RNA binding protein", "PROBLEM", 7, 29], ["the poliovirus RNA", "TEST", 67, 85], ["poliovirus", "PROBLEM", 207, 217], ["induced stress granules", "PROBLEM", 218, 241], ["poliovirus", "OBSERVATION", 207, 217], ["stress granules", "OBSERVATION", 226, 241]]], ["A more recent report suggests that poliovirus infection can induce typical stress granules, which contain TIA-1, translation initiation factors, mRNA, and RNA binding proteins, only early in infection (White and Lloyd, 2011).", [["stress granules", "ANATOMY", 75, 90], ["poliovirus infection", "DISEASE", 35, 55], ["infection", "DISEASE", 191, 200], ["poliovirus", "ORGANISM", 35, 45], ["stress granules", "CELLULAR_COMPONENT", 75, 90], ["TIA-1", "GENE_OR_GENE_PRODUCT", 106, 111], ["RNA binding proteins", "GENE_OR_GENE_PRODUCT", 155, 175], ["TIA-1", "PROTEIN", 106, 111], ["translation initiation factors", "PROTEIN", 113, 143], ["mRNA", "RNA", 145, 149], ["RNA binding proteins", "PROTEIN", 155, 175], ["poliovirus", "SPECIES", 35, 45], ["poliovirus infection", "PROBLEM", 35, 55], ["typical stress granules", "PROBLEM", 67, 90], ["TIA", "PROBLEM", 106, 109], ["translation initiation factors", "PROBLEM", 113, 143], ["mRNA, and RNA binding proteins", "PROBLEM", 145, 175], ["poliovirus infection", "OBSERVATION", 35, 55], ["stress granules", "OBSERVATION", 75, 90], ["infection", "OBSERVATION", 191, 200]]], ["Later in infection the granules are atypical, and still contain TIA-1 although they lack some of the other constituents usually found in stress granules.", [["granules", "ANATOMY", 23, 31], ["stress granules", "ANATOMY", 137, 152], ["infection", "DISEASE", 9, 18], ["TIA", "DISEASE", 64, 67], ["granules", "ORGANISM_SUBSTANCE", 23, 31], ["TIA-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["stress granules", "CELLULAR_COMPONENT", 137, 152], ["infection the granules", "PROBLEM", 9, 31], ["TIA", "PROBLEM", 64, 67], ["stress granules", "PROBLEM", 137, 152], ["infection", "OBSERVATION", 9, 18], ["granules", "OBSERVATION_MODIFIER", 23, 31], ["atypical", "OBSERVATION_MODIFIER", 36, 44], ["TIA", "OBSERVATION", 64, 67], ["stress granules", "OBSERVATION", 137, 152]]], ["Importantly, it is still not understood what role (if any) stress granules play during poliovirus infection.IntroductionPoliovirus is an enterovirus and a member of the Picornaviridae family of single-stranded, positive-sense RNA viruses.", [["stress granules", "ANATOMY", 59, 74], ["poliovirus infection", "DISEASE", 87, 107], ["enterovirus", "DISEASE", 137, 148], ["stress granules", "CELLULAR_COMPONENT", 59, 74], ["Poliovirus", "ORGANISM", 120, 130], ["poliovirus", "SPECIES", 87, 97], ["stress granules", "PROBLEM", 59, 74], ["poliovirus infection", "PROBLEM", 87, 107], ["IntroductionPoliovirus", "PROBLEM", 108, 130], ["an enterovirus", "PROBLEM", 134, 148], ["sense RNA viruses", "PROBLEM", 220, 237], ["poliovirus infection", "OBSERVATION", 87, 107]]], ["The genome of \u223c7.4 kb can be immediately translated in the cytoplasm of the infected cell via an IRES-mediated, cap-independent mechanism of initiation.", [["cytoplasm", "ANATOMY", 59, 68], ["cell", "ANATOMY", 85, 89], ["cytoplasm", "ORGANISM_SUBSTANCE", 59, 68], ["cell", "CELL", 85, 89], ["IRES", "DNA", 97, 101], ["infected cell", "OBSERVATION", 76, 89]]], ["Poliovirus translation produces the proteins required for viral RNA synthesis as well as for modulation of the subcellular environment (for review, see Rozovics and Semler, 2010).", [["subcellular", "ANATOMY", 111, 122], ["Poliovirus", "ORGANISM", 0, 10], ["Poliovirus", "SPECIES", 0, 10], ["Poliovirus translation", "PROBLEM", 0, 22], ["the proteins", "PROBLEM", 32, 44], ["viral RNA synthesis", "TREATMENT", 58, 77]]], ["During infection, viral proteinases 2A and 3C cleave several cellular proteins, including eIF4G and PABP, to down-regulate host cell translation (Etchison et al., 1982, Joachims et al., 1999, Krausslich et al., 1987, Kuyumcu-Martinez et al., 2002, Lloyd et al., 1987).", [["cellular", "ANATOMY", 61, 69], ["cell", "ANATOMY", 128, 132], ["infection", "DISEASE", 7, 16], ["viral proteinases 2A", "GENE_OR_GENE_PRODUCT", 18, 38], ["3C", "GENE_OR_GENE_PRODUCT", 43, 45], ["cellular", "CELL", 61, 69], ["eIF4G", "GENE_OR_GENE_PRODUCT", 90, 95], ["PABP", "GENE_OR_GENE_PRODUCT", 100, 104], ["cell", "CELL", 128, 132], ["viral proteinases 2A and 3C", "PROTEIN", 18, 45], ["cellular proteins", "PROTEIN", 61, 78], ["eIF4G", "PROTEIN", 90, 95], ["PABP", "PROTEIN", 100, 104], ["infection", "PROBLEM", 7, 16], ["viral proteinases 2A", "PROBLEM", 18, 38], ["several cellular proteins", "PROBLEM", 53, 78], ["eIF4G and PABP", "TREATMENT", 90, 104], ["infection", "OBSERVATION", 7, 16], ["cellular proteins", "OBSERVATION", 61, 78], ["host cell", "OBSERVATION", 123, 132]]], ["Viral proteinases also cause the inhibition of host cellular transcription (Clark et al., 1991, Clark et al., 1993, Yalamanchili et al., 1997a, Yalamanchili et al., 1997b).", [["cellular", "ANATOMY", 52, 60], ["cellular", "CELL", 52, 60], ["Viral proteinases", "PROTEIN", 0, 17], ["Viral proteinases", "PROBLEM", 0, 17]]], ["In addition, several nuclear pore complex proteins have been shown to be cleaved, which is thought to disrupt specific transport pathways and result in the redistribution of certain host cell nuclear factors (Belov et al., 2000, Belov et al., 2004, Gustin and Sarnow, 2001).", [["nuclear pore", "ANATOMY", 21, 33], ["cell nuclear", "ANATOMY", 187, 199], ["cell", "CELL", 187, 191], ["nuclear pore complex proteins", "PROTEIN", 21, 50], ["host cell nuclear factors", "PROTEIN", 182, 207], ["several nuclear pore complex proteins", "PROBLEM", 13, 50], ["redistribution", "OBSERVATION_MODIFIER", 156, 170], ["host cell nuclear factors", "OBSERVATION", 182, 207]]], ["Our work has demonstrated that poliovirus infection causes a dramatic nucleo-cytoplasmic re-localization of cellular splicing factor SRp20, an important IRES trans-acting factor, or ITAF, that interacts with PCBP2 and stimulates poliovirus translation (Fitzgerald and Semler, 2011).", [["cytoplasmic", "ANATOMY", 77, 88], ["cellular", "ANATOMY", 108, 116], ["poliovirus infection", "DISEASE", 31, 51], ["poliovirus", "ORGANISM", 31, 41], ["cytoplasmic", "ORGANISM_SUBSTANCE", 77, 88], ["cellular", "CELL", 108, 116], ["SRp20", "GENE_OR_GENE_PRODUCT", 133, 138], ["trans-acting factor", "GENE_OR_GENE_PRODUCT", 158, 177], ["ITAF", "GENE_OR_GENE_PRODUCT", 182, 186], ["PCBP2", "GENE_OR_GENE_PRODUCT", 208, 213], ["cellular splicing factor", "PROTEIN", 108, 132], ["SRp20", "PROTEIN", 133, 138], ["IRES trans-acting factor", "PROTEIN", 153, 177], ["ITAF", "PROTEIN", 182, 186], ["PCBP2", "PROTEIN", 208, 213], ["poliovirus", "SPECIES", 31, 41], ["poliovirus infection", "PROBLEM", 31, 51], ["PCBP2", "TREATMENT", 208, 213], ["poliovirus infection", "OBSERVATION", 31, 51], ["dramatic", "OBSERVATION_MODIFIER", 61, 69], ["cellular splicing", "OBSERVATION", 108, 125]]], ["As recently reported, this re-localization is also observed during coxsackievirus B3 infection or human rhinovirus 16 infection, albeit with decreased efficiency in the latter case (Fitzgerald et al., 2013).", [["coxsackievirus B3 infection", "DISEASE", 67, 94], ["rhinovirus 16 infection", "DISEASE", 104, 127], ["coxsackievirus B3", "ORGANISM", 67, 84], ["human", "ORGANISM", 98, 103], ["rhinovirus 16", "ORGANISM", 104, 117], ["human", "SPECIES", 98, 103], ["rhinovirus", "SPECIES", 104, 114], ["coxsackievirus B3", "SPECIES", 67, 84], ["human rhinovirus 16", "SPECIES", 98, 117], ["coxsackievirus B3 infection", "PROBLEM", 67, 94], ["human rhinovirus 16 infection", "PROBLEM", 98, 127], ["decreased efficiency", "PROBLEM", 141, 161], ["decreased", "OBSERVATION_MODIFIER", 141, 150], ["efficiency", "OBSERVATION_MODIFIER", 151, 161]]], ["Interestingly, both the poliovirus and human rhinovirus 16 2A proteinases, when expressed alone, can direct the cytoplasmic redistribution of SRp20.", [["cytoplasmic", "ANATOMY", 112, 123], ["human rhinovirus 16 2A", "ORGANISM", 39, 61], ["cytoplasmic", "ORGANISM_SUBSTANCE", 112, 123], ["SRp20", "GENE_OR_GENE_PRODUCT", 142, 147], ["poliovirus and human rhinovirus 16 2A proteinases", "PROTEIN", 24, 73], ["SRp20", "PROTEIN", 142, 147], ["human", "SPECIES", 39, 44], ["rhinovirus", "SPECIES", 45, 55], ["human rhinovirus", "SPECIES", 39, 55], ["the poliovirus and human rhinovirus", "PROBLEM", 20, 55], ["poliovirus", "OBSERVATION", 24, 34], ["cytoplasmic redistribution", "OBSERVATION", 112, 138]]], ["Taken together, it is clear that picornavirus infections generate an altered cellular environment that contributes to specific steps in virus replication.IntroductionStress granule formation has recently been shown to be among the many subcellular changes induced by poliovirus infection.", [["cellular", "ANATOMY", 77, 85], ["IntroductionStress granule", "ANATOMY", 154, 180], ["subcellular", "ANATOMY", 236, 247], ["picornavirus infections", "DISEASE", 33, 56], ["poliovirus infection", "DISEASE", 267, 287], ["picornavirus", "ORGANISM", 33, 45], ["cellular", "CELL", 77, 85], ["IntroductionStress granule", "CELLULAR_COMPONENT", 154, 180], ["poliovirus", "ORGANISM", 267, 277], ["poliovirus", "SPECIES", 267, 277], ["picornavirus infections", "PROBLEM", 33, 56], ["an altered cellular environment", "PROBLEM", 66, 97], ["virus replication", "TREATMENT", 136, 153], ["IntroductionStress granule formation", "PROBLEM", 154, 190], ["poliovirus infection", "PROBLEM", 267, 287], ["picornavirus infections", "OBSERVATION", 33, 56], ["altered", "OBSERVATION_MODIFIER", 69, 76], ["cellular environment", "OBSERVATION", 77, 97], ["granule formation", "OBSERVATION", 173, 190], ["poliovirus infection", "OBSERVATION", 267, 287]]], ["It is not clear whether poliovirus directs the formation of stress granules, or if these cytoplasmic foci are a type of general cellular stress response to viral infection.", [["stress granules", "ANATOMY", 60, 75], ["cytoplasmic foci", "ANATOMY", 89, 105], ["cellular", "ANATOMY", 128, 136], ["viral infection", "DISEASE", 156, 171], ["poliovirus", "ORGANISM", 24, 34], ["stress granules", "CELLULAR_COMPONENT", 60, 75], ["cytoplasmic", "ORGANISM_SUBSTANCE", 89, 100], ["cellular", "CELL", 128, 136], ["poliovirus", "SPECIES", 24, 34], ["poliovirus", "PROBLEM", 24, 34], ["stress granules", "PROBLEM", 60, 75], ["these cytoplasmic foci", "PROBLEM", 83, 105], ["general cellular stress response", "PROBLEM", 120, 152], ["viral infection", "PROBLEM", 156, 171], ["not", "UNCERTAINTY", 6, 9], ["poliovirus", "OBSERVATION", 24, 34], ["stress granules", "OBSERVATION", 60, 75], ["cytoplasmic", "OBSERVATION_MODIFIER", 89, 100], ["foci", "OBSERVATION", 101, 105], ["cellular stress response", "OBSERVATION", 128, 152], ["viral infection", "OBSERVATION", 156, 171]]], ["It is also not known precisely how stress granules affect poliovirus infection, but expression of an altered version of a key stress granule component (G3BP) that is resistant to cleavage by the poliovirus 3C proteinase resulted in an eight-fold reduction in viral titer (White et al., 2007).", [["stress granules", "ANATOMY", 35, 50], ["stress granule", "ANATOMY", 126, 140], ["poliovirus infection", "DISEASE", 58, 78], ["stress granules", "CELLULAR_COMPONENT", 35, 50], ["poliovirus", "ORGANISM", 58, 68], ["stress granule", "CELLULAR_COMPONENT", 126, 140], ["G3BP", "GENE_OR_GENE_PRODUCT", 152, 156], ["poliovirus 3C", "ORGANISM", 195, 208], ["stress granule component", "PROTEIN", 126, 150], ["G3BP", "PROTEIN", 152, 156], ["poliovirus 3C proteinase", "PROTEIN", 195, 219], ["poliovirus", "SPECIES", 195, 205], ["stress granules", "PROBLEM", 35, 50], ["poliovirus infection", "PROBLEM", 58, 78], ["an altered version", "PROBLEM", 98, 116], ["a key stress granule component", "PROBLEM", 120, 150], ["cleavage", "TREATMENT", 179, 187], ["the poliovirus 3C proteinase", "PROBLEM", 191, 219], ["an eight-fold reduction", "TREATMENT", 232, 255], ["viral titer", "PROBLEM", 259, 270], ["poliovirus infection", "OBSERVATION", 58, 78], ["eight", "OBSERVATION_MODIFIER", 235, 240], ["-fold", "OBSERVATION_MODIFIER", 240, 245], ["reduction", "OBSERVATION_MODIFIER", 246, 255], ["viral titer", "OBSERVATION", 259, 270]]], ["Our previous work has demonstrated that SRp20 displays a punctate pattern of localization in the cytoplasm of poliovirus-infected cells, reminiscent of the stress granules observed to develop during infection.", [["cytoplasm", "ANATOMY", 97, 106], ["cells", "ANATOMY", 130, 135], ["stress granules", "ANATOMY", 156, 171], ["infection", "DISEASE", 199, 208], ["SRp20", "GENE_OR_GENE_PRODUCT", 40, 45], ["cytoplasm", "ORGANISM_SUBSTANCE", 97, 106], ["cells", "CELL", 130, 135], ["stress granules", "CELLULAR_COMPONENT", 156, 171], ["SRp20", "PROTEIN", 40, 45], ["poliovirus-infected cells", "CELL_TYPE", 110, 135], ["a punctate pattern", "PROBLEM", 55, 73], ["poliovirus", "PROBLEM", 110, 120], ["infected cells", "PROBLEM", 121, 135], ["the stress granules", "PROBLEM", 152, 171], ["infection", "PROBLEM", 199, 208], ["punctate", "OBSERVATION_MODIFIER", 57, 65], ["cytoplasm", "OBSERVATION_MODIFIER", 97, 106], ["poliovirus", "OBSERVATION", 110, 120], ["infected cells", "OBSERVATION", 121, 135], ["stress granules", "OBSERVATION", 156, 171], ["infection", "OBSERVATION", 199, 208]]], ["In this study we sought to further define the role of stress granule formation during poliovirus infection, with particular focus on the cytoplasmic patterning of SRp20, as well as the effect of stress granules on viral translation.", [["stress granule", "ANATOMY", 54, 68], ["cytoplasmic", "ANATOMY", 137, 148], ["stress granules", "ANATOMY", 195, 210], ["poliovirus infection", "DISEASE", 86, 106], ["stress granule", "CELLULAR_COMPONENT", 54, 68], ["cytoplasmic", "ORGANISM_SUBSTANCE", 137, 148], ["SRp20", "GENE_OR_GENE_PRODUCT", 163, 168], ["stress granules", "CELLULAR_COMPONENT", 195, 210], ["SRp20", "PROTEIN", 163, 168], ["poliovirus", "SPECIES", 86, 96], ["this study", "TEST", 3, 13], ["stress granule formation", "PROBLEM", 54, 78], ["poliovirus infection", "PROBLEM", 86, 106], ["SRp20", "TREATMENT", 163, 168], ["stress granules", "PROBLEM", 195, 210], ["viral translation", "TREATMENT", 214, 231], ["stress granule formation", "OBSERVATION", 54, 78], ["poliovirus infection", "OBSERVATION", 86, 106], ["stress granules", "OBSERVATION", 195, 210], ["viral translation", "OBSERVATION", 214, 231]]], ["We found that SRp20 partially co-localized with a stress granule marker protein (TIA-1) in the cytoplasm of poliovirus-infected cells at 3 h post-infection.", [["stress granule", "ANATOMY", 50, 64], ["cytoplasm", "ANATOMY", 95, 104], ["cells", "ANATOMY", 128, 133], ["SRp20", "GENE_OR_GENE_PRODUCT", 14, 19], ["stress granule", "CELLULAR_COMPONENT", 50, 64], ["TIA-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["cytoplasm", "ORGANISM_SUBSTANCE", 95, 104], ["poliovirus", "ORGANISM", 108, 118], ["cells", "CELL", 128, 133], ["SRp20", "PROTEIN", 14, 19], ["stress granule marker protein", "PROTEIN", 50, 79], ["TIA-1", "PROTEIN", 81, 86], ["poliovirus-infected cells", "CELL_TYPE", 108, 133], ["a stress granule marker protein", "PROBLEM", 48, 79], ["TIA", "TEST", 81, 84], ["poliovirus", "PROBLEM", 108, 118], ["infected cells", "PROBLEM", 119, 133], ["poliovirus", "OBSERVATION", 108, 118], ["infected cells", "OBSERVATION", 119, 133]]], ["SRp20 was observed to be present in some, but not all, TIA-1 positive cytoplasmic foci that formed.", [["cytoplasmic foci", "ANATOMY", 70, 86], ["TIA", "DISEASE", 55, 58], ["SRp20", "GENE_OR_GENE_PRODUCT", 0, 5], ["TIA-1", "GENE_OR_GENE_PRODUCT", 55, 60], ["cytoplasmic", "ORGANISM_SUBSTANCE", 70, 81], ["SRp20", "PROTEIN", 0, 5], ["TIA", "TEST", 55, 58], ["1 positive cytoplasmic foci", "PROBLEM", 59, 86], ["cytoplasmic", "OBSERVATION_MODIFIER", 70, 81], ["foci", "OBSERVATION", 82, 86]]], ["We demonstrated that oxidative stress via arsenite treatment of the cells did not result in SRp20 co-localization with TIA-1.", [["cells", "ANATOMY", 68, 73], ["arsenite", "CHEMICAL", 42, 50], ["arsenite", "CHEMICAL", 42, 50], ["arsenite", "SIMPLE_CHEMICAL", 42, 50], ["cells", "CELL", 68, 73], ["SRp20", "GENE_OR_GENE_PRODUCT", 92, 97], ["TIA-1", "GENE_OR_GENE_PRODUCT", 119, 124], ["SRp20", "PROTEIN", 92, 97], ["TIA", "PROTEIN", 119, 122], ["oxidative stress via arsenite treatment", "TREATMENT", 21, 60], ["the cells", "PROBLEM", 64, 73], ["TIA", "PROBLEM", 119, 122]]], ["Expression of a dominant negative version of TIA-1 (TIA-1-PRD) was confirmed to disrupt stress granule formation during oxidative stress.", [["stress granule", "ANATOMY", 88, 102], ["TIA", "DISEASE", 45, 48], ["TIA-1", "GENE_OR_GENE_PRODUCT", 45, 50], ["TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 52, 61], ["stress granule", "CELLULAR_COMPONENT", 88, 102], ["TIA", "PROTEIN", 45, 48], ["TIA", "PROTEIN", 52, 55], ["PRD", "PROTEIN", 58, 61], ["TIA", "PROBLEM", 45, 48], ["TIA", "TEST", 52, 55], ["stress granule formation", "PROBLEM", 88, 112], ["oxidative stress", "PROBLEM", 120, 136], ["dominant", "OBSERVATION_MODIFIER", 16, 24], ["negative", "OBSERVATION", 25, 33], ["stress granule formation", "OBSERVATION", 88, 112], ["oxidative stress", "OBSERVATION", 120, 136]]], ["However, we observed that with expression of either wild type TIA-1 or dominant negative TIA-1-PRD, levels of poliovirus translation were not dramatically affected.", [["TIA-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["TIA-1", "GENE_OR_GENE_PRODUCT", 89, 94], ["PRD", "GENE_OR_GENE_PRODUCT", 95, 98], ["poliovirus", "ORGANISM", 110, 120], ["wild type TIA-1", "PROTEIN", 52, 67], ["dominant negative TIA-1", "DNA", 71, 94], ["PRD", "PROTEIN", 95, 98], ["poliovirus", "SPECIES", 110, 120], ["wild type TIA", "PROBLEM", 52, 65], ["dominant negative TIA", "PROBLEM", 71, 92], ["poliovirus translation", "PROBLEM", 110, 132], ["poliovirus", "OBSERVATION", 110, 120]]], ["Collectively, these results highlight the unique composition of poliovirus-induced stress granules as part of a myriad of virus-induced host modifications brought about during infection.Cell culture and DNA constructs ::: MethodsHeLa cells were grown as monolayers in Dulbecco's Modified Eagle's Media (DMEM) supplemented with 8% newborn calf serum (NCS).", [["stress granules", "ANATOMY", 83, 98], ["Cell", "ANATOMY", 186, 190], ["MethodsHeLa cells", "ANATOMY", 222, 239], ["monolayers", "ANATOMY", 254, 264], ["calf serum", "ANATOMY", 338, 348], ["infection", "DISEASE", 176, 185], ["poliovirus", "ORGANISM", 64, 74], ["stress granules", "CELLULAR_COMPONENT", 83, 98], ["Cell", "CELL", 186, 190], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["MethodsHeLa cells", "CELL", 222, 239], ["monolayers", "CELL", 254, 264], ["calf", "ORGANISM", 338, 342], ["serum", "ORGANISM_SUBSTANCE", 343, 348], ["DNA constructs", "DNA", 203, 217], ["MethodsHeLa cells", "CELL_LINE", 222, 239], ["calf", "SPECIES", 338, 342], ["poliovirus", "PROBLEM", 64, 74], ["stress granules", "PROBLEM", 83, 98], ["virus", "PROBLEM", 122, 127], ["infection", "PROBLEM", 176, 185], ["Cell culture", "TEST", 186, 198], ["MethodsHeLa cells", "TREATMENT", 222, 239], ["monolayers", "TEST", 254, 264], ["Dulbecco's Modified Eagle's Media (DMEM", "TREATMENT", 268, 307], ["8% newborn calf serum (NCS", "TREATMENT", 327, 353], ["poliovirus", "OBSERVATION", 64, 74], ["stress granules", "OBSERVATION", 83, 98], ["virus", "OBSERVATION", 122, 127], ["infection", "OBSERVATION", 176, 185]]], ["SK-N-SH cells (American Type Culture Collection number: HTB-11) were grown in DMEM supplemented with 20% fetal calf serum (FCS).", [["SK-N-SH cells", "ANATOMY", 0, 13], ["fetal calf serum", "ANATOMY", 105, 121], ["SK-N-SH cells", "CELL", 0, 13], ["HTB-11", "CELL", 56, 62], ["fetal calf", "ORGANISM_SUBSTANCE", 105, 115], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["FCS", "ORGANISM_SUBSTANCE", 123, 126], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["calf", "SPECIES", 111, 115], ["SK", "TEST", 0, 2], ["SH cells", "PROBLEM", 5, 13], ["Type Culture", "TEST", 24, 36], ["HTB", "TEST", 56, 59], ["calf", "ANATOMY", 111, 115]]], ["COS cells were grown in DMEM supplemented with 10% FCS. pEGFP and pEGFP-SRp20 plasmids were kindly provided by Dr. Roz Sandri-Goldin.", [["COS cells", "ANATOMY", 0, 9], ["COS cells", "CELL", 0, 9], ["pEGFP", "GENE_OR_GENE_PRODUCT", 56, 61], ["pEGFP", "GENE_OR_GENE_PRODUCT", 66, 71], ["SRp20", "GENE_OR_GENE_PRODUCT", 72, 77], ["COS cells", "CELL_LINE", 0, 9], ["pEGFP and pEGFP-SRp20 plasmids", "DNA", 56, 86], ["COS cells", "PROBLEM", 0, 9], ["10% FCS", "TREATMENT", 47, 54], ["pEGFP", "TREATMENT", 56, 61], ["pEGFP", "TREATMENT", 66, 71], ["SRp20 plasmids", "TREATMENT", 72, 86]]], ["The pMT2, pMT2-HA-TIA-1, and pMT2-HA-TIA-1-PRD plasmids were generously provided by Dr. Paul Anderson (Gilks et al., 2004, Kedersha et al., 2000).DNA transfection and virus infection ::: MethodsHeLa cells or SK-N-SH cells were seeded on coverslips and allowed to grow to approximately 70% confluency.", [["MethodsHeLa cells", "ANATOMY", 187, 204], ["SK-N-SH cells", "ANATOMY", 208, 221], ["infection", "DISEASE", 173, 182], ["pMT2", "GENE_OR_GENE_PRODUCT", 4, 8], ["pMT2", "GENE_OR_GENE_PRODUCT", 10, 14], ["TIA-1", "GENE_OR_GENE_PRODUCT", 18, 23], ["pMT2", "GENE_OR_GENE_PRODUCT", 29, 33], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["MethodsHeLa cells", "CELL", 187, 204], ["SK-N-SH cells", "CELL", 208, 221], ["pMT2, pMT2-HA-TIA-1, and pMT2-HA-TIA-1-PRD plasmids", "DNA", 4, 55], ["MethodsHeLa cells", "CELL_LINE", 187, 204], ["SK-N-SH cells", "CELL_LINE", 208, 221], ["The pMT2", "TEST", 0, 8], ["pMT2", "TEST", 10, 14], ["HA", "TEST", 15, 17], ["TIA", "TEST", 18, 21], ["pMT2", "TEST", 29, 33], ["HA", "PROBLEM", 34, 36], ["TIA", "PROBLEM", 37, 40], ["PRD plasmids", "TREATMENT", 43, 55], ["DNA transfection and virus infection", "PROBLEM", 146, 182], ["MethodsHeLa cells", "TEST", 187, 204], ["SK", "TEST", 208, 210], ["SH cells", "PROBLEM", 213, 221], ["coverslips", "TEST", 237, 247], ["virus infection", "OBSERVATION", 167, 182]]], ["Cells were transfected with EGFP-SRp20 (or EGFP) using Fugene transfection reagent (Roche).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["EGFP", "GENE_OR_GENE_PRODUCT", 28, 32], ["SRp20", "GENE_OR_GENE_PRODUCT", 33, 38], ["EGFP", "GENE_OR_GENE_PRODUCT", 43, 47], ["EGFP", "PROTEIN", 28, 32], ["SRp20", "PROTEIN", 33, 38], ["EGFP", "DNA", 43, 47], ["Cells", "TEST", 0, 5], ["EGFP", "TEST", 28, 32], ["Fugene transfection reagent", "TREATMENT", 55, 82]]], ["Twenty-four hours post-transfection, cells were mock-infected or infected with poliovirus at an MOI of 25.", [["cells", "ANATOMY", 37, 42], ["cells", "CELL", 37, 42], ["poliovirus", "ORGANISM", 79, 89], ["poliovirus", "SPECIES", 79, 89], ["infected", "PROBLEM", 65, 73], ["poliovirus", "PROBLEM", 79, 89]]], ["At 3 h post-infection, cells were washed once with 1\u00d7 phosphate-buffered saline (1\u00d7 PBS) and processed for imaging.Arsenite stress experiments ::: MethodsSK-N-SH cells were seeded on coverslips and allowed to grow to approximately 70% confluency.", [["cells", "ANATOMY", 23, 28], ["MethodsSK-N-SH cells", "ANATOMY", 147, 167], ["infection", "DISEASE", 12, 21], ["phosphate", "CHEMICAL", 54, 63], ["Arsenite", "CHEMICAL", 115, 123], ["phosphate", "CHEMICAL", 54, 63], ["Arsenite", "CHEMICAL", 115, 123], ["cells", "CELL", 23, 28], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 54, 79], ["Arsenite", "SIMPLE_CHEMICAL", 115, 123], ["MethodsSK-N-SH cells", "CELL", 147, 167], ["MethodsSK-N-SH cells", "CELL_LINE", 147, 167], ["infection", "PROBLEM", 12, 21], ["1\u00d7 phosphate-buffered saline", "TREATMENT", 51, 79], ["imaging", "TEST", 107, 114], ["MethodsSK", "TEST", 147, 156], ["N-SH cells", "TREATMENT", 157, 167], ["infection", "OBSERVATION", 12, 21]]], ["Cells were transfected with either EGFP-SRp20, or with HA-TIA-1 or HA-TIA-1-PRD (or empty vector, not shown).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["EGFP-SRp20", "GENE_OR_GENE_PRODUCT", 35, 45], ["HA-TIA-1", "GENE_OR_GENE_PRODUCT", 55, 63], ["HA-TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 67, 79], ["EGFP", "PROTEIN", 35, 39], ["SRp20", "PROTEIN", 40, 45], ["HA-TIA-1 or HA-TIA-1-PRD", "DNA", 55, 79], ["empty vector", "DNA", 84, 96], ["EGFP", "TEST", 35, 39], ["HA", "PROBLEM", 55, 57], ["TIA", "PROBLEM", 58, 61], ["HA", "PROBLEM", 67, 69], ["TIA", "PROBLEM", 70, 73], ["PRD", "PROBLEM", 76, 79], ["empty vector", "TREATMENT", 84, 96]]], ["Transfections were carried out using Fugene transfection reagent.", [["Transfections", "TEST", 0, 13], ["Fugene transfection reagent", "TREATMENT", 37, 64]]], ["Twenty-four hours post-transfection, media was replaced and oxidative stress was induced via the addition of 0.5 mM sodium arsenite (Sigma).", [["sodium arsenite", "CHEMICAL", 116, 131], ["sodium arsenite", "CHEMICAL", 116, 131], ["sodium arsenite", "SIMPLE_CHEMICAL", 116, 131], ["Sigma", "SIMPLE_CHEMICAL", 133, 138], ["media", "TREATMENT", 37, 42], ["oxidative stress", "PROBLEM", 60, 76], ["0.5 mM sodium arsenite", "TREATMENT", 109, 131]]], ["Cells were stressed for 30 min or 1 h at 37 \u00b0C, washed once with 1\u00d7 PBS and processed for imaging.Fluorescence microscopy and laser scanning confocal microscopy ::: MethodsFollowing transfection and virus infection or arsenite stress (as described), cells were fixed with 3.7% paraformaldehyde at room temperature for 20 min.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 250, 255], ["infection", "DISEASE", 205, 214], ["arsenite", "CHEMICAL", 218, 226], ["paraformaldehyde", "CHEMICAL", 277, 293], ["arsenite", "CHEMICAL", 218, 226], ["paraformaldehyde", "CHEMICAL", 277, 293], ["Cells", "CELL", 0, 5], ["arsenite", "SIMPLE_CHEMICAL", 218, 226], ["cells", "CELL", 250, 255], ["paraformaldehyde", "SIMPLE_CHEMICAL", 277, 293], ["PBS", "TEST", 68, 71], ["imaging", "TEST", 90, 97], ["Fluorescence microscopy", "TEST", 98, 121], ["laser scanning confocal microscopy", "TEST", 126, 160], ["MethodsFollowing transfection", "TREATMENT", 165, 194], ["virus infection", "PROBLEM", 199, 214], ["arsenite stress", "PROBLEM", 218, 233]]], ["Cells were washed with 1\u00d7 PBS twice, and cell membranes were permeabilized with 0.5% NP-40 in PBS for 5 min.", [["Cells", "ANATOMY", 0, 5], ["cell membranes", "ANATOMY", 41, 55], ["NP-40", "CHEMICAL", 85, 90], ["Cells", "CELL", 0, 5], ["cell membranes", "CELL", 41, 55], ["NP-40", "SIMPLE_CHEMICAL", 85, 90], ["PBS", "TEST", 26, 29], ["cell membranes", "TREATMENT", 41, 55], ["0.5% NP", "TREATMENT", 80, 87], ["cell membranes", "OBSERVATION", 41, 55]]], ["Cells for initial SRp20 cytoplasmic granule examination were washed with 1% NCS in PBS and incubated with DAPI to stain nuclei.", [["Cells", "ANATOMY", 0, 5], ["cytoplasmic granule", "ANATOMY", 24, 43], ["nuclei", "ANATOMY", 120, 126], ["DAPI", "CHEMICAL", 106, 110], ["Cells", "CELL", 0, 5], ["cytoplasmic", "ORGANISM_SUBSTANCE", 24, 35], ["DAPI", "SIMPLE_CHEMICAL", 106, 110], ["nuclei", "CELLULAR_COMPONENT", 120, 126], ["SRp20", "PROTEIN", 18, 23], ["Cells", "TEST", 0, 5], ["initial SRp20 cytoplasmic granule examination", "TEST", 10, 55], ["1% NCS in PBS", "TREATMENT", 73, 86], ["DAPI", "TREATMENT", 106, 110]]], ["For the rest of the imaging experiments, cells were washed with 1% NCS in PBS and incubated with normal donkey serum (Jackson Immunoresearch) for 1 h to block nonspecific interactions.", [["cells", "ANATOMY", 41, 46], ["serum", "ANATOMY", 111, 116], ["NCS", "CHEMICAL", 67, 70], ["cells", "CELL", 41, 46], ["NCS", "SIMPLE_CHEMICAL", 67, 70], ["donkey", "ORGANISM", 104, 110], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["donkey", "SPECIES", 104, 110], ["donkey", "SPECIES", 104, 110], ["the imaging experiments", "TEST", 16, 39], ["1% NCS in PBS", "TREATMENT", 64, 77], ["block nonspecific interactions", "PROBLEM", 153, 183]]], ["Cells were then incubated with an anti-TIA-1 (kindly provided by Dr. Kurt Gustin) or anti-HA (Sigma) monoclonal antibody for 1 h.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["anti-TIA-1", "GENE_OR_GENE_PRODUCT", 34, 44], ["kindly", "ORGANISM", 46, 52], ["Gustin", "SIMPLE_CHEMICAL", 74, 80], ["anti-HA", "GENE_OR_GENE_PRODUCT", 85, 92], ["anti-HA (Sigma) monoclonal antibody", "PROTEIN", 85, 120], ["an anti-TIA", "TEST", 31, 42], ["anti-HA (Sigma) monoclonal antibody", "TREATMENT", 85, 120]]], ["Cells were washed and incubated with AlexaFluor594 donkey anti-goat or AlexaFluor594 goat anti-mouse secondary antibody (Molecular Probes), respectively, for 45 min.", [["Cells", "ANATOMY", 0, 5], ["AlexaFluor594", "CHEMICAL", 37, 50], ["AlexaFluor594", "CHEMICAL", 71, 84], ["Cells", "CELL", 0, 5], ["AlexaFluor594", "SIMPLE_CHEMICAL", 71, 84], ["AlexaFluor594 donkey anti-goat", "PROTEIN", 37, 67], ["AlexaFluor594 goat anti-mouse secondary antibody", "PROTEIN", 71, 119], ["Molecular Probes", "PROTEIN", 121, 137], ["donkey", "SPECIES", 51, 57], ["goat", "SPECIES", 85, 89], ["anti-mouse", "SPECIES", 90, 100], ["AlexaFluor594 donkey", "SPECIES", 37, 57], ["AlexaFluor", "SPECIES", 71, 81], ["goat", "SPECIES", 85, 89], ["AlexaFluor", "TREATMENT", 37, 47], ["AlexaFluor", "TREATMENT", 71, 81]]], ["Cells were washed with 1% NCS-PBS and incubated with DAPI to stain nuclei.", [["Cells", "ANATOMY", 0, 5], ["nuclei", "ANATOMY", 67, 73], ["DAPI", "CHEMICAL", 53, 57], ["Cells", "CELL", 0, 5], ["NCS-PBS", "SIMPLE_CHEMICAL", 26, 33], ["DAPI", "SIMPLE_CHEMICAL", 53, 57], ["nuclei", "CELLULAR_COMPONENT", 67, 73], ["1% NCS-PBS", "TREATMENT", 23, 33], ["DAPI", "TREATMENT", 53, 57]]], ["Following DAPI incubation, all cells were washed with PBS; coverslips were mounted on microscope slides with mounting media (Biomeda) and allowed to dry overnight at room temperature.", [["cells", "ANATOMY", 31, 36], ["DAPI", "CHEMICAL", 10, 14], ["DAPI", "SIMPLE_CHEMICAL", 10, 14], ["cells", "CELL", 31, 36], ["DAPI incubation", "TREATMENT", 10, 25], ["all cells", "TREATMENT", 27, 36], ["PBS", "TREATMENT", 54, 57], ["coverslips", "TREATMENT", 59, 69], ["microscope slides", "TEST", 86, 103], ["mounting media (Biomeda)", "TREATMENT", 109, 133]]], ["Coverslips were sealed with nail polish, and cells were imaged using a Zeiss Axiovert 200 inverted fluorescence microscope or a Zeiss LSM 510 multi-photon laser scanning confocal microscope.", [["nail", "ANATOMY", 28, 32], ["cells", "ANATOMY", 45, 50], ["cells", "CELL", 45, 50], ["Coverslips", "TREATMENT", 0, 10], ["a Zeiss Axiovert", "TREATMENT", 69, 85], ["nail", "ANATOMY", 28, 32]]], ["Images were processed using the Axiovision software or the LSM 510 software, respectively.Poliovirus infection and [35S]-methionine-labeling of viral proteins ::: MethodsCOS cells were seeded and allowed to grow to approximately 70% confluency.", [["MethodsCOS cells", "ANATOMY", 163, 179], ["Poliovirus infection", "DISEASE", 90, 110], ["[35S]-methionine", "CHEMICAL", 115, 131], ["[35S]-methionine", "CHEMICAL", 115, 131], ["Poliovirus", "ORGANISM", 90, 100], ["[35S]-methionine", "SIMPLE_CHEMICAL", 115, 131], ["MethodsCOS cells", "CELL", 163, 179], ["LSM 510 software", "DNA", 59, 75], ["viral proteins", "PROTEIN", 144, 158], ["MethodsCOS cells", "CELL_LINE", 163, 179], ["Poliovirus", "SPECIES", 90, 100], ["Images", "TEST", 0, 6], ["Poliovirus infection", "PROBLEM", 90, 110], ["methionine", "TREATMENT", 121, 131], ["MethodsCOS cells", "TREATMENT", 163, 179], ["infection", "OBSERVATION", 101, 110]]], ["Cells were transfected with pMT2, HA-TIA-1, or HA-TIA-1-PRD using Lipofectamine transfection reagent (Invitrogen).", [["Cells", "ANATOMY", 0, 5], ["HA-TIA-1-PRD", "CHEMICAL", 47, 59], ["Cells", "CELL", 0, 5], ["pMT2", "GENE_OR_GENE_PRODUCT", 28, 32], ["HA-TIA-1", "GENE_OR_GENE_PRODUCT", 34, 42], ["HA-TIA-1-PRD", "SIMPLE_CHEMICAL", 47, 59], ["Lipofectamine", "ORGANISM", 66, 79], ["pMT2", "PROTEIN", 28, 32], ["HA", "PROTEIN", 34, 36], ["HA-TIA-1", "DNA", 47, 55], ["PRD", "DNA", 56, 59], ["Cells", "TEST", 0, 5], ["pMT2", "TEST", 28, 32], ["HA", "TEST", 34, 36], ["TIA", "TEST", 37, 40], ["HA", "PROBLEM", 47, 49], ["TIA", "PROBLEM", 50, 53], ["Lipofectamine transfection reagent", "TREATMENT", 66, 100]]], ["Twenty-four hours post-transfection, cells were mock-infected or infected with poliovirus at an MOI of 25 in methionine-free media (MP Biomedicals).", [["cells", "ANATOMY", 37, 42], ["methionine", "CHEMICAL", 109, 119], ["methionine", "CHEMICAL", 109, 119], ["cells", "CELL", 37, 42], ["poliovirus", "ORGANISM", 79, 89], ["methionine", "SIMPLE_CHEMICAL", 109, 119], ["poliovirus", "SPECIES", 79, 89], ["infected", "PROBLEM", 65, 73], ["poliovirus", "PROBLEM", 79, 89], ["methionine-free media (MP Biomedicals", "TREATMENT", 109, 146]]], ["After 2 h of methionine starvation, 23 \u03bcCi of [35S]-Met (PerkinElmer) was added to each well and infection was carried out for an additional 6 h.", [["methionine", "CHEMICAL", 13, 23], ["[35S]-Met", "CHEMICAL", 46, 55], ["infection", "DISEASE", 97, 106], ["methionine", "CHEMICAL", 13, 23], ["[35S]-Met", "CHEMICAL", 46, 55], ["methionine", "SIMPLE_CHEMICAL", 13, 23], ["[35S]-Met", "SIMPLE_CHEMICAL", 46, 55], ["PerkinElmer", "SIMPLE_CHEMICAL", 57, 68], ["methionine starvation", "TREATMENT", 13, 34], ["35S]-Met (PerkinElmer)", "TREATMENT", 47, 69], ["infection", "PROBLEM", 97, 106], ["infection", "OBSERVATION", 97, 106]]], ["Cells were harvested every 2 h from the beginning of infection, from 0 to 8 h post-infection.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 53, 62], ["infection", "DISEASE", 83, 92], ["Cells", "CELL", 0, 5], ["infection", "PROBLEM", 53, 62], ["infection", "PROBLEM", 83, 92], ["infection", "OBSERVATION", 53, 62], ["infection", "OBSERVATION", 83, 92]]], ["Mock-infected cells were collected at 8 h post-infection.", [["cells", "ANATOMY", 14, 19], ["infection", "DISEASE", 47, 56], ["cells", "CELL", 14, 19], ["Mock-infected cells", "CELL_TYPE", 0, 19], ["infected cells", "PROBLEM", 5, 19], ["infection", "PROBLEM", 47, 56], ["infected cells", "OBSERVATION", 5, 19], ["infection", "OBSERVATION", 47, 56]]], ["At each time point, cells were washed with 1\u00d7 PBS and harvested by scraping.", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25], ["PBS", "TEST", 46, 49], ["harvested", "OBSERVATION", 54, 63], ["scraping", "OBSERVATION", 67, 75]]], ["Cells were pelleted and lysed in RIPA buffer (50 mM Tris\u2013HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 5 \u03bcg/ml Aprotinin, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) on ice for 10 min.", [["Cells", "ANATOMY", 0, 5], ["NaCl", "CHEMICAL", 76, 80], ["Aprotinin", "CHEMICAL", 101, 110], ["Triton X-100", "CHEMICAL", 115, 127], ["sodium deoxycholate", "CHEMICAL", 132, 151], ["NaCl", "CHEMICAL", 76, 80], ["EDTA", "CHEMICAL", 87, 91], ["Aprotinin", "CHEMICAL", 101, 110], ["sodium deoxycholate", "CHEMICAL", 132, 151], ["Cells", "CELL", 0, 5], ["EDTA", "SIMPLE_CHEMICAL", 87, 91], ["Aprotinin", "SIMPLE_CHEMICAL", 101, 110], ["Triton X-100", "SIMPLE_CHEMICAL", 115, 127], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 132, 151], ["Cells", "TEST", 0, 5], ["Tris\u2013HCl", "TEST", 52, 60], ["pH", "TEST", 61, 63], ["NaCl", "TEST", 76, 80], ["EDTA", "TEST", 87, 91], ["Aprotinin", "TREATMENT", 101, 110], ["1% Triton", "TREATMENT", 112, 121], ["1% sodium deoxycholate", "TREATMENT", 129, 151]]], ["Debris was pelleted by centrifugation at 16,000 \u00d7g for 20 min, and equal volumes of cleared lysate were subjected to SDS-PAGE.", [["lysate", "ANATOMY", 92, 98], ["lysate", "ORGANISM_SUBSTANCE", 92, 98], ["Debris", "PROBLEM", 0, 6]]], ["Radiolabeled proteins were visualized by autoradiography.SRp20 partially co-localizes with a stress granule marker protein during poliovirus infection ::: ResultsWe have previously demonstrated the dramatic nucleo-cytoplasmic re-localization of SRp20 during poliovirus infection, in both neuroblastoma cells (SK-N-SH) and HeLa cells (Fitzgerald and Semler, 2011).", [["stress granule", "ANATOMY", 93, 107], ["cytoplasmic", "ANATOMY", 214, 225], ["neuroblastoma cells", "ANATOMY", 288, 307], ["SK-N-SH)", "ANATOMY", 309, 317], ["HeLa cells", "ANATOMY", 322, 332], ["poliovirus infection", "DISEASE", 130, 150], ["poliovirus infection", "DISEASE", 258, 278], ["neuroblastoma", "DISEASE", 288, 301], ["SRp20", "GENE_OR_GENE_PRODUCT", 57, 62], ["stress granule", "CELLULAR_COMPONENT", 93, 107], ["cytoplasmic", "ORGANISM_SUBSTANCE", 214, 225], ["SRp20", "GENE_OR_GENE_PRODUCT", 245, 250], ["neuroblastoma cells", "CELL", 288, 307], ["SK-N-SH)", "CELL", 309, 317], ["HeLa cells", "CELL", 322, 332], ["Fitzgerald", "CELL", 334, 344], ["SRp20", "PROTEIN", 57, 62], ["stress granule marker protein", "PROTEIN", 93, 122], ["SRp20", "PROTEIN", 245, 250], ["neuroblastoma cells", "CELL_TYPE", 288, 307], ["SK-N-SH", "CELL_LINE", 309, 316], ["HeLa cells", "CELL_LINE", 322, 332], ["poliovirus", "SPECIES", 130, 140], ["poliovirus", "SPECIES", 258, 268], ["Radiolabeled proteins", "TEST", 0, 21], ["autoradiography", "TEST", 41, 56], ["a stress granule marker protein during poliovirus infection", "PROBLEM", 91, 150], ["poliovirus infection", "PROBLEM", 258, 278], ["both neuroblastoma cells", "PROBLEM", 283, 307], ["SK", "TEST", 309, 311], ["HeLa cells", "TEST", 322, 332], ["Fitzgerald", "TEST", 334, 344], ["poliovirus infection", "OBSERVATION", 130, 150], ["dramatic", "OBSERVATION_MODIFIER", 198, 206], ["poliovirus infection", "OBSERVATION", 258, 278], ["both", "ANATOMY_MODIFIER", 283, 287], ["neuroblastoma cells", "OBSERVATION", 288, 307], ["HeLa cells", "ANATOMY", 322, 332]]], ["Beginning around 3 h post-infection, we also observed that SRp20 displayed a readily identifiable punctate pattern of localization in the cytoplasm of infected cells, reminiscent of stress granules that form under certain conditions of cellular stress.", [["cytoplasm", "ANATOMY", 138, 147], ["cells", "ANATOMY", 160, 165], ["stress granules", "ANATOMY", 182, 197], ["cellular", "ANATOMY", 236, 244], ["SRp20", "GENE_OR_GENE_PRODUCT", 59, 64], ["cytoplasm", "ORGANISM_SUBSTANCE", 138, 147], ["cells", "CELL", 160, 165], ["stress granules", "CELLULAR_COMPONENT", 182, 197], ["cellular", "CELL", 236, 244], ["SRp20", "PROTEIN", 59, 64], ["infected cells", "CELL_TYPE", 151, 165], ["post-infection", "PROBLEM", 21, 35], ["infected cells", "PROBLEM", 151, 165], ["stress granules", "PROBLEM", 182, 197], ["cellular stress", "PROBLEM", 236, 251], ["infection", "OBSERVATION", 26, 35], ["punctate", "OBSERVATION_MODIFIER", 98, 106], ["infected cells", "OBSERVATION", 151, 165], ["stress granules", "OBSERVATION", 182, 197], ["cellular stress", "OBSERVATION", 236, 251]]], ["We observed this cytoplasmic punctate pattern in SK-N-SH cells (Fig. 1A) as well as in HeLa cells (Fig. 1B) visualized by expression of GFP-tagged SRp20.", [["cytoplasmic", "ANATOMY", 17, 28], ["SK-N-SH cells", "ANATOMY", 49, 62], ["HeLa cells", "ANATOMY", 87, 97], ["cytoplasmic", "ORGANISM_SUBSTANCE", 17, 28], ["SK-N-SH cells", "CELL", 49, 62], ["HeLa cells", "CELL", 87, 97], ["1B", "GENE_OR_GENE_PRODUCT", 104, 106], ["GFP", "GENE_OR_GENE_PRODUCT", 136, 139], ["SRp20", "GENE_OR_GENE_PRODUCT", 147, 152], ["SK-N-SH cells", "CELL_LINE", 49, 62], ["HeLa cells", "CELL_LINE", 87, 97], ["GFP", "PROTEIN", 136, 139], ["SRp20", "PROTEIN", 147, 152], ["this cytoplasmic punctate pattern", "PROBLEM", 12, 45], ["SK", "TEST", 49, 51], ["GFP", "TEST", 136, 139], ["punctate", "OBSERVATION_MODIFIER", 29, 37], ["HeLa cells", "OBSERVATION", 87, 97]]], ["We have previously demonstrated that overexpression of GFP-SRp20 does not affect the kinetics of poliovirus infection (Fitzgerald and Semler, 2011).", [["poliovirus infection", "DISEASE", 97, 117], ["GFP", "GENE_OR_GENE_PRODUCT", 55, 58], ["SRp20", "GENE_OR_GENE_PRODUCT", 59, 64], ["poliovirus", "ORGANISM", 97, 107], ["GFP", "PROTEIN", 55, 58], ["SRp20", "PROTEIN", 59, 64], ["poliovirus", "SPECIES", 97, 107], ["GFP", "TEST", 55, 58], ["poliovirus infection", "PROBLEM", 97, 117], ["poliovirus infection", "OBSERVATION", 97, 117]]], ["We have also carried out experiments using a monoclonal antibody to label endogenous SRp20, and we found that the endogenous protein re-localizes from the nucleus to the cytoplasm during poliovirus infection (data not shown).", [["nucleus", "ANATOMY", 155, 162], ["cytoplasm", "ANATOMY", 170, 179], ["poliovirus infection", "DISEASE", 187, 207], ["SRp20", "GENE_OR_GENE_PRODUCT", 85, 90], ["nucleus", "CELLULAR_COMPONENT", 155, 162], ["cytoplasm", "ORGANISM_SUBSTANCE", 170, 179], ["monoclonal antibody", "PROTEIN", 45, 64], ["SRp20", "PROTEIN", 85, 90], ["endogenous protein", "PROTEIN", 114, 132], ["a monoclonal antibody", "TREATMENT", 43, 64], ["the endogenous protein", "PROBLEM", 110, 132], ["poliovirus infection", "PROBLEM", 187, 207], ["endogenous protein", "OBSERVATION", 114, 132], ["nucleus", "ANATOMY", 155, 162], ["cytoplasm", "OBSERVATION_MODIFIER", 170, 179], ["poliovirus infection", "OBSERVATION", 187, 207]]], ["Transfection of the GFP-tagged version of the protein provided the advantage of a consistent signal from the GFP fluorescence, in contrast to labeling SRp20 with the monoclonal antibody, which resulted in a higher variability of the signal obtained.", [["GFP", "GENE_OR_GENE_PRODUCT", 20, 23], ["GFP", "GENE_OR_GENE_PRODUCT", 109, 112], ["SRp20", "GENE_OR_GENE_PRODUCT", 151, 156], ["GFP", "PROTEIN", 20, 23], ["SRp20", "PROTEIN", 151, 156], ["monoclonal antibody", "PROTEIN", 166, 185], ["the GFP", "TEST", 16, 23], ["the protein", "TEST", 42, 53], ["the GFP fluorescence", "TEST", 105, 125], ["the monoclonal antibody", "TEST", 162, 185]]], ["GFP-SRp20 has been previously shown to localize and function similarly to endogenous SRp20 (Escudero-Paunetto et al., 2010).", [["GFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["SRp20", "GENE_OR_GENE_PRODUCT", 4, 9], ["SRp20", "GENE_OR_GENE_PRODUCT", 85, 90], ["GFP", "PROTEIN", 0, 3], ["SRp20", "PROTEIN", 4, 9], ["endogenous SRp20", "PROTEIN", 74, 90], ["GFP", "TEST", 0, 3]]], ["While SRp20 was localized throughout the cytoplasm, a portion of the protein could be seen forming granule-like clusters.", [["cytoplasm", "ANATOMY", 41, 50], ["granule", "ANATOMY", 99, 106], ["SRp20", "GENE_OR_GENE_PRODUCT", 6, 11], ["cytoplasm", "ORGANISM_SUBSTANCE", 41, 50], ["SRp20", "PROTEIN", 6, 11], ["the protein", "TEST", 65, 76], ["granule", "OBSERVATION", 99, 106]]], ["We investigated whether these cytoplasmic puncta also contained the RNA binding protein TIA-1, a protein that appears to be critical for stress granule formation and is known to localize to stress granules during poliovirus infection (Piotrowska et al., 2010, White and Lloyd, 2011).", [["cytoplasmic puncta", "ANATOMY", 30, 48], ["stress granule", "ANATOMY", 137, 151], ["stress granules", "ANATOMY", 190, 205], ["poliovirus infection", "DISEASE", 213, 233], ["cytoplasmic", "ORGANISM_SUBSTANCE", 30, 41], ["puncta", "CELLULAR_COMPONENT", 42, 48], ["TIA-1", "GENE_OR_GENE_PRODUCT", 88, 93], ["stress granule", "CELLULAR_COMPONENT", 137, 151], ["stress granules", "CELLULAR_COMPONENT", 190, 205], ["RNA binding protein TIA-1", "PROTEIN", 68, 93], ["these cytoplasmic puncta", "TEST", 24, 48], ["the RNA binding protein TIA", "TEST", 64, 91], ["a protein", "TEST", 95, 104], ["stress granule formation", "PROBLEM", 137, 161], ["stress granules", "PROBLEM", 190, 205], ["poliovirus infection", "PROBLEM", 213, 233], ["cytoplasmic puncta", "OBSERVATION", 30, 48], ["appears to be", "UNCERTAINTY", 110, 123], ["granule formation", "OBSERVATION", 144, 161], ["poliovirus infection", "OBSERVATION", 213, 233]]], ["We transfected SK-N-SH cells with a GFP-SRp20 construct (or GFP empty vector), and subsequently infected the cells with poliovirus for 3 h (the time point during infection at which SRp20 cytoplasmic granules could first be detected).", [["SK-N-SH cells", "ANATOMY", 15, 28], ["cells", "ANATOMY", 109, 114], ["cytoplasmic granules", "ANATOMY", 187, 207], ["infection", "DISEASE", 162, 171], ["SK-N-SH cells", "CELL", 15, 28], ["GFP", "GENE_OR_GENE_PRODUCT", 36, 39], ["SRp20", "GENE_OR_GENE_PRODUCT", 40, 45], ["GFP", "GENE_OR_GENE_PRODUCT", 60, 63], ["cells", "CELL", 109, 114], ["cytoplasmic", "ORGANISM_SUBSTANCE", 187, 198], ["granules", "ORGANISM_SUBSTANCE", 199, 207], ["SK-N-SH cells", "CELL_LINE", 15, 28], ["GFP-SRp20 construct", "DNA", 36, 55], ["GFP empty vector", "DNA", 60, 76], ["poliovirus", "SPECIES", 120, 130], ["SK", "TEST", 15, 17], ["a GFP", "TEST", 34, 39], ["poliovirus", "PROBLEM", 120, 130], ["infection", "PROBLEM", 162, 171], ["infected", "OBSERVATION", 96, 104], ["infection", "OBSERVATION", 162, 171]]], ["We used SK-N-SH cells for these experiments because they have a more distinct cytoplasmic space compared to other cell types (e.g., HeLa cells).", [["SK-N-SH cells", "ANATOMY", 8, 21], ["cytoplasmic space", "ANATOMY", 78, 95], ["cell", "ANATOMY", 114, 118], ["HeLa cells", "ANATOMY", 132, 142], ["SK-N-SH cells", "CELL", 8, 21], ["cytoplasmic", "ORGANISM_SUBSTANCE", 78, 89], ["cell", "CELL", 114, 118], ["HeLa cells", "CELL", 132, 142], ["SK-N-SH cells", "CELL_LINE", 8, 21], ["HeLa cells", "CELL_LINE", 132, 142], ["SK-N-SH cells", "TREATMENT", 8, 21], ["these experiments", "TREATMENT", 26, 43], ["a more distinct cytoplasmic space", "PROBLEM", 62, 95], ["more distinct", "OBSERVATION_MODIFIER", 64, 77], ["cytoplasmic space", "OBSERVATION", 78, 95]]], ["Cells were labeled with an anti-TIA-1 antibody to identify stress granules and then analyzed for co-localization of SRp20 and TIA-1.", [["Cells", "ANATOMY", 0, 5], ["stress granules", "ANATOMY", 59, 74], ["Cells", "CELL", 0, 5], ["anti-TIA-1 antibody", "GENE_OR_GENE_PRODUCT", 27, 46], ["granules", "ORGANISM_SUBSTANCE", 66, 74], ["SRp20", "GENE_OR_GENE_PRODUCT", 116, 121], ["TIA-1", "GENE_OR_GENE_PRODUCT", 126, 131], ["anti-TIA-1 antibody", "PROTEIN", 27, 46], ["SRp20", "PROTEIN", 116, 121], ["TIA-1", "PROTEIN", 126, 131], ["Cells", "TEST", 0, 5], ["an anti-TIA", "TEST", 24, 35], ["stress granules", "PROBLEM", 59, 74], ["SRp20", "TEST", 116, 121], ["TIA", "PROBLEM", 126, 129]]], ["The results of these experiments are shown in Fig. 2, which displays the localization of SRp20 and TIA-1 in cells that were mock-infected (top panels) or poliovirus-infected (bottom panels).", [["cells", "ANATOMY", 108, 113], ["poliovirus-infected", "DISEASE", 154, 173], ["SRp20", "GENE_OR_GENE_PRODUCT", 89, 94], ["TIA-1", "GENE_OR_GENE_PRODUCT", 99, 104], ["cells", "CELL", 108, 113], ["SRp20", "PROTEIN", 89, 94], ["TIA-1", "PROTEIN", 99, 104], ["these experiments", "TEST", 15, 32], ["SRp20", "TEST", 89, 94], ["TIA", "PROBLEM", 99, 102], ["top panels", "TEST", 139, 149], ["poliovirus", "PROBLEM", 154, 164], ["infected", "OBSERVATION_MODIFIER", 165, 173]]], ["As we have shown previously, SRp20 was predominantly nuclear in mock-infected cells but re-localized to the cytoplasm during poliovirus infection, where a punctate pattern of localization could also be observed (Fitzgerald and Semler, 2011).", [["nuclear", "ANATOMY", 53, 60], ["cells", "ANATOMY", 78, 83], ["cytoplasm", "ANATOMY", 108, 117], ["poliovirus infection", "DISEASE", 125, 145], ["SRp20", "GENE_OR_GENE_PRODUCT", 29, 34], ["nuclear", "CELLULAR_COMPONENT", 53, 60], ["cells", "CELL", 78, 83], ["cytoplasm", "ORGANISM_SUBSTANCE", 108, 117], ["SRp20", "PROTEIN", 29, 34], ["mock-infected cells", "CELL_TYPE", 64, 83], ["poliovirus", "SPECIES", 125, 135], ["infected cells", "PROBLEM", 69, 83], ["the cytoplasm", "PROBLEM", 104, 117], ["poliovirus infection", "PROBLEM", 125, 145], ["infected cells", "OBSERVATION", 69, 83], ["cytoplasm", "OBSERVATION_MODIFIER", 108, 117], ["poliovirus infection", "OBSERVATION", 125, 145], ["punctate", "OBSERVATION_MODIFIER", 155, 163], ["could also be", "UNCERTAINTY", 188, 201]]], ["TIA-1 was found in both the nucleus and the cytoplasm of mock- and poliovirus-infected cells, but during infection we observed TIA-1 positive puncta in the cytoplasm, consistent with stress granule formation.", [["nucleus", "ANATOMY", 28, 35], ["cytoplasm", "ANATOMY", 44, 53], ["cells", "ANATOMY", 87, 92], ["puncta", "ANATOMY", 142, 148], ["cytoplasm", "ANATOMY", 156, 165], ["stress granule", "ANATOMY", 183, 197], ["TIA", "DISEASE", 0, 3], ["infection", "DISEASE", 105, 114], ["TIA-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["nucleus", "CELLULAR_COMPONENT", 28, 35], ["cytoplasm", "ORGANISM_SUBSTANCE", 44, 53], ["poliovirus", "ORGANISM", 67, 77], ["cells", "CELL", 87, 92], ["TIA-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["puncta", "CELLULAR_COMPONENT", 142, 148], ["cytoplasm", "ORGANISM_SUBSTANCE", 156, 165], ["stress granule", "CELLULAR_COMPONENT", 183, 197], ["mock- and poliovirus-infected cells", "CELL_TYPE", 57, 92], ["TIA", "PROTEIN", 127, 130], ["TIA", "PROBLEM", 0, 3], ["poliovirus", "PROBLEM", 67, 77], ["infected cells", "PROBLEM", 78, 92], ["infection", "PROBLEM", 105, 114], ["TIA", "TEST", 127, 130], ["1 positive puncta in the cytoplasm", "PROBLEM", 131, 165], ["stress granule formation", "PROBLEM", 183, 207], ["both", "ANATOMY_MODIFIER", 19, 23], ["nucleus", "ANATOMY", 28, 35], ["infected cells", "OBSERVATION", 78, 92], ["puncta", "OBSERVATION", 142, 148], ["cytoplasm", "ANATOMY", 156, 165], ["consistent with", "UNCERTAINTY", 167, 182], ["stress granule formation", "OBSERVATION", 183, 207]]], ["These TIA-1 containing stress granules were observed with or without the expression of GFP-SRp20 (data not shown; also refer to Fig. 2B).", [["stress granules", "ANATOMY", 23, 38], ["TIA", "DISEASE", 6, 9], ["TIA-1", "GENE_OR_GENE_PRODUCT", 6, 11], ["stress granules", "CELLULAR_COMPONENT", 23, 38], ["GFP-SRp20", "GENE_OR_GENE_PRODUCT", 87, 96], ["GFP", "PROTEIN", 87, 90], ["SRp20", "PROTEIN", 91, 96], ["These TIA", "PROBLEM", 0, 9], ["stress granules", "PROBLEM", 23, 38], ["GFP", "TEST", 87, 90]]], ["Interestingly, we observed co-localization of SRp20 and TIA-1 in the cytoplasm of cells during poliovirus infection at 3 h post-infection (see the merged panels in Fig. 2A; co-localization denoted with white arrows).", [["cytoplasm", "ANATOMY", 69, 78], ["cells", "ANATOMY", 82, 87], ["poliovirus infection", "DISEASE", 95, 115], ["SRp20", "GENE_OR_GENE_PRODUCT", 46, 51], ["TIA-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["cytoplasm", "ORGANISM_SUBSTANCE", 69, 78], ["cells", "CELL", 82, 87], ["poliovirus", "ORGANISM", 95, 105], ["2A", "GENE_OR_GENE_PRODUCT", 169, 171], ["SRp20", "PROTEIN", 46, 51], ["TIA-1", "PROTEIN", 56, 61], ["poliovirus", "SPECIES", 95, 105], ["SRp20", "TEST", 46, 51], ["TIA", "PROBLEM", 56, 59], ["poliovirus infection", "PROBLEM", 95, 115], ["post-infection", "PROBLEM", 123, 137], ["poliovirus infection", "OBSERVATION", 95, 115], ["infection", "OBSERVATION", 128, 137]]], ["Additional experiments confirmed the co-localization of SRp20 and TIA-1 in some, but not all, TIA-1 positive cytoplasmic foci (data not shown).", [["cytoplasmic foci", "ANATOMY", 109, 125], ["TIA", "DISEASE", 94, 97], ["SRp20", "GENE_OR_GENE_PRODUCT", 56, 61], ["TIA-1", "GENE_OR_GENE_PRODUCT", 66, 71], ["TIA-1", "GENE_OR_GENE_PRODUCT", 94, 99], ["cytoplasmic", "ORGANISM_SUBSTANCE", 109, 120], ["SRp20", "PROTEIN", 56, 61], ["TIA-1", "PROTEIN", 66, 71], ["TIA", "PROTEIN", 94, 97], ["Additional experiments", "TEST", 0, 22], ["SRp20", "TEST", 56, 61], ["TIA", "TEST", 66, 69], ["TIA", "TEST", 94, 97], ["1 positive cytoplasmic foci", "PROBLEM", 98, 125], ["cytoplasmic", "OBSERVATION_MODIFIER", 109, 120], ["foci", "OBSERVATION", 121, 125]]], ["As a control, in Fig. 2B we demonstrated that GFP alone did not co-localize with TIA-1 in either mock- or poliovirus-infected cells (although stress granules were still observed during infection; bottom panels), indicating that the GFP tag alone did not contribute to the localization of SRp20.", [["cells", "ANATOMY", 126, 131], ["stress granules", "ANATOMY", 142, 157], ["infection", "DISEASE", 185, 194], ["2B", "GENE_OR_GENE_PRODUCT", 22, 24], ["GFP", "GENE_OR_GENE_PRODUCT", 46, 49], ["TIA-1", "GENE_OR_GENE_PRODUCT", 81, 86], ["poliovirus", "ORGANISM", 106, 116], ["cells", "CELL", 126, 131], ["granules", "ORGANISM_SUBSTANCE", 149, 157], ["GFP", "GENE_OR_GENE_PRODUCT", 232, 235], ["SRp20", "GENE_OR_GENE_PRODUCT", 288, 293], ["GFP", "PROTEIN", 46, 49], ["TIA-1", "PROTEIN", 81, 86], ["poliovirus-infected cells", "CELL_TYPE", 106, 131], ["GFP tag", "DNA", 232, 239], ["SRp20", "PROTEIN", 288, 293], ["GFP", "TEST", 46, 49], ["TIA", "TEST", 81, 84], ["poliovirus", "PROBLEM", 106, 116], ["infected cells", "PROBLEM", 117, 131], ["stress granules", "PROBLEM", 142, 157], ["infection", "PROBLEM", 185, 194], ["bottom panels", "TEST", 196, 209], ["the GFP tag", "TEST", 228, 239], ["infected cells", "OBSERVATION", 117, 131]]], ["Therefore, SRp20 and TIA-1 can be visualized in very close proximity to each other in some of the TIA-1-containing cytoplasmic stress granules that form during poliovirus-infection.Oxidative stress via arsenite treatment of cells causes TIA-1 positive foci formation but does not result in co-localization of SRp20 and TIA-1 ::: ResultsWe next investigated if SRp20 could be observed to co-localize, at least in part, with TIA-1 during other conditions of cellular stress in addition to virus infection.", [["cytoplasmic stress granules", "ANATOMY", 115, 142], ["cells", "ANATOMY", 224, 229], ["foci", "ANATOMY", 252, 256], ["cellular", "ANATOMY", 456, 464], ["TIA", "DISEASE", 98, 101], ["poliovirus-infection", "DISEASE", 160, 180], ["arsenite", "CHEMICAL", 202, 210], ["TIA", "DISEASE", 319, 322], ["TIA", "DISEASE", 423, 426], ["infection", "DISEASE", 493, 502], ["arsenite", "CHEMICAL", 202, 210], ["SRp20", "GENE_OR_GENE_PRODUCT", 11, 16], ["TIA-1", "GENE_OR_GENE_PRODUCT", 21, 26], ["TIA-1", "GENE_OR_GENE_PRODUCT", 98, 103], ["cytoplasmic", "ORGANISM_SUBSTANCE", 115, 126], ["stress", "CELLULAR_COMPONENT", 127, 133], ["granules", "ORGANISM_SUBSTANCE", 134, 142], ["poliovirus", "ORGANISM", 160, 170], ["arsenite", "SIMPLE_CHEMICAL", 202, 210], ["cells", "CELL", 224, 229], ["TIA-1", "GENE_OR_GENE_PRODUCT", 237, 242], ["SRp20", "GENE_OR_GENE_PRODUCT", 309, 314], ["TIA-1", "GENE_OR_GENE_PRODUCT", 319, 324], ["SRp20", "GENE_OR_GENE_PRODUCT", 360, 365], ["TIA-1", "GENE_OR_GENE_PRODUCT", 423, 428], ["cellular", "CELL", 456, 464], ["SRp20", "PROTEIN", 11, 16], ["TIA", "PROTEIN", 21, 24], ["TIA-1", "DNA", 98, 103], ["SRp20", "PROTEIN", 309, 314], ["TIA", "PROTEIN", 319, 322], ["SRp20", "PROTEIN", 360, 365], ["SRp20", "TEST", 11, 16], ["TIA", "TEST", 21, 24], ["the TIA", "TEST", 94, 101], ["cytoplasmic stress granules", "PROBLEM", 115, 142], ["poliovirus", "PROBLEM", 160, 170], ["infection", "PROBLEM", 171, 180], ["Oxidative stress via arsenite treatment of cells", "TREATMENT", 181, 229], ["TIA", "PROBLEM", 237, 240], ["1 positive foci formation", "PROBLEM", 241, 266], ["TIA", "PROBLEM", 319, 322], ["TIA", "PROBLEM", 423, 426], ["cellular stress", "PROBLEM", 456, 471], ["virus infection", "PROBLEM", 487, 502], ["TIA", "OBSERVATION", 98, 101], ["cytoplasmic stress granules", "OBSERVATION", 115, 142], ["infection", "OBSERVATION", 171, 180], ["foci", "OBSERVATION", 252, 256], ["cellular stress", "OBSERVATION", 456, 471], ["virus infection", "OBSERVATION", 487, 502]]], ["Our goal was to determine whether the localization of SRp20 to stress granules was potentially a general response to stress within the cells.", [["stress granules", "ANATOMY", 63, 78], ["cells", "ANATOMY", 135, 140], ["SRp20", "GENE_OR_GENE_PRODUCT", 54, 59], ["stress granules", "CELLULAR_COMPONENT", 63, 78], ["cells", "CELL", 135, 140], ["SRp20", "PROTEIN", 54, 59], ["stress granules", "PROBLEM", 63, 78], ["stress within the cells", "PROBLEM", 117, 140]]], ["For these experiments, we transfected SK-N-SH cells with GFP-SRp20 and subsequently treated the cells with sodium arsenite, which induces oxidative stress.", [["SK-N-SH cells", "ANATOMY", 38, 51], ["cells", "ANATOMY", 96, 101], ["sodium arsenite", "CHEMICAL", 107, 122], ["sodium arsenite", "CHEMICAL", 107, 122], ["SK-N-SH cells", "CELL", 38, 51], ["GFP-SRp20", "GENE_OR_GENE_PRODUCT", 57, 66], ["cells", "CELL", 96, 101], ["sodium arsenite", "SIMPLE_CHEMICAL", 107, 122], ["SK-N-SH cells", "CELL_LINE", 38, 51], ["GFP", "PROTEIN", 57, 60], ["SRp20", "PROTEIN", 61, 66], ["SK", "TEST", 38, 40], ["GFP", "TEST", 57, 60], ["sodium arsenite", "TREATMENT", 107, 122], ["oxidative stress", "PROBLEM", 138, 154], ["oxidative stress", "OBSERVATION", 138, 154]]], ["We then labeled the cells with anti-TIA-1 antibody to detect arsenite-induced stress granules and determined the localization of SRp20 in mock- and arsenite-treated cells.", [["cells", "ANATOMY", 20, 25], ["stress granules", "ANATOMY", 78, 93], ["cells", "ANATOMY", 165, 170], ["arsenite", "CHEMICAL", 61, 69], ["arsenite", "CHEMICAL", 148, 156], ["arsenite", "CHEMICAL", 61, 69], ["arsenite", "CHEMICAL", 148, 156], ["cells", "CELL", 20, 25], ["anti-TIA-1 antibody", "GENE_OR_GENE_PRODUCT", 31, 50], ["arsenite", "SIMPLE_CHEMICAL", 61, 69], ["stress", "CELLULAR_COMPONENT", 78, 84], ["granules", "ORGANISM_SUBSTANCE", 85, 93], ["SRp20", "GENE_OR_GENE_PRODUCT", 129, 134], ["arsenite", "SIMPLE_CHEMICAL", 148, 156], ["cells", "CELL", 165, 170], ["anti-TIA-1 antibody", "PROTEIN", 31, 50], ["SRp20", "PROTEIN", 129, 134], ["mock- and arsenite-treated cells", "CELL_LINE", 138, 170], ["anti-TIA", "TEST", 31, 39], ["stress granules", "PROBLEM", 78, 93]]], ["Oxidative stress was carried out for 30 min (Fig. 3A) or for 1 h (Fig. 3B) prior to cell fixation, immuno-labeling, and fluorescence imaging.", [["cell", "ANATOMY", 84, 88], ["cell", "CELL", 84, 88], ["Oxidative stress", "PROBLEM", 0, 16], ["cell fixation", "TREATMENT", 84, 97], ["immuno-labeling", "TEST", 99, 114], ["fluorescence imaging", "TEST", 120, 140], ["cell fixation", "OBSERVATION", 84, 97]]], ["In the mock-treated cells (top panels in Fig. 3A and B), TIA-1 was localized in both the nucleus and the cytoplasm without any distinct subcellular pattern of localization.", [["cells", "ANATOMY", 20, 25], ["nucleus", "ANATOMY", 89, 96], ["cytoplasm", "ANATOMY", 105, 114], ["subcellular", "ANATOMY", 136, 147], ["TIA", "DISEASE", 57, 60], ["cells", "CELL", 20, 25], ["B", "GENE_OR_GENE_PRODUCT", 53, 54], ["TIA-1", "GENE_OR_GENE_PRODUCT", 57, 62], ["nucleus", "CELLULAR_COMPONENT", 89, 96], ["cytoplasm", "ORGANISM_SUBSTANCE", 105, 114], ["mock-treated cells", "CELL_LINE", 7, 25], ["TIA", "PROTEIN", 57, 60], ["top panels", "TEST", 27, 37], ["TIA", "PROBLEM", 57, 60], ["TIA", "OBSERVATION", 57, 60], ["both", "ANATOMY_MODIFIER", 80, 84], ["nucleus", "ANATOMY", 89, 96], ["cytoplasm", "OBSERVATION", 105, 114], ["distinct", "OBSERVATION_MODIFIER", 127, 135], ["subcellular pattern", "OBSERVATION", 136, 155]]], ["However, after 30 min of stress treatment, TIA-1-containing stress granules were apparent in the cytoplasm of the cells (bottom panels in Fig. 3A), and were even more pronounced after 1 h of stress (bottom panels in Fig. 3B).", [["stress granules", "ANATOMY", 60, 75], ["cytoplasm", "ANATOMY", 97, 106], ["cells", "ANATOMY", 114, 119], ["TIA-1", "CHEMICAL", 43, 48], ["TIA-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["granules", "ORGANISM_SUBSTANCE", 67, 75], ["cytoplasm", "ORGANISM_SUBSTANCE", 97, 106], ["cells", "CELL", 114, 119], ["stress treatment", "TREATMENT", 25, 41], ["TIA", "TEST", 43, 46], ["stress granules", "PROBLEM", 60, 75], ["bottom panels", "TEST", 121, 134], ["stress (bottom panels", "TEST", 191, 212], ["stress granules", "OBSERVATION", 60, 75], ["cells", "ANATOMY", 114, 119]]], ["Despite the readily detectable cytoplasmic stress granules, SRp20 remained localized in the nucleus of the arsenite-stressed cells and did not co-localize with TIA-1 (see merged panels in Fig. 3A and B).", [["cytoplasmic stress granules", "ANATOMY", 31, 58], ["nucleus", "ANATOMY", 92, 99], ["cells", "ANATOMY", 125, 130], ["arsenite", "CHEMICAL", 107, 115], ["arsenite", "CHEMICAL", 107, 115], ["cytoplasmic", "ORGANISM_SUBSTANCE", 31, 42], ["stress granules", "CELLULAR_COMPONENT", 43, 58], ["SRp20", "GENE_OR_GENE_PRODUCT", 60, 65], ["nucleus", "CELLULAR_COMPONENT", 92, 99], ["arsenite", "SIMPLE_CHEMICAL", 107, 115], ["cells", "CELL", 125, 130], ["TIA-1", "GENE_OR_GENE_PRODUCT", 160, 165], ["B", "GENE_OR_GENE_PRODUCT", 200, 201], ["SRp20", "PROTEIN", 60, 65], ["arsenite-stressed cells", "CELL_LINE", 107, 130], ["TIA", "PROTEIN", 160, 163], ["the readily detectable cytoplasmic stress granules", "PROBLEM", 8, 58], ["stressed cells", "PROBLEM", 116, 130], ["TIA", "TEST", 160, 163], ["cytoplasmic stress granules", "OBSERVATION", 31, 58], ["nucleus", "ANATOMY_MODIFIER", 92, 99]]], ["Thus, SRp20 does not localize to TIA-1-containing stress granules formed during conditions of oxidative stress.", [["stress granules", "ANATOMY", 50, 65], ["TIA", "DISEASE", 33, 36], ["SRp20", "GENE_OR_GENE_PRODUCT", 6, 11], ["TIA-1", "GENE_OR_GENE_PRODUCT", 33, 38], ["stress granules", "CELLULAR_COMPONENT", 50, 65], ["SRp20", "PROTEIN", 6, 11], ["TIA-1", "PROTEIN", 33, 38], ["TIA", "TEST", 33, 36], ["stress granules", "PROBLEM", 50, 65], ["oxidative stress", "PROBLEM", 94, 110]]], ["Taken together, we conclude that the partial co-localization of SRp20 and TIA-1 observed during poliovirus infection does not represent a general response to cellular stress.Expression of wild type or dominant negative TIA-1 does not dramatically stimulate or inhibit poliovirus translation ::: ResultsBecause poliovirus infection induces the formation of stress granules, we investigated the effect of disrupting these cytoplasmic foci specifically on viral translation.", [["cellular", "ANATOMY", 158, 166], ["stress granules", "ANATOMY", 356, 371], ["cytoplasmic foci", "ANATOMY", 420, 436], ["TIA", "DISEASE", 74, 77], ["poliovirus infection", "DISEASE", 96, 116], ["TIA", "DISEASE", 219, 222], ["poliovirus infection", "DISEASE", 310, 330], ["SRp20", "GENE_OR_GENE_PRODUCT", 64, 69], ["TIA-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["poliovirus", "ORGANISM", 96, 106], ["cellular", "CELL", 158, 166], ["TIA-1", "GENE_OR_GENE_PRODUCT", 219, 224], ["poliovirus", "ORGANISM", 310, 320], ["stress granules", "CELLULAR_COMPONENT", 356, 371], ["cytoplasmic", "ORGANISM_SUBSTANCE", 420, 431], ["SRp20", "PROTEIN", 64, 69], ["TIA-1", "PROTEIN", 74, 79], ["dominant negative TIA-1", "DNA", 201, 224], ["poliovirus", "SPECIES", 96, 106], ["poliovirus", "SPECIES", 268, 278], ["poliovirus", "SPECIES", 310, 320], ["SRp20", "TEST", 64, 69], ["TIA", "PROBLEM", 74, 77], ["poliovirus infection", "PROBLEM", 96, 116], ["cellular stress", "PROBLEM", 158, 173], ["dominant negative TIA", "PROBLEM", 201, 222], ["poliovirus infection", "PROBLEM", 310, 330], ["stress granules", "PROBLEM", 356, 371], ["disrupting these cytoplasmic foci", "PROBLEM", 403, 436], ["infection", "OBSERVATION", 107, 116], ["cellular stress", "OBSERVATION", 158, 173], ["poliovirus infection", "OBSERVATION", 310, 330], ["stress granules", "OBSERVATION", 356, 371], ["cytoplasmic", "OBSERVATION_MODIFIER", 420, 431], ["foci", "OBSERVATION", 432, 436]]], ["If a portion of the cytoplasmic SRp20 is aggregated in stress granules during infection, it may be unavailable for viral translation.", [["cytoplasmic", "ANATOMY", 20, 31], ["stress granules", "ANATOMY", 55, 70], ["infection", "DISEASE", 78, 87], ["cytoplasmic", "ORGANISM_SUBSTANCE", 20, 31], ["SRp20", "GENE_OR_GENE_PRODUCT", 32, 37], ["stress granules", "CELLULAR_COMPONENT", 55, 70], ["cytoplasmic SRp20", "PROTEIN", 20, 37], ["the cytoplasmic SRp20", "TEST", 16, 37], ["stress granules", "PROBLEM", 55, 70], ["infection", "PROBLEM", 78, 87], ["viral translation", "PROBLEM", 115, 132], ["infection", "OBSERVATION", 78, 87]]], ["We hypothesized that disruption of stress granules during infection may boost levels of poliovirus translation, as more SRp20 is made available to the virus.", [["stress granules", "ANATOMY", 35, 50], ["infection", "DISEASE", 58, 67], ["stress granules", "CELLULAR_COMPONENT", 35, 50], ["SRp20", "GENE_OR_GENE_PRODUCT", 120, 125], ["SRp20", "PROTEIN", 120, 125], ["poliovirus", "SPECIES", 88, 98], ["stress granules", "PROBLEM", 35, 50], ["infection", "PROBLEM", 58, 67], ["poliovirus translation", "TREATMENT", 88, 110], ["the virus", "PROBLEM", 147, 156], ["stress granules", "OBSERVATION", 35, 50]]], ["To disrupt stress granule formation, we utilized a construct encoding a dominant negative version of TIA-1, termed TIA-1-PRD (Gilks et al., 2004, Kedersha et al., 2000).", [["stress granule", "ANATOMY", 11, 25], ["TIA", "DISEASE", 101, 104], ["stress granule", "CELLULAR_COMPONENT", 11, 25], ["TIA-1", "GENE_OR_GENE_PRODUCT", 101, 106], ["TIA-1", "GENE_OR_GENE_PRODUCT", 115, 120], ["TIA", "PROTEIN", 101, 104], ["PRD", "PROTEIN", 121, 124], ["stress granule formation", "PROBLEM", 11, 35], ["TIA", "PROBLEM", 101, 104], ["stress granule formation", "OBSERVATION", 11, 35]]], ["This protein contains only the C-terminal domain of TIA-1 and its over-expression has been previously shown to disrupt stress granule formation during arsenite stress (Gilks et al., 2004) as well as during poliovirus infection (Piotrowska et al., 2010).", [["stress granule", "ANATOMY", 119, 133], ["arsenite", "CHEMICAL", 151, 159], ["poliovirus infection", "DISEASE", 206, 226], ["C", "CHEMICAL", 31, 32], ["arsenite", "CHEMICAL", 151, 159], ["TIA-1", "GENE_OR_GENE_PRODUCT", 52, 57], ["stress granule", "CELLULAR_COMPONENT", 119, 133], ["arsenite", "SIMPLE_CHEMICAL", 151, 159], ["C-terminal domain", "PROTEIN", 31, 48], ["TIA", "PROTEIN", 52, 55], ["poliovirus", "SPECIES", 206, 216], ["This protein", "TEST", 0, 12], ["TIA", "PROBLEM", 52, 55], ["stress granule formation", "PROBLEM", 119, 143], ["arsenite stress", "PROBLEM", 151, 166], ["poliovirus infection", "PROBLEM", 206, 226], ["TIA", "OBSERVATION", 52, 55], ["stress granule formation", "OBSERVATION", 119, 143]]], ["We first validated the effect of expressing either wild type TIA-1 or dominant negative TIA-1-PRD on stress granule formation, utilizing arsenite stress to induce stress granules in the cells.", [["stress granule", "ANATOMY", 101, 115], ["stress granules", "ANATOMY", 163, 178], ["cells", "ANATOMY", 186, 191], ["TIA", "DISEASE", 61, 64], ["arsenite", "CHEMICAL", 137, 145], ["arsenite", "CHEMICAL", 137, 145], ["TIA-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 88, 97], ["stress granule", "CELLULAR_COMPONENT", 101, 115], ["arsenite", "SIMPLE_CHEMICAL", 137, 145], ["stress granules", "CELLULAR_COMPONENT", 163, 178], ["cells", "CELL", 186, 191], ["wild type TIA-1", "PROTEIN", 51, 66], ["dominant negative TIA-1-PRD", "PROTEIN", 70, 97], ["wild type TIA", "PROBLEM", 51, 64], ["dominant negative TIA", "PROBLEM", 70, 91], ["stress granule formation", "PROBLEM", 101, 125], ["arsenite stress", "PROBLEM", 137, 152], ["stress granules in the cells", "PROBLEM", 163, 191], ["granule formation", "OBSERVATION", 108, 125], ["stress granules", "OBSERVATION", 163, 178], ["cells", "ANATOMY", 186, 191]]], ["SK-N-SH cells were transfected with HA-tagged wild type TIA-1 or TIA-1-PRD (or vector only, data not shown) and subsequently mock- or arsenite-treated for 30 min.", [["SK-N-SH cells", "ANATOMY", 0, 13], ["arsenite", "CHEMICAL", 134, 142], ["arsenite", "CHEMICAL", 134, 142], ["SK-N-SH cells", "CELL", 0, 13], ["TIA-1", "GENE_OR_GENE_PRODUCT", 56, 61], ["TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 65, 74], ["arsenite", "SIMPLE_CHEMICAL", 134, 142], ["SK-N-SH cells", "CELL_LINE", 0, 13], ["HA", "PROTEIN", 36, 38], ["TIA-1-PRD", "DNA", 65, 74], ["SK", "TEST", 0, 2], ["SH cells", "PROBLEM", 5, 13], ["HA", "PROBLEM", 36, 38], ["tagged wild type TIA", "PROBLEM", 39, 59], ["TIA", "PROBLEM", 65, 68]]], ["Cells were fixed and incubated with an HA antibody to label the wild type or dominant negative TIA-1 proteins, and then processed for imaging.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["TIA-1", "GENE_OR_GENE_PRODUCT", 95, 100], ["HA antibody", "PROTEIN", 39, 50], ["dominant negative TIA-1 proteins", "PROTEIN", 77, 109], ["Cells", "TEST", 0, 5], ["an HA antibody", "TEST", 36, 50], ["imaging", "TEST", 134, 141]]], ["Wild type HA-tagged TIA-1 was localized in both the nucleus and the cytoplasm in mock-treated cells (Fig. 4A, top panels).", [["nucleus", "ANATOMY", 52, 59], ["cytoplasm", "ANATOMY", 68, 77], ["cells", "ANATOMY", 94, 99], ["TIA-1", "GENE_OR_GENE_PRODUCT", 20, 25], ["nucleus", "CELLULAR_COMPONENT", 52, 59], ["cytoplasm", "ORGANISM_SUBSTANCE", 68, 77], ["cells", "CELL", 94, 99], ["Wild type HA-tagged TIA-1", "PROTEIN", 0, 25], ["mock-treated cells", "CELL_LINE", 81, 99], ["Wild type HA", "PROBLEM", 0, 12], ["tagged TIA", "TEST", 13, 23], ["top panels", "TEST", 110, 120], ["nucleus", "ANATOMY", 52, 59]]], ["Upon arsenite treatment, the HA-TIA-1 formed cytoplasmic foci as expected (Fig. 4A, bottom panels).", [["cytoplasmic foci", "ANATOMY", 45, 61], ["arsenite", "CHEMICAL", 5, 13], ["arsenite", "CHEMICAL", 5, 13], ["arsenite", "SIMPLE_CHEMICAL", 5, 13], ["HA-TIA-1", "GENE_OR_GENE_PRODUCT", 29, 37], ["cytoplasmic", "ORGANISM_SUBSTANCE", 45, 56], ["TIA", "PROTEIN", 32, 35], ["arsenite treatment", "TREATMENT", 5, 23], ["the HA", "PROBLEM", 25, 31], ["TIA", "PROBLEM", 32, 35], ["1 formed cytoplasmic foci", "PROBLEM", 36, 61], ["cytoplasmic", "OBSERVATION_MODIFIER", 45, 56], ["foci", "OBSERVATION", 57, 61]]], ["Dominant negative HA-tagged TIA-1-PRD was localized predominantly in the cytoplasm of mock-treated cells and formed nonspecific aggregates, consistent with published data for this protein (Fig. 4B, top panels).", [["cytoplasm", "ANATOMY", 73, 82], ["cells", "ANATOMY", 99, 104], ["TIA-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["PRD", "GENE_OR_GENE_PRODUCT", 34, 37], ["cytoplasm", "ORGANISM_SUBSTANCE", 73, 82], ["cells", "CELL", 99, 104], ["Dominant negative HA-tagged TIA-1", "PROTEIN", 0, 33], ["PRD", "PROTEIN", 34, 37], ["mock-treated cells", "CELL_LINE", 86, 104], ["Fig. 4B", "PROTEIN", 189, 196], ["Dominant negative HA", "PROBLEM", 0, 20], ["tagged TIA", "PROBLEM", 21, 31], ["PRD", "PROBLEM", 34, 37], ["formed nonspecific aggregates", "PROBLEM", 109, 138], ["this protein", "TEST", 175, 187], ["top panels", "TEST", 198, 208], ["negative", "OBSERVATION_MODIFIER", 9, 17], ["HA", "OBSERVATION_MODIFIER", 18, 20], ["TIA", "OBSERVATION", 28, 31], ["predominantly", "OBSERVATION_MODIFIER", 52, 65], ["nonspecific", "OBSERVATION_MODIFIER", 116, 127], ["aggregates", "OBSERVATION", 128, 138]]], ["After arsenite treatment, HA-TIA-1-PRD was dispersed throughout the cytoplasm, and no authentic stress granule formation was observed (Fig. 4B, bottom panels).Expression of wild type or dominant negative TIA-1 does not dramatically stimulate or inhibit poliovirus translation ::: ResultsWe next determined the effect of expressing wild type or dominant negative TIA-1 (or vector alone) on poliovirus translation via [35S]-methionine-labeling of viral proteins during infection.", [["cytoplasm", "ANATOMY", 68, 77], ["stress granule", "ANATOMY", 96, 110], ["arsenite", "CHEMICAL", 6, 14], ["HA-TIA-1-PRD", "CHEMICAL", 26, 38], ["TIA", "DISEASE", 204, 207], ["[35S]-methionine", "CHEMICAL", 416, 432], ["infection", "DISEASE", 467, 476], ["arsenite", "CHEMICAL", 6, 14], ["[35S]-methionine", "CHEMICAL", 416, 432], ["arsenite", "SIMPLE_CHEMICAL", 6, 14], ["HA-TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 26, 38], ["cytoplasm", "ORGANISM_SUBSTANCE", 68, 77], ["stress granule", "CELLULAR_COMPONENT", 96, 110], ["TIA-1", "GENE_OR_GENE_PRODUCT", 204, 209], ["TIA-1", "GENE_OR_GENE_PRODUCT", 362, 367], ["poliovirus", "ORGANISM", 389, 399], ["[35S]-methionine", "SIMPLE_CHEMICAL", 416, 432], ["PRD", "PROTEIN", 35, 38], ["dominant negative TIA-1", "DNA", 186, 209], ["dominant negative TIA-1", "DNA", 344, 367], ["viral proteins", "PROTEIN", 445, 459], ["poliovirus", "SPECIES", 253, 263], ["poliovirus", "SPECIES", 389, 399], ["arsenite treatment", "TREATMENT", 6, 24], ["HA", "PROBLEM", 26, 28], ["TIA", "PROBLEM", 29, 32], ["PRD", "PROBLEM", 35, 38], ["authentic stress granule formation", "PROBLEM", 86, 120], ["bottom panels", "TEST", 144, 157], ["dominant negative TIA", "PROBLEM", 186, 207], ["dominant negative TIA", "PROBLEM", 344, 365], ["poliovirus translation", "TREATMENT", 389, 411], ["methionine", "TREATMENT", 422, 432], ["viral proteins during infection", "PROBLEM", 445, 476], ["no", "UNCERTAINTY", 83, 85], ["stress granule formation", "OBSERVATION", 96, 120], ["viral proteins", "OBSERVATION", 445, 459], ["infection", "OBSERVATION", 467, 476]]], ["These experiments were carried out in COS cells, a cell line permissive for poliovirus infection with virus growth kinetics similar to HeLa cells, often utilized due to high efficiency uptake and replication of plasmid DNA following transfection (Gluzman, 1981, Mellon et al., 1981).", [["COS cells", "ANATOMY", 38, 47], ["cell line", "ANATOMY", 51, 60], ["HeLa cells", "ANATOMY", 135, 145], ["plasmid", "ANATOMY", 211, 218], ["poliovirus infection", "DISEASE", 76, 96], ["COS cells", "CELL", 38, 47], ["cell line", "CELL", 51, 60], ["poliovirus", "ORGANISM", 76, 86], ["HeLa cells", "CELL", 135, 145], ["DNA", "CELLULAR_COMPONENT", 219, 222], ["COS cells", "CELL_LINE", 38, 47], ["cell line", "CELL_LINE", 51, 60], ["HeLa cells", "CELL_LINE", 135, 145], ["plasmid DNA", "DNA", 211, 222], ["poliovirus", "SPECIES", 76, 86], ["These experiments", "TEST", 0, 17], ["a cell line", "TREATMENT", 49, 60], ["poliovirus infection", "PROBLEM", 76, 96], ["virus growth kinetics", "PROBLEM", 102, 123], ["HeLa cells", "PROBLEM", 135, 145], ["high efficiency uptake", "PROBLEM", 169, 191], ["plasmid DNA", "PROBLEM", 211, 222], ["cell line", "OBSERVATION", 51, 60], ["poliovirus infection", "OBSERVATION", 76, 96], ["HeLa cells", "OBSERVATION", 135, 145], ["plasmid DNA", "OBSERVATION", 211, 222]]], ["In addition, previously published work has demonstrated the induction of stress granules in COS cells during poliovirus infection, as well as the disruption of stress granules during infection with expression of TIA-1-PRD in this cell type (Piotrowska et al., 2010).", [["stress granules", "ANATOMY", 73, 88], ["COS cells", "ANATOMY", 92, 101], ["stress granules", "ANATOMY", 160, 175], ["cell", "ANATOMY", 230, 234], ["poliovirus infection", "DISEASE", 109, 129], ["infection", "DISEASE", 183, 192], ["stress granules", "CELLULAR_COMPONENT", 73, 88], ["COS cells", "CELL", 92, 101], ["poliovirus", "ORGANISM", 109, 119], ["stress granules", "CELLULAR_COMPONENT", 160, 175], ["TIA-1", "GENE_OR_GENE_PRODUCT", 212, 217], ["PRD", "GENE_OR_GENE_PRODUCT", 218, 221], ["cell type", "CELL", 230, 239], ["COS cells", "CELL_LINE", 92, 101], ["TIA", "PROTEIN", 212, 215], ["PRD", "PROTEIN", 218, 221], ["poliovirus", "SPECIES", 109, 119], ["stress granules in COS cells", "PROBLEM", 73, 101], ["poliovirus infection", "PROBLEM", 109, 129], ["stress granules during infection", "PROBLEM", 160, 192], ["TIA", "PROBLEM", 212, 215], ["COS cells", "OBSERVATION", 92, 101], ["poliovirus infection", "OBSERVATION", 109, 129], ["stress granules", "OBSERVATION", 160, 175], ["infection", "OBSERVATION", 183, 192]]], ["We transfected COS cells with HA-TIA-1 or HA-TIA-1-PRD (or empty vector), and then mock-infected cells or infected cells with poliovirus at an MOI of 25 in methionine-free media.", [["COS cells", "ANATOMY", 15, 24], ["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 115, 120], ["HA-TIA-1-PRD", "CHEMICAL", 42, 54], ["methionine", "CHEMICAL", 156, 166], ["methionine", "CHEMICAL", 156, 166], ["COS cells", "CELL", 15, 24], ["HA-TIA-1", "GENE_OR_GENE_PRODUCT", 30, 38], ["HA-TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 42, 54], ["cells", "CELL", 97, 102], ["cells", "CELL", 115, 120], ["poliovirus", "ORGANISM", 126, 136], ["methionine", "SIMPLE_CHEMICAL", 156, 166], ["COS cells", "CELL_LINE", 15, 24], ["HA-TIA-1-PRD", "DNA", 42, 54], ["mock-infected cells", "CELL_TYPE", 83, 102], ["infected cells", "CELL_TYPE", 106, 120], ["HA", "PROBLEM", 30, 32], ["TIA", "PROBLEM", 33, 36], ["HA", "PROBLEM", 42, 44], ["TIA", "PROBLEM", 45, 48], ["PRD", "PROBLEM", 51, 54], ["infected cells", "PROBLEM", 88, 102], ["infected cells", "PROBLEM", 106, 120], ["poliovirus", "PROBLEM", 126, 136], ["methionine-free media", "TREATMENT", 156, 177], ["COS cells", "OBSERVATION", 15, 24], ["infected cells", "OBSERVATION", 88, 102], ["infected cells", "OBSERVATION", 106, 120]]], ["After 2 h of methionine starvation, [35S]-methionine was added to radiolabel the viral proteins produced.", [["methionine", "CHEMICAL", 13, 23], ["[35S]-methionine", "CHEMICAL", 36, 52], ["methionine", "CHEMICAL", 13, 23], ["[35S]-methionine", "CHEMICAL", 36, 52], ["methionine", "SIMPLE_CHEMICAL", 13, 23], ["[35S]-methionine", "SIMPLE_CHEMICAL", 36, 52], ["viral proteins", "PROTEIN", 81, 95], ["methionine starvation", "TREATMENT", 13, 34], ["methionine", "TREATMENT", 42, 52], ["radiolabel the viral proteins", "TEST", 66, 95], ["viral proteins", "OBSERVATION", 81, 95]]], ["Infections were carried out for 8 h total, and every 2 h cells were harvested and lysed.", [["cells", "ANATOMY", 57, 62], ["cells", "CELL", 57, 62], ["Infections", "PROBLEM", 0, 10]]], ["Equal volumes of lysates were subjected to SDS-PAGE, and labeled proteins were analyzed via autoradiography.", [["lysates", "ANATOMY", 17, 24], ["lysates", "ORGANISM_SUBSTANCE", 17, 24], ["lysates", "PROBLEM", 17, 24], ["SDS", "TEST", 43, 46], ["labeled proteins", "TEST", 57, 73], ["autoradiography", "TEST", 92, 107]]], ["Of note, the expression vectors utilized in these experiments allowed for continual production of their encoded products (indicated by the asterisks) during the course of poliovirus infection.", [["poliovirus infection", "DISEASE", 171, 191], ["poliovirus", "ORGANISM", 171, 181], ["expression vectors", "DNA", 13, 31], ["poliovirus", "SPECIES", 171, 181], ["the expression vectors", "TREATMENT", 9, 31], ["poliovirus infection", "PROBLEM", 171, 191], ["infection", "OBSERVATION", 182, 191]]], ["Compared to empty vector (Fig. 5A, lanes 2\u20137), expression of wild type TIA-1 appeared to just slightly decrease the levels of viral proteins produced (lanes 8\u201313), although it did not dramatically inhibit viral translation.", [["TIA-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["wild type TIA-1", "PROTEIN", 61, 76], ["viral proteins", "PROTEIN", 126, 140], ["wild type TIA", "PROBLEM", 61, 74], ["viral proteins", "PROBLEM", 126, 140], ["viral proteins", "OBSERVATION", 126, 140]]], ["Expression of the dominant negative TIA-1-PRD appeared to have only a slight stimulatory effect on viral translation (Fig. 5B, lanes 8\u201313) compared to empty vector (lanes 2\u20137).", [["TIA-1", "GENE_OR_GENE_PRODUCT", 36, 41], ["PRD", "GENE_OR_GENE_PRODUCT", 42, 45], ["dominant negative TIA-1", "DNA", 18, 41], ["PRD", "PROTEIN", 42, 45], ["the dominant negative TIA", "PROBLEM", 14, 39], ["a slight stimulatory effect", "PROBLEM", 68, 95], ["dominant", "OBSERVATION_MODIFIER", 18, 26], ["negative", "OBSERVATION_MODIFIER", 27, 35], ["TIA", "OBSERVATION", 36, 39], ["slight", "OBSERVATION_MODIFIER", 70, 76], ["stimulatory effect", "OBSERVATION", 77, 95]]], ["Thus, in the transfection/infection assays described here, neither wild type TIA-1 nor dominant negative TIA-1-PRD expression resulted in a dramatic difference in poliovirus translation.DiscussionCertain conditions within cells can generate dramatic alterations in the intracellular environment.", [["cells", "ANATOMY", 222, 227], ["intracellular", "ANATOMY", 269, 282], ["infection", "DISEASE", 26, 35], ["TIA", "DISEASE", 77, 80], ["TIA-1", "GENE_OR_GENE_PRODUCT", 77, 82], ["TIA-1", "GENE_OR_GENE_PRODUCT", 105, 110], ["PRD", "GENE_OR_GENE_PRODUCT", 111, 114], ["cells", "CELL", 222, 227], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 269, 282], ["TIA", "PROTEIN", 105, 108], ["PRD", "PROTEIN", 111, 114], ["poliovirus", "SPECIES", 163, 173], ["the transfection/infection assays", "PROBLEM", 9, 42], ["dominant negative TIA", "PROBLEM", 87, 108], ["a dramatic difference in poliovirus translation", "PROBLEM", 138, 185], ["dramatic alterations", "PROBLEM", 241, 261], ["infection", "OBSERVATION", 26, 35], ["dramatic", "OBSERVATION_MODIFIER", 140, 148], ["poliovirus translation", "OBSERVATION", 163, 185], ["intracellular environment", "OBSERVATION", 269, 294]]], ["Beyond the changes that occur during development and cell cycling, conditions of cellular stress can affect the translation of mRNAs.", [["cell", "ANATOMY", 53, 57], ["cellular", "ANATOMY", 81, 89], ["cell", "CELL", 53, 57], ["cellular", "CELL", 81, 89], ["mRNAs", "RNA", 127, 132], ["cell cycling", "PROBLEM", 53, 65], ["cellular stress", "PROBLEM", 81, 96], ["cellular stress", "OBSERVATION", 81, 96]]], ["Many RNAs are translationally silenced and/or degraded during stress conditions, while others are up-regulated in response to stress.", [["RNAs", "RNA", 5, 9], ["Many RNAs", "PROBLEM", 0, 9], ["stress conditions", "PROBLEM", 62, 79], ["stress", "PROBLEM", 126, 132]]], ["Some of these conditions include hypoxia, oxidative stress, heat shock, as well as virus infection.", [["hypoxia", "DISEASE", 33, 40], ["heat shock", "DISEASE", 60, 70], ["infection", "DISEASE", 89, 98], ["hypoxia", "PROBLEM", 33, 40], ["oxidative stress", "PROBLEM", 42, 58], ["heat shock", "PROBLEM", 60, 70], ["virus infection", "PROBLEM", 83, 98], ["hypoxia", "OBSERVATION", 33, 40], ["oxidative stress", "OBSERVATION", 42, 58], ["shock", "OBSERVATION", 65, 70]]], ["Cellular stressors can induce the formation of cytoplasmic stress granules, which are foci considered to be a temporary holding place for mRNAs that are not being actively translated, but are not targeted for degradation.", [["Cellular", "ANATOMY", 0, 8], ["cytoplasmic stress granules", "ANATOMY", 47, 74], ["cytoplasmic", "ORGANISM_SUBSTANCE", 47, 58], ["stress granules", "CELLULAR_COMPONENT", 59, 74], ["mRNAs", "RNA", 138, 143], ["Cellular stressors", "PROBLEM", 0, 18], ["cytoplasmic stress granules", "PROBLEM", 47, 74], ["foci", "PROBLEM", 86, 90], ["mRNAs", "PROBLEM", 138, 143], ["cytoplasmic stress granules", "OBSERVATION", 47, 74]]], ["These foci contain the specific proteins required for their formation, stalled translation complexes, and mRNPs.", [["foci", "ANATOMY", 6, 10], ["mRNPs", "ANATOMY", 106, 111], ["mRNPs", "CELLULAR_COMPONENT", 106, 111], ["stalled translation complexes", "PROTEIN", 71, 100], ["mRNPs", "PROTEIN", 106, 111], ["These foci", "PROBLEM", 0, 10], ["the specific proteins", "PROBLEM", 19, 40], ["stalled translation complexes", "PROBLEM", 71, 100], ["foci", "OBSERVATION", 6, 10]]], ["Recent studies have identified unique stress granules that form during poliovirus infection (Piotrowska et al., 2010, White et al., 2007, White and Lloyd, 2011).", [["stress granules", "ANATOMY", 38, 53], ["poliovirus infection", "DISEASE", 71, 91], ["stress granules", "CELLULAR_COMPONENT", 38, 53], ["poliovirus", "SPECIES", 71, 81], ["Recent studies", "TEST", 0, 14], ["unique stress granules", "PROBLEM", 31, 53], ["poliovirus infection", "PROBLEM", 71, 91], ["stress granules", "OBSERVATION", 38, 53]]], ["It has been shown that stress granules formed early in infection contain some proteins and mRNAs that are common to stress granules that form during other conditions of stress.", [["stress granules", "ANATOMY", 23, 38], ["stress granules", "ANATOMY", 116, 131], ["infection", "DISEASE", 55, 64], ["stress granules", "CELLULAR_COMPONENT", 23, 38], ["stress granules", "CELLULAR_COMPONENT", 116, 131], ["mRNAs", "RNA", 91, 96], ["stress granules", "PROBLEM", 23, 38], ["infection", "PROBLEM", 55, 64], ["some proteins and mRNAs", "PROBLEM", 73, 96], ["stress granules", "PROBLEM", 116, 131], ["stress", "PROBLEM", 169, 175], ["stress", "OBSERVATION_MODIFIER", 23, 29], ["granules", "OBSERVATION_MODIFIER", 30, 38], ["formed", "OBSERVATION_MODIFIER", 39, 45], ["early", "OBSERVATION_MODIFIER", 46, 51], ["infection", "OBSERVATION", 55, 64], ["some proteins", "OBSERVATION_MODIFIER", 73, 86]]], ["While the foci persist throughout infection, the stress granules found later in infection appear compositionally distinct, although they consistently contain the RNA binding protein TIA-1 (Piotrowska et al., 2010, White and Lloyd, 2011).", [["foci", "ANATOMY", 10, 14], ["stress granules", "ANATOMY", 49, 64], ["infection", "DISEASE", 34, 43], ["infection", "DISEASE", 80, 89], ["stress granules", "CELLULAR_COMPONENT", 49, 64], ["TIA-1", "GENE_OR_GENE_PRODUCT", 182, 187], ["RNA binding protein", "PROTEIN", 162, 181], ["TIA", "PROTEIN", 182, 185], ["the foci", "PROBLEM", 6, 14], ["infection", "PROBLEM", 34, 43], ["the stress granules", "PROBLEM", 45, 64], ["infection", "PROBLEM", 80, 89], ["the RNA binding protein TIA", "TEST", 158, 185], ["foci", "OBSERVATION", 10, 14], ["infection", "OBSERVATION", 34, 43], ["stress granules", "OBSERVATION", 49, 64], ["infection", "OBSERVATION", 80, 89], ["compositionally distinct", "OBSERVATION_MODIFIER", 97, 121]]], ["For this reason, TIA-1 is an appropriate marker protein to identify the stress granules that form under many conditions of stress, including poliovirus infection.DiscussionDuring our initial studies of the re-localization of SRp20 during poliovirus infection, we observed a punctate pattern of localization for this protein in the cytoplasm of cells beginning around 3 h post-infection.", [["stress granules", "ANATOMY", 72, 87], ["cytoplasm", "ANATOMY", 331, 340], ["cells", "ANATOMY", 344, 349], ["TIA", "DISEASE", 17, 20], ["poliovirus infection", "DISEASE", 141, 161], ["poliovirus infection", "DISEASE", 238, 258], ["TIA-1", "GENE_OR_GENE_PRODUCT", 17, 22], ["stress granules", "CELLULAR_COMPONENT", 72, 87], ["SRp20", "GENE_OR_GENE_PRODUCT", 225, 230], ["poliovirus", "ORGANISM", 238, 248], ["cytoplasm", "ORGANISM_SUBSTANCE", 331, 340], ["cells", "CELL", 344, 349], ["TIA", "PROTEIN", 17, 20], ["SRp20", "PROTEIN", 225, 230], ["poliovirus", "SPECIES", 141, 151], ["poliovirus", "SPECIES", 238, 248], ["TIA", "PROBLEM", 17, 20], ["the stress granules", "PROBLEM", 68, 87], ["stress", "PROBLEM", 123, 129], ["poliovirus infection", "PROBLEM", 141, 161], ["poliovirus infection", "PROBLEM", 238, 258], ["this protein in the cytoplasm of cells", "PROBLEM", 311, 349], ["stress granules", "OBSERVATION", 72, 87], ["poliovirus infection", "OBSERVATION", 141, 161], ["punctate", "OBSERVATION_MODIFIER", 274, 282]]], ["We considered the possibility that this signal represented the presence of SRp20 in poliovirus-induced stress granules and investigated whether SRp20 co-localized with TIA-1, a protein that appears to be required for stress granule assembly.", [["stress granules", "ANATOMY", 103, 118], ["stress granule", "ANATOMY", 217, 231], ["SRp20", "GENE_OR_GENE_PRODUCT", 75, 80], ["poliovirus", "ORGANISM", 84, 94], ["stress granules", "CELLULAR_COMPONENT", 103, 118], ["SRp20", "GENE_OR_GENE_PRODUCT", 144, 149], ["TIA-1", "GENE_OR_GENE_PRODUCT", 168, 173], ["stress granule", "CELLULAR_COMPONENT", 217, 231], ["SRp20", "PROTEIN", 75, 80], ["SRp20", "PROTEIN", 144, 149], ["TIA-1", "PROTEIN", 168, 173], ["SRp20", "PROBLEM", 75, 80], ["poliovirus", "PROBLEM", 84, 94], ["stress granules", "PROBLEM", 103, 118], ["TIA", "TEST", 168, 171], ["a protein", "TEST", 175, 184], ["stress granule assembly", "PROBLEM", 217, 240], ["considered the possibility", "UNCERTAINTY", 3, 29], ["stress granules", "OBSERVATION", 103, 118]]], ["We determined that SRp20 co-localized with TIA-1 in some, but not all, TIA-1 positive foci at 3 h post-infection.", [["foci", "ANATOMY", 86, 90], ["TIA", "DISEASE", 71, 74], ["SRp20", "GENE_OR_GENE_PRODUCT", 19, 24], ["TIA-1", "GENE_OR_GENE_PRODUCT", 43, 48], ["TIA-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["SRp20", "PROTEIN", 19, 24], ["TIA-1", "DNA", 43, 48], ["TIA", "PROBLEM", 43, 46], ["TIA", "TEST", 71, 74], ["1 positive foci", "PROBLEM", 75, 90], ["foci", "OBSERVATION", 86, 90]]], ["The partial co-localization with TIA-1 suggests that SRp20 is found in some of the unique stress granules that form during poliovirus infection.", [["stress granules", "ANATOMY", 90, 105], ["poliovirus infection", "DISEASE", 123, 143], ["TIA-1", "GENE_OR_GENE_PRODUCT", 33, 38], ["SRp20", "GENE_OR_GENE_PRODUCT", 53, 58], ["stress granules", "CELLULAR_COMPONENT", 90, 105], ["TIA", "PROTEIN", 33, 36], ["SRp20", "PROTEIN", 53, 58], ["poliovirus", "SPECIES", 123, 133], ["TIA", "PROBLEM", 33, 36], ["the unique stress granules", "PROBLEM", 79, 105], ["poliovirus infection", "PROBLEM", 123, 143], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["co-localization", "OBSERVATION", 12, 27], ["stress granules", "OBSERVATION", 90, 105], ["poliovirus infection", "OBSERVATION", 123, 143]]], ["It is not clear why SRp20 is only localized to a subset of TIA-1-containing stress granules, and this would suggest that even the unique virally induced granules that form are not all compositionally uniform.", [["stress granules", "ANATOMY", 76, 91], ["granules", "ANATOMY", 153, 161], ["TIA", "DISEASE", 59, 62], ["SRp20", "GENE_OR_GENE_PRODUCT", 20, 25], ["TIA-1", "GENE_OR_GENE_PRODUCT", 59, 64], ["stress granules", "CELLULAR_COMPONENT", 76, 91], ["granules", "CELLULAR_COMPONENT", 153, 161], ["SRp20", "PROTEIN", 20, 25], ["TIA-1", "PROTEIN", 59, 64], ["TIA", "PROBLEM", 59, 62], ["stress granules", "PROBLEM", 76, 91], ["the unique virally induced granules", "PROBLEM", 126, 161], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["stress granules", "OBSERVATION", 76, 91]]], ["Indeed, stress granules in general are considered to be transient, dynamic accumulations of different proteins and mRNAs.", [["stress granules", "ANATOMY", 8, 23], ["stress granules", "CELLULAR_COMPONENT", 8, 23], ["mRNAs", "RNA", 115, 120], ["stress granules", "PROBLEM", 8, 23], ["dynamic accumulations of different proteins", "PROBLEM", 67, 110], ["stress granules", "OBSERVATION", 8, 23], ["transient", "OBSERVATION_MODIFIER", 56, 65], ["different proteins", "OBSERVATION", 92, 110]]], ["The SRp20-containing granules may represent accumulations of proteins that function in a manner that is distinct from the foci that do not contain SRp20.", [["granules", "ANATOMY", 21, 29], ["foci", "ANATOMY", 122, 126], ["SRp20", "GENE_OR_GENE_PRODUCT", 4, 9], ["granules", "ORGANISM_SUBSTANCE", 21, 29], ["SRp20", "PROTEIN", 4, 9], ["The SRp20", "TREATMENT", 0, 9], ["accumulations of proteins", "PROBLEM", 44, 69], ["may represent", "UNCERTAINTY", 30, 43], ["accumulations of proteins", "OBSERVATION", 44, 69], ["distinct", "OBSERVATION_MODIFIER", 104, 112], ["foci", "OBSERVATION", 122, 126]]], ["Additional studies are necessary to investigate other proteins that co-localize with SRp20 and TIA-1 within these cytoplasmic foci during infection and to examine whether viral proteins and viral RNA are present in these foci.DiscussionIf SRp20 localizes to stress granules during poliovirus infection, we hypothesized that this localization may be a general response to cellular stress.", [["cytoplasmic foci", "ANATOMY", 114, 130], ["foci", "ANATOMY", 221, 225], ["stress granules", "ANATOMY", 258, 273], ["cellular", "ANATOMY", 371, 379], ["infection", "DISEASE", 138, 147], ["poliovirus infection", "DISEASE", 281, 301], ["SRp20", "GENE_OR_GENE_PRODUCT", 85, 90], ["TIA-1", "GENE_OR_GENE_PRODUCT", 95, 100], ["cytoplasmic", "ORGANISM_SUBSTANCE", 114, 125], ["SRp20", "GENE_OR_GENE_PRODUCT", 239, 244], ["stress granules", "CELLULAR_COMPONENT", 258, 273], ["cellular", "CELL", 371, 379], ["SRp20", "PROTEIN", 85, 90], ["TIA-1", "PROTEIN", 95, 100], ["viral proteins", "PROTEIN", 171, 185], ["viral RNA", "RNA", 190, 199], ["SRp20", "PROTEIN", 239, 244], ["poliovirus", "SPECIES", 281, 291], ["Additional studies", "TEST", 0, 18], ["other proteins", "PROBLEM", 48, 62], ["SRp20", "TEST", 85, 90], ["TIA", "PROBLEM", 95, 98], ["these cytoplasmic foci", "PROBLEM", 108, 130], ["infection", "PROBLEM", 138, 147], ["viral proteins", "PROBLEM", 171, 185], ["viral RNA", "PROBLEM", 190, 199], ["stress granules", "PROBLEM", 258, 273], ["poliovirus infection", "PROBLEM", 281, 301], ["cellular stress", "PROBLEM", 371, 386], ["cytoplasmic", "OBSERVATION_MODIFIER", 114, 125], ["foci", "OBSERVATION", 126, 130], ["infection", "OBSERVATION", 138, 147], ["viral RNA", "OBSERVATION", 190, 199], ["foci", "OBSERVATION", 221, 225], ["poliovirus infection", "OBSERVATION", 281, 301], ["cellular stress", "OBSERVATION", 371, 386]]], ["We investigated whether SRp20 co-localized with TIA-1 during other conditions of stress, by examining the stress granules that form in cells during oxidative stress (i.e., following arsenite treatment).", [["stress granules", "ANATOMY", 106, 121], ["cells", "ANATOMY", 135, 140], ["TIA", "DISEASE", 48, 51], ["arsenite", "CHEMICAL", 182, 190], ["arsenite", "CHEMICAL", 182, 190], ["SRp20", "GENE_OR_GENE_PRODUCT", 24, 29], ["TIA-1", "GENE_OR_GENE_PRODUCT", 48, 53], ["stress granules", "CELLULAR_COMPONENT", 106, 121], ["cells", "CELL", 135, 140], ["arsenite", "SIMPLE_CHEMICAL", 182, 190], ["SRp20", "PROTEIN", 24, 29], ["TIA-1", "PROTEIN", 48, 53], ["TIA", "PROBLEM", 48, 51], ["stress", "PROBLEM", 81, 87], ["the stress granules", "PROBLEM", 102, 121], ["oxidative stress", "PROBLEM", 148, 164], ["arsenite treatment", "TREATMENT", 182, 200]]], ["We found that SRp20 did not co-localize with TIA-1 in any of the stress granules induced upon arsenite treatment.", [["stress granules", "ANATOMY", 65, 80], ["arsenite", "CHEMICAL", 94, 102], ["arsenite", "CHEMICAL", 94, 102], ["SRp20", "GENE_OR_GENE_PRODUCT", 14, 19], ["TIA-1", "GENE_OR_GENE_PRODUCT", 45, 50], ["granules", "ORGANISM_SUBSTANCE", 72, 80], ["arsenite", "SIMPLE_CHEMICAL", 94, 102], ["SRp20", "PROTEIN", 14, 19], ["TIA-1", "PROTEIN", 45, 50], ["TIA", "PROBLEM", 45, 48], ["the stress granules", "PROBLEM", 61, 80], ["arsenite treatment", "TREATMENT", 94, 112]]], ["We interpret these results to suggest that stress alone is not sufficient to cause the co-localization of TIA-1 and SRp20.", [["TIA", "DISEASE", 106, 109], ["TIA-1", "GENE_OR_GENE_PRODUCT", 106, 111], ["SRp20", "GENE_OR_GENE_PRODUCT", 116, 121], ["TIA", "PROTEIN", 106, 109], ["SRp20", "PROTEIN", 116, 121], ["TIA", "TEST", 106, 109], ["TIA", "OBSERVATION", 106, 109]]], ["It is becoming increasingly apparent that different stress conditions direct the assembly of foci that are inherently different and partially dependent on the specific stress that is applied.", [["foci", "ANATOMY", 93, 97], ["different stress conditions", "PROBLEM", 42, 69], ["foci", "PROBLEM", 93, 97], ["stress conditions", "OBSERVATION", 52, 69], ["foci", "OBSERVATION", 93, 97], ["inherently different", "OBSERVATION_MODIFIER", 107, 127], ["partially", "OBSERVATION_MODIFIER", 132, 141], ["dependent", "OBSERVATION_MODIFIER", 142, 151]]], ["Indeed, poliovirus infection provides another example for differences that exist in stress granule composition.", [["stress granule", "ANATOMY", 84, 98], ["poliovirus infection", "DISEASE", 8, 28], ["stress granule", "CELLULAR_COMPONENT", 84, 98], ["poliovirus", "SPECIES", 8, 18], ["poliovirus infection", "PROBLEM", 8, 28], ["stress granule composition", "PROBLEM", 84, 110], ["poliovirus infection", "OBSERVATION", 8, 28], ["stress granule composition", "OBSERVATION", 84, 110]]], ["G3BP (Ras-GAP SH3 domain binding protein) is cleaved by the viral proteinase 3C during infection, and no longer localizes to stress granules; however, TIA-1-containing stress granules still persist during poliovirus infection (Piotrowska et al., 2010, White et al., 2007, White and Lloyd, 2011).", [["stress granules", "ANATOMY", 125, 140], ["stress granules", "ANATOMY", 168, 183], ["infection", "DISEASE", 87, 96], ["TIA", "DISEASE", 151, 154], ["poliovirus infection", "DISEASE", 205, 225], ["G3BP", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ras-GAP SH3 domain binding protein", "GENE_OR_GENE_PRODUCT", 6, 40], ["viral proteinase 3C", "GENE_OR_GENE_PRODUCT", 60, 79], ["stress granules", "CELLULAR_COMPONENT", 125, 140], ["TIA-1", "GENE_OR_GENE_PRODUCT", 151, 156], ["stress granules", "CELLULAR_COMPONENT", 168, 183], ["G3BP", "PROTEIN", 0, 4], ["Ras-GAP SH3 domain binding protein", "PROTEIN", 6, 40], ["viral proteinase 3C", "PROTEIN", 60, 79], ["poliovirus", "SPECIES", 205, 215], ["G3BP", "TEST", 0, 4], ["Ras-GAP SH3 domain binding protein)", "PROBLEM", 6, 41], ["the viral proteinase 3C", "PROBLEM", 56, 79], ["infection", "PROBLEM", 87, 96], ["stress granules", "PROBLEM", 125, 140], ["TIA", "TEST", 151, 154], ["stress granules", "PROBLEM", 168, 183], ["poliovirus infection", "PROBLEM", 205, 225], ["infection", "OBSERVATION", 87, 96], ["no longer", "UNCERTAINTY", 102, 111], ["poliovirus infection", "OBSERVATION", 205, 225]]], ["G3BP is thought to be required for stress granule assembly and is consistently localized to stress granules formed under other conditions of stress.", [["stress granule", "ANATOMY", 35, 49], ["stress granules", "ANATOMY", 92, 107], ["G3BP", "GENE_OR_GENE_PRODUCT", 0, 4], ["stress granule", "CELLULAR_COMPONENT", 35, 49], ["stress granules", "CELLULAR_COMPONENT", 92, 107], ["G3BP", "PROTEIN", 0, 4], ["stress granule assembly", "PROBLEM", 35, 58], ["stress granules", "PROBLEM", 92, 107], ["stress", "PROBLEM", 141, 147], ["thought to be", "UNCERTAINTY", 8, 21], ["stress granules", "OBSERVATION", 92, 107]]], ["We also take into account that poliovirus infection directs the nucleo-cytoplasmic redistribution of some nuclear proteins, including SRp20 (Belov et al., 2004, Fitzgerald et al., 2013, Fitzgerald and Semler, 2011, Gustin and Sarnow, 2001).", [["cytoplasmic", "ANATOMY", 71, 82], ["nuclear", "ANATOMY", 106, 113], ["poliovirus infection", "DISEASE", 31, 51], ["poliovirus", "ORGANISM", 31, 41], ["cytoplasmic", "ORGANISM_SUBSTANCE", 71, 82], ["nuclear", "CELLULAR_COMPONENT", 106, 113], ["SRp20", "GENE_OR_GENE_PRODUCT", 134, 139], ["nuclear proteins", "PROTEIN", 106, 122], ["SRp20", "PROTEIN", 134, 139], ["poliovirus", "SPECIES", 31, 41], ["poliovirus infection", "PROBLEM", 31, 51], ["some nuclear proteins", "PROBLEM", 101, 122], ["poliovirus", "OBSERVATION_MODIFIER", 31, 41], ["infection", "OBSERVATION", 42, 51], ["cytoplasmic redistribution", "OBSERVATION", 71, 97], ["some", "OBSERVATION_MODIFIER", 101, 105], ["nuclear proteins", "OBSERVATION", 106, 122]]], ["Arsenite stress alone did not induce any significant re-localization of SRp20 to the cytoplasm of stressed cells, and this may contribute to the lack of SRp20 stress granule localization.", [["cytoplasm", "ANATOMY", 85, 94], ["cells", "ANATOMY", 107, 112], ["granule", "ANATOMY", 166, 173], ["Arsenite", "CHEMICAL", 0, 8], ["Arsenite", "CHEMICAL", 0, 8], ["Arsenite", "SIMPLE_CHEMICAL", 0, 8], ["SRp20", "GENE_OR_GENE_PRODUCT", 72, 77], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["cells", "CELL", 107, 112], ["SRp20", "GENE_OR_GENE_PRODUCT", 153, 158], ["granule", "CELLULAR_COMPONENT", 166, 173], ["SRp20", "PROTEIN", 72, 77], ["stressed cells", "CELL_TYPE", 98, 112], ["SRp20", "PROTEIN", 153, 158], ["Arsenite stress", "PROBLEM", 0, 15], ["stressed cells", "PROBLEM", 98, 112], ["SRp20 stress granule localization", "PROBLEM", 153, 186], ["stressed cells", "OBSERVATION", 98, 112]]], ["Although some portion of cellular SRp20 shuttles continuously between the nucleus and the cytoplasm (Caceres et al., 1998), stress granule association (or potentially the visualization of this association) may require a greater abundance of cytoplasmic SRp20.", [["cellular", "ANATOMY", 25, 33], ["nucleus", "ANATOMY", 74, 81], ["cytoplasm", "ANATOMY", 90, 99], ["stress granule", "ANATOMY", 124, 138], ["cytoplasmic", "ANATOMY", 241, 252], ["cellular", "CELL", 25, 33], ["SRp20", "GENE_OR_GENE_PRODUCT", 34, 39], ["nucleus", "CELLULAR_COMPONENT", 74, 81], ["cytoplasm", "ORGANISM_SUBSTANCE", 90, 99], ["stress granule", "CELLULAR_COMPONENT", 124, 138], ["cytoplasmic", "ORGANISM_SUBSTANCE", 241, 252], ["SRp20", "GENE_OR_GENE_PRODUCT", 253, 258], ["SRp20", "PROTEIN", 34, 39], ["cytoplasmic SRp20", "PROTEIN", 241, 258], ["stress granule association", "PROBLEM", 124, 150], ["cellular SRp20", "OBSERVATION", 25, 39], ["nucleus", "ANATOMY", 74, 81], ["cytoplasm", "OBSERVATION_MODIFIER", 90, 99]]], ["It is not clear whether cytoplasmic accumulation of SRp20 is required for its partial co-localization with TIA-1.", [["cytoplasmic", "ANATOMY", 24, 35], ["cytoplasmic", "ORGANISM_SUBSTANCE", 24, 35], ["SRp20", "GENE_OR_GENE_PRODUCT", 52, 57], ["TIA-1", "GENE_OR_GENE_PRODUCT", 107, 112], ["SRp20", "PROTEIN", 52, 57], ["TIA-1", "PROTEIN", 107, 112], ["cytoplasmic accumulation of SRp20", "PROBLEM", 24, 57], ["TIA", "PROBLEM", 107, 110], ["cytoplasmic", "OBSERVATION_MODIFIER", 24, 35], ["accumulation", "OBSERVATION", 36, 48]]], ["However, our confocal images do not show extensive co-localization of SRp20 and TIA-1 in the nuclei of uninfected or arsenite-treated cells (refer to Fig. 3).DiscussionA key unanswered question is whether stress granule formation is actively directed by poliovirus infection, or if the foci formation is a cellular response to the virus infection.", [["nuclei", "ANATOMY", 93, 99], ["cells", "ANATOMY", 134, 139], ["stress granule", "ANATOMY", 205, 219], ["foci", "ANATOMY", 286, 290], ["cellular", "ANATOMY", 306, 314], ["arsenite", "CHEMICAL", 117, 125], ["poliovirus infection", "DISEASE", 254, 274], ["infection", "DISEASE", 337, 346], ["arsenite", "CHEMICAL", 117, 125], ["SRp20", "GENE_OR_GENE_PRODUCT", 70, 75], ["TIA-1", "GENE_OR_GENE_PRODUCT", 80, 85], ["nuclei", "CELLULAR_COMPONENT", 93, 99], ["arsenite", "SIMPLE_CHEMICAL", 117, 125], ["cells", "CELL", 134, 139], ["stress granule", "CELLULAR_COMPONENT", 205, 219], ["cellular", "CELL", 306, 314], ["SRp20", "PROTEIN", 70, 75], ["TIA-1", "PROTEIN", 80, 85], ["arsenite-treated cells", "CELL_LINE", 117, 139], ["poliovirus", "SPECIES", 254, 264], ["our confocal images", "TEST", 9, 28], ["SRp20", "TEST", 70, 75], ["TIA", "PROBLEM", 80, 83], ["stress granule formation", "PROBLEM", 205, 229], ["poliovirus infection", "PROBLEM", 254, 274], ["the foci formation", "PROBLEM", 282, 300], ["the virus infection", "PROBLEM", 327, 346], ["nuclei", "ANATOMY", 93, 99], ["uninfected", "OBSERVATION", 103, 113], ["infection", "OBSERVATION", 265, 274], ["foci", "OBSERVATION", 286, 290]]], ["For example, cells may respond to poliovirus infection by directing stress granule formation in an attempt to globally down-regulate translation.", [["cells", "ANATOMY", 13, 18], ["stress granule", "ANATOMY", 68, 82], ["infection", "DISEASE", 45, 54], ["cells", "CELL", 13, 18], ["poliovirus", "ORGANISM", 34, 44], ["stress granule", "CELLULAR_COMPONENT", 68, 82], ["poliovirus", "SPECIES", 34, 44], ["cells", "PROBLEM", 13, 18], ["poliovirus infection", "PROBLEM", 34, 54], ["stress granule formation", "PROBLEM", 68, 92], ["poliovirus infection", "OBSERVATION", 34, 54], ["stress granule formation", "OBSERVATION", 68, 92]]], ["It is also not clear if stress granules aid or impede the viral infection itself.", [["stress granules", "ANATOMY", 24, 39], ["infection", "DISEASE", 64, 73], ["granules", "ORGANISM_SUBSTANCE", 31, 39], ["stress granules", "PROBLEM", 24, 39], ["the viral infection itself", "PROBLEM", 54, 80], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 64, 73]]], ["Published studies have not specifically determined the effect of disrupting stress granule formation on poliovirus RNA replication, translation, or overall growth kinetics.", [["stress granule", "ANATOMY", 76, 90], ["stress granule", "CELLULAR_COMPONENT", 76, 90], ["poliovirus", "SPECIES", 104, 114], ["Published studies", "TEST", 0, 17], ["disrupting stress granule formation", "PROBLEM", 65, 100], ["poliovirus RNA replication", "TREATMENT", 104, 130], ["overall growth kinetics", "PROBLEM", 148, 171], ["growth kinetics", "OBSERVATION", 156, 171]]], ["One study examined the effect of maintaining an uncleavable version of G3BP in virus-induced stress granules and found an eight-fold decrease in virus yield (White et al., 2007).", [["stress granules", "ANATOMY", 93, 108], ["G3BP", "CHEMICAL", 71, 75], ["G3BP", "GENE_OR_GENE_PRODUCT", 71, 75], ["stress", "CELLULAR_COMPONENT", 93, 99], ["granules", "ORGANISM_SUBSTANCE", 100, 108], ["G3BP", "PROTEIN", 71, 75], ["One study", "TEST", 0, 9], ["G3BP in virus", "PROBLEM", 71, 84], ["stress granules", "PROBLEM", 93, 108], ["an eight-fold decrease in virus yield", "PROBLEM", 119, 156], ["stress granules", "OBSERVATION", 93, 108]]], ["The basis for this decrease remains to be determined, because G3BP is not maintained in stress granules over the course of poliovirus infection.", [["stress granules", "ANATOMY", 88, 103], ["poliovirus infection", "DISEASE", 123, 143], ["G3BP", "GENE_OR_GENE_PRODUCT", 62, 66], ["stress granules", "CELLULAR_COMPONENT", 88, 103], ["G3BP", "PROTEIN", 62, 66], ["poliovirus", "SPECIES", 123, 133], ["G3BP", "PROBLEM", 62, 66], ["stress granules", "PROBLEM", 88, 103], ["poliovirus infection", "PROBLEM", 123, 143], ["stress granules", "OBSERVATION", 88, 103], ["infection", "OBSERVATION", 134, 143]]], ["To this end, we investigated whether disrupting stress granules had any effect on poliovirus translation during infection.", [["stress granules", "ANATOMY", 48, 63], ["infection", "DISEASE", 112, 121], ["stress granules", "CELLULAR_COMPONENT", 48, 63], ["poliovirus", "SPECIES", 82, 92], ["disrupting stress granules", "PROBLEM", 37, 63], ["poliovirus translation", "PROBLEM", 82, 104], ["infection", "PROBLEM", 112, 121], ["infection", "OBSERVATION", 112, 121]]], ["A recent study demonstrated that expression of the C-terminal domain of TIA-1 (TIA-1-PRD) interferes with the formation of stress granules during poliovirus infection (Piotrowska et al., 2010), but no functional studies were presented.", [["stress granules", "ANATOMY", 123, 138], ["TIA", "DISEASE", 72, 75], ["TIA-1-PRD", "CHEMICAL", 79, 88], ["poliovirus infection", "DISEASE", 146, 166], ["TIA-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["TIA-1-PRD", "GENE_OR_GENE_PRODUCT", 79, 88], ["stress granules", "CELLULAR_COMPONENT", 123, 138], ["C-terminal domain", "PROTEIN", 51, 68], ["TIA", "PROTEIN", 72, 75], ["TIA", "PROTEIN", 79, 82], ["PRD", "PROTEIN", 85, 88], ["A recent study", "TEST", 0, 14], ["the C-terminal domain of TIA", "PROBLEM", 47, 75], ["TIA", "TEST", 79, 82], ["stress granules", "PROBLEM", 123, 138], ["poliovirus infection", "PROBLEM", 146, 166], ["functional studies", "TEST", 201, 219], ["stress granules", "OBSERVATION", 123, 138], ["poliovirus infection", "OBSERVATION", 146, 166]]], ["Our results suggested that expression of wild type TIA-1 or the dominant negative TIA-1-PRD had no significant effect on poliovirus IRES-mediated translation.", [["TIA-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["TIA-1", "GENE_OR_GENE_PRODUCT", 82, 87], ["PRD", "GENE_OR_GENE_PRODUCT", 88, 91], ["poliovirus", "ORGANISM", 121, 131], ["wild type TIA-1", "PROTEIN", 41, 56], ["dominant negative TIA-1-PRD", "DNA", 64, 91], ["poliovirus IRES", "DNA", 121, 136], ["poliovirus", "SPECIES", 121, 131], ["wild type TIA", "PROBLEM", 41, 54], ["the dominant negative TIA", "PROBLEM", 60, 85], ["poliovirus IRES", "TREATMENT", 121, 136], ["no", "UNCERTAINTY", 96, 98], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["poliovirus IRES", "OBSERVATION", 121, 136]]], ["While our transfection efficiencies were estimated at around 70% in COS cells (data not shown), it is possible that some deleterious effects on translation were masked by the population of untransfected cells.", [["COS cells", "ANATOMY", 68, 77], ["cells", "ANATOMY", 203, 208], ["COS cells", "CELL", 68, 77], ["cells", "CELL", 203, 208], ["COS cells", "CELL_LINE", 68, 77], ["untransfected cells", "CELL_LINE", 189, 208], ["our transfection efficiencies", "PROBLEM", 6, 35], ["some deleterious effects", "PROBLEM", 116, 140], ["untransfected cells", "PROBLEM", 189, 208], ["transfection efficiencies", "OBSERVATION", 10, 35], ["untransfected cells", "OBSERVATION", 189, 208]]], ["This potential shortcoming could be addressed by electroporation of cells as an alternative to transfection or by FACS sorting of transfected cells using the HA tag prior to poliovirus infection.DiscussionOverall, it remains to be determined what role, if any, stress granule formation plays during poliovirus infection or why SRp20, an important ITAF for poliovirus IRES-mediated translation, is partially localized to these cytoplasmic foci during infection.", [["cells", "ANATOMY", 68, 73], ["cells", "ANATOMY", 142, 147], ["stress granule", "ANATOMY", 261, 275], ["cytoplasmic foci", "ANATOMY", 426, 442], ["poliovirus infection", "DISEASE", 174, 194], ["poliovirus infection", "DISEASE", 299, 319], ["infection", "DISEASE", 450, 459], ["cells", "CELL", 68, 73], ["cells", "CELL", 142, 147], ["HA tag", "GENE_OR_GENE_PRODUCT", 158, 164], ["stress granule", "CELLULAR_COMPONENT", 261, 275], ["poliovirus", "ORGANISM", 299, 309], ["SRp20", "GENE_OR_GENE_PRODUCT", 327, 332], ["ITAF", "GENE_OR_GENE_PRODUCT", 347, 351], ["cytoplasmic", "ORGANISM_SUBSTANCE", 426, 437], ["transfected cells", "CELL_LINE", 130, 147], ["SRp20", "PROTEIN", 327, 332], ["ITAF", "DNA", 347, 351], ["poliovirus IRES", "DNA", 356, 371], ["poliovirus", "SPECIES", 174, 184], ["poliovirus", "SPECIES", 299, 309], ["poliovirus", "SPECIES", 356, 366], ["electroporation of cells", "TREATMENT", 49, 73], ["transfected cells", "PROBLEM", 130, 147], ["the HA tag", "TREATMENT", 154, 164], ["poliovirus infection", "PROBLEM", 174, 194], ["stress granule formation", "PROBLEM", 261, 285], ["poliovirus infection", "PROBLEM", 299, 319], ["poliovirus IRES", "PROBLEM", 356, 371], ["these cytoplasmic foci", "PROBLEM", 420, 442], ["infection", "PROBLEM", 450, 459], ["infection", "OBSERVATION", 185, 194], ["cytoplasmic", "OBSERVATION_MODIFIER", 426, 437], ["foci", "OBSERVATION", 438, 442], ["infection", "OBSERVATION", 450, 459]]], ["Considering that stress granules typically contain stalled translation complexes, 40S ribosomal subunits, and other canonical translation initiation factors and RNA binding proteins, it is tempting to speculate that stress granule formation during poliovirus infection may actually contribute to a temporal shift from high levels of viral translation to increasing levels of RNA replication.", [["stress granules", "ANATOMY", 17, 32], ["stress granule", "ANATOMY", 216, 230], ["poliovirus infection", "DISEASE", 248, 268], ["stress granules", "CELLULAR_COMPONENT", 17, 32], ["RNA binding proteins", "GENE_OR_GENE_PRODUCT", 161, 181], ["stress granule", "CELLULAR_COMPONENT", 216, 230], ["stalled translation complexes", "PROTEIN", 51, 80], ["40S ribosomal subunits", "PROTEIN", 82, 104], ["canonical translation initiation factors", "PROTEIN", 116, 156], ["RNA binding proteins", "PROTEIN", 161, 181], ["poliovirus", "SPECIES", 248, 258], ["stress granules", "PROBLEM", 17, 32], ["stalled translation complexes", "PROBLEM", 51, 80], ["40S ribosomal subunits", "TREATMENT", 82, 104], ["RNA binding proteins", "PROBLEM", 161, 181], ["stress granule formation", "PROBLEM", 216, 240], ["poliovirus infection", "PROBLEM", 248, 268], ["a temporal shift", "PROBLEM", 296, 312], ["viral translation", "PROBLEM", 333, 350], ["RNA replication", "TREATMENT", 375, 390], ["stress granules", "OBSERVATION", 17, 32], ["stalled", "OBSERVATION_MODIFIER", 51, 58], ["translation complexes", "OBSERVATION", 59, 80], ["granule formation", "OBSERVATION", 223, 240], ["poliovirus infection", "OBSERVATION", 248, 268], ["viral translation", "OBSERVATION", 333, 350], ["RNA replication", "OBSERVATION", 375, 390]]], ["Such a shift has been previously ascribed, in part, to viral-mediated cleavage of ITAFs during the course of infection (Back et al., 2002, Perera et al., 2007).", [["infection", "DISEASE", 109, 118], ["ITAFs", "GENE_OR_GENE_PRODUCT", 82, 87], ["ITAFs", "PROTEIN", 82, 87], ["ITAFs", "PROBLEM", 82, 87], ["infection", "PROBLEM", 109, 118], ["infection", "OBSERVATION", 109, 118]]]], "PMC7537221": [["Since the emergence of SARS\u2010CoV\u20102, many diagnostic tests including molecular and serological assays have been developed and approved by the Food and Drug Administration (FDA) for diagnosis of COVID\u201019.1,2However, concerns about the sensitivity and specificity of many diagnostic assays, especially the rapid tests, have been raised.", [["SARS", "DISEASE", 23, 27], ["COVID", "DISEASE", 192, 197], ["SARS\u2010CoV\u20102", "ORGANISM", 23, 33], ["SARS\u2010CoV", "SPECIES", 23, 31], ["many diagnostic tests", "TEST", 35, 56], ["molecular and serological assays", "TEST", 67, 99], ["COVID\u2010", "TEST", 192, 198], ["the sensitivity", "TEST", 228, 243], ["diagnostic assays", "TEST", 268, 285], ["the rapid tests", "TEST", 298, 313]]], ["Diagnostic tests with unacceptable rates of false positive and false\u2010negative results interfere with therapeutic management of patients and can have serious implications for public health authorities in the decision\u2010making process regarding COVID\u201019 control.", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["Diagnostic tests", "TEST", 0, 16], ["false positive", "PROBLEM", 44, 58], ["therapeutic management", "TREATMENT", 101, 123], ["COVID\u2010", "TREATMENT", 241, 247], ["false positive", "OBSERVATION", 44, 58]]]], "PMC3557141": [["BackgroundIn vitro systems for studying tissue mitochondrial O2 consumption (cellular respiration) and morphology in BALB/c mice are recently described [1-3].", [["tissue mitochondrial", "ANATOMY", 40, 60], ["cellular", "ANATOMY", 77, 85], ["O2", "CHEMICAL", 61, 63], ["O2", "CHEMICAL", 61, 63], ["tissue", "TISSUE", 40, 46], ["O2", "SIMPLE_CHEMICAL", 61, 63], ["cellular", "CELL", 77, 85], ["BALB/c mice", "ORGANISM", 117, 128], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["BackgroundIn vitro systems", "TREATMENT", 0, 26], ["studying tissue mitochondrial O2 consumption", "PROBLEM", 31, 75], ["cellular respiration", "TEST", 77, 97]]], ["These parameters, however, are insufficient for fully assessing cellular viability.", [["cellular", "ANATOMY", 64, 72], ["cellular", "CELL", 64, 72], ["These parameters", "TEST", 0, 16], ["viability", "OBSERVATION_MODIFIER", 73, 82]]], ["For example, cells may respire (consume O2) at a higher rate due to uncoupling oxidative phosphorylation (short-circuiting the inner mitochondrial membrane), an event that results from increased caspase activities [4].", [["cells", "ANATOMY", 13, 18], ["inner mitochondrial membrane", "ANATOMY", 127, 155], ["O2", "CHEMICAL", 40, 42], ["O2", "CHEMICAL", 40, 42], ["cells", "CELL", 13, 18], ["O2", "SIMPLE_CHEMICAL", 40, 42], ["inner", "CELLULAR_COMPONENT", 127, 132], ["mitochondrial membrane", "CELLULAR_COMPONENT", 133, 155], ["caspase", "GENE_OR_GENE_PRODUCT", 195, 202], ["caspase", "PROTEIN", 195, 202], ["O2", "TREATMENT", 40, 42], ["uncoupling oxidative phosphorylation", "PROBLEM", 68, 104], ["increased caspase activities", "PROBLEM", 185, 213], ["inner", "ANATOMY_MODIFIER", 127, 132], ["mitochondrial membrane", "ANATOMY", 133, 155]]], ["Therefore, measuring cellular ATP and caspase activity are essential biomarkers for a more comprehensive assessment of tissues in vitro.BackgroundLung toxicity is a major health concern in the drug development.", [["cellular", "ANATOMY", 21, 29], ["tissues", "ANATOMY", 119, 126], ["ATP", "CHEMICAL", 30, 33], ["toxicity", "DISEASE", 151, 159], ["ATP", "CHEMICAL", 30, 33], ["cellular", "CELL", 21, 29], ["ATP", "SIMPLE_CHEMICAL", 30, 33], ["caspase", "GENE_OR_GENE_PRODUCT", 38, 45], ["tissues", "TISSUE", 119, 126], ["caspase", "PROTEIN", 38, 45], ["measuring cellular ATP", "TEST", 11, 33], ["caspase activity", "TEST", 38, 54], ["a more comprehensive assessment", "TEST", 84, 115], ["BackgroundLung toxicity", "PROBLEM", 136, 159], ["cellular ATP", "OBSERVATION", 21, 33], ["caspase activity", "OBSERVATION", 38, 54], ["toxicity", "OBSERVATION", 151, 159]]], ["The US Food and Drug Administration (FDA) has issued several post-marketing drug recalls due to adverse events related to mitochondrial dysfunctions [5].", [["mitochondrial", "ANATOMY", 122, 135], ["mitochondrial dysfunctions", "DISEASE", 122, 148], ["mitochondrial", "CELLULAR_COMPONENT", 122, 135], ["adverse events", "PROBLEM", 96, 110], ["mitochondrial dysfunctions", "PROBLEM", 122, 148], ["mitochondrial dysfunctions", "OBSERVATION", 122, 148]]], ["Thus, developing in vitro systems to assess adverse effects of drugs on lung tissue bioenergetics is important.", [["lung tissue", "ANATOMY", 72, 83], ["lung tissue", "MULTI-TISSUE_STRUCTURE", 72, 83], ["vitro systems", "TEST", 20, 33], ["drugs", "TREATMENT", 63, 68], ["lung tissue bioenergetics", "TREATMENT", 72, 97], ["lung", "ANATOMY", 72, 76], ["tissue", "OBSERVATION", 77, 83]]], ["Drug-induced mitochondrial disturbances have been investigated using different methods, including fluorescence-based oxygen sensitive probes [6-8].BackgroundIn this study, the previously described method [1-3,7] is expanded to include measurements of lung tissue ATP content and caspase activity in Wistar rats and C57Bl/6 mice.", [["mitochondrial", "ANATOMY", 13, 26], ["lung tissue", "ANATOMY", 251, 262], ["mitochondrial disturbances", "DISEASE", 13, 39], ["oxygen", "CHEMICAL", 117, 123], ["ATP", "CHEMICAL", 263, 266], ["oxygen", "CHEMICAL", 117, 123], ["ATP", "CHEMICAL", 263, 266], ["Drug", "SIMPLE_CHEMICAL", 0, 4], ["mitochondrial", "CELLULAR_COMPONENT", 13, 26], ["oxygen", "SIMPLE_CHEMICAL", 117, 123], ["lung tissue", "TISSUE", 251, 262], ["ATP", "SIMPLE_CHEMICAL", 263, 266], ["caspase", "GENE_OR_GENE_PRODUCT", 279, 286], ["Wistar rats", "ORGANISM", 299, 310], ["C57Bl/6 mice", "ORGANISM", 315, 327], ["caspase", "PROTEIN", 279, 286], ["rats", "SPECIES", 306, 310], ["mice", "SPECIES", 323, 327], ["mice", "SPECIES", 323, 327], ["Drug-induced mitochondrial disturbances", "PROBLEM", 0, 39], ["fluorescence", "TEST", 98, 110], ["oxygen sensitive probes", "TREATMENT", 117, 140], ["this study", "TEST", 160, 170], ["lung tissue ATP content", "TEST", 251, 274], ["caspase activity", "TEST", 279, 295], ["Wistar rats", "TREATMENT", 299, 310], ["lung tissue", "ANATOMY", 251, 262], ["ATP content", "OBSERVATION", 263, 274], ["caspase activity", "OBSERVATION", 279, 295]]], ["The work aimed to establish an in vitro system suitable for investigating respiratory pathogens and toxins.", [["investigating respiratory pathogens", "PROBLEM", 60, 95], ["toxins", "PROBLEM", 100, 106]]], ["The impacts of experimental conditions (e.g., anesthetic agents, incubation solutions, and oxygenation) are also addressed.Animals ::: MethodsWistar rats (weighing about 215 grams) and C57Bl/6 mice (weighing about 32.5 grams) and BALB/c mice (Additional file 1: Table S2) used in this study were maintained at the animal facility that was in compliance with NIH guidelines (http://grants.nih.gov/grants/olaw/references/phspol.htm).", [["Animals", "ORGANISM", 123, 130], ["MethodsWistar rats", "ORGANISM", 135, 153], ["C57Bl/6 mice", "ORGANISM", 185, 197], ["BALB/c mice", "ORGANISM", 230, 241], ["rats", "SPECIES", 149, 153], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 237, 241], ["experimental conditions", "TREATMENT", 15, 38], ["anesthetic agents", "TREATMENT", 46, 63], ["incubation solutions", "TREATMENT", 65, 85], ["MethodsWistar rats", "TREATMENT", 135, 153], ["this study", "TEST", 280, 290], ["experimental conditions", "OBSERVATION", 15, 38]]], ["They had ad libitum access to standard rodent chow and filtered water.", [["rodent", "SPECIES", 39, 45]]], ["The study was approved by the Animal Research Ethics Committee for care and use of laboratory animals at the College of Medicine and Health Sciences, UAE University.Lung tissue ::: MethodsThe animals were anesthetized by sevoflurane inhalation (100 \u03bcL per 10 g) and sacrificed as outlined [2,3].", [["Lung tissue", "ANATOMY", 165, 176], ["sevoflurane", "CHEMICAL", 221, 232], ["sevoflurane", "CHEMICAL", 221, 232], ["Lung tissue", "TISSUE", 165, 176], ["animals", "ORGANISM", 192, 199], ["sevoflurane", "SIMPLE_CHEMICAL", 221, 232], ["The study", "TEST", 0, 9], ["Methods", "TREATMENT", 181, 188], ["sevoflurane inhalation", "TREATMENT", 221, 243], ["tissue", "ANATOMY", 170, 176]]], ["Lung specimens were immediately immersed in continuously gassed with 95% O2:5% CO2 ice-cold MEM or KH buffer.", [["Lung specimens", "ANATOMY", 0, 14], ["O2", "CHEMICAL", 73, 75], ["CO2", "CHEMICAL", 79, 82], ["O2", "CHEMICAL", 73, 75], ["CO2", "CHEMICAL", 79, 82], ["Lung specimens", "CANCER", 0, 14], ["O2", "SIMPLE_CHEMICAL", 73, 75], ["CO2", "SIMPLE_CHEMICAL", 79, 82], ["Lung specimens", "TEST", 0, 14], ["KH buffer", "TREATMENT", 99, 108]]], ["For O2 measurements, specimens were placed in 1.0 mL MEM or KH buffer containing 0.5% fat-free bovine albumin and 3 \u03bcM Pd phosphor.", [["specimens", "ANATOMY", 21, 30], ["Pd", "CHEMICAL", 119, 121], ["O2", "CHEMICAL", 4, 6], ["Pd", "CHEMICAL", 119, 121], ["O2", "SIMPLE_CHEMICAL", 4, 6], ["fat", "SIMPLE_CHEMICAL", 86, 89], ["bovine", "ORGANISM", 95, 101], ["albumin", "SIMPLE_CHEMICAL", 102, 109], ["Pd phosphor", "SIMPLE_CHEMICAL", 119, 130], ["bovine", "SPECIES", 95, 101], ["O2 measurements", "TEST", 4, 19], ["specimens", "TEST", 21, 30], ["KH buffer", "TREATMENT", 60, 69], ["free bovine albumin", "TREATMENT", 90, 109], ["3 \u03bcM Pd phosphor", "TREATMENT", 114, 130]]], ["Specimens were also processed for histology and measurements of caspase activity and ATP content as described below.Lung tissue ::: MethodsSpecimens were fixed in 10% buffered formalin solution and embedded in paraffin wax blocks.", [["Specimens", "ANATOMY", 0, 9], ["Lung tissue", "ANATOMY", 116, 127], ["ATP", "CHEMICAL", 85, 88], ["formalin", "CHEMICAL", 176, 184], ["ATP", "CHEMICAL", 85, 88], ["formalin", "CHEMICAL", 176, 184], ["paraffin", "CHEMICAL", 210, 218], ["caspase", "GENE_OR_GENE_PRODUCT", 64, 71], ["ATP", "SIMPLE_CHEMICAL", 85, 88], ["Lung tissue", "TISSUE", 116, 127], ["caspase", "PROTEIN", 64, 71], ["Specimens", "TEST", 0, 9], ["histology", "TEST", 34, 43], ["caspase activity", "TEST", 64, 80], ["ATP content", "TEST", 85, 96], ["MethodsSpecimens", "TREATMENT", 132, 148], ["10% buffered formalin solution", "TREATMENT", 163, 193], ["embedded in paraffin wax blocks", "TREATMENT", 198, 229], ["tissue", "ANATOMY", 121, 127], ["paraffin wax", "OBSERVATION", 210, 222]]], ["Sections of the fixed lung pieces (of 3 \u03bcm thickness) were stained with haematoxylin and eosin (H&E) and examined under a light microscope.Lung tissue ::: MethodsStaining for apoptosis was performed using avidin-biotin immunoperoxidase method that detects activated caspase-3 (Cell Signaling Technology, Boston, MA).", [["lung pieces", "ANATOMY", 22, 33], ["Lung tissue", "ANATOMY", 139, 150], ["Cell", "ANATOMY", 277, 281], ["haematoxylin", "CHEMICAL", 72, 84], ["eosin", "CHEMICAL", 89, 94], ["biotin", "CHEMICAL", 212, 218], ["lung pieces", "MULTI-TISSUE_STRUCTURE", 22, 33], ["haematoxylin", "SIMPLE_CHEMICAL", 72, 84], ["Lung tissue", "TISSUE", 139, 150], ["avidin", "GENE_OR_GENE_PRODUCT", 205, 211], ["biotin", "SIMPLE_CHEMICAL", 212, 218], ["caspase-3", "GENE_OR_GENE_PRODUCT", 266, 275], ["Cell", "CELL", 277, 281], ["avidin", "PROTEIN", 205, 211], ["caspase-3", "PROTEIN", 266, 275], ["the fixed lung pieces", "TREATMENT", 12, 33], ["haematoxylin", "TREATMENT", 72, 84], ["a light microscope", "TEST", 120, 138], ["apoptosis", "PROBLEM", 175, 184], ["avidin-biotin immunoperoxidase method", "TREATMENT", 205, 242], ["activated caspase", "TEST", 256, 273], ["fixed", "ANATOMY_MODIFIER", 16, 21], ["lung", "ANATOMY", 22, 26], ["pieces", "ANATOMY_MODIFIER", 27, 33], ["tissue", "ANATOMY", 144, 150]]], ["The procedure was performed on 3-\u03bcm paraffin sections using rabbit anti-cleaved caspase-3 antibody.", [["sections", "ANATOMY", 45, 53], ["paraffin", "CHEMICAL", 36, 44], ["rabbit", "ORGANISM", 60, 66], ["caspase-3", "GENE_OR_GENE_PRODUCT", 80, 89], ["rabbit anti-cleaved caspase-3 antibody", "PROTEIN", 60, 98], ["rabbit", "SPECIES", 60, 66], ["rabbit", "SPECIES", 60, 66], ["The procedure", "TREATMENT", 0, 13], ["3-\u03bcm paraffin sections", "TREATMENT", 31, 53], ["rabbit anti-cleaved caspase", "TREATMENT", 60, 87]]], ["Positive and negative control sections for apoptosis were used.Intracellular caspase activity ::: MethodsLung fragments (about 20 mg each) were collected from Wistar rats and C57Bl/6 mice as described [2].", [["sections", "ANATOMY", 30, 38], ["Intracellular", "ANATOMY", 63, 76], ["fragments", "ANATOMY", 110, 119], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["caspase", "GENE_OR_GENE_PRODUCT", 77, 84], ["Wistar rats", "ORGANISM", 159, 170], ["C57Bl/6 mice", "ORGANISM", 175, 187], ["caspase", "PROTEIN", 77, 84], ["rats", "SPECIES", 166, 170], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["apoptosis", "PROBLEM", 43, 52], ["MethodsLung fragments", "TREATMENT", 98, 119], ["negative control", "OBSERVATION_MODIFIER", 13, 29], ["caspase activity", "OBSERVATION", 77, 93], ["fragments", "OBSERVATION", 110, 119]]], ["The samples were incubated in vitro at 37\u00b0C in 50 mL KH buffer or MEM (continuously gassed with 95% O2:5% CO2) for up to 6 h.", [["samples", "ANATOMY", 4, 11], ["MEM", "CHEMICAL", 66, 69], ["CO2", "CHEMICAL", 106, 109], ["O2", "CHEMICAL", 100, 102], ["CO2", "CHEMICAL", 106, 109], ["CO2", "SIMPLE_CHEMICAL", 106, 109], ["The samples", "TEST", 0, 11]]], ["At specific time points, samples were incubated in oxygenated KH buffer or MEM with 32 \u03bcM zVAD-fmk or 15 \u03bcL DMSO for 20 min (f/v = 1.0 mL).", [["samples", "ANATOMY", 25, 32], ["DMSO", "CHEMICAL", 108, 112], ["DMSO", "CHEMICAL", 108, 112], ["zVAD-fmk", "SIMPLE_CHEMICAL", 90, 98], ["DMSO", "SIMPLE_CHEMICAL", 108, 112]]], ["Ac-DEVD-AMC (37 \u03bcM) was then added and the incubation continued for additional 20 min.", [["Ac-DEVD-AMC", "CHEMICAL", 0, 11], ["Ac-DEVD-AMC", "CHEMICAL", 0, 11], ["Ac-DEVD-AMC", "SIMPLE_CHEMICAL", 0, 11], ["Ac", "TEST", 0, 2], ["the incubation", "TREATMENT", 39, 53]]], ["At the end of incubation, the tissue was disrupted by vigorous homogenization for 2 min, sonication for 3 min and 10 passages through a 27-G needle.", [["tissue", "ANATOMY", 30, 36], ["tissue", "TISSUE", 30, 36], ["a 27-G needle", "TREATMENT", 134, 147], ["tissue", "ANATOMY", 30, 36], ["vigorous", "OBSERVATION_MODIFIER", 54, 62]]], ["This disruption procedure quenched the Ac-DEVD-AMC cleavage reaction due to dilution.", [["Ac-DEVD", "CHEMICAL", 39, 46], ["Ac-DEVD-AMC", "CHEMICAL", 39, 50], ["Ac-DEVD", "SIMPLE_CHEMICAL", 39, 46], ["This disruption procedure", "TREATMENT", 0, 25], ["the Ac", "TREATMENT", 35, 41], ["DEVD", "PROBLEM", 42, 46], ["AMC cleavage reaction", "PROBLEM", 47, 68]]], ["The supernatants were collected by centrifugation (~16,300g for 90 min) through Microcentrifuge Filter (nominal molecular weight limit = 10,000 Dalton, Sigma\u00a9), separated on HPLC, and analyzed for the fluorogenic AMC moiety.HPLC ::: MethodsThe analysis was performed on a Waters reversed-phase HPLC system, which consisted of a manual injector, a pump and a fluorescent detector.", [["supernatants", "ANATOMY", 4, 16], ["Microcentrifuge Filter", "TREATMENT", 80, 102], ["HPLC", "TEST", 174, 178], ["the fluorogenic AMC moiety", "TREATMENT", 197, 223], ["The analysis", "TEST", 240, 252], ["a manual injector", "TREATMENT", 326, 343], ["a pump", "TREATMENT", 345, 351], ["a fluorescent detector", "TEST", 356, 378]]], ["The excitation wavelength was 380 nm and the emission wavelength 460 nm.", [["The excitation wavelength", "TREATMENT", 0, 25]]], ["Solvents A and B were HPLC-grade methanol:dH2O 1:1 (isocratic).", [["Solvents A and B", "CHEMICAL", 0, 16], ["H2O", "CHEMICAL", 43, 46], ["methanol", "CHEMICAL", 33, 41], ["H2O", "CHEMICAL", 43, 46], ["B", "SIMPLE_CHEMICAL", 15, 16], ["dH2O 1:1", "SIMPLE_CHEMICAL", 42, 50], ["HPLC", "TEST", 22, 26]]], ["The column, 4.6 \u00d7 250 mm Beckman Ultrasphere IP column, was operated at 25\u00b0C at 1.0 ml/min.", [["The column", "TEST", 0, 10], ["4.6 \u00d7 250 mm Beckman Ultrasphere IP column", "TREATMENT", 12, 54], ["column", "ANATOMY", 4, 10]]], ["The run time was 10 min and the injection volume was 20 \u03bcL.Oxygen measurements ::: MethodsA phosphorescence oxygen analyzer was used to monitor O2 consumption by lung specimens [2,3].", [["lung specimens", "ANATOMY", 162, 176], ["oxygen", "CHEMICAL", 108, 114], ["O2", "CHEMICAL", 144, 146], ["Oxygen", "CHEMICAL", 59, 65], ["oxygen", "CHEMICAL", 108, 114], ["O2", "CHEMICAL", 144, 146], ["Oxygen", "SIMPLE_CHEMICAL", 59, 65], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["O2", "SIMPLE_CHEMICAL", 144, 146], ["lung", "ORGAN", 162, 166], ["the injection volume", "TEST", 28, 48], ["Oxygen measurements", "TEST", 59, 78], ["MethodsA phosphorescence oxygen analyzer", "TREATMENT", 83, 123], ["O2 consumption", "TEST", 144, 158], ["lung", "ANATOMY", 162, 166]]], ["Briefly, O2 detection was performed with the aid of Pd phosphor (absorption maximum at 625 nm and phosphorescence maximum at 800 nm).", [["O2", "CHEMICAL", 9, 11], ["Pd", "CHEMICAL", 52, 54], ["O2", "CHEMICAL", 9, 11], ["Pd", "CHEMICAL", 52, 54], ["O2", "SIMPLE_CHEMICAL", 9, 11], ["O2 detection", "TEST", 9, 21], ["Pd phosphor (absorption maximum", "TREATMENT", 52, 83]]], ["Samples were exposed to light flashes (600 per min) from a pulsed light-emitting diode array with peak output at 625 nm (OTL630A-5-10-66-E, Opto Technology, Inc., Wheeling, IL).", [["Samples", "ANATOMY", 0, 7], ["light flashes", "PROBLEM", 24, 37], ["a pulsed light-emitting diode array", "TREATMENT", 57, 92], ["peak output", "TEST", 98, 109]]], ["Emitted phosphorescent light was detected by a Hamamatsu photomultiplier tube after passing through an interference filter centered at 800 nm.", [["a Hamamatsu photomultiplier tube", "TREATMENT", 45, 77], ["an interference filter", "TREATMENT", 100, 122], ["800 nm", "OBSERVATION_MODIFIER", 135, 141]]], ["The amplified phosphorescence decay was digitized at 1.0 MHz by a 20-MHz A/D converter (Computer Boards, Inc., Mansfield, MA).Oxygen measurements ::: MethodsA program was developed using Microsoft Visual Basic 6, Microsoft Access Database 2007, and Universal Library components (Universal Library for Measurements Computing Devices; http://www.mccdaq.com/daq-software/universal-library.aspx).", [["Oxygen", "CHEMICAL", 126, 132], ["Oxygen", "SIMPLE_CHEMICAL", 126, 132], ["The amplified phosphorescence decay", "PROBLEM", 0, 35], ["Oxygen measurements", "TEST", 126, 145], ["MethodsA program", "TREATMENT", 150, 166], ["Universal Library components", "TREATMENT", 249, 277], ["Measurements Computing Devices", "TREATMENT", 301, 331]]], ["It allowed direct reading from the PCI-DAS 4020/12 I/O Board (PCI-DAS 4020/12 I/O Board; http://www.mccdaq.com/pci-data-acquisition/PCI-DAS4020-12.aspx).", [["the PCI", "TREATMENT", 31, 38], ["PCI", "TREATMENT", 62, 65]]], ["The pulse detection was accomplished by searching for 10 phosphorescence intensities >1.0 volt (by default).", [["The pulse detection", "TEST", 0, 19], ["phosphorescence intensities", "TEST", 57, 84]]], ["Peak detection was accomplished by searching for the highest 10 data points of a pulse and choosing the data point closest to the pulse decay curve [7].Oxygen measurements ::: MethodsThe phosphorescence decay rate (1/\u03c4) was characterized by a single exponential; I = Ae-t/\u03c4, where I = Pd phosphor phosphorescence intensity.", [["Oxygen", "CHEMICAL", 152, 158], ["Pd", "CHEMICAL", 285, 287], ["Oxygen", "SIMPLE_CHEMICAL", 152, 158], ["Pd phosphor", "SIMPLE_CHEMICAL", 285, 296], ["Peak detection", "TEST", 0, 14], ["a pulse", "TEST", 79, 86], ["the pulse decay curve", "TEST", 126, 147], ["Oxygen measurements", "TEST", 152, 171], ["Methods", "TREATMENT", 176, 183], ["The phosphorescence decay rate", "TEST", 183, 213], ["Pd phosphor phosphorescence intensity", "TEST", 285, 322]]], ["The values of 1/\u03c4 were linear with dissolved O2: 1/\u03c4 = 1/\u03c4o + kq[O2, where 1/\u03c4 = the phosphorescence decay rate in the presence of O2, 1/\u03c4o = the phosphorescence decay rate in the absence of O2, and kq = the second-order O2 quenching rate constant in s-1 \u00b7 \u03bcM-1[8].Oxygen measurements ::: MethodsLung tissue respiration was measured at 37\u00b0C in 1-mL sealed vials.", [["tissue", "ANATOMY", 301, 307], ["O2", "CHEMICAL", 45, 47], ["O2", "CHEMICAL", 131, 133], ["O2", "CHEMICAL", 191, 193], ["O2", "CHEMICAL", 221, 223], ["O2", "CHEMICAL", 45, 47], ["O2", "CHEMICAL", 65, 67], ["O2", "CHEMICAL", 131, 133], ["O2", "CHEMICAL", 191, 193], ["O2", "CHEMICAL", 221, 223], ["Oxygen", "CHEMICAL", 265, 271], ["O2", "SIMPLE_CHEMICAL", 45, 47], ["O2", "SIMPLE_CHEMICAL", 65, 67], ["O2", "SIMPLE_CHEMICAL", 131, 133], ["O2", "SIMPLE_CHEMICAL", 191, 193], ["O2", "SIMPLE_CHEMICAL", 221, 223], ["Oxygen", "SIMPLE_CHEMICAL", 265, 271], ["MethodsLung tissue", "TISSUE", 289, 307], ["The values", "TEST", 0, 10], ["dissolved O2", "TEST", 35, 47], ["O2", "TREATMENT", 65, 67], ["the phosphorescence", "TEST", 81, 100], ["O2", "TREATMENT", 131, 133], ["O2", "TREATMENT", 191, 193], ["O2 quenching rate", "TEST", 221, 238], ["Oxygen measurements", "TEST", 265, 284], ["MethodsLung tissue respiration", "TEST", 289, 319], ["respiration", "OBSERVATION_MODIFIER", 308, 319]]], ["Mixing was with the aid of parylene-coated stirring bars.", [["parylene", "CHEMICAL", 27, 35], ["parylene", "CHEMICAL", 27, 35], ["parylene", "SIMPLE_CHEMICAL", 27, 35], ["parylene-coated stirring bars", "TREATMENT", 27, 56]]], ["In vials sealed from air, [O2] decreased linearly with time, indicating the kinetics of mitochondrial O2 consumption was zero-order.", [["mitochondrial", "ANATOMY", 88, 101], ["O2", "CHEMICAL", 27, 29], ["O2", "CHEMICAL", 102, 104], ["O2", "CHEMICAL", 27, 29], ["O2", "CHEMICAL", 102, 104], ["[O2]", "SIMPLE_CHEMICAL", 26, 30], ["mitochondrial", "CELLULAR_COMPONENT", 88, 101], ["O2", "SIMPLE_CHEMICAL", 102, 104], ["mitochondrial O2 consumption", "TREATMENT", 88, 116], ["sealed", "OBSERVATION_MODIFIER", 9, 15], ["air", "OBSERVATION_MODIFIER", 21, 24]]], ["The rate of respiration (k, in \u03bcM O2 min-1) was thus the negative of the slope d[O2]/dt.", [["O2", "CHEMICAL", 34, 36], ["O2", "CHEMICAL", 81, 83], ["respiration", "TEST", 12, 23], ["k", "TEST", 25, 26], ["O2 min", "TEST", 34, 40], ["dt", "PROBLEM", 85, 87]]], ["Sodium cyanide (NaCN) inhibited respiration, confirming O2 was being consumed in the mitochondrial respiratory chain.Oxygen measurements ::: MethodsThe calibration reaction contained PBS with 3 \u03bcM Pd phosphor, 0.5% fat-free albumin, 50 \u03bcg/mL glucose oxidase and various concentrations of \u03b2-glucose [2].", [["mitochondrial", "ANATOMY", 85, 98], ["Sodium cyanide", "CHEMICAL", 0, 14], ["NaCN", "CHEMICAL", 16, 20], ["O2", "CHEMICAL", 56, 58], ["Pd", "CHEMICAL", 197, 199], ["glucose", "CHEMICAL", 242, 249], ["\u03b2-glucose", "CHEMICAL", 288, 297], ["Sodium cyanide", "CHEMICAL", 0, 14], ["NaCN", "CHEMICAL", 16, 20], ["O2", "CHEMICAL", 56, 58], ["Oxygen", "CHEMICAL", 117, 123], ["Pd", "CHEMICAL", 197, 199], ["glucose", "CHEMICAL", 242, 249], ["\u03b2-glucose", "CHEMICAL", 288, 297], ["Sodium cyanide", "SIMPLE_CHEMICAL", 0, 14], ["NaCN", "SIMPLE_CHEMICAL", 16, 20], ["O2", "SIMPLE_CHEMICAL", 56, 58], ["mitochondrial", "CELLULAR_COMPONENT", 85, 98], ["Oxygen", "SIMPLE_CHEMICAL", 117, 123], ["Pd phosphor", "SIMPLE_CHEMICAL", 197, 208], ["fat", "SIMPLE_CHEMICAL", 215, 218], ["albumin", "SIMPLE_CHEMICAL", 224, 231], ["glucose", "SIMPLE_CHEMICAL", 242, 249], ["oxidase", "GENE_OR_GENE_PRODUCT", 250, 257], ["\u03b2-glucose", "SIMPLE_CHEMICAL", 288, 297], ["mitochondrial respiratory chain", "PROTEIN", 85, 116], ["glucose oxidase", "PROTEIN", 242, 257], ["Sodium cyanide", "TEST", 0, 14], ["respiration", "TEST", 32, 43], ["O2", "TREATMENT", 56, 58], ["Oxygen measurements", "TEST", 117, 136], ["Methods", "TREATMENT", 141, 148], ["The calibration reaction", "TEST", 148, 172], ["PBS", "TEST", 183, 186], ["3 \u03bcM Pd phosphor", "TREATMENT", 192, 208], ["albumin", "TEST", 224, 231], ["glucose oxidase", "TEST", 242, 257], ["\u03b2-glucose", "TEST", 288, 297], ["mitochondrial", "ANATOMY", 85, 98], ["respiratory chain", "OBSERVATION", 99, 116]]], ["[O2 was calculated using, 1/\u03c4 = 1/\u03c4o + kq[O2[8].Cellular ATP contents ::: MethodsLung tissue fragments were homogenized in 0.5 mL of ice-cold 2% trichloroacetic acid for 2 min.", [["Cellular", "ANATOMY", 48, 56], ["tissue fragments", "ANATOMY", 86, 102], ["ATP", "CHEMICAL", 57, 60], ["trichloroacetic acid", "CHEMICAL", 145, 165], ["O2", "CHEMICAL", 1, 3], ["O2", "CHEMICAL", 42, 44], ["ATP", "CHEMICAL", 57, 60], ["trichloroacetic acid", "CHEMICAL", 145, 165], ["O2", "SIMPLE_CHEMICAL", 1, 3], ["ATP", "SIMPLE_CHEMICAL", 57, 60], ["MethodsLung tissue", "TISSUE", 74, 92], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 145, 165], ["O2", "TREATMENT", 1, 3], ["Cellular ATP contents", "TEST", 48, 69], ["MethodsLung tissue fragments", "TREATMENT", 74, 102], ["ice-cold 2% trichloroacetic acid", "TREATMENT", 133, 165], ["ATP contents", "OBSERVATION", 57, 69], ["fragments", "OBSERVATION", 93, 102]]], ["The supernatants were collected by centrifugation (1000xg at 4\u00b0C for 5 min) and stored at -20\u00b0C until analysis.", [["supernatants", "ANATOMY", 4, 16], ["analysis", "TEST", 102, 110]]], ["Immediately before ATP measurement, the samples were thawed and neutralized with 0.5 mL 100 mM Tris-acetate, 2 mM EDTA (final pH, 7.75).", [["samples", "ANATOMY", 40, 47], ["ATP", "CHEMICAL", 19, 22], ["Tris-acetate", "CHEMICAL", 95, 107], ["ATP", "CHEMICAL", 19, 22], ["Tris-acetate", "CHEMICAL", 95, 107], ["EDTA", "CHEMICAL", 114, 118], ["ATP", "SIMPLE_CHEMICAL", 19, 22], ["Tris-acetate", "SIMPLE_CHEMICAL", 95, 107], ["EDTA", "SIMPLE_CHEMICAL", 114, 118], ["ATP measurement", "TEST", 19, 34], ["the samples", "TEST", 36, 47], ["final pH", "TEST", 120, 128]]], ["ATP concentration was determined using the Enliten ATP Assay System (Bioluminescence Detection Kit, Promega, Madison, WI).", [["ATP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 51, 54], ["ATP", "CHEMICAL", 0, 3], ["ATP", "CHEMICAL", 51, 54], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 51, 54], ["ATP concentration", "TEST", 0, 17], ["the Enliten ATP", "TREATMENT", 39, 54]]], ["Briefly, 2.5 \u03bcL of the supernatant was added to 25 \u03bcL of the luciferin/luciferase reagent.", [["supernatant", "ANATOMY", 23, 34], ["luciferin", "CHEMICAL", 61, 70], ["luciferin", "CHEMICAL", 61, 70], ["luciferin", "SIMPLE_CHEMICAL", 61, 70], ["luciferase", "GENE_OR_GENE_PRODUCT", 71, 81], ["luciferase", "PROTEIN", 71, 81], ["the supernatant", "TREATMENT", 19, 34], ["the luciferin/luciferase reagent", "TREATMENT", 57, 89]]], ["The luminescence intensity was then measured at 25\u00b0C using Glomax Luminometer (Promega, Madison, WI).", [["The luminescence intensity", "TEST", 0, 26], ["Glomax Luminometer", "TREATMENT", 59, 77], ["luminescence", "OBSERVATION_MODIFIER", 4, 16], ["intensity", "OBSERVATION_MODIFIER", 17, 26]]], ["The ATP standard curve ranged from 10 pM to 100 nM (R2 >0.9999).ResultsFigure 1 shows Wistar rat lung tissue respiration, ATP content and caspase activity in 50 mL MEM that was continuously gassed with 95% O2: 5% CO2.", [["lung tissue", "ANATOMY", 97, 108], ["ATP", "CHEMICAL", 4, 7], ["ATP", "CHEMICAL", 122, 125], ["O2", "CHEMICAL", 206, 208], ["CO2", "CHEMICAL", 213, 216], ["ATP", "CHEMICAL", 4, 7], ["ATP", "CHEMICAL", 122, 125], ["O2", "CHEMICAL", 206, 208], ["CO2", "CHEMICAL", 213, 216], ["ATP", "SIMPLE_CHEMICAL", 4, 7], ["rat", "ORGANISM", 93, 96], ["lung tissue", "TISSUE", 97, 108], ["ATP", "SIMPLE_CHEMICAL", 122, 125], ["caspase", "GENE_OR_GENE_PRODUCT", 138, 145], ["O2", "SIMPLE_CHEMICAL", 206, 208], ["CO2", "SIMPLE_CHEMICAL", 213, 216], ["caspase", "PROTEIN", 138, 145], ["rat", "SPECIES", 93, 96], ["rat", "SPECIES", 93, 96], ["The ATP standard curve", "TEST", 0, 22], ["R2", "TEST", 52, 54], ["Wistar rat lung tissue respiration", "PROBLEM", 86, 120], ["ATP content", "TEST", 122, 133], ["caspase activity", "TREATMENT", 138, 154], ["lung", "ANATOMY", 97, 101], ["tissue respiration", "OBSERVATION", 102, 120], ["ATP content", "OBSERVATION", 122, 133]]], ["Lung fragments were incubated at 37\u00b0C for up to ~7 h.", [["Lung fragments", "ANATOMY", 0, 14], ["Lung", "ORGAN", 0, 4], ["Lung fragments", "PROBLEM", 0, 14], ["fragments", "OBSERVATION", 5, 14]]], ["At indicated time periods, samples were removed from the incubation medium and processed for measurement of cellular mitochondrial O2 consumption (expressed as, kc in \u03bcM O2 min-1 mg-1), ATP content (pmol mg-1) and caspase activity (AMC peak areas in arbitrary units mg-1).", [["samples", "ANATOMY", 27, 34], ["cellular", "ANATOMY", 108, 116], ["mitochondrial", "ANATOMY", 117, 130], ["O2", "CHEMICAL", 131, 133], ["ATP", "CHEMICAL", 186, 189], ["O2", "CHEMICAL", 131, 133], ["O2", "CHEMICAL", 170, 172], ["ATP", "CHEMICAL", 186, 189], ["cellular", "CELL", 108, 116], ["mitochondrial", "CELLULAR_COMPONENT", 117, 130], ["O2", "SIMPLE_CHEMICAL", 131, 133], ["ATP", "SIMPLE_CHEMICAL", 186, 189], ["caspase", "GENE_OR_GENE_PRODUCT", 214, 221], ["caspase", "PROTEIN", 214, 221], ["the incubation medium", "TREATMENT", 53, 74], ["cellular mitochondrial O2 consumption", "TREATMENT", 108, 145], ["O2 min", "TREATMENT", 170, 176], ["ATP content (pmol mg", "TREATMENT", 186, 206], ["caspase activity", "TEST", 214, 230], ["AMC peak areas", "TEST", 232, 246], ["mitochondrial", "OBSERVATION", 117, 130], ["O2 consumption", "OBSERVATION", 131, 145]]], ["Figure 1A shows the values (mean \u00b1 SD) of kc for 0 \u2264 t \u2264 7 h were 0.147 \u00b1 0.038 (n = 7, Cv = 26%).", [["Figure 1A", "TEST", 0, 9], ["the values", "TEST", 16, 26], ["kc", "TEST", 42, 44], ["Cv", "TEST", 88, 90]]], ["The corresponding values of cellular ATP (Figure 1B, done in triplicates) for 0 \u2264 t \u2264 6 h was 91.0 \u00b1 25.3 pmol mg-1 (n = 6, Cv = 28%).", [["cellular", "ANATOMY", 28, 36], ["ATP", "CHEMICAL", 37, 40], ["ATP", "CHEMICAL", 37, 40], ["cellular", "CELL", 28, 36], ["ATP", "SIMPLE_CHEMICAL", 37, 40], ["cellular ATP", "TEST", 28, 40], ["Figure 1B", "TEST", 42, 51], ["pmol mg", "TEST", 106, 113], ["Cv", "TEST", 124, 126]]], ["Figure 1C\u2013D show the AMC peak areas (arbitrary units mg-1 \u00f7106 performed in duplicates, reflecting caspase activity) for 0 \u2264 t \u2264 6 h were 1.0 \u00b1 0.5 (n = 8).", [["caspase", "GENE_OR_GENE_PRODUCT", 99, 106], ["caspase", "PROTEIN", 99, 106], ["Figure", "TEST", 0, 6], ["the AMC peak areas", "PROBLEM", 17, 35], ["arbitrary units mg", "TEST", 37, 55], ["caspase activity", "TEST", 99, 115]]], ["These AMC peak areas were relatively small (compared to Figure 2D) despite the 3 to 5 fold increments over 6 h.", [["These AMC peak areas", "PROBLEM", 0, 20], ["AMC", "OBSERVATION_MODIFIER", 6, 9], ["peak", "OBSERVATION_MODIFIER", 10, 14], ["areas", "OBSERVATION_MODIFIER", 15, 20], ["relatively", "OBSERVATION_MODIFIER", 26, 36], ["small", "OBSERVATION_MODIFIER", 37, 42]]], ["The AMC peak area for Ac-DEVD-AMC incubated without lung specimen (substrate alone) at hour 6 was also relatively small (Figure 1C\u2013D).", [["lung specimen", "ANATOMY", 52, 65], ["Ac-DEVD-AMC", "CHEMICAL", 22, 33], ["Ac-DEVD", "SIMPLE_CHEMICAL", 22, 29], ["lung specimen", "MULTI-TISSUE_STRUCTURE", 52, 65], ["DEVD", "PROTEIN", 25, 29], ["The AMC peak area", "TEST", 0, 17], ["Ac", "TEST", 22, 24], ["DEVD", "PROBLEM", 25, 29], ["AMC", "PROBLEM", 30, 33], ["lung specimen", "TEST", 52, 65], ["without", "UNCERTAINTY", 44, 51], ["lung", "ANATOMY", 52, 56], ["small", "OBSERVATION_MODIFIER", 114, 119]]], ["Thus, this preparation resulted in a stable cellular bioenergetics (respiration and ATP content) with minimal caspase activity for at least 6 h.ResultsThe need for continuous gassing with O2:CO2 was then investigated.", [["cellular", "ANATOMY", 44, 52], ["ATP", "CHEMICAL", 84, 87], ["O2", "CHEMICAL", 188, 190], ["CO2", "CHEMICAL", 191, 194], ["ATP", "CHEMICAL", 84, 87], ["O2", "CHEMICAL", 188, 190], ["CO2", "CHEMICAL", 191, 194], ["cellular", "CELL", 44, 52], ["ATP", "SIMPLE_CHEMICAL", 84, 87], ["caspase", "GENE_OR_GENE_PRODUCT", 110, 117], ["O2", "SIMPLE_CHEMICAL", 188, 190], ["CO2", "SIMPLE_CHEMICAL", 191, 194], ["caspase", "PROTEIN", 110, 117], ["a stable cellular bioenergetics", "PROBLEM", 35, 66], ["ATP content", "TEST", 84, 95], ["minimal caspase activity", "TREATMENT", 102, 126], ["continuous gassing with O2", "TREATMENT", 164, 190], ["CO2", "TREATMENT", 191, 194], ["stable", "OBSERVATION_MODIFIER", 37, 43], ["cellular bioenergetics", "OBSERVATION", 44, 66], ["minimal", "OBSERVATION_MODIFIER", 102, 109], ["caspase activity", "OBSERVATION", 110, 126]]], ["Figure 2A\u2013D show Wistar rat lung tissue respiration, ATP content and caspase activity in KH buffer without gassing.", [["lung tissue", "ANATOMY", 28, 39], ["ATP", "CHEMICAL", 53, 56], ["ATP", "CHEMICAL", 53, 56], ["rat", "ORGANISM", 24, 27], ["lung tissue", "TISSUE", 28, 39], ["ATP", "SIMPLE_CHEMICAL", 53, 56], ["caspase", "GENE_OR_GENE_PRODUCT", 69, 76], ["caspase", "PROTEIN", 69, 76], ["rat", "SPECIES", 24, 27], ["rat", "SPECIES", 24, 27], ["Wistar rat lung tissue respiration", "PROBLEM", 17, 51], ["ATP content", "TREATMENT", 53, 64], ["caspase activity in KH buffer", "TREATMENT", 69, 98], ["gassing", "PROBLEM", 107, 114], ["lung", "ANATOMY", 28, 32], ["tissue respiration", "OBSERVATION", 33, 51], ["ATP content", "OBSERVATION", 53, 64]]], ["The values of kc (1.5 \u2264 t \u2264 8 h) were 0.118 \u00b1 0.041 (n = 6; Cv = 35%), which were lower than those in Figure 1A (p = 0.181).", [["The values", "TEST", 0, 10], ["kc", "TEST", 14, 16], ["n", "TEST", 53, 54], ["Cv", "TEST", 60, 62]]], ["The values of cellular ATP (Figure 2B, done in triplicates for 0 \u2264 t \u2264 8 h) was 2.9 \u00b11.4 pmol mg-1 (n = 8, Cv = 48%), which were significantly less (p = 0.001) than in Figure 1B.", [["cellular", "ANATOMY", 14, 22], ["ATP", "CHEMICAL", 23, 26], ["ATP", "CHEMICAL", 23, 26], ["cellular", "CELL", 14, 22], ["ATP", "SIMPLE_CHEMICAL", 23, 26], ["The values", "TEST", 0, 10], ["cellular ATP", "TEST", 14, 26], ["Figure 2B", "TEST", 28, 37], ["triplicates", "TEST", 47, 58], ["mg", "TEST", 94, 96], ["Cv", "TEST", 107, 109]]], ["Figure 2D shows the AMC moiety was highest at 2 h (area = 5.6 \u00b1 1.8), while the AMC peak area for Ac-DEVD-AMC incubated without lung specimen (substrate alone) for 6 h was relatively small.", [["lung specimen", "ANATOMY", 128, 141], ["Ac-DEVD-AMC", "CHEMICAL", 98, 109], ["Ac-DEVD-AMC", "CHEMICAL", 98, 109], ["Ac-DEVD-AMC", "SIMPLE_CHEMICAL", 98, 109], ["lung specimen", "MULTI-TISSUE_STRUCTURE", 128, 141], ["DEVD", "PROTEIN", 101, 105], ["AMC", "PROTEIN", 106, 109], ["Figure 2D", "TEST", 0, 9], ["the AMC moiety", "TEST", 16, 30], ["area", "TEST", 51, 55], ["the AMC peak area", "TEST", 76, 93], ["Ac", "TEST", 98, 100], ["DEVD", "PROBLEM", 101, 105], ["AMC", "PROBLEM", 106, 109], ["lung specimen", "TEST", 128, 141], ["lung", "ANATOMY", 128, 132], ["small", "OBSERVATION_MODIFIER", 183, 188]]], ["Thus, continuous tissue oxygenation was necessary for maintaining cellular bioenergetics and preventing caspase activation.", [["tissue", "ANATOMY", 17, 23], ["cellular", "ANATOMY", 66, 74], ["tissue", "TISSUE", 17, 23], ["cellular", "CELL", 66, 74], ["caspase", "GENE_OR_GENE_PRODUCT", 104, 111], ["caspase", "PROTEIN", 104, 111], ["continuous tissue oxygenation", "TREATMENT", 6, 35], ["cellular bioenergetics", "TREATMENT", 66, 88], ["caspase activation", "TREATMENT", 104, 122]]], ["Furthermore, the incubation in room air (21% O2) invoked deleterious effects on cellular bioenergetics with increased caspase activity.ResultsThe same experiment was repeated in room air supplemented with 5% CO2.", [["cellular", "ANATOMY", 80, 88], ["O2", "CHEMICAL", 45, 47], ["CO2", "CHEMICAL", 208, 211], ["O2", "CHEMICAL", 45, 47], ["CO2", "CHEMICAL", 208, 211], ["O2", "SIMPLE_CHEMICAL", 45, 47], ["cellular", "CELL", 80, 88], ["caspase", "GENE_OR_GENE_PRODUCT", 118, 125], ["CO2", "SIMPLE_CHEMICAL", 208, 211], ["caspase", "PROTEIN", 118, 125], ["21% O2", "TREATMENT", 41, 47], ["deleterious effects", "PROBLEM", 57, 76], ["cellular bioenergetics", "TREATMENT", 80, 102], ["increased caspase activity", "TREATMENT", 108, 134], ["5% CO2", "TREATMENT", 205, 211], ["cellular bioenergetics", "OBSERVATION", 80, 102], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["caspase activity", "OBSERVATION", 118, 134]]], ["Briefly, lung fragments from a Wistar rat were incubated at 37\u00b0C in 50 mL MEM in a CO2 tissue culture incubator.", [["lung fragments", "ANATOMY", 9, 23], ["tissue", "ANATOMY", 87, 93], ["CO2", "CHEMICAL", 83, 86], ["CO2", "CHEMICAL", 83, 86], ["lung", "ORGAN", 9, 13], ["Wistar rat", "ORGANISM", 31, 41], ["rat", "SPECIES", 38, 41], ["rat", "SPECIES", 38, 41], ["lung fragments", "PROBLEM", 9, 23], ["a CO2 tissue culture incubator", "TREATMENT", 81, 111], ["lung", "ANATOMY", 9, 13], ["fragments", "OBSERVATION", 14, 23], ["CO2 tissue", "OBSERVATION", 83, 93]]], ["Samples were removed from the incubation medium at 0, 3 and 6 h and processed for measurements of O2 consumption, ATP content and caspase activity.", [["Samples", "ANATOMY", 0, 7], ["O2", "CHEMICAL", 98, 100], ["ATP", "CHEMICAL", 114, 117], ["O2", "CHEMICAL", 98, 100], ["ATP", "CHEMICAL", 114, 117], ["O2", "SIMPLE_CHEMICAL", 98, 100], ["ATP", "SIMPLE_CHEMICAL", 114, 117], ["caspase", "GENE_OR_GENE_PRODUCT", 130, 137], ["caspase", "PROTEIN", 130, 137], ["Samples", "TEST", 0, 7], ["the incubation medium", "TREATMENT", 26, 47], ["O2 consumption", "TREATMENT", 98, 112], ["ATP content", "TREATMENT", 114, 125], ["caspase activity", "TREATMENT", 130, 146]]], ["The values of kc (\u03bcM O2 min-1 mg-1) increased with time and the values of ATP (pmol mg-1) decreased with time, confirming uncoupling of oxidative phosphorylation (Additional file 1: Figure S2).", [["ATP", "CHEMICAL", 74, 77], ["O2", "CHEMICAL", 21, 23], ["ATP", "CHEMICAL", 74, 77], ["ATP", "SIMPLE_CHEMICAL", 74, 77], ["The values", "TEST", 0, 10], ["kc", "TEST", 14, 16], ["O2 min", "TEST", 21, 27], ["ATP (pmol mg", "TEST", 74, 86], ["oxidative phosphorylation", "PROBLEM", 136, 161], ["oxidative phosphorylation", "OBSERVATION", 136, 161]]], ["Thus, the incubation in 21% O2:5% CO2 also invoked deleterious effects on cellular bioenergetics.ResultsTo further investigate the impaired bioenergetics and caspase activation observed in Figure 2, Wistar rat lung tissue was incubated in O2 depleted MEM for 30 min.", [["cellular", "ANATOMY", 74, 82], ["lung tissue", "ANATOMY", 210, 221], ["O2", "CHEMICAL", 28, 30], ["CO2", "CHEMICAL", 34, 37], ["O2", "CHEMICAL", 239, 241], ["O2", "CHEMICAL", 28, 30], ["CO2", "CHEMICAL", 34, 37], ["O2", "CHEMICAL", 239, 241], ["O2", "SIMPLE_CHEMICAL", 28, 30], ["CO2", "SIMPLE_CHEMICAL", 34, 37], ["cellular", "CELL", 74, 82], ["caspase", "GENE_OR_GENE_PRODUCT", 158, 165], ["Wistar rat", "ORGANISM", 199, 209], ["lung tissue", "TISSUE", 210, 221], ["O2", "SIMPLE_CHEMICAL", 239, 241], ["caspase", "PROTEIN", 158, 165], ["rat", "SPECIES", 206, 209], ["rat", "SPECIES", 206, 209], ["the incubation", "TEST", 6, 20], ["O2", "TEST", 28, 30], ["deleterious effects", "PROBLEM", 51, 70], ["cellular bioenergetics", "TREATMENT", 74, 96], ["the impaired bioenergetics", "PROBLEM", 127, 153], ["caspase activation", "TREATMENT", 158, 176], ["Wistar rat lung tissue", "TREATMENT", 199, 221], ["cellular bioenergetics", "OBSERVATION", 74, 96], ["lung tissue", "ANATOMY", 210, 221]]], ["Briefly lung fragments were incubated at 37\u00b0C in 2.0 mL MEM with and without 200 \u03bcg glucose oxidase (which totally depleted O2 from the solution) for 30 min.", [["lung fragments", "ANATOMY", 8, 22], ["glucose", "CHEMICAL", 84, 91], ["O2", "CHEMICAL", 124, 126], ["glucose", "CHEMICAL", 84, 91], ["O2", "CHEMICAL", 124, 126], ["lung", "ORGAN", 8, 12], ["glucose oxidase", "SIMPLE_CHEMICAL", 84, 99], ["O2", "SIMPLE_CHEMICAL", 124, 126], ["Briefly lung fragments", "PROBLEM", 0, 22], ["200 \u03bcg glucose oxidase", "TREATMENT", 77, 99], ["O2", "TREATMENT", 124, 126], ["lung", "ANATOMY", 8, 12], ["fragments", "OBSERVATION", 13, 22]]], ["The samples were then rinsed with MEM and incubated at 37\u00b0C in 50 mL MEM (continuously gassed with 95% O2: 5% CO2) for up to ~7 h.", [["samples", "ANATOMY", 4, 11], ["MEM", "CHEMICAL", 34, 37], ["O2", "CHEMICAL", 103, 105], ["CO2", "CHEMICAL", 110, 113], ["O2", "CHEMICAL", 103, 105], ["CO2", "CHEMICAL", 110, 113], ["O2", "SIMPLE_CHEMICAL", 103, 105], ["CO2", "SIMPLE_CHEMICAL", 110, 113], ["The samples", "TEST", 0, 11]]], ["At indicated time periods, samples were removed from the incubation medium and processed for measurements of O2 consumption, ATP content and caspase activity.", [["samples", "ANATOMY", 27, 34], ["O2", "CHEMICAL", 109, 111], ["ATP", "CHEMICAL", 125, 128], ["O2", "CHEMICAL", 109, 111], ["ATP", "CHEMICAL", 125, 128], ["O2", "SIMPLE_CHEMICAL", 109, 111], ["ATP", "SIMPLE_CHEMICAL", 125, 128], ["caspase", "GENE_OR_GENE_PRODUCT", 141, 148], ["caspase", "PROTEIN", 141, 148], ["the incubation medium", "TREATMENT", 53, 74], ["O2 consumption", "TREATMENT", 109, 123], ["ATP content", "TREATMENT", 125, 136], ["caspase activity", "TREATMENT", 141, 157]]], ["As shown in Figure 3A, the values of kc with and without pre-incubation with glucose oxidase were the same 0.14 \u00b1 0.00 (n = 3 and 4, respectively).", [["glucose", "CHEMICAL", 77, 84], ["glucose", "CHEMICAL", 77, 84], ["glucose oxidase", "GENE_OR_GENE_PRODUCT", 77, 92], ["glucose oxidase", "PROTEIN", 77, 92], ["glucose oxidase", "TEST", 77, 92]]], ["The values of cellular ATP (done in triplicates) without treatment with glucose oxidase were 19.4 \u00b1 9.6 pmol mg-1 (n = 4, Cv = 49%) and with glucose oxidase 12.1 \u00b1 3.9 pmol mg-1 (n = 3, Cv = 32%), p = 0.400 (Figure 3B).", [["cellular", "ANATOMY", 14, 22], ["ATP", "CHEMICAL", 23, 26], ["glucose", "CHEMICAL", 72, 79], ["glucose", "CHEMICAL", 141, 148], ["ATP", "CHEMICAL", 23, 26], ["glucose", "CHEMICAL", 72, 79], ["glucose", "CHEMICAL", 141, 148], ["cellular", "CELL", 14, 22], ["ATP", "SIMPLE_CHEMICAL", 23, 26], ["glucose oxidase", "GENE_OR_GENE_PRODUCT", 72, 87], ["glucose oxidase", "GENE_OR_GENE_PRODUCT", 141, 156], ["glucose oxidase", "PROTEIN", 72, 87], ["glucose oxidase", "PROTEIN", 141, 156], ["cellular ATP", "TEST", 14, 26], ["glucose oxidase", "TEST", 72, 87], ["mg", "TEST", 109, 111], ["Cv", "TEST", 122, 124], ["glucose oxidase", "TEST", 141, 156], ["pmol mg", "TEST", 168, 175], ["Cv", "TEST", 186, 188], ["p", "TEST", 197, 198]]], ["Although, the AMC peak with glucose oxidase was relatively higher immediately post tissue collection (Figure 3C\u2013D), its value did not significantly increase with time indicating no further caspase activation.", [["tissue", "ANATOMY", 83, 89], ["glucose", "CHEMICAL", 28, 35], ["glucose", "CHEMICAL", 28, 35], ["glucose oxidase", "GENE_OR_GENE_PRODUCT", 28, 43], ["tissue", "TISSUE", 83, 89], ["caspase", "GENE_OR_GENE_PRODUCT", 189, 196], ["glucose oxidase", "PROTEIN", 28, 43], ["caspase", "PROTEIN", 189, 196], ["the AMC peak", "TEST", 10, 22], ["glucose oxidase", "TEST", 28, 43], ["further caspase activation", "TREATMENT", 181, 207], ["higher", "OBSERVATION_MODIFIER", 59, 65], ["post tissue", "OBSERVATION_MODIFIER", 78, 89], ["collection", "OBSERVATION_MODIFIER", 90, 100], ["caspase activation", "OBSERVATION", 189, 207]]], ["The significance of background caspase activity at min zero (lung specimens immediately immersed in the Ac-DEVD-AMC reaction for 20 min) was unclear.", [["lung specimens", "ANATOMY", 61, 75], ["caspase", "GENE_OR_GENE_PRODUCT", 31, 38], ["lung specimens", "MULTI-TISSUE_STRUCTURE", 61, 75], ["caspase", "PROTEIN", 31, 38], ["background caspase activity", "PROBLEM", 20, 47], ["lung specimens", "TEST", 61, 75], ["the Ac", "TEST", 100, 106], ["AMC reaction", "PROBLEM", 112, 124], ["caspase activity", "OBSERVATION", 31, 47], ["lung", "ANATOMY", 61, 65]]], ["The AMC peak area for Ac-DEVD-AMC incubated without lung specimen for 6 h was relatively small.", [["lung specimen", "ANATOMY", 52, 65], ["Ac-DEVD-AMC", "CHEMICAL", 22, 33], ["Ac-DEVD", "SIMPLE_CHEMICAL", 22, 29], ["lung specimen", "MULTI-TISSUE_STRUCTURE", 52, 65], ["DEVD", "PROTEIN", 25, 29], ["The AMC peak area", "TEST", 0, 17], ["Ac", "TEST", 22, 24], ["DEVD", "PROBLEM", 25, 29], ["AMC", "PROBLEM", 30, 33], ["lung specimen", "TEST", 52, 65], ["without", "UNCERTAINTY", 44, 51], ["lung", "ANATOMY", 52, 56], ["small", "OBSERVATION_MODIFIER", 89, 94]]], ["Thus, the 30-min O2 depletion had no measurable effects on cellular bioenergetics and caspase activity.ResultsThe effects of the anesthetic agent sevoflurane vs. urethane were then tested.", [["cellular", "ANATOMY", 59, 67], ["O2", "CHEMICAL", 17, 19], ["sevoflurane", "CHEMICAL", 146, 157], ["urethane", "CHEMICAL", 162, 170], ["O2", "CHEMICAL", 17, 19], ["sevoflurane", "CHEMICAL", 146, 157], ["urethane", "CHEMICAL", 162, 170], ["O2", "SIMPLE_CHEMICAL", 17, 19], ["cellular", "CELL", 59, 67], ["caspase", "GENE_OR_GENE_PRODUCT", 86, 93], ["sevoflurane", "SIMPLE_CHEMICAL", 146, 157], ["urethane", "SIMPLE_CHEMICAL", 162, 170], ["caspase", "PROTEIN", 86, 93], ["min O2 depletion", "TREATMENT", 13, 29], ["cellular bioenergetics", "TREATMENT", 59, 81], ["caspase activity", "TREATMENT", 86, 102], ["the anesthetic agent sevoflurane", "TREATMENT", 125, 157], ["urethane", "TREATMENT", 162, 170], ["no", "UNCERTAINTY", 34, 36], ["measurable", "OBSERVATION_MODIFIER", 37, 47], ["cellular bioenergetics", "OBSERVATION", 59, 81]]], ["Lung fragments were incubated at 37\u00b0C in 50 mL MEM (continuously gassed with 95% O2: 5% CO2) for up to ~7 h.", [["Lung fragments", "ANATOMY", 0, 14], ["O2", "CHEMICAL", 81, 83], ["CO2", "CHEMICAL", 88, 91], ["O2", "CHEMICAL", 81, 83], ["CO2", "CHEMICAL", 88, 91], ["Lung", "ORGAN", 0, 4], ["O2", "SIMPLE_CHEMICAL", 81, 83], ["CO2", "SIMPLE_CHEMICAL", 88, 91], ["Lung fragments", "PROBLEM", 0, 14], ["fragments", "OBSERVATION", 5, 14]]], ["The values of kc for sevoflurane anesthesia were 0.15 \u00b1 0.01 (n = 4; Cv = 7%) and for urethane 0.16 \u00b1 0.02 (n = 3; Cv = 13%), p = 0.857 (Figure 4A).", [["sevoflurane", "CHEMICAL", 21, 32], ["urethane", "CHEMICAL", 86, 94], ["sevoflurane", "CHEMICAL", 21, 32], ["urethane", "CHEMICAL", 86, 94], ["sevoflurane", "SIMPLE_CHEMICAL", 21, 32], ["The values", "TEST", 0, 10], ["sevoflurane anesthesia", "TREATMENT", 21, 43], ["Cv", "TEST", 69, 71], ["urethane", "TEST", 86, 94], ["Cv", "TEST", 115, 117], ["p", "TEST", 126, 127]]], ["The values of cellular ATP (Figure 4B, done in triplicates) for sevoflurane was 22.4 \u00b1 18.7 pmol mg-1 (n = 4, Cv = 83%) and for urethane 13.3 \u00b1 5.6 pmol mg-1 (n = 3, Cv = 42%), p = 0.857 (Figure 4B).", [["cellular", "ANATOMY", 14, 22], ["ATP", "CHEMICAL", 23, 26], ["sevoflurane", "CHEMICAL", 64, 75], ["urethane", "CHEMICAL", 128, 136], ["ATP", "CHEMICAL", 23, 26], ["sevoflurane", "CHEMICAL", 64, 75], ["urethane", "CHEMICAL", 128, 136], ["cellular", "CELL", 14, 22], ["ATP", "SIMPLE_CHEMICAL", 23, 26], ["sevoflurane", "SIMPLE_CHEMICAL", 64, 75], ["urethane", "SIMPLE_CHEMICAL", 128, 136], ["The values", "TEST", 0, 10], ["cellular ATP", "TEST", 14, 26], ["Figure 4B", "TEST", 28, 37], ["sevoflurane", "TEST", 64, 75], ["mg", "TEST", 97, 99], ["Cv", "TEST", 110, 112], ["urethane", "TEST", 128, 136], ["mg", "TEST", 153, 155], ["Cv", "TEST", 166, 168], ["p", "TEST", 177, 178]]], ["The AMC moiety was stable with sevoflurane anesthesia over 6 h (3.0 \u00b1 0.5, n = 3), but progressively increased with time for urethane anesthesia (4.5 \u00b1 2.4, n = 3; p = 0.700), Figure 4C\u2013D. The AMC peak area for Ac-DEVD-AMC incubated without lung specimen for 6 h was relatively small.", [["lung specimen", "ANATOMY", 241, 254], ["sevoflurane", "CHEMICAL", 31, 42], ["urethane", "CHEMICAL", 125, 133], ["Ac-DEVD-AMC", "CHEMICAL", 211, 222], ["sevoflurane", "CHEMICAL", 31, 42], ["urethane", "CHEMICAL", 125, 133], ["AMC", "SIMPLE_CHEMICAL", 4, 7], ["sevoflurane", "SIMPLE_CHEMICAL", 31, 42], ["urethane", "SIMPLE_CHEMICAL", 125, 133], ["Ac-DEVD", "SIMPLE_CHEMICAL", 211, 218], ["lung specimen", "MULTI-TISSUE_STRUCTURE", 241, 254], ["DEVD", "PROTEIN", 214, 218], ["sevoflurane anesthesia", "TREATMENT", 31, 53], ["urethane anesthesia", "TREATMENT", 125, 144], ["The AMC peak area", "TEST", 189, 206], ["Ac", "TEST", 211, 213], ["DEVD", "PROBLEM", 214, 218], ["AMC", "PROBLEM", 219, 222], ["lung specimen", "TEST", 241, 254], ["stable", "OBSERVATION_MODIFIER", 19, 25], ["without", "UNCERTAINTY", 233, 240], ["lung", "ANATOMY", 241, 245], ["small", "OBSERVATION_MODIFIER", 278, 283]]], ["Therefore, sevoflurane was the preferred anesthetic agent.ResultsFigure 5 shows two independent experiments of C57Bl/6 mouse lung tissue respiration and caspase activity in KH buffer (intermittently 60 sec every h) gassed with 95% O2: 5% CO2.", [["lung tissue", "ANATOMY", 125, 136], ["sevoflurane", "CHEMICAL", 11, 22], ["O2", "CHEMICAL", 231, 233], ["CO2", "CHEMICAL", 238, 241], ["sevoflurane", "CHEMICAL", 11, 22], ["O2", "CHEMICAL", 231, 233], ["CO2", "CHEMICAL", 238, 241], ["sevoflurane", "SIMPLE_CHEMICAL", 11, 22], ["mouse", "ORGANISM", 119, 124], ["lung tissue", "TISSUE", 125, 136], ["caspase", "GENE_OR_GENE_PRODUCT", 153, 160], ["O2", "SIMPLE_CHEMICAL", 231, 233], ["CO2", "SIMPLE_CHEMICAL", 238, 241], ["caspase", "PROTEIN", 153, 160], ["mouse", "SPECIES", 119, 124], ["mouse", "SPECIES", 119, 124], ["sevoflurane", "TREATMENT", 11, 22], ["anesthetic agent", "TREATMENT", 41, 57], ["C57Bl/6 mouse lung tissue respiration", "TREATMENT", 111, 148], ["caspase activity in KH buffer", "TREATMENT", 153, 182], ["lung", "ANATOMY", 125, 129], ["tissue respiration", "OBSERVATION", 130, 148]]], ["The values of kc for both experiments were 0.15 \u00b1 0.03 (Figure 5A).", [["The values", "TEST", 0, 10], ["both experiments", "TEST", 21, 37]]], ["The AMC peak was increased with time in both experiments (Figure 5B).", [["The AMC peak", "TEST", 0, 12], ["AMC", "OBSERVATION_MODIFIER", 4, 7], ["peak", "OBSERVATION_MODIFIER", 8, 12], ["increased", "OBSERVATION_MODIFIER", 17, 26]]], ["In Figure 5C\u2013D, the same experiment was repeated in MEM that was continuously gassed with 95% O2:5% CO2.", [["O2", "CHEMICAL", 94, 96], ["CO2", "CHEMICAL", 100, 103], ["O2", "CHEMICAL", 94, 96], ["CO2", "CHEMICAL", 100, 103], ["O2", "SIMPLE_CHEMICAL", 94, 96], ["CO2", "SIMPLE_CHEMICAL", 100, 103]]], ["The values of kc for both experiments were 0.17 \u00b1 0.05 (n = 7, Cv = 29%).ResultsLight microscopy of lung tissue from a Wistar rat is shown in Figure 6.", [["lung tissue", "ANATOMY", 100, 111], ["lung tissue", "TISSUE", 100, 111], ["Wistar rat", "ORGANISM", 119, 129], ["rat", "SPECIES", 126, 129], ["rat", "SPECIES", 126, 129], ["The values", "TEST", 0, 10], ["both experiments", "TEST", 21, 37], ["Cv", "TEST", 63, 65], ["Light microscopy", "TEST", 80, 96], ["lung tissue", "PROBLEM", 100, 111], ["a Wistar rat", "TREATMENT", 117, 129], ["lung", "ANATOMY", 100, 104], ["tissue", "OBSERVATION", 105, 111]]], ["The specimens were incubated at 37\u00b0C in MEM continuously gassed with 95% O2:5% CO2 or kept at 37\u00b0C without gassing for 0, 3, and 6 h.", [["specimens", "ANATOMY", 4, 13], ["O2", "CHEMICAL", 73, 75], ["CO2", "CHEMICAL", 79, 82], ["O2", "CHEMICAL", 73, 75], ["CO2", "CHEMICAL", 79, 82], ["specimens", "CELL", 4, 13], ["O2", "SIMPLE_CHEMICAL", 73, 75], ["CO2", "SIMPLE_CHEMICAL", 79, 82], ["The specimens", "TEST", 0, 13]]], ["At 0 h (Figure 6A), there is good tissue preservation with unremarkable pulmonary parenchyma composed of delicate thin alveolar walls lined by pneumatocytes.", [["tissue", "ANATOMY", 34, 40], ["pulmonary parenchyma", "ANATOMY", 72, 92], ["alveolar walls", "ANATOMY", 119, 133], ["pneumatocytes", "ANATOMY", 143, 156], ["tissue", "TISSUE", 34, 40], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 72, 92], ["alveolar walls", "TISSUE", 119, 133], ["delicate thin alveolar walls", "PROBLEM", 105, 133], ["pneumatocytes", "PROBLEM", 143, 156], ["good tissue", "OBSERVATION", 29, 40], ["unremarkable", "OBSERVATION", 59, 71], ["pulmonary", "ANATOMY", 72, 81], ["parenchyma", "ANATOMY_MODIFIER", 82, 92], ["delicate", "OBSERVATION_MODIFIER", 105, 113], ["thin", "OBSERVATION_MODIFIER", 114, 118], ["alveolar", "ANATOMY_MODIFIER", 119, 127], ["walls", "ANATOMY_MODIFIER", 128, 133], ["pneumatocytes", "OBSERVATION", 143, 156]]], ["In oxygenated MEM at 3 h (Figure 6B), the pulmonary parenchyma is well preserved and composed of delicate thin alveolar wall lined by unremarkable pneumatocytes and a preserved bronchiolar epithelium; a few alveolar macrophages were noted.", [["pulmonary parenchyma", "ANATOMY", 42, 62], ["alveolar wall", "ANATOMY", 111, 124], ["pneumatocytes", "ANATOMY", 147, 160], ["bronchiolar epithelium", "ANATOMY", 177, 199], ["alveolar macrophages", "ANATOMY", 207, 227], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 42, 62], ["alveolar wall", "TISSUE", 111, 124], ["pneumatocytes", "CANCER", 147, 160], ["bronchiolar epithelium", "TISSUE", 177, 199], ["alveolar macrophages", "CELL", 207, 227], ["alveolar macrophages", "CELL_TYPE", 207, 227], ["delicate thin alveolar wall lined by unremarkable pneumatocytes", "PROBLEM", 97, 160], ["a preserved bronchiolar epithelium", "PROBLEM", 165, 199], ["a few alveolar macrophages", "PROBLEM", 201, 227], ["oxygenated MEM", "OBSERVATION", 3, 17], ["pulmonary", "ANATOMY", 42, 51], ["parenchyma", "ANATOMY_MODIFIER", 52, 62], ["well", "OBSERVATION_MODIFIER", 66, 70], ["preserved", "OBSERVATION", 71, 80], ["delicate", "OBSERVATION_MODIFIER", 97, 105], ["thin", "OBSERVATION_MODIFIER", 106, 110], ["alveolar", "ANATOMY_MODIFIER", 111, 119], ["wall", "ANATOMY_MODIFIER", 120, 124], ["lined", "ANATOMY_MODIFIER", 125, 130], ["unremarkable", "OBSERVATION_MODIFIER", 134, 146], ["pneumatocytes", "OBSERVATION", 147, 160], ["preserved", "OBSERVATION_MODIFIER", 167, 176], ["bronchiolar epithelium", "OBSERVATION", 177, 199], ["few", "OBSERVATION_MODIFIER", 203, 206], ["alveolar macrophages", "OBSERVATION", 207, 227]]], ["Tissue architecture is partially preserved at 6 h, with foci of alveolar edema, cytoplasmic disintegration of the alveolar lining epithelium and a few alveolar macrophages (Figure 6C).", [["Tissue", "ANATOMY", 0, 6], ["foci", "ANATOMY", 56, 60], ["alveolar edema", "ANATOMY", 64, 78], ["cytoplasmic", "ANATOMY", 80, 91], ["alveolar lining epithelium", "ANATOMY", 114, 140], ["alveolar macrophages", "ANATOMY", 151, 171], ["alveolar edema", "DISEASE", 64, 78], ["Tissue", "TISSUE", 0, 6], ["alveolar edema", "PATHOLOGICAL_FORMATION", 64, 78], ["cytoplasmic", "ORGANISM_SUBSTANCE", 80, 91], ["alveolar lining epithelium", "TISSUE", 114, 140], ["alveolar macrophages", "CELL", 151, 171], ["alveolar macrophages", "CELL_TYPE", 151, 171], ["alveolar edema", "PROBLEM", 64, 78], ["cytoplasmic disintegration of the alveolar lining epithelium", "PROBLEM", 80, 140], ["a few alveolar macrophages", "PROBLEM", 145, 171], ["partially", "OBSERVATION_MODIFIER", 23, 32], ["preserved", "OBSERVATION", 33, 42], ["foci", "OBSERVATION_MODIFIER", 56, 60], ["alveolar", "ANATOMY_MODIFIER", 64, 72], ["edema", "OBSERVATION", 73, 78], ["cytoplasmic", "OBSERVATION_MODIFIER", 80, 91], ["disintegration", "OBSERVATION_MODIFIER", 92, 106], ["alveolar", "ANATOMY_MODIFIER", 114, 122], ["lining", "ANATOMY_MODIFIER", 123, 129], ["epithelium", "ANATOMY_MODIFIER", 130, 140], ["few", "OBSERVATION_MODIFIER", 147, 150], ["alveolar macrophages", "OBSERVATION", 151, 171]]], ["In unoxygenated MEM, tissue architecture was still preserved at 3 h, but with appearance of alveolar macrophages and early cytoplasmic disintegration of the alveolar lining epithelium (Figure 6E).", [["tissue", "ANATOMY", 21, 27], ["alveolar macrophages", "ANATOMY", 92, 112], ["cytoplasmic", "ANATOMY", 123, 134], ["alveolar lining epithelium", "ANATOMY", 157, 183], ["tissue", "TISSUE", 21, 27], ["alveolar macrophages", "CELL", 92, 112], ["cytoplasmic", "ORGANISM_SUBSTANCE", 123, 134], ["alveolar lining epithelium", "TISSUE", 157, 183], ["alveolar macrophages", "CELL_TYPE", 92, 112], ["alveolar macrophages", "PROBLEM", 92, 112], ["early cytoplasmic disintegration of the alveolar lining epithelium", "PROBLEM", 117, 183], ["tissue", "OBSERVATION_MODIFIER", 21, 27], ["architecture", "OBSERVATION_MODIFIER", 28, 40], ["alveolar macrophages", "OBSERVATION", 92, 112], ["early", "OBSERVATION_MODIFIER", 117, 122], ["cytoplasmic disintegration", "OBSERVATION", 123, 149], ["alveolar", "ANATOMY_MODIFIER", 157, 165], ["lining", "ANATOMY_MODIFIER", 166, 172], ["epithelium", "ANATOMY_MODIFIER", 173, 183]]], ["Tissue preservation was poor at 6 h, showing collapse of alveolar walls, sloughing of bronchiolar epithelium and extravasation of red blood cells and fluid into alveolar spaces (Figure 6F).ResultsLung tissue immunostaining with rabbit anti-cleaved caspase-3 antibody is shown in Figure 7; the pictures correspond to the same areas in Figure 6.", [["Tissue", "ANATOMY", 0, 6], ["alveolar walls", "ANATOMY", 57, 71], ["bronchiolar epithelium", "ANATOMY", 86, 108], ["red blood cells", "ANATOMY", 130, 145], ["fluid", "ANATOMY", 150, 155], ["alveolar", "ANATOMY", 161, 169], ["Lung tissue", "ANATOMY", 196, 207], ["Tissue", "TISSUE", 0, 6], ["alveolar walls", "PATHOLOGICAL_FORMATION", 57, 71], ["bronchiolar epithelium", "TISSUE", 86, 108], ["red blood cells", "CELL", 130, 145], ["fluid", "ORGANISM_SUBSTANCE", 150, 155], ["alveolar", "MULTI-TISSUE_STRUCTURE", 161, 169], ["Lung tissue", "TISSUE", 196, 207], ["rabbit", "ORGANISM", 228, 234], ["caspase-3", "GENE_OR_GENE_PRODUCT", 248, 257], ["red blood cells", "CELL_TYPE", 130, 145], ["rabbit anti-cleaved caspase-3 antibody", "PROTEIN", 228, 266], ["rabbit", "SPECIES", 228, 234], ["rabbit", "SPECIES", 228, 234], ["Tissue preservation", "TEST", 0, 19], ["collapse of alveolar walls", "PROBLEM", 45, 71], ["sloughing of bronchiolar epithelium", "PROBLEM", 73, 108], ["extravasation of red blood cells", "PROBLEM", 113, 145], ["fluid into alveolar spaces", "PROBLEM", 150, 176], ["Lung tissue immunostaining", "TEST", 196, 222], ["rabbit anti-cleaved caspase", "TREATMENT", 228, 255], ["collapse", "OBSERVATION", 45, 53], ["alveolar", "ANATOMY_MODIFIER", 57, 65], ["walls", "ANATOMY_MODIFIER", 66, 71], ["sloughing", "OBSERVATION_MODIFIER", 73, 82], ["bronchiolar epithelium", "OBSERVATION", 86, 108], ["extravasation", "OBSERVATION", 113, 126], ["red blood cells", "OBSERVATION", 130, 145], ["fluid", "OBSERVATION_MODIFIER", 150, 155], ["alveolar", "ANATOMY_MODIFIER", 161, 169], ["Lung", "ANATOMY", 196, 200]]], ["The apoptotic cells in pulmonary tissue at 0 h were 5% (Figure 7A).", [["cells", "ANATOMY", 14, 19], ["pulmonary tissue", "ANATOMY", 23, 39], ["cells", "CELL", 14, 19], ["pulmonary tissue", "TISSUE", 23, 39], ["apoptotic cells", "CELL_TYPE", 4, 19], ["The apoptotic cells in pulmonary tissue", "PROBLEM", 0, 39], ["apoptotic cells", "OBSERVATION", 4, 19], ["pulmonary tissue", "ANATOMY", 23, 39]]], ["In oxygenated MEM, the apoptotic cells were 10% and 30% at 3 h and 6 h, respectively (Figure 7B\u2013C).", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["apoptotic cells", "CELL_TYPE", 23, 38], ["the apoptotic cells", "TEST", 19, 38], ["oxygenated MEM", "OBSERVATION", 3, 17], ["apoptotic cells", "OBSERVATION", 23, 38]]], ["In unoxygenated MEM, the apoptotic cells were 10% and 20% at 3 h and 6 h, respectively (Figure 7E\u2013F).ResultsAdditional file 1: Tables S1\u2013S3 summarize the impacts of oxygen supply and anesthetic agents on the measured parameters; these results clearly demonstrate the need for tissue oxygenation and sevoflurane anesthesia.DiscussionThe term cellular respiration implies delivery of O2 and metabolic fuels to the mitochondria, oxidation of reduced metabolic fuels with passage of electrons to O2, and ATP synthesis.", [["cells", "ANATOMY", 35, 40], ["tissue", "ANATOMY", 276, 282], ["cellular", "ANATOMY", 341, 349], ["mitochondria", "ANATOMY", 412, 424], ["oxygen", "CHEMICAL", 165, 171], ["sevoflurane", "CHEMICAL", 299, 310], ["O2", "CHEMICAL", 382, 384], ["O2", "CHEMICAL", 492, 494], ["ATP", "CHEMICAL", 500, 503], ["oxygen", "CHEMICAL", 165, 171], ["sevoflurane", "CHEMICAL", 299, 310], ["O2", "CHEMICAL", 382, 384], ["O2", "CHEMICAL", 492, 494], ["ATP", "CHEMICAL", 500, 503], ["cells", "CELL", 35, 40], ["oxygen", "SIMPLE_CHEMICAL", 165, 171], ["tissue", "TISSUE", 276, 282], ["sevoflurane", "SIMPLE_CHEMICAL", 299, 310], ["cellular", "CELL", 341, 349], ["O2", "SIMPLE_CHEMICAL", 382, 384], ["mitochondria", "CELLULAR_COMPONENT", 412, 424], ["O2", "SIMPLE_CHEMICAL", 492, 494], ["ATP", "SIMPLE_CHEMICAL", 500, 503], ["apoptotic cells", "CELL_TYPE", 25, 40], ["the apoptotic cells", "TEST", 21, 40], ["oxygen supply", "TREATMENT", 165, 178], ["anesthetic agents", "TREATMENT", 183, 200], ["tissue oxygenation", "TREATMENT", 276, 294], ["sevoflurane anesthesia", "TREATMENT", 299, 321], ["delivery of O2", "TREATMENT", 370, 384], ["reduced metabolic fuels", "PROBLEM", 439, 462], ["O2", "TREATMENT", 492, 494], ["ATP synthesis", "TREATMENT", 500, 513], ["apoptotic cells", "OBSERVATION", 25, 40], ["sevoflurane anesthesia", "OBSERVATION", 299, 321], ["metabolic fuels", "OBSERVATION", 447, 462]]], ["Impaired respiration thus entails an interference with any of these processes.", [["Impaired respiration", "PROBLEM", 0, 20], ["respiration", "OBSERVATION", 9, 20]]], ["O2 consumption is a highly sensitive parameter in detecting cellular injury, since an intact biological system is required for consuming O2 and producing ATP.", [["cellular", "ANATOMY", 60, 68], ["O2", "CHEMICAL", 0, 2], ["O2", "CHEMICAL", 137, 139], ["ATP", "CHEMICAL", 154, 157], ["O2", "CHEMICAL", 0, 2], ["O2", "CHEMICAL", 137, 139], ["ATP", "CHEMICAL", 154, 157], ["O2", "SIMPLE_CHEMICAL", 0, 2], ["cellular", "CELL", 60, 68], ["O2", "SIMPLE_CHEMICAL", 137, 139], ["ATP", "SIMPLE_CHEMICAL", 154, 157], ["O2 consumption", "TEST", 0, 14], ["cellular injury", "PROBLEM", 60, 75], ["O2", "TREATMENT", 137, 139], ["cellular injury", "OBSERVATION", 60, 75], ["intact", "OBSERVATION", 86, 92]]], ["Interruptions at any level, such as the cell membrane, mitochondria and enzymes lead to impaired energy conversion and ATP production [4].", [["cell membrane", "ANATOMY", 40, 53], ["mitochondria", "ANATOMY", 55, 67], ["ATP", "CHEMICAL", 119, 122], ["ATP", "CHEMICAL", 119, 122], ["cell membrane", "CELLULAR_COMPONENT", 40, 53], ["mitochondria", "CELLULAR_COMPONENT", 55, 67], ["ATP", "SIMPLE_CHEMICAL", 119, 122], ["the cell membrane", "TEST", 36, 53], ["enzymes", "TEST", 72, 79], ["impaired energy conversion", "PROBLEM", 88, 114], ["ATP production", "PROBLEM", 119, 133]]], ["For example, mitochondria isolated from hamster lungs were inhibited by amiodarone (an antidysrhythmic agent with potent pulmonary toxicities) [9].", [["mitochondria", "ANATOMY", 13, 25], ["hamster lungs", "ANATOMY", 40, 53], ["pulmonary", "ANATOMY", 121, 130], ["amiodarone", "CHEMICAL", 72, 82], ["pulmonary toxicities", "DISEASE", 121, 141], ["amiodarone", "CHEMICAL", 72, 82], ["mitochondria", "CELLULAR_COMPONENT", 13, 25], ["hamster", "ORGANISM", 40, 47], ["lungs", "ORGAN", 48, 53], ["amiodarone", "SIMPLE_CHEMICAL", 72, 82], ["pulmonary", "ORGAN", 121, 130], ["hamster", "SPECIES", 40, 47], ["hamster", "SPECIES", 40, 47], ["mitochondria", "PROBLEM", 13, 25], ["hamster lungs", "PROBLEM", 40, 53], ["amiodarone", "TREATMENT", 72, 82], ["an antidysrhythmic agent", "TREATMENT", 84, 108], ["potent pulmonary toxicities", "PROBLEM", 114, 141], ["lungs", "ANATOMY", 48, 53], ["pulmonary", "ANATOMY", 121, 130]]], ["Similarly, inefficient oxidative phosphorylation was reported in lung mitochondria after exposure to environmental pollutants, such as dioxins and furans [10].DiscussionCells are expected to repair damages if sufficient ATP is present.", [["lung mitochondria", "ANATOMY", 65, 82], ["dioxins", "CHEMICAL", 135, 142], ["furans", "CHEMICAL", 147, 153], ["ATP", "CHEMICAL", 220, 223], ["dioxins", "CHEMICAL", 135, 142], ["furans", "CHEMICAL", 147, 153], ["ATP", "CHEMICAL", 220, 223], ["lung mitochondria", "MULTI-TISSUE_STRUCTURE", 65, 82], ["dioxins", "SIMPLE_CHEMICAL", 135, 142], ["furans [10]", "SIMPLE_CHEMICAL", 147, 158], ["ATP", "SIMPLE_CHEMICAL", 220, 223], ["inefficient oxidative phosphorylation", "PROBLEM", 11, 48], ["lung mitochondria", "PROBLEM", 65, 82], ["environmental pollutants", "TREATMENT", 101, 125], ["repair damages", "TREATMENT", 191, 205], ["oxidative phosphorylation", "OBSERVATION", 23, 48], ["lung", "ANATOMY", 65, 69]]], ["ATP depletion, on the other hand, inevitably leads to cell death.", [["cell", "ANATOMY", 54, 58], ["ATP", "CHEMICAL", 0, 3], ["death", "DISEASE", 59, 64], ["ATP", "CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["cell", "CELL", 54, 58], ["ATP depletion", "PROBLEM", 0, 13], ["cell death", "PROBLEM", 54, 64], ["depletion", "OBSERVATION", 4, 13], ["cell death", "OBSERVATION", 54, 64]]], ["Thus, the fate of the cell, for most part, is determined by its bioenergetic status [11].", [["cell", "ANATOMY", 22, 26], ["cell", "CELL", 22, 26]]], ["This fact reflects the inherent dependency of our biologic system on high rates of aerobic metabolism.", [["aerobic metabolism", "PROBLEM", 83, 101], ["inherent", "OBSERVATION_MODIFIER", 23, 31], ["dependency", "OBSERVATION", 32, 42], ["aerobic metabolism", "OBSERVATION", 83, 101]]], ["Cancer cells, on the other hand, are capable of surviving on anaerobic metabolism (commonly referred to as: \u201caerobic glycolysis\u201d or Warburg effect) [12].DiscussionOne study suggested that the mitochondrial electron transport chain could be responsible for indirect DNA damages in lung tissue [13].", [["Cancer cells", "ANATOMY", 0, 12], ["mitochondrial", "ANATOMY", 192, 205], ["lung tissue", "ANATOMY", 280, 291], ["Cancer", "DISEASE", 0, 6], ["Cancer cells", "CELL", 0, 12], ["mitochondrial", "CELLULAR_COMPONENT", 192, 205], ["DNA", "CELLULAR_COMPONENT", 265, 268], ["lung tissue", "TISSUE", 280, 291], ["Cancer cells", "CELL_TYPE", 0, 12], ["mitochondrial electron transport chain", "PROTEIN", 192, 230], ["Cancer cells", "PROBLEM", 0, 12], ["One study", "TEST", 163, 172], ["the mitochondrial electron transport chain", "TREATMENT", 188, 230], ["indirect DNA damages in lung tissue", "PROBLEM", 256, 291], ["lung", "ANATOMY", 280, 284]]], ["Therefore, monitoring cellular O2 consumption by mitochondrial cytochrome oxidase is important for assessing cytotoxicity.DiscussionThe main purpose of this work was to develop an in vitro method to study the impact of respiratory pathogens and toxins on metabolic biomarkers (cellular respiration, ATP content and caspase activity) in lung tissue.", [["cellular", "ANATOMY", 22, 30], ["mitochondrial", "ANATOMY", 49, 62], ["respiratory", "ANATOMY", 219, 230], ["cellular", "ANATOMY", 277, 285], ["lung tissue", "ANATOMY", 336, 347], ["O2", "CHEMICAL", 31, 33], ["ATP", "CHEMICAL", 299, 302], ["O2", "CHEMICAL", 31, 33], ["ATP", "CHEMICAL", 299, 302], ["cellular", "CELL", 22, 30], ["O2", "SIMPLE_CHEMICAL", 31, 33], ["mitochondrial", "CELLULAR_COMPONENT", 49, 62], ["cytochrome oxidase", "GENE_OR_GENE_PRODUCT", 63, 81], ["cellular", "CELL", 277, 285], ["ATP", "SIMPLE_CHEMICAL", 299, 302], ["caspase", "GENE_OR_GENE_PRODUCT", 315, 322], ["lung tissue", "TISSUE", 336, 347], ["mitochondrial cytochrome oxidase", "PROTEIN", 49, 81], ["caspase", "PROTEIN", 315, 322], ["cellular O2 consumption", "TREATMENT", 22, 45], ["mitochondrial cytochrome oxidase", "TREATMENT", 49, 81], ["cytotoxicity", "PROBLEM", 109, 121], ["respiratory pathogens", "PROBLEM", 219, 240], ["toxins", "PROBLEM", 245, 251], ["metabolic biomarkers", "TEST", 255, 275], ["cellular respiration", "TEST", 277, 297], ["ATP content", "TEST", 299, 310], ["caspase activity", "TREATMENT", 315, 331], ["respiratory", "ANATOMY", 219, 230], ["pathogens", "OBSERVATION", 231, 240], ["lung", "ANATOMY", 336, 340]]], ["The procedure described in Figure 1 resulted in reasonable preservation of lung tissue bioenergetics and structure (Figure 6B\u2013C) for up to 6 h with minimum caspase activation.", [["lung tissue", "ANATOMY", 75, 86], ["lung tissue", "TISSUE", 75, 86], ["caspase", "GENE_OR_GENE_PRODUCT", 156, 163], ["caspase", "PROTEIN", 156, 163], ["The procedure", "TREATMENT", 0, 13], ["lung tissue bioenergetics", "PROBLEM", 75, 100], ["minimum caspase activation", "TREATMENT", 148, 174], ["lung", "ANATOMY", 75, 79], ["tissue bioenergetics", "OBSERVATION", 80, 100]]], ["The success of this method relied on three critical procedural steps.", [["this method", "TREATMENT", 15, 26]]], ["The first step involved anesthesia and tissue collection.", [["tissue", "ANATOMY", 39, 45], ["tissue", "TISSUE", 39, 45], ["anesthesia", "TREATMENT", 24, 34], ["tissue collection", "PROBLEM", 39, 56], ["tissue", "ANATOMY", 39, 45], ["collection", "OBSERVATION", 46, 56]]], ["Anesthesia with sevoflurane and rapid (within 20 sec) removal of thin lung fragments from the animal were essential.", [["lung fragments", "ANATOMY", 70, 84], ["sevoflurane", "CHEMICAL", 16, 27], ["sevoflurane", "CHEMICAL", 16, 27], ["sevoflurane", "SIMPLE_CHEMICAL", 16, 27], ["lung", "ORGAN", 70, 74], ["Anesthesia", "TREATMENT", 0, 10], ["sevoflurane", "TREATMENT", 16, 27], ["removal", "TREATMENT", 54, 61], ["thin lung fragments", "PROBLEM", 65, 84], ["rapid", "OBSERVATION_MODIFIER", 32, 37], ["thin", "OBSERVATION_MODIFIER", 65, 69], ["lung", "ANATOMY", 70, 74], ["fragments", "OBSERVATION", 75, 84]]], ["It was vital to avoid organ ischemia or hypoxia before specimen collection, i.e., the organ should be well perfused during specimens\u2019 collection.", [["organ", "ANATOMY", 22, 27], ["specimen", "ANATOMY", 55, 63], ["organ", "ANATOMY", 86, 91], ["specimens", "ANATOMY", 123, 132], ["ischemia", "DISEASE", 28, 36], ["hypoxia", "DISEASE", 40, 47], ["organ", "ORGAN", 22, 27], ["organ", "ORGAN", 86, 91], ["organ ischemia", "PROBLEM", 22, 36], ["hypoxia", "PROBLEM", 40, 47], ["specimen collection", "TEST", 55, 74], ["ischemia", "OBSERVATION", 28, 36], ["hypoxia", "OBSERVATION", 40, 47], ["organ", "ANATOMY", 86, 91]]], ["The second step involved tissue processing which required immediate immersion of collected tissues in oxygenated ice-cold MEM or KH buffer.", [["tissue", "ANATOMY", 25, 31], ["tissues", "ANATOMY", 91, 98], ["tissue", "TISSUE", 25, 31], ["tissues", "TISSUE", 91, 98], ["immediate immersion of collected tissues", "TREATMENT", 58, 98]]], ["The specimens were then cut into small slices using a sharp blade or punch biopsy device, while remaining in ice cold buffer or MEM continuously gassed with 95% O2:5% CO2.", [["specimens", "ANATOMY", 4, 13], ["slices", "ANATOMY", 39, 45], ["O2", "CHEMICAL", 161, 163], ["CO2", "CHEMICAL", 167, 170], ["O2", "CHEMICAL", 161, 163], ["CO2", "CHEMICAL", 167, 170], ["specimens", "CANCER", 4, 13], ["O2", "SIMPLE_CHEMICAL", 161, 163], ["CO2", "SIMPLE_CHEMICAL", 167, 170], ["The specimens", "TEST", 0, 13], ["a sharp blade", "TREATMENT", 52, 65], ["punch biopsy device", "TREATMENT", 69, 88]]], ["The third step involved sample incubation in a large volume solution (e.g., 50 mL) with continuous gassing with 95% O2: 5% CO2.", [["sample", "ANATOMY", 24, 30], ["O2", "CHEMICAL", 116, 118], ["CO2", "CHEMICAL", 123, 126], ["O2", "CHEMICAL", 116, 118], ["CO2", "CHEMICAL", 123, 126], ["O2", "SIMPLE_CHEMICAL", 116, 118], ["CO2", "SIMPLE_CHEMICAL", 123, 126], ["a large volume solution", "TREATMENT", 45, 68]]], ["Having adhered to these procedural steps, a coefficient of variation (Cv) for rates of respiration of 13% and for ATP of 53% over 6 h was achieved.", [["ATP", "CHEMICAL", 114, 117], ["ATP", "CHEMICAL", 114, 117], ["ATP", "SIMPLE_CHEMICAL", 114, 117], ["respiration", "TEST", 87, 98], ["ATP", "TEST", 114, 117]]], ["The larger variation in ATP was likely reflecting inability to maintain a tissue perfusion comparable to that of in vivo and induction of apoptosis (Figure 7B\u2013C).DiscussionCompared to unoxygenated MEM, a better-preserved lung structure was evident in oxygenated medium, despite time-dependent increases in apoptotic cells in both conditions (Figures 6, 7).DiscussionAs noted in Figure 2, in unoxygenated solutions cellular ATP was depleted and lung structure was altered (Figure 6E\u2013F), while rates of respiration were progressively increasing indicating uncoupling oxidative phosphorylation.", [["tissue", "ANATOMY", 74, 80], ["lung", "ANATOMY", 221, 225], ["cells", "ANATOMY", 316, 321], ["cellular", "ANATOMY", 414, 422], ["lung", "ANATOMY", 444, 448], ["ATP", "CHEMICAL", 24, 27], ["ATP", "CHEMICAL", 423, 426], ["ATP", "CHEMICAL", 24, 27], ["ATP", "CHEMICAL", 423, 426], ["ATP", "SIMPLE_CHEMICAL", 24, 27], ["tissue", "TISSUE", 74, 80], ["lung", "ORGAN", 221, 225], ["cells", "CELL", 316, 321], ["cellular", "CELL", 414, 422], ["ATP", "SIMPLE_CHEMICAL", 423, 426], ["lung", "ORGAN", 444, 448], ["apoptotic cells", "CELL_TYPE", 306, 321], ["The larger variation in ATP", "PROBLEM", 0, 27], ["a tissue perfusion", "TEST", 72, 90], ["apoptosis", "PROBLEM", 138, 147], ["apoptotic cells", "PROBLEM", 306, 321], ["uncoupling oxidative phosphorylation", "PROBLEM", 554, 590], ["larger", "OBSERVATION_MODIFIER", 4, 10], ["variation", "OBSERVATION_MODIFIER", 11, 20], ["lung", "ANATOMY", 221, 225], ["structure", "OBSERVATION", 226, 235], ["oxygenated medium", "OBSERVATION", 251, 268], ["dependent", "OBSERVATION_MODIFIER", 283, 292], ["increases", "OBSERVATION_MODIFIER", 293, 302], ["apoptotic cells", "OBSERVATION", 306, 321], ["lung", "ANATOMY", 444, 448], ["altered", "OBSERVATION_MODIFIER", 463, 470], ["uncoupling", "OBSERVATION", 554, 564], ["oxidative phosphorylation", "OBSERVATION", 565, 590]]], ["This presumption was supported by the fact that caspase activity was noted by 2 hr (also see Figure 7E\u2013F).", [["caspase", "GENE_OR_GENE_PRODUCT", 48, 55], ["caspase", "PROTEIN", 48, 55], ["caspase activity", "PROBLEM", 48, 64]]], ["Activation of caspases leads to opening of the transition permeability pores in the inner mitochondrial membranes, which results in uncoupling oxidative phosphorylation.", [["inner mitochondrial membranes", "ANATOMY", 84, 113], ["caspases", "GENE_OR_GENE_PRODUCT", 14, 22], ["inner", "CELLULAR_COMPONENT", 84, 89], ["mitochondrial membranes", "CELLULAR_COMPONENT", 90, 113], ["caspases", "PROTEIN", 14, 22], ["caspases", "TREATMENT", 14, 22], ["the transition permeability pores", "TREATMENT", 43, 76], ["uncoupling oxidative phosphorylation", "PROBLEM", 132, 168], ["transition permeability", "OBSERVATION", 47, 70], ["pores", "OBSERVATION_MODIFIER", 71, 76], ["inner", "ANATOMY_MODIFIER", 84, 89], ["mitochondrial membranes", "ANATOMY", 90, 113], ["oxidative phosphorylation", "OBSERVATION", 143, 168]]], ["This process results in rapid cellular ATP and nutrient depletions.", [["cellular", "ANATOMY", 30, 38], ["ATP", "CHEMICAL", 39, 42], ["ATP", "CHEMICAL", 39, 42], ["cellular", "CELL", 30, 38], ["ATP", "SIMPLE_CHEMICAL", 39, 42], ["rapid cellular ATP", "PROBLEM", 24, 42], ["nutrient depletions", "TREATMENT", 47, 66], ["rapid", "OBSERVATION_MODIFIER", 24, 29], ["cellular ATP", "OBSERVATION", 30, 42], ["nutrient depletions", "OBSERVATION", 47, 66]]], ["These two consequences contribute to further damage of lung tissue.", [["lung tissue", "ANATOMY", 55, 66], ["lung tissue", "TISSUE", 55, 66], ["further damage of lung tissue", "PROBLEM", 37, 66], ["damage", "OBSERVATION", 45, 51], ["lung", "ANATOMY", 55, 59], ["tissue", "OBSERVATION", 60, 66]]], ["Thus, initial toxic effects become compound by overwhelming insults resulting from mitochondrial and metabolic derangements.", [["mitochondrial", "ANATOMY", 83, 96], ["mitochondrial", "CELLULAR_COMPONENT", 83, 96], ["overwhelming insults", "PROBLEM", 47, 67], ["mitochondrial and metabolic derangements", "PROBLEM", 83, 123], ["toxic", "OBSERVATION_MODIFIER", 14, 19], ["metabolic derangements", "OBSERVATION", 101, 123]]], ["At this stage, inevitable cell death occurs despite the removal of the initial toxic insult, as cellular repair requires ATP.", [["cell", "ANATOMY", 26, 30], ["cellular", "ANATOMY", 96, 104], ["death", "DISEASE", 31, 36], ["ATP", "CHEMICAL", 121, 124], ["ATP", "CHEMICAL", 121, 124], ["cell", "CELL", 26, 30], ["cellular", "CELL", 96, 104], ["ATP", "SIMPLE_CHEMICAL", 121, 124], ["inevitable cell death", "PROBLEM", 15, 36], ["the removal", "TREATMENT", 52, 63], ["the initial toxic insult", "PROBLEM", 67, 91], ["cellular repair", "TREATMENT", 96, 111], ["ATP", "TREATMENT", 121, 124], ["inevitable cell death", "OBSERVATION", 15, 36], ["toxic insult", "OBSERVATION", 79, 91], ["cellular repair", "OBSERVATION", 96, 111]]], ["These concepts are relevant to human lung diseases, such as adult respiratory distress syndrome (ARDS).", [["lung", "ANATOMY", 37, 41], ["respiratory", "ANATOMY", 66, 77], ["lung diseases", "DISEASE", 37, 50], ["adult respiratory distress syndrome", "DISEASE", 60, 95], ["ARDS", "DISEASE", 97, 101], ["human", "ORGANISM", 31, 36], ["lung", "ORGAN", 37, 41], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["human lung diseases", "PROBLEM", 31, 50], ["adult respiratory distress syndrome", "PROBLEM", 60, 95], ["ARDS", "PROBLEM", 97, 101], ["lung", "ANATOMY", 37, 41], ["diseases", "OBSERVATION", 42, 50], ["respiratory distress", "OBSERVATION", 66, 86]]], ["Interestingly, the findings in Figure 2 were not reproduced in later experiments when lung tissue was incubated in O2 depleted buffer for 30 min (Figure 3).", [["lung tissue", "ANATOMY", 86, 97], ["O2", "CHEMICAL", 115, 117], ["O2", "CHEMICAL", 115, 117], ["lung tissue", "TISSUE", 86, 97], ["O2", "SIMPLE_CHEMICAL", 115, 117], ["lung tissue", "PROBLEM", 86, 97], ["O2 depleted buffer", "TREATMENT", 115, 133], ["lung", "ANATOMY", 86, 90], ["tissue", "OBSERVATION", 91, 97]]], ["This result could be explained by residual cellular ATP under our experimental conditions (rather than its total depletion), and hence the tissue was able to endure this brief hypoxia.DiscussionIn one study, the susceptibility of mitochondria isolated from pneumatocytes of pigs to in vitro hypoxia was investigated [14].", [["cellular", "ANATOMY", 43, 51], ["tissue", "ANATOMY", 139, 145], ["mitochondria", "ANATOMY", 230, 242], ["pneumatocytes", "ANATOMY", 257, 270], ["ATP", "CHEMICAL", 52, 55], ["hypoxia", "DISEASE", 176, 183], ["hypoxia", "DISEASE", 291, 298], ["ATP", "CHEMICAL", 52, 55], ["cellular", "CELL", 43, 51], ["ATP", "SIMPLE_CHEMICAL", 52, 55], ["tissue", "TISSUE", 139, 145], ["mitochondria", "CELLULAR_COMPONENT", 230, 242], ["pigs", "ORGANISM", 274, 278], ["pigs", "SPECIES", 274, 278], ["pigs", "SPECIES", 274, 278], ["residual cellular ATP", "PROBLEM", 34, 55], ["its total depletion", "TREATMENT", 103, 122], ["this brief hypoxia", "PROBLEM", 165, 183], ["one study", "TEST", 197, 206], ["mitochondria", "PROBLEM", 230, 242], ["pneumatocytes of pigs", "TREATMENT", 257, 278], ["vitro hypoxia", "PROBLEM", 285, 298], ["could be explained", "UNCERTAINTY", 12, 30], ["residual", "OBSERVATION_MODIFIER", 34, 42], ["cellular ATP", "OBSERVATION", 43, 55], ["hypoxia", "OBSERVATION", 176, 183]]], ["The results showed oxidative phosphorylation was unaffected by a 45-min hypoxia (as shown in Figure 3), suggesting the mitochondria were not directly responsible for damages observed after in vivo ischemia.", [["mitochondria", "ANATOMY", 119, 131], ["hypoxia", "DISEASE", 72, 79], ["ischemia", "DISEASE", 197, 205], ["mitochondria", "CELLULAR_COMPONENT", 119, 131], ["oxidative phosphorylation", "PROBLEM", 19, 44], ["damages", "PROBLEM", 166, 173], ["vivo ischemia", "PROBLEM", 192, 205], ["oxidative phosphorylation", "OBSERVATION", 19, 44], ["ischemia", "OBSERVATION", 197, 205]]], ["Mitochondrial injuries were presumed to result from cellular insults, such as execution of apoptosis.DiscussionUrethane is a commonly used anesthetic agent in animal research.", [["Mitochondrial", "ANATOMY", 0, 13], ["cellular", "ANATOMY", 52, 60], ["Mitochondrial injuries", "DISEASE", 0, 22], ["DiscussionUrethane", "CHEMICAL", 101, 119], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["cellular", "CELL", 52, 60], ["Mitochondrial injuries", "PROBLEM", 0, 22], ["cellular insults", "PROBLEM", 52, 68], ["apoptosis", "PROBLEM", 91, 100], ["anesthetic agent", "TREATMENT", 139, 155], ["injuries", "OBSERVATION", 14, 22], ["presumed to result", "UNCERTAINTY", 28, 46], ["cellular insults", "OBSERVATION", 52, 68], ["apoptosis", "OBSERVATION", 91, 100]]], ["The results show that more caspases were induced in urethane compared to sevoflurane (Figure 4).", [["urethane", "CHEMICAL", 52, 60], ["sevoflurane", "CHEMICAL", 73, 84], ["urethane", "CHEMICAL", 52, 60], ["sevoflurane", "CHEMICAL", 73, 84], ["caspases", "GENE_OR_GENE_PRODUCT", 27, 35], ["urethane", "SIMPLE_CHEMICAL", 52, 60], ["sevoflurane", "SIMPLE_CHEMICAL", 73, 84], ["caspases", "PROTEIN", 27, 35], ["more caspases", "PROBLEM", 22, 35], ["sevoflurane", "TREATMENT", 73, 84]]], ["Therefore, anesthesia with sevoflurane is recommended.DiscussionThe mitochondrial function is best assessed in intact cells and tissues (rather than isolated organelles), using accurate determinations of cellular oxygen consumption and ATP synthesis.", [["mitochondrial", "ANATOMY", 68, 81], ["cells", "ANATOMY", 118, 123], ["tissues", "ANATOMY", 128, 135], ["organelles", "ANATOMY", 158, 168], ["cellular", "ANATOMY", 204, 212], ["sevoflurane", "CHEMICAL", 27, 38], ["oxygen", "CHEMICAL", 213, 219], ["ATP", "CHEMICAL", 236, 239], ["sevoflurane", "CHEMICAL", 27, 38], ["oxygen", "CHEMICAL", 213, 219], ["ATP", "CHEMICAL", 236, 239], ["sevoflurane", "SIMPLE_CHEMICAL", 27, 38], ["mitochondrial", "CELLULAR_COMPONENT", 68, 81], ["cells", "CELL", 118, 123], ["tissues", "TISSUE", 128, 135], ["cellular", "CELL", 204, 212], ["oxygen", "SIMPLE_CHEMICAL", 213, 219], ["ATP", "SIMPLE_CHEMICAL", 236, 239], ["intact cells", "CELL_TYPE", 111, 123], ["anesthesia", "TREATMENT", 11, 21], ["sevoflurane", "TREATMENT", 27, 38], ["The mitochondrial function", "TEST", 64, 90], ["cellular oxygen consumption", "TREATMENT", 204, 231], ["ATP synthesis", "TREATMENT", 236, 249], ["oxygen consumption", "OBSERVATION", 213, 231]]], ["The conventional polarographic method for detecting oxygen is limited, especially for biological samples that require measurements over several hours [15].", [["samples", "ANATOMY", 97, 104], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 52, 58], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["The conventional polarographic method", "TEST", 0, 37], ["biological samples", "TEST", 86, 104]]], ["The more recent use of fluorescence-based oxygen probes has significantly improved the detection methodology [6-8].DiscussionThe results here are consistent with observed energy deficits during hypoxia in kidney proximal tubule cells [16].", [["kidney proximal tubule cells", "ANATOMY", 205, 233], ["oxygen", "CHEMICAL", 42, 48], ["hypoxia", "DISEASE", 194, 201], ["oxygen", "CHEMICAL", 42, 48], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["kidney proximal tubule cells", "CELL", 205, 233], ["kidney proximal tubule cells", "CELL_TYPE", 205, 233], ["fluorescence-based oxygen probes", "TREATMENT", 23, 55], ["observed energy deficits", "PROBLEM", 162, 186], ["hypoxia in kidney proximal tubule cells", "PROBLEM", 194, 233], ["consistent with", "UNCERTAINTY", 146, 161], ["hypoxia", "OBSERVATION", 194, 201], ["kidney", "ANATOMY", 205, 211], ["proximal", "ANATOMY_MODIFIER", 212, 220], ["tubule cells", "OBSERVATION", 221, 233]]], ["Moreover, ischemia is well known to induce a mitochondrial damage that predisposes to superoxide anion production at the level of the respiratory chain [17].", [["mitochondrial", "ANATOMY", 45, 58], ["ischemia", "DISEASE", 10, 18], ["mitochondrial damage", "DISEASE", 45, 65], ["superoxide", "CHEMICAL", 86, 96], ["superoxide", "CHEMICAL", 86, 96], ["mitochondrial", "CELLULAR_COMPONENT", 45, 58], ["superoxide anion", "SIMPLE_CHEMICAL", 86, 102], ["ischemia", "PROBLEM", 10, 18], ["a mitochondrial damage", "PROBLEM", 43, 65], ["superoxide anion production", "PROBLEM", 86, 113], ["ischemia", "OBSERVATION", 10, 18], ["respiratory chain", "ANATOMY", 134, 151]]], ["For example, nitric oxide donors to the mitochondria (mediated by S-nitrosates thiol proteins) during ischemia inhibit O2 consumption [18].", [["mitochondria", "ANATOMY", 40, 52], ["nitric oxide", "CHEMICAL", 13, 25], ["ischemia", "DISEASE", 102, 110], ["O2", "CHEMICAL", 119, 121], ["nitric oxide", "CHEMICAL", 13, 25], ["S-nitrosates thiol", "CHEMICAL", 66, 84], ["O2", "CHEMICAL", 119, 121], ["nitric oxide", "SIMPLE_CHEMICAL", 13, 25], ["mitochondria", "CELLULAR_COMPONENT", 40, 52], ["S-nitrosates thiol proteins", "GENE_OR_GENE_PRODUCT", 66, 93], ["O2", "SIMPLE_CHEMICAL", 119, 121], ["S-nitrosates thiol proteins", "PROTEIN", 66, 93], ["nitric oxide donors", "TREATMENT", 13, 32], ["S-nitrosates thiol proteins", "TREATMENT", 66, 93], ["ischemia inhibit O2 consumption", "PROBLEM", 102, 133]]], ["Abnormal lung bioenergetics has been also reported in smokers (especially in patients with chronic obstructive lung disease and down-regulation of prohibitin-1) and with exposures to particulate matters of aerodynamic diameters of \u226410 \u03bcm [19,20].DiscussionAs a proof of concept, Additional file 1: Figure S1 shows induction of caspases in the presence of 8 \u03bcM dactinomycin, a well known potent inducer of apoptosis [11].", [["lung", "ANATOMY", 9, 13], ["lung", "ANATOMY", 111, 115], ["chronic obstructive lung disease", "DISEASE", 91, 123], ["dactinomycin", "CHEMICAL", 360, 372], ["dactinomycin", "CHEMICAL", 360, 372], ["lung", "ORGAN", 9, 13], ["patients", "ORGANISM", 77, 85], ["lung", "ORGAN", 111, 115], ["prohibitin-1", "GENE_OR_GENE_PRODUCT", 147, 159], ["caspases", "GENE_OR_GENE_PRODUCT", 327, 335], ["dactinomycin", "SIMPLE_CHEMICAL", 360, 372], ["prohibitin", "PROTEIN", 147, 157], ["caspases", "PROTEIN", 327, 335], ["patients", "SPECIES", 77, 85], ["Abnormal lung bioenergetics", "PROBLEM", 0, 27], ["chronic obstructive lung disease", "PROBLEM", 91, 123], ["prohibitin", "TREATMENT", 147, 157], ["caspases", "TREATMENT", 327, 335], ["8 \u03bcM dactinomycin", "TREATMENT", 355, 372], ["apoptosis", "PROBLEM", 405, 414], ["lung", "ANATOMY", 9, 13], ["bioenergetics", "OBSERVATION", 14, 27], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["obstructive", "OBSERVATION_MODIFIER", 99, 110], ["lung", "ANATOMY", 111, 115], ["disease", "OBSERVATION", 116, 123]]], ["Additional file 1: Figure S3 also shows the feasibility of utilizing the described method to monitor the effects of influenza A virus on cellular respiration and caspase induction following in vitro exposure of lung tissue to the virus.DiscussionThe main limitation of the method described here is the need to collect and maintain viable lung tissue, avoiding ischemia and hypoxia.", [["cellular", "ANATOMY", 137, 145], ["lung tissue", "ANATOMY", 211, 222], ["lung tissue", "ANATOMY", 338, 349], ["ischemia", "DISEASE", 360, 368], ["hypoxia", "DISEASE", 373, 380], ["influenza A virus", "ORGANISM", 116, 133], ["cellular", "CELL", 137, 145], ["caspase", "GENE_OR_GENE_PRODUCT", 162, 169], ["lung tissue", "TISSUE", 211, 222], ["lung tissue", "TISSUE", 338, 349], ["caspase", "PROTEIN", 162, 169], ["influenza A virus", "SPECIES", 116, 133], ["influenza A virus", "PROBLEM", 116, 133], ["cellular respiration", "TREATMENT", 137, 157], ["caspase induction", "TREATMENT", 162, 179], ["lung tissue", "PROBLEM", 211, 222], ["the virus", "PROBLEM", 226, 235], ["viable lung tissue", "PROBLEM", 331, 349], ["ischemia", "PROBLEM", 360, 368], ["hypoxia", "PROBLEM", 373, 380], ["influenza", "OBSERVATION", 116, 125], ["lung", "ANATOMY", 211, 215], ["lung", "ANATOMY", 338, 342], ["tissue", "OBSERVATION", 343, 349], ["ischemia", "OBSERVATION", 360, 368], ["hypoxia", "OBSERVATION", 373, 380]]], ["The lung should be well perfused and oxygenated throughout the procedure.", [["lung", "ANATOMY", 4, 8], ["lung", "ORGAN", 4, 8], ["the procedure", "TREATMENT", 59, 72], ["lung", "ANATOMY", 4, 8], ["perfused", "OBSERVATION", 24, 32], ["oxygenated", "OBSERVATION_MODIFIER", 37, 47]]], ["Another limitation is the use of high oxygen concentration during in vitro incubation, which may promote free radical reactions.", [["oxygen", "CHEMICAL", 38, 44], ["oxygen", "CHEMICAL", 38, 44], ["oxygen", "SIMPLE_CHEMICAL", 38, 44], ["high oxygen concentration", "TREATMENT", 33, 58], ["vitro incubation", "TREATMENT", 69, 85], ["free radical reactions", "PROBLEM", 105, 127], ["free radical", "OBSERVATION", 105, 117]]], ["Thus, the described system is not ideal for testing pathogens, as exposure to high concentrations of O2 may produce non-physiological aberrations.", [["O2", "CHEMICAL", 101, 103], ["O2", "CHEMICAL", 101, 103], ["O2", "SIMPLE_CHEMICAL", 101, 103], ["testing pathogens", "PROBLEM", 44, 61], ["high concentrations of O2", "PROBLEM", 78, 103], ["non-physiological aberrations", "PROBLEM", 116, 145], ["non-physiological aberrations", "OBSERVATION", 116, 145]]], ["The use of 95% oxygen, however, was not associated with noticeable toxicities (Figure 1).", [["oxygen", "CHEMICAL", 15, 21], ["toxicities", "DISEASE", 67, 77], ["oxygen", "CHEMICAL", 15, 21], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["95% oxygen", "TREATMENT", 11, 21], ["noticeable toxicities", "PROBLEM", 56, 77]]], ["Nevertheless, this method may not be applicable to toxins that are likely to generate reactive oxygen species.", [["oxygen", "CHEMICAL", 95, 101], ["oxygen", "CHEMICAL", 95, 101], ["reactive oxygen species", "SIMPLE_CHEMICAL", 86, 109], ["reactive oxygen species", "PROBLEM", 86, 109], ["reactive", "OBSERVATION_MODIFIER", 86, 94], ["oxygen species", "OBSERVATION", 95, 109]]], ["Adequate buffering with a free radical scavenger (e.g., glutathione) may be helpful.", [["glutathione", "CHEMICAL", 56, 67], ["glutathione", "CHEMICAL", 56, 67], ["glutathione", "SIMPLE_CHEMICAL", 56, 67], ["a free radical scavenger", "TREATMENT", 24, 48]]], ["The use of air-saturated buffer (Figure 2), intermittently oxygenated solution (Additional file 1: Figure S1, Panels A\u2013C) or room air saturated with 5% CO2 (Additional file 1: Figure S2, Panel A) was associated with impaired cellular bioenergetics.ConclusionsThe described method is relatively simple and requires minimal tissue handling.", [["cellular", "ANATOMY", 225, 233], ["tissue", "ANATOMY", 322, 328], ["CO2", "CHEMICAL", 152, 155], ["CO2", "CHEMICAL", 152, 155], ["CO2", "SIMPLE_CHEMICAL", 152, 155], ["cellular", "CELL", 225, 233], ["tissue", "TISSUE", 322, 328], ["air-saturated buffer", "TREATMENT", 11, 31], ["intermittently oxygenated solution", "TREATMENT", 44, 78], ["impaired cellular bioenergetics", "PROBLEM", 216, 247], ["cellular bioenergetics", "OBSERVATION", 225, 247], ["relatively", "OBSERVATION_MODIFIER", 283, 293], ["simple", "OBSERVATION", 294, 300], ["minimal tissue", "OBSERVATION", 314, 328]]], ["It permits comprehensive analyses (e.g., cellular respiration, ATP and caspase activity) over several hours.", [["cellular", "ANATOMY", 41, 49], ["ATP", "CHEMICAL", 63, 66], ["ATP", "CHEMICAL", 63, 66], ["cellular", "CELL", 41, 49], ["ATP", "SIMPLE_CHEMICAL", 63, 66], ["caspase", "GENE_OR_GENE_PRODUCT", 71, 78], ["caspase", "PROTEIN", 71, 78], ["comprehensive analyses", "TEST", 11, 33], ["cellular respiration", "TEST", 41, 61], ["ATP", "TREATMENT", 63, 66], ["caspase activity", "TEST", 71, 87]]], ["These biomarkers can be used to study the effects of toxins and pathogens on lung tissue.Competing interestsThe author(s) declare that they have no competing interests.Authors\u2019 contributionsARA, MTA, and ASA designed the study, carried out the analysis, interpreted the data and drafted the manuscript.", [["lung tissue", "ANATOMY", 77, 88], ["lung tissue", "TISSUE", 77, 88], ["These biomarkers", "TEST", 0, 16], ["toxins", "PROBLEM", 53, 59], ["pathogens on lung tissue", "PROBLEM", 64, 88], ["MTA", "TREATMENT", 195, 198], ["ASA", "TREATMENT", 204, 207], ["the study", "TEST", 217, 226], ["the analysis", "TEST", 240, 252], ["lung", "ANATOMY", 77, 81], ["tissue", "OBSERVATION", 82, 88]]], ["ARO measured caspase activity.", [["caspase", "GENE_OR_GENE_PRODUCT", 13, 20], ["caspase", "PROTEIN", 13, 20], ["caspase activity", "OBSERVATION", 13, 29]]], ["SA and AA performed the histology.", [["AA", "CHEMICAL", 7, 9], ["the histology", "TEST", 20, 33]]], ["TP conceived of the study, measured respiration and ATP content.", [["ATP", "CHEMICAL", 52, 55], ["ATP", "CHEMICAL", 52, 55], ["TP", "GENE_OR_GENE_PRODUCT", 0, 2], ["ATP", "SIMPLE_CHEMICAL", 52, 55], ["the study", "TEST", 16, 25], ["ATP content", "TEST", 52, 63], ["ATP content", "OBSERVATION", 52, 63]]], ["SMH and SMV prepared influenza virus.", [["SMH", "CHEMICAL", 0, 3], ["influenza virus", "DISEASE", 21, 36], ["SMH", "GENE_OR_GENE_PRODUCT", 0, 3], ["SMV", "ORGANISM", 8, 11], ["influenza virus", "ORGANISM", 21, 36], ["influenza virus", "SPECIES", 21, 36], ["SMV", "SPECIES", 8, 11], ["SMH", "PROBLEM", 0, 3], ["SMV prepared influenza virus", "PROBLEM", 8, 36], ["SMV", "ANATOMY", 8, 11], ["influenza virus", "OBSERVATION", 21, 36]]]], "60093aec8af44fbfe6f2ac7f9fedb580f43949a2": [["The first case of severe acute respiratory syndrome (SARS) was identified in China in November, 2002 and was followed by a worldwide epidemic that had caused, by September 2003, 8098 cases and 774 deaths in 29 countries World Health Organization 2003) .", [["acute respiratory syndrome", "DISEASE", 25, 51], ["SARS", "DISEASE", 53, 57], ["deaths", "DISEASE", 197, 203], ["severe acute respiratory syndrome", "PROBLEM", 18, 51], ["SARS", "PROBLEM", 53, 57], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["respiratory syndrome", "OBSERVATION", 31, 51]]], ["Research groups rapidly identified the cause to be a novel coronavirus that was designated as SARS-associated coronavirus (SARS-CoV) (Drosten et al. 2003; Fouchier et al. 2003a; Ksiazek et al. 2003; Peiris et al. 2003b) .", [["coronavirus", "DISEASE", 59, 70], ["SARS-associated coronavirus", "DISEASE", 94, 121], ["SARS-CoV)", "DISEASE", 123, 132], ["coronavirus", "ORGANISM", 59, 70], ["SARS-associated coronavirus", "ORGANISM", 94, 121], ["SARS-CoV", "ORGANISM", 123, 131], ["SARS-associated coronavirus", "SPECIES", 94, 121], ["SARS-CoV", "SPECIES", 123, 131], ["a novel coronavirus", "PROBLEM", 51, 70], ["SARS", "PROBLEM", 94, 98], ["coronavirus", "PROBLEM", 110, 121]]]], "PMC7111202": [["IntroductionHuman monoclonal antibodies (mAbs) are promising therapeutic molecules that can be used for the prevention or treatment of viral infectious diseases.", [["viral infectious diseases", "DISEASE", 135, 160], ["IntroductionHuman monoclonal antibodies", "PROTEIN", 0, 39], ["mAbs", "PROTEIN", 41, 45], ["IntroductionHuman monoclonal antibodies (mAbs", "TREATMENT", 0, 45], ["therapeutic molecules", "TREATMENT", 61, 82], ["viral infectious diseases", "PROBLEM", 135, 160], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["infectious", "OBSERVATION", 141, 151]]], ["In recent years, advances in human B cell isolation techniques have led to the identification of large numbers of therapeutic mAb candidates against many life-threatening viral pathogens.", [["B cell", "ANATOMY", 35, 41], ["human", "ORGANISM", 29, 34], ["B cell", "CELL", 35, 41], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["human B cell isolation techniques", "TREATMENT", 29, 62], ["therapeutic mAb candidates", "TREATMENT", 114, 140], ["threatening viral pathogens", "PROBLEM", 159, 186], ["large", "OBSERVATION_MODIFIER", 97, 102], ["viral pathogens", "OBSERVATION", 171, 186]]], ["These targets include antigenically variable viruses, such as human immunodeficiency virus (HIV) (Sok and Burton, 2018) and influenza virus (Laursen and Wilson, 2013), or newly emerging pathogens with high epidemic potential, including Ebola virus (Bornholdt et al., 2016), Marburg virus (Flyak et al., 2015), Zika virus (Sapparapu et al., 2016, Stettler et al., 2016, Wang et al., 2016b), Lassa virus (Robinson et al., 2016), Middle East respiratory syndrome coronavirus (MERS-CoV) (Corti et al., 2016b), poxviruses (Gilchuk et al., 2016), Nipah virus (Geisbert et al., 2014), and many other medically important viruses.", [["human immunodeficiency virus (HIV)", "DISEASE", 62, 96], ["influenza virus", "DISEASE", 124, 139], ["Ebola virus", "DISEASE", 236, 247], ["Lassa virus", "DISEASE", 390, 401], ["Middle East respiratory syndrome coronavirus", "DISEASE", 427, 471], ["Nipah virus", "DISEASE", 541, 552], ["human immunodeficiency virus", "ORGANISM", 62, 90], ["HIV", "ORGANISM", 92, 95], ["influenza virus", "ORGANISM", 124, 139], ["Ebola virus", "ORGANISM", 236, 247], ["Marburg virus", "ORGANISM", 274, 287], ["Zika virus", "ORGANISM", 310, 320], ["Lassa virus", "ORGANISM", 390, 401], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 427, 471], ["MERS-CoV", "ORGANISM", 473, 481], ["poxviruses", "ORGANISM", 506, 516], ["Nipah virus", "ORGANISM", 541, 552], ["human immunodeficiency virus (HIV", "SPECIES", 62, 95], ["influenza virus", "SPECIES", 124, 139], ["Ebola virus", "SPECIES", 236, 247], ["Marburg virus", "SPECIES", 274, 287], ["Lassa virus", "SPECIES", 390, 401], ["Nipah virus", "SPECIES", 541, 552], ["human immunodeficiency virus", "SPECIES", 62, 90], ["HIV", "SPECIES", 92, 95], ["Ebola virus", "SPECIES", 236, 247], ["Marburg virus", "SPECIES", 274, 287], ["Zika virus", "SPECIES", 310, 320], ["Lassa virus", "SPECIES", 390, 401], ["Middle East respiratory syndrome coronavirus", "SPECIES", 427, 471], ["MERS-CoV", "SPECIES", 473, 481], ["Nipah virus", "SPECIES", 541, 552], ["antigenically variable viruses", "PROBLEM", 22, 52], ["human immunodeficiency virus", "PROBLEM", 62, 90], ["influenza virus", "PROBLEM", 124, 139], ["newly emerging pathogens", "PROBLEM", 171, 195], ["Ebola virus", "PROBLEM", 236, 247], ["Marburg virus", "PROBLEM", 274, 287], ["Zika virus", "PROBLEM", 310, 320], ["Lassa virus", "PROBLEM", 390, 401], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 427, 471], ["poxviruses", "PROBLEM", 506, 516], ["Nipah virus", "PROBLEM", 541, 552], ["variable", "OBSERVATION_MODIFIER", 36, 44], ["viruses", "OBSERVATION", 45, 52], ["Middle", "ANATOMY_MODIFIER", 427, 433], ["respiratory syndrome", "ANATOMY", 439, 459], ["viruses", "OBSERVATION", 613, 620]]], ["Over 25 antiviral human mAbs are now being evaluated as human therapeutics in clinical trials (Walker and Burton, 2018), including several for ebolavirus therapy (NIH, 2019).IntroductionAntibodies can mediate protection by direct virus neutralization and/or by engagement of innate immune cells via their Fc receptors (FcRs) (Crowe, 2017, Lu et al., 2018).", [["immune cells", "ANATOMY", 282, 294], ["human", "ORGANISM", 18, 23], ["human", "ORGANISM", 56, 61], ["innate immune cells", "CELL", 275, 294], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 305, 317], ["FcRs", "GENE_OR_GENE_PRODUCT", 319, 323], ["antiviral human mAbs", "PROTEIN", 8, 28], ["innate immune cells", "CELL_TYPE", 275, 294], ["Fc receptors", "PROTEIN", 305, 317], ["FcRs", "PROTEIN", 319, 323], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 56, 61], ["antiviral human mAbs", "TREATMENT", 8, 28], ["Walker", "TREATMENT", 95, 101], ["ebolavirus therapy", "TREATMENT", 143, 161], ["IntroductionAntibodies", "TREATMENT", 174, 196], ["direct virus neutralization", "TREATMENT", 223, 250]]], ["Potent neutralization, broad reactivity, and protective capacity are desirable mAb features, which could be used to select leads for development as a monotherapy or cocktail.", [["mAb", "PROTEIN", 79, 82], ["Potent neutralization", "TREATMENT", 0, 21], ["protective capacity", "PROBLEM", 45, 64], ["a monotherapy or cocktail", "TREATMENT", 148, 173], ["neutralization", "OBSERVATION", 7, 21], ["broad", "OBSERVATION_MODIFIER", 23, 28], ["reactivity", "OBSERVATION_MODIFIER", 29, 39]]], ["A cocktail might offer greater efficacy and resistance to viral escape (Corti et al., 2016a, Keeffe et al., 2018, Wec et al., 2019), but the molecular and structural basis for the optimal combination of mAbs is ill-defined.", [["mAbs", "GENE_OR_GENE_PRODUCT", 203, 207], ["mAbs", "PROTEIN", 203, 207], ["A cocktail", "TREATMENT", 0, 10], ["mAbs", "OBSERVATION", 203, 207], ["ill", "OBSERVATION_MODIFIER", 211, 214]]], ["Current mAb discovery approaches typically are focused on antibody variable fragment (Fv)-region-mediated biological functions of single isolated mAbs (e.g., binding and neutralization) or Fc-region-mediated effector functions (Walker and Burton, 2018).", [["Fc-", "GENE_OR_GENE_PRODUCT", 189, 192], ["mAb", "PROTEIN", 8, 11], ["Fv", "PROTEIN", 86, 88], ["mAbs", "PROTEIN", 146, 150], ["Fc-region", "PROTEIN", 189, 198], ["antibody variable fragment", "PROBLEM", 58, 84], ["single isolated mAbs", "PROBLEM", 130, 150], ["Fc-region", "PROBLEM", 189, 198], ["fragment", "OBSERVATION_MODIFIER", 76, 84], ["mAbs", "OBSERVATION", 146, 150]]], ["Molecular interactions in which two or more mAbs recognize the same antigen in an enhanced (e.g., cooperative or synergistic) fashion are less well investigated, but these interactions might contribute greatly to the overall efficacy of protective cocktails (Carlsen et al., 2014, Doria-Rose et al., 2012, Howell et al., 2017, Mascola et al., 1997).", [["mAbs", "PROTEIN", 44, 48], ["Molecular interactions", "PROBLEM", 0, 22], ["protective cocktails", "TREATMENT", 237, 257]]], ["One key challenge that impedes progress in this area is that the structural determinants of cooperativity by neutralizing antibodies are poorly understood.", [["neutralizing antibodies", "PROTEIN", 109, 132]]], ["Development of synergistic mAb cocktails against viruses with high antigenic variability, including HIV, hepatitis C, norovirus, influenza virus, or Ebola virus, is also thwarted by the fact that only a small subset of virus-specific mAbs available for incorporation in cocktails is broadly cross-reactive to all field strains.", [["HIV, hepatitis C", "DISEASE", 100, 116], ["norovirus", "DISEASE", 118, 127], ["influenza virus", "DISEASE", 129, 144], ["Ebola virus", "DISEASE", 149, 160], ["mAb", "GENE_OR_GENE_PRODUCT", 27, 30], ["HIV", "ORGANISM", 100, 103], ["hepatitis C", "ORGANISM", 105, 116], ["norovirus", "ORGANISM", 118, 127], ["influenza virus", "ORGANISM", 129, 144], ["Ebola virus", "ORGANISM", 149, 160], ["mAbs", "GENE_OR_GENE_PRODUCT", 234, 238], ["mAbs", "PROTEIN", 234, 238], ["HIV", "SPECIES", 100, 103], ["influenza virus", "SPECIES", 129, 144], ["Ebola virus", "SPECIES", 149, 160], ["HIV", "SPECIES", 100, 103], ["influenza virus", "SPECIES", 129, 144], ["Ebola virus", "SPECIES", 149, 160], ["synergistic mAb cocktails", "TREATMENT", 15, 40], ["viruses", "PROBLEM", 49, 56], ["high antigenic variability", "PROBLEM", 62, 88], ["HIV", "PROBLEM", 100, 103], ["hepatitis C", "PROBLEM", 105, 116], ["norovirus", "PROBLEM", 118, 127], ["influenza virus", "PROBLEM", 129, 144], ["Ebola virus", "PROBLEM", 149, 160], ["a small subset of virus", "PROBLEM", 201, 224], ["specific mAbs", "TREATMENT", 225, 238], ["incorporation in cocktails", "TREATMENT", 253, 279], ["synergistic", "OBSERVATION_MODIFIER", 15, 26], ["mAb", "OBSERVATION", 27, 30], ["high", "OBSERVATION_MODIFIER", 62, 66], ["antigenic variability", "OBSERVATION", 67, 88], ["Ebola virus", "OBSERVATION", 149, 160], ["small", "OBSERVATION_MODIFIER", 203, 208]]], ["Another challenge is the relatively small number of mAb combinations that can be tested iteratively for therapeutic efficacy given the high cost and labor of in vivo virus challenge studies, especially when non-human primate (NHP) large animal model testing is needed.", [["mAb", "GENE_OR_GENE_PRODUCT", 52, 55], ["non-human primate", "ORGANISM", 207, 224], ["NHP", "ORGANISM", 226, 229], ["mAb", "PROTEIN", 52, 55], ["mAb combinations", "TREATMENT", 52, 68], ["therapeutic efficacy", "TREATMENT", 104, 124], ["the high cost", "PROBLEM", 131, 144], ["labor", "PROBLEM", 149, 154], ["vivo virus challenge studies", "TEST", 161, 189], ["large animal model testing", "TEST", 231, 257], ["small", "OBSERVATION_MODIFIER", 36, 41]]], ["Therefore, for the rational development of antiviral therapeutic mAb cocktails it is important to implement approaches to identify combinations of mAbs with optimized molecular interactions in formulated cocktails, along with structural and functional analysis to define features that mediate efficient protection by these mAbs.IntroductionIn this study, we describe the design of a cooperative two-antibody cocktail possessing neutralizing activity against the primary ebolaviruses that are responsible for outbreaks in humans\u2014Ebola (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses (Kuhn, 2017).", [["primary ebolaviruses", "DISEASE", 462, 482], ["Ebola", "DISEASE", 528, 533], ["mAbs", "GENE_OR_GENE_PRODUCT", 323, 327], ["ebolaviruses", "CANCER", 470, 482], ["humans", "ORGANISM", 521, 527], ["Ebola", "ORGANISM", 528, 533], ["EBOV", "ORGANISM", 535, 539], ["Bundibugyo (BDBV", "ORGANISM", 542, 558], ["Sudan (SUDV", "ORGANISM", 565, 576], ["mAbs", "PROTEIN", 147, 151], ["mAbs", "PROTEIN", 323, 327], ["humans", "SPECIES", 521, 527], ["Ebola", "SPECIES", 528, 533], ["humans", "SPECIES", 521, 527], ["EBOV", "SPECIES", 535, 539], ["BDBV", "SPECIES", 554, 558], ["SUDV", "SPECIES", 572, 576], ["antiviral therapeutic mAb cocktails", "TREATMENT", 43, 78], ["mAbs", "TREATMENT", 147, 151], ["formulated cocktails", "TREATMENT", 193, 213], ["structural and functional analysis", "TEST", 226, 260], ["this study", "TEST", 343, 353], ["a cooperative two-antibody cocktail", "TREATMENT", 381, 416], ["the primary ebolaviruses", "PROBLEM", 458, 482], ["Ebola", "PROBLEM", 528, 533], ["Bundibugyo", "TEST", 542, 552]]], ["EBOV causes a severe disease in humans with 25% to 90% case fatality rates and significant epidemic potential.", [["EBOV", "DISEASE", 0, 4], ["EBOV", "ORGANISM", 0, 4], ["humans", "ORGANISM", 32, 38], ["humans", "SPECIES", 32, 38], ["EBOV", "SPECIES", 0, 4], ["humans", "SPECIES", 32, 38], ["a severe disease in humans", "PROBLEM", 12, 38], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["disease", "OBSERVATION", 21, 28], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["epidemic", "OBSERVATION_MODIFIER", 91, 99]]], ["The largest epidemic to date occurred in 2013\u20132016 in West Africa with a total of 28,646 cases of Ebola virus disease (EVD) and 11,323 deaths reported (Coltart et al., 2017).", [["Ebola virus disease", "DISEASE", 98, 117], ["EVD", "DISEASE", 119, 122], ["deaths", "DISEASE", 135, 141], ["Ebola virus", "ORGANISM", 98, 109], ["Ebola virus", "SPECIES", 98, 109], ["Ebola virus", "SPECIES", 98, 109], ["Ebola virus disease", "PROBLEM", 98, 117], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["epidemic", "OBSERVATION", 12, 20], ["Ebola virus disease", "OBSERVATION", 98, 117]]], ["This and the new ongoing outbreak in the Democratic Republic of the Congo (DRC) (CDC, 2019) highlighted the need to accelerate development of EVD therapeutics (Park et al., 2015, Urbanowicz et al., 2016).", [["EVD therapeutics", "TREATMENT", 142, 158], ["new", "OBSERVATION_MODIFIER", 13, 16], ["ongoing", "OBSERVATION_MODIFIER", 17, 24], ["outbreak", "OBSERVATION_MODIFIER", 25, 33]]], ["The ebolavirus envelope (E) contains a single surface protein, the glycoprotein (GP), which is the major target for neutralizing mAbs (Lee and Saphire, 2009).", [["surface", "ANATOMY", 46, 53], ["ebolavirus envelope", "ORGANISM", 4, 23], ["GP", "GENE_OR_GENE_PRODUCT", 81, 83], ["surface protein", "PROTEIN", 46, 61], ["glycoprotein", "PROTEIN", 67, 79], ["GP", "PROTEIN", 81, 83], ["neutralizing mAbs", "PROTEIN", 116, 133], ["a single surface protein", "TEST", 37, 61], ["ebolavirus", "OBSERVATION", 4, 14]]], ["We conducted analysis of >1,800 human mAbs against the GP and identified two classes of broadly reactive mAbs that cooperate for binding to the GP and neutralization of the virus.", [["human", "ORGANISM", 32, 37], ["mAbs", "GENE_OR_GENE_PRODUCT", 105, 109], ["GP", "GENE_OR_GENE_PRODUCT", 144, 146], ["human mAbs", "PROTEIN", 32, 42], ["GP", "PROTEIN", 55, 57], ["mAbs", "PROTEIN", 105, 109], ["GP", "PROTEIN", 144, 146], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["analysis", "TEST", 13, 21], ["broadly reactive mAbs", "TREATMENT", 88, 109], ["the virus", "PROBLEM", 169, 178], ["broadly", "OBSERVATION_MODIFIER", 88, 95], ["reactive mAbs", "OBSERVATION", 96, 109]]], ["High-resolution structures illuminated a mechanism of cooperativity.", [["-resolution", "OBSERVATION_MODIFIER", 4, 15]]], ["The two-antibody cocktail offered protection in mice against the most antigenically divergent virus SUDV and demonstrated high therapeutic efficacy against live EBOV challenge in NHPs.", [["SUDV", "CHEMICAL", 100, 104], ["EBOV", "DISEASE", 161, 165], ["mice", "ORGANISM", 48, 52], ["EBOV", "ORGANISM", 161, 165], ["NHPs", "ORGANISM", 179, 183], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["SUDV", "SPECIES", 100, 104], ["EBOV", "SPECIES", 161, 165], ["NHPs", "SPECIES", 179, 183], ["The two-antibody cocktail", "TREATMENT", 0, 25], ["protection", "TREATMENT", 34, 44], ["high therapeutic", "OBSERVATION_MODIFIER", 122, 138]]], ["These findings offered a rational strategy for development of a potent two-antibody cocktail design based on structural features of mAb interactions with ebolavirus GPs.Identification and Functional Properties of Candidate Cocktail Human mAbs ::: ResultsOur previous work identified two potent therapeutic candidate mAbs EBOV-515 (immunoglobulin G1 [IgG1] subclass) and EBOV-520 (IgG4 subclass) from the B cells in human survivors of EVD.", [["B cells", "ANATOMY", 404, 411], ["EVD", "DISEASE", 434, 437], ["mAb", "GENE_OR_GENE_PRODUCT", 132, 135], ["Human", "ORGANISM", 232, 237], ["EBOV", "ORGANISM", 321, 325], ["immunoglobulin G1", "GENE_OR_GENE_PRODUCT", 331, 348], ["IgG1", "GENE_OR_GENE_PRODUCT", 350, 354], ["EBOV-520", "GENE_OR_GENE_PRODUCT", 370, 378], ["IgG4", "GENE_OR_GENE_PRODUCT", 380, 384], ["B cells", "CELL", 404, 411], ["human", "ORGANISM", 415, 420], ["mAb", "PROTEIN", 132, 135], ["Candidate Cocktail Human mAbs", "PROTEIN", 213, 242], ["mAbs EBOV-515", "PROTEIN", 316, 329], ["immunoglobulin G1", "PROTEIN", 331, 348], ["IgG1] subclass", "PROTEIN", 350, 364], ["EBOV-520", "PROTEIN", 370, 378], ["IgG4 subclass", "PROTEIN", 380, 393], ["B cells", "CELL_TYPE", 404, 411], ["Human", "SPECIES", 232, 237], ["human", "SPECIES", 415, 420], ["human", "SPECIES", 415, 420], ["a potent two-antibody cocktail", "TREATMENT", 62, 92], ["mAb interactions", "PROBLEM", 132, 148], ["ebolavirus GPs", "PROBLEM", 154, 168], ["EBOV", "TEST", 321, 325], ["immunoglobulin G1", "TEST", 331, 348], ["subclass", "TEST", 356, 364], ["EBOV", "TEST", 370, 374], ["IgG4 subclass", "TEST", 380, 393], ["EVD", "TREATMENT", 434, 437], ["EVD", "OBSERVATION", 434, 437]]], ["Each of these mAbs binds to a conserved epitope on the base of the GP, neutralizes all three ebolaviruses causing the disease in humans (EBOV, SUDV, and BDBV), protects mice challenged with EBOV, and offers partial protection against BDBV and SUDV (Gilchuk et al., 2018).", [["BDBV", "CHEMICAL", 234, 238], ["mAbs", "GENE_OR_GENE_PRODUCT", 14, 18], ["GP", "GENE_OR_GENE_PRODUCT", 67, 69], ["humans", "ORGANISM", 129, 135], ["EBOV", "ORGANISM", 137, 141], ["SUDV", "GENE_OR_GENE_PRODUCT", 143, 147], ["BDBV", "GENE_OR_GENE_PRODUCT", 153, 157], ["mice", "ORGANISM", 169, 173], ["EBOV", "ORGANISM", 190, 194], ["BDBV", "SIMPLE_CHEMICAL", 234, 238], ["mAbs", "PROTEIN", 14, 18], ["GP", "PROTEIN", 67, 69], ["humans", "SPECIES", 129, 135], ["mice", "SPECIES", 169, 173], ["humans", "SPECIES", 129, 135], ["EBOV", "SPECIES", 137, 141], ["SUDV", "SPECIES", 143, 147], ["BDBV", "SPECIES", 153, 157], ["mice", "SPECIES", 169, 173], ["EBOV", "SPECIES", 190, 194], ["BDBV", "SPECIES", 234, 238], ["SUDV", "SPECIES", 243, 247], ["these mAbs binds", "PROBLEM", 8, 24], ["the disease in humans", "PROBLEM", 114, 135], ["EBOV", "TREATMENT", 137, 141], ["SUDV", "TREATMENT", 143, 147], ["EBOV", "TREATMENT", 190, 194], ["partial protection", "TREATMENT", 207, 225], ["epitope", "OBSERVATION", 40, 47], ["base", "ANATOMY_MODIFIER", 55, 59], ["disease", "OBSERVATION", 118, 125]]], ["This work also revealed the class of non-competing, glycan-cap-region-specific mAbs that enhance binding of EBOV-515 and EBOV-520 to the GP in a cooperative manner (Gilchuk et al., 2018), suggesting a strategy for two-antibody cocktail design.", [["EBOV-515", "CHEMICAL", 108, 116], ["EBOV-520", "CHEMICAL", 121, 129], ["EBOV", "ORGANISM", 108, 112], ["EBOV", "ORGANISM", 121, 125], ["non-competing, glycan-cap-region", "PROTEIN", 37, 69], ["mAbs", "PROTEIN", 79, 83], ["GP", "PROTEIN", 137, 139], ["EBOV", "TEST", 108, 112], ["EBOV", "TEST", 121, 125], ["a strategy", "TREATMENT", 199, 209], ["two-antibody cocktail design", "TREATMENT", 214, 242]]], ["Here, we screened >1,800 GP-reactive human mAbs and identified two previously described glycan-cap-specific EBOV-437 and EBOV-442 (Gilchuk et al., 2018) and one additional mAb EBOV-548 (all IgG1 originally) as suitable partners to EBOV-515 or EBOV-520 for the design of cooperative two-antibody cocktail (Figures S1A\u2013E; Table S1).", [["EBOV-515", "CHEMICAL", 231, 239], ["EBOV-520", "CHEMICAL", 243, 251], ["human", "ORGANISM", 37, 42], ["mAbs", "CELL", 43, 47], ["EBOV", "ORGANISM", 108, 112], ["EBOV-442", "ORGANISM", 121, 129], ["IgG1", "GENE_OR_GENE_PRODUCT", 190, 194], ["EBOV-515", "ORGANISM", 231, 239], ["EBOV-520", "ORGANISM", 243, 251], ["GP", "PROTEIN", 25, 27], ["human mAbs", "PROTEIN", 37, 47], ["glycan-cap", "PROTEIN", 88, 98], ["mAb EBOV-548", "PROTEIN", 172, 184], ["IgG1", "PROTEIN", 190, 194], ["S1A\u2013E", "PROTEIN", 313, 318], ["S1", "PROTEIN", 326, 328], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["EBOV-437", "SPECIES", 108, 116], ["EBOV-442", "SPECIES", 121, 129], ["EBOV-515", "SPECIES", 231, 239], ["glycan-cap", "TEST", 88, 98], ["specific EBOV", "TEST", 99, 112], ["EBOV", "TEST", 121, 125], ["mAb EBOV", "TEST", 172, 180], ["all IgG1", "TEST", 186, 194], ["EBOV", "TEST", 231, 235], ["EBOV", "TEST", 243, 247], ["cooperative two-antibody cocktail", "TREATMENT", 270, 303]]], ["Partner candidate mAbs were filtered on the basis of (1) neutralizing activity against wild-type (WT) ebolavirus (EBOV at least); (2) broad reactivity to EBOV, BDBV, and SUDV GPs; (3) cooperative enhancement of EBOV-515 and EBOV-520 binding to the EBOV GP; and (4) capacity to protect against EBOV challenge in mice.Identification and Functional Properties of Candidate Cocktail Human mAbs ::: ResultsBecause of the potential utility of these mAbs as components of a therapeutic cocktail, we sought to characterize in depth the cooperative effects mediated by combinations of two mAbs.", [["EBOV-515", "CHEMICAL", 211, 219], ["EBOV-520", "CHEMICAL", 224, 232], ["mAbs", "GENE_OR_GENE_PRODUCT", 18, 22], ["wild-type (WT) ebolavirus", "ORGANISM", 87, 112], ["EBOV", "ORGANISM", 114, 118], ["EBOV", "ORGANISM", 154, 158], ["EBOV-515", "ORGANISM", 211, 219], ["EBOV-520", "ORGANISM", 224, 232], ["EBOV", "ORGANISM", 248, 252], ["EBOV", "ORGANISM", 293, 297], ["mice", "ORGANISM", 311, 315], ["Human", "ORGANISM", 379, 384], ["Partner candidate mAbs", "PROTEIN", 0, 22], ["Candidate Cocktail Human mAbs", "PROTEIN", 360, 389], ["mAbs", "PROTEIN", 443, 447], ["mAbs", "PROTEIN", 580, 584], ["mice", "SPECIES", 311, 315], ["Human", "SPECIES", 379, 384], ["EBOV", "SPECIES", 114, 118], ["EBOV", "SPECIES", 154, 158], ["BDBV", "SPECIES", 160, 164], ["EBOV-515", "SPECIES", 211, 219], ["EBOV-520", "SPECIES", 224, 232], ["EBOV", "SPECIES", 248, 252], ["EBOV", "SPECIES", 293, 297], ["mice", "SPECIES", 311, 315], ["type (WT) ebolavirus", "PROBLEM", 92, 112], ["EBOV", "TEST", 154, 158], ["BDBV", "TEST", 160, 164], ["EBOV", "TEST", 211, 215], ["EBOV", "TEST", 224, 228], ["these mAbs", "TREATMENT", 437, 447], ["a therapeutic cocktail", "TREATMENT", 465, 487]]], ["As the first partner of the cocktail, we chose the most well-characterized base-region-specific mAb EBOV-520.", [["EBOV-520", "CHEMICAL", 100, 108], ["mAb EBOV-520", "PROTEIN", 96, 108], ["the cocktail", "TREATMENT", 24, 36]]], ["We expressed the variable gene sequences for this mAb in Chinese hamster ovary (CHO) cells as a recombinant IgG1-LALA Fc mutant molecule (rEBOV-520 LALA, or rEBOV-520) to diminish Fc effector function. rEBOV-520 LALA possessed the highest protective efficacy with low-dose treatment against EBOV in mice (Kuzmina et al., 2018) and acted principally via neutralization to protect against EBOV (Gilchuk et al., 2018).", [["hamster ovary (CHO) cells", "ANATOMY", 65, 90], ["rEBOV-520 LALA", "CHEMICAL", 138, 152], ["rEBOV-520", "CHEMICAL", 157, 166], ["rEBOV-520 LALA", "CHEMICAL", 202, 216], ["EBOV", "DISEASE", 291, 295], ["rEBOV-520", "CHEMICAL", 202, 211], ["Chinese hamster ovary (CHO) cells", "CELL", 57, 90], ["IgG1", "GENE_OR_GENE_PRODUCT", 108, 112], ["rEBOV-520", "SIMPLE_CHEMICAL", 157, 166], ["Fc", "GENE_OR_GENE_PRODUCT", 180, 182], ["EBOV", "ORGANISM", 291, 295], ["mice", "ORGANISM", 299, 303], ["EBOV", "ORGANISM", 387, 391], ["variable gene sequences", "DNA", 17, 40], ["mAb", "PROTEIN", 50, 53], ["Chinese hamster ovary (CHO) cells", "CELL_LINE", 57, 90], ["IgG1", "PROTEIN", 108, 112], ["LALA Fc mutant molecule", "PROTEIN", 113, 136], ["rEBOV", "PROTEIN", 138, 143], ["rEBOV", "PROTEIN", 157, 162], ["Fc", "PROTEIN", 180, 182], ["mice", "SPECIES", 299, 303], ["Chinese hamster", "SPECIES", 57, 72], ["EBOV", "SPECIES", 291, 295], ["mice", "SPECIES", 299, 303], ["EBOV", "SPECIES", 387, 391], ["the variable gene sequences", "PROBLEM", 13, 40], ["this mAb", "TREATMENT", 45, 53], ["a recombinant IgG1", "TEST", 94, 112], ["rEBOV", "TEST", 138, 143], ["LALA", "TEST", 148, 152], ["rEBOV", "TEST", 157, 162], ["rEBOV", "TEST", 202, 207], ["low-dose treatment", "TREATMENT", 264, 282], ["EBOV in mice", "TREATMENT", 291, 303], ["ovary", "ANATOMY", 73, 78]]], ["The second cocktail partner, mAb EBOV-548, potently neutralized EBOV and showed the highest activity of three identified cooperative glycan-cap-specific mAbs in a cooperative binding to the GP with rEBOV-520 as a partner mAb.", [["EBOV-548", "CHEMICAL", 33, 41], ["rEBOV-520", "CHEMICAL", 198, 207], ["rEBOV-520", "CHEMICAL", 198, 207], ["EBOV", "ORGANISM", 64, 68], ["rEBOV-520", "SIMPLE_CHEMICAL", 198, 207], ["cooperative glycan-cap-specific mAbs", "PROTEIN", 121, 157], ["GP", "PROTEIN", 190, 192], ["rEBOV", "PROTEIN", 198, 203], ["partner mAb", "PROTEIN", 213, 224], ["EBOV-548", "SPECIES", 33, 41], ["EBOV", "SPECIES", 64, 68], ["mAb EBOV", "TEST", 29, 37], ["rEBOV", "TEST", 198, 203]]], ["EBOV-548 was produced as a functionally competent IgG1 (designated here as rEBOV-548 IgG1 or rEBOV-548), because engagement of the Fc region might be important for protection by the GP glycan-cap-specific mAbs (Gunn et al., 2018).Identification and Functional Properties of Candidate Cocktail Human mAbs ::: ResultsTo assess the Fc-mediated killing of antigen-expressing cells by engineered variants of EBOV-520 and EBOV-548, we used a stably transfected EBOV-GP-expressing SNAP-tagged 293F cell line as a target and heterologous human peripheral blood mononuclear cells (PBMCs) as a source of effector cells.", [["cells", "ANATOMY", 371, 376], ["293F cell line", "ANATOMY", 486, 500], ["peripheral blood mononuclear cells", "ANATOMY", 536, 570], ["PBMCs", "ANATOMY", 572, 577], ["effector cells", "ANATOMY", 594, 608], ["EBOV-548", "CHEMICAL", 0, 8], ["rEBOV-548", "CHEMICAL", 93, 102], ["EBOV-520", "CHEMICAL", 403, 411], ["EBOV-548", "CHEMICAL", 416, 424], ["SNAP", "CHEMICAL", 474, 478], ["EBOV", "ORGANISM", 0, 4], ["IgG1", "GENE_OR_GENE_PRODUCT", 50, 54], ["rEBOV-548 IgG1", "GENE_OR_GENE_PRODUCT", 75, 89], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 93, 102], ["Fc", "GENE_OR_GENE_PRODUCT", 131, 133], ["Human", "ORGANISM", 293, 298], ["Fc", "GENE_OR_GENE_PRODUCT", 329, 331], ["antigen", "GENE_OR_GENE_PRODUCT", 352, 359], ["cells", "CELL", 371, 376], ["EBOV-520", "ORGANISM", 403, 411], ["EBOV-548", "ORGANISM", 416, 424], ["EBOV", "ORGANISM", 455, 459], ["GP", "GENE_OR_GENE_PRODUCT", 460, 462], ["SNAP", "GENE_OR_GENE_PRODUCT", 474, 478], ["293F cell line", "CELL", 486, 500], ["human", "ORGANISM", 530, 535], ["peripheral blood mononuclear cells", "CELL", 536, 570], ["PBMCs", "CELL", 572, 577], ["cells", "CELL", 603, 608], ["IgG1", "PROTEIN", 50, 54], ["rEBOV", "PROTEIN", 75, 80], ["548 IgG1", "PROTEIN", 81, 89], ["rEBOV", "PROTEIN", 93, 98], ["548", "PROTEIN", 99, 102], ["Fc region", "PROTEIN", 131, 140], ["GP glycan-cap-specific mAbs", "PROTEIN", 182, 209], ["Candidate Cocktail Human mAbs", "PROTEIN", 274, 303], ["Fc", "PROTEIN", 329, 331], ["antigen-expressing cells", "CELL_TYPE", 352, 376], ["EBOV-GP-expressing SNAP-tagged 293F cell line", "CELL_LINE", 455, 500], ["heterologous human peripheral blood mononuclear cells", "CELL_TYPE", 517, 570], ["PBMCs", "CELL_TYPE", 572, 577], ["effector cells", "CELL_TYPE", 594, 608], ["Human", "SPECIES", 293, 298], ["human", "SPECIES", 530, 535], ["EBOV-548", "SPECIES", 0, 8], ["EBOV-520", "SPECIES", 403, 411], ["EBOV-548", "SPECIES", 416, 424], ["EBOV", "SPECIES", 455, 459], ["human", "SPECIES", 530, 535], ["the Fc", "TEST", 325, 331], ["EBOV", "TEST", 403, 407], ["EBOV", "TEST", 416, 420], ["SNAP", "TEST", 474, 478], ["heterologous human peripheral blood mononuclear cells", "PROBLEM", 517, 570], ["PBMCs", "TEST", 572, 577], ["effector cells", "PROBLEM", 594, 608], ["cell line", "OBSERVATION", 491, 500], ["mononuclear cells", "OBSERVATION", 553, 570], ["effector cells", "OBSERVATION", 594, 608]]], ["The SNAP-tag is a self-labeling protein tag that allows specific labeling of a target cell line with fluorescent dye, facilitating detection of effector-cell-mediated killing activity by flow cytometry (Domi et al., 2018). rEBOV-520 LALA showed low cytotoxic activity when compared with that of the control rEBOV-520 WT IgG1. rEBOV-548 IgG1 mediated efficient cell killing that was comparable to that of a recombinant form of a glycan-cap-directed mAb c13C6, which is included in the ZMapp\u2122 cocktail (Figure 1A) (Davidson et al., 2015).", [["cell line", "ANATOMY", 86, 95], ["effector-cell", "ANATOMY", 144, 157], ["cell", "ANATOMY", 360, 364], ["SNAP", "CHEMICAL", 4, 8], ["rEBOV-520", "CHEMICAL", 223, 232], ["LALA", "CHEMICAL", 233, 237], ["rEBOV-548", "CHEMICAL", 326, 335], ["rEBOV-520", "CHEMICAL", 223, 232], ["SNAP", "SIMPLE_CHEMICAL", 4, 8], ["cell line", "CELL", 86, 95], ["fluorescent dye", "SIMPLE_CHEMICAL", 101, 116], ["cell", "CELL", 153, 157], ["IgG1", "GENE_OR_GENE_PRODUCT", 320, 324], ["IgG1", "GENE_OR_GENE_PRODUCT", 336, 340], ["cell", "CELL", 360, 364], ["mAb c13C6", "SIMPLE_CHEMICAL", 448, 457], ["SNAP-tag", "DNA", 4, 12], ["target cell line", "CELL_LINE", 79, 95], ["rEBOV-520 WT IgG1", "PROTEIN", 307, 324], ["rEBOV-548 IgG1", "PROTEIN", 326, 340], ["glycan-cap-directed mAb c13C6", "PROTEIN", 428, 457], ["ZMapp\u2122 cocktail", "PROTEIN", 484, 499], ["The SNAP", "TEST", 0, 8], ["a self-labeling protein tag", "PROBLEM", 16, 43], ["a target cell line", "TREATMENT", 77, 95], ["fluorescent dye", "TEST", 101, 116], ["flow cytometry", "TEST", 187, 201], ["rEBOV", "TEST", 223, 228], ["LALA", "TEST", 233, 237], ["low cytotoxic activity", "PROBLEM", 245, 267], ["rEBOV", "TEST", 326, 331], ["efficient cell killing", "PROBLEM", 350, 372], ["target cell line", "OBSERVATION", 79, 95], ["low", "OBSERVATION_MODIFIER", 245, 248], ["cytotoxic activity", "OBSERVATION", 249, 267], ["cell killing", "OBSERVATION", 360, 372]]], ["Similar functional profiles of these two mAbs were obtained using bead- or solid-phase-immobilized GP ectodomains and various human effector cells (Figures S1A and S1C).", [["effector cells", "ANATOMY", 132, 146], ["mAbs", "GENE_OR_GENE_PRODUCT", 41, 45], ["human", "ORGANISM", 126, 131], ["effector cells", "CELL", 132, 146], ["Figures S1A", "GENE_OR_GENE_PRODUCT", 148, 159], ["S1C", "GENE_OR_GENE_PRODUCT", 164, 167], ["mAbs", "PROTEIN", 41, 45], ["GP ectodomains", "PROTEIN", 99, 113], ["human effector cells", "CELL_TYPE", 126, 146], ["S1A", "PROTEIN", 156, 159], ["S1C", "PROTEIN", 164, 167], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["these two mAbs", "TEST", 31, 45], ["bead- or solid-phase", "TEST", 66, 86], ["effector cells", "OBSERVATION", 132, 146]]], ["These findings confirmed the relatively high capacity of rEBOV-548 IgG1 to engage the Fc and diminished Fc function of rEBOV-520 LALA.", [["rEBOV-520", "CHEMICAL", 119, 128], ["IgG1", "GENE_OR_GENE_PRODUCT", 67, 71], ["Fc", "GENE_OR_GENE_PRODUCT", 86, 88], ["Fc", "GENE_OR_GENE_PRODUCT", 104, 106], ["rEBOV", "PROTEIN", 57, 62], ["548 IgG1", "PROTEIN", 63, 71], ["Fc", "PROTEIN", 86, 88], ["Fc", "PROTEIN", 104, 106], ["rEBOV", "PROTEIN", 119, 124], ["rEBOV", "TEST", 57, 62], ["the Fc", "TEST", 82, 88], ["rEBOV", "TEST", 119, 124], ["diminished", "OBSERVATION_MODIFIER", 93, 103], ["Fc", "OBSERVATION_MODIFIER", 104, 106]]], ["All our next studies utilized these two Fc forms of rEBOV-520 and rEBOV-548.Identification and Functional Properties of Candidate Cocktail Human mAbs ::: ResultsWe next assessed neutralizing activity of individual mAbs. rEBOV-520 potently neutralized all three ebolaviruses, whereas rEBOV-548 potently neutralized only EBOV and BDBV (Figures 1B and S1A).", [["rEBOV-520", "CHEMICAL", 52, 61], ["rEBOV-548", "CHEMICAL", 66, 75], ["rEBOV-520", "CHEMICAL", 220, 229], ["rEBOV-548", "CHEMICAL", 283, 292], ["rEBOV-520", "CHEMICAL", 52, 61], ["rEBOV-548", "CHEMICAL", 66, 75], ["rEBOV-520", "CHEMICAL", 220, 229], ["rEBOV-548", "CHEMICAL", 283, 292], ["rEBOV-520", "SIMPLE_CHEMICAL", 52, 61], ["rEBOV-548", "SIMPLE_CHEMICAL", 66, 75], ["Human", "ORGANISM", 139, 144], ["rEBOV-520", "SIMPLE_CHEMICAL", 220, 229], ["rEBOV-548", "SIMPLE_CHEMICAL", 283, 292], ["EBOV", "ORGANISM", 319, 323], ["S1A", "GENE_OR_GENE_PRODUCT", 349, 352], ["Candidate Cocktail Human mAbs", "PROTEIN", 120, 149], ["mAbs", "PROTEIN", 214, 218], ["BDBV", "PROTEIN", 328, 332], ["S1A", "PROTEIN", 349, 352], ["Human", "SPECIES", 139, 144], ["rEBOV-548", "SPECIES", 283, 292], ["EBOV", "SPECIES", 319, 323], ["BDBV", "SPECIES", 328, 332], ["rEBOV", "TEST", 52, 57], ["rEBOV", "TEST", 66, 71]]], ["However, both mAbs were broadly reactive, as measured by binding to recombinant GP ectodomains or binding to full-length EBOV, BDBV, or SUDV GPs displayed on the surface of stably transduced Jurkat cell lines (Figures 1C, S1A, and S1B).", [["surface", "ANATOMY", 162, 169], ["Jurkat cell lines", "ANATOMY", 191, 208], ["mAbs", "GENE_OR_GENE_PRODUCT", 14, 18], ["GP ectodomains", "GENE_OR_GENE_PRODUCT", 80, 94], ["EBOV", "ORGANISM", 121, 125], ["BDBV", "GENE_OR_GENE_PRODUCT", 127, 131], ["SUDV", "GENE_OR_GENE_PRODUCT", 136, 140], ["surface", "CELLULAR_COMPONENT", 162, 169], ["Jurkat cell lines", "CELL", 191, 208], ["Figures 1C", "CELL", 210, 220], ["S1A", "GENE_OR_GENE_PRODUCT", 222, 225], ["S1B", "GENE_OR_GENE_PRODUCT", 231, 234], ["mAbs", "PROTEIN", 14, 18], ["recombinant GP ectodomains", "PROTEIN", 68, 94], ["BDBV", "PROTEIN", 127, 131], ["SUDV GPs", "PROTEIN", 136, 144], ["Jurkat cell lines", "CELL_LINE", 191, 208], ["S1A", "PROTEIN", 222, 225], ["BDBV", "TEST", 127, 131], ["SUDV GPs", "TEST", 136, 144], ["Figures", "TEST", 210, 217], ["1C", "TEST", 218, 220], ["S1A", "TEST", 222, 225], ["broadly", "OBSERVATION_MODIFIER", 24, 31], ["reactive", "OBSERVATION", 32, 40], ["transduced Jurkat cell lines", "OBSERVATION", 180, 208]]], ["We then tested mAb binding to each of the three Jurkat GP cell lines after treatment with thermolysin to mimic endosomal cathepsin cleavage to create a membrane-displayed cleaved GP (GPCL). rEBOV-520 bound weakly to the intact GP but strongly to the GPCL, demonstrating a saturable dose-response curve and \u223c500- to \u223c1,000-fold increase in binding to the GPCL over the intact GP (Figure 1C).", [["Jurkat GP cell lines", "ANATOMY", 48, 68], ["endosomal", "ANATOMY", 111, 120], ["membrane", "ANATOMY", 152, 160], ["rEBOV-520", "CHEMICAL", 190, 199], ["rEBOV-520", "CHEMICAL", 190, 199], ["Jurkat GP cell lines", "CELL", 48, 68], ["thermolysin", "GENE_OR_GENE_PRODUCT", 90, 101], ["endosomal", "CELLULAR_COMPONENT", 111, 120], ["cathepsin", "GENE_OR_GENE_PRODUCT", 121, 130], ["membrane", "CELLULAR_COMPONENT", 152, 160], ["GP", "GENE_OR_GENE_PRODUCT", 179, 181], ["GPCL", "GENE_OR_GENE_PRODUCT", 250, 254], ["mAb", "PROTEIN", 15, 18], ["Jurkat GP cell lines", "CELL_LINE", 48, 68], ["thermolysin", "PROTEIN", 90, 101], ["endosomal cathepsin", "PROTEIN", 111, 130], ["membrane-displayed cleaved GP", "PROTEIN", 152, 181], ["GPCL", "PROTEIN", 183, 187], ["GP", "PROTEIN", 227, 229], ["GPCL", "DNA", 250, 254], ["GPCL", "PROTEIN", 354, 358], ["GP", "PROTEIN", 375, 377], ["thermolysin", "TREATMENT", 90, 101], ["endosomal cathepsin cleavage", "TREATMENT", 111, 139], ["a membrane", "TEST", 150, 160], ["rEBOV", "TEST", 190, 195], ["response curve", "TEST", 287, 301], ["fold increase in binding", "PROBLEM", 322, 346], ["cell lines", "OBSERVATION", 58, 68]]], ["More efficient binding to the GPCL was concordant with higher neutralizing activity of EBOV-520 against the virus displaying the EBOV GPCL than the virus with the intact EBOV GP that we described in a previous study (Gilchuk et al., 2018).", [["EBOV-520", "CHEMICAL", 87, 95], ["GPCL", "GENE_OR_GENE_PRODUCT", 30, 34], ["EBOV-520", "ORGANISM", 87, 95], ["EBOV", "ORGANISM", 129, 133], ["GPCL", "GENE_OR_GENE_PRODUCT", 134, 138], ["EBOV", "ORGANISM", 170, 174], ["GP", "ORGANISM", 175, 177], ["GPCL", "DNA", 30, 34], ["EBOV GPCL", "PROTEIN", 129, 138], ["EBOV GP", "PROTEIN", 170, 177], ["EBOV-520", "SPECIES", 87, 95], ["EBOV", "SPECIES", 129, 133], ["EBOV", "SPECIES", 170, 174], ["the GPCL", "TEST", 26, 34], ["higher neutralizing activity of EBOV", "PROBLEM", 55, 91], ["the virus", "PROBLEM", 104, 113], ["the EBOV GPCL", "PROBLEM", 125, 138], ["the virus", "PROBLEM", 144, 153], ["a previous study", "TEST", 199, 215], ["intact", "OBSERVATION_MODIFIER", 163, 169], ["EBOV", "OBSERVATION", 170, 174]]], ["The glycan-cap-specific rEBOV-548 bound moderately and less efficiently to intact cell-surface-displayed GPs when compared with its binding to recombinant GPs (Figures 1C and S1B).", [["cell", "ANATOMY", 82, 86], ["surface", "ANATOMY", 87, 94], ["rEBOV-548", "CHEMICAL", 24, 33], ["cell", "CELL", 82, 86], ["S1B", "GENE_OR_GENE_PRODUCT", 175, 178], ["rEBOV", "PROTEIN", 24, 29], ["recombinant GPs", "PROTEIN", 143, 158], ["S1B", "PROTEIN", 175, 178], ["The glycan", "TEST", 0, 10], ["specific rEBOV", "TEST", 15, 29]]], ["Together, these results defined binding and functional features of the cocktail candidate mAbs and showed that the exposure of rEBOV-520 epitope is limited on the intact GPs of all three ebolaviruses.mAbs in the Cocktail Cooperate, Enabling Enhanced GP Binding, Virus Neutralization, and In\u00a0Vivo Protection ::: ResultsNegative stain electron microscopy (EM) analysis showed that rEBOV-520 and rEBOV-548 can bind to GPs simultaneously (Figure 2A).", [["rEBOV-520", "CHEMICAL", 127, 136], ["rEBOV-520", "CHEMICAL", 379, 388], ["rEBOV-548", "CHEMICAL", 393, 402], ["rEBOV-520", "CHEMICAL", 379, 388], ["rEBOV-548", "CHEMICAL", 393, 402], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 127, 136], ["rEBOV-520", "SIMPLE_CHEMICAL", 379, 388], ["rEBOV-548", "SIMPLE_CHEMICAL", 393, 402], ["cocktail candidate mAbs", "PROTEIN", 71, 94], ["rEBOV", "PROTEIN", 127, 132], ["Abs", "PROTEIN", 201, 204], ["rEBOV", "TEST", 127, 132], ["Virus Neutralization", "TREATMENT", 262, 282], ["rEBOV", "TEST", 379, 384], ["rEBOV", "TEST", 393, 398]]], ["To characterize the cooperative effects of these two mAbs as a cocktail, we first assessed GP binding for each mAb in the presence or absence of the partner mAb.", [["mAb", "GENE_OR_GENE_PRODUCT", 157, 160], ["mAbs", "PROTEIN", 53, 57], ["mAb", "PROTEIN", 111, 114], ["partner mAb", "PROTEIN", 149, 160], ["these two mAbs", "TREATMENT", 43, 57], ["a cocktail", "TREATMENT", 61, 71]]], ["Fluorescently labeled rEBOV-520 or rEBOV-548 was titrated into a constant concentration of unlabeled partner mAb, as previously described (Gilchuk et al., 2018), and relative fluorescence from binding of the labeled mAb to the intact cell-surface-displayed EBOV, BDBV, or SUDV GP was determined.", [["cell", "ANATOMY", 234, 238], ["surface", "ANATOMY", 239, 246], ["rEBOV-520", "CHEMICAL", 22, 31], ["rEBOV-548", "CHEMICAL", 35, 44], ["rEBOV-520", "CHEMICAL", 22, 31], ["rEBOV-548", "CHEMICAL", 35, 44], ["rEBOV-520", "SIMPLE_CHEMICAL", 22, 31], ["rEBOV-548", "SIMPLE_CHEMICAL", 35, 44], ["mAb", "GENE_OR_GENE_PRODUCT", 216, 219], ["cell", "CELL", 234, 238], ["surface", "CELLULAR_COMPONENT", 239, 246], ["EBOV", "ORGANISM", 257, 261], ["BDBV", "GENE_OR_GENE_PRODUCT", 263, 267], ["SUDV GP", "GENE_OR_GENE_PRODUCT", 272, 279], ["unlabeled partner mAb", "PROTEIN", 91, 112], ["labeled mAb", "PROTEIN", 208, 219], ["BDBV", "PROTEIN", 263, 267], ["SUDV GP", "PROTEIN", 272, 279], ["EBOV", "SPECIES", 257, 261], ["SUDV", "SPECIES", 272, 276], ["EBOV", "PROBLEM", 257, 261], ["intact cell", "OBSERVATION", 227, 238], ["EBOV", "OBSERVATION", 257, 261]]], ["At a constant concentration of 20 \u03bcg/mL, rEBOV-548 enhanced binding of rEBOV-520 to the GPs of all three ebolaviruses 2- to 3-fold when compared with binding of rEBOV-520 alone.", [["rEBOV-548", "CHEMICAL", 41, 50], ["rEBOV-520", "CHEMICAL", 71, 80], ["rEBOV-520", "CHEMICAL", 161, 170], ["rEBOV-548", "CHEMICAL", 41, 50], ["rEBOV-520", "CHEMICAL", 71, 80], ["rEBOV-520", "CHEMICAL", 161, 170], ["rEBOV-548", "SIMPLE_CHEMICAL", 41, 50], ["rEBOV-520", "SIMPLE_CHEMICAL", 71, 80], ["rEBOV-520", "SIMPLE_CHEMICAL", 161, 170], ["rEBOV", "PROTEIN", 71, 76], ["rEBOV", "PROTEIN", 161, 166], ["rEBOV", "TEST", 41, 46], ["rEBOV", "TEST", 71, 76], ["rEBOV", "TEST", 161, 166]]], ["The cooperativity was mediated by rEBOV-548, because rEBOV-520 had a minor effect on binding of rEBOV-548 to the GP (Figure 2B).", [["rEBOV-548", "CHEMICAL", 34, 43], ["rEBOV-520", "CHEMICAL", 53, 62], ["rEBOV-548", "CHEMICAL", 96, 105], ["rEBOV-548", "CHEMICAL", 34, 43], ["rEBOV-520", "CHEMICAL", 53, 62], ["rEBOV-548", "CHEMICAL", 96, 105], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 34, 43], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 53, 62], ["rEBOV", "PROTEIN", 34, 39], ["rEBOV", "PROTEIN", 53, 58], ["rEBOV", "PROTEIN", 96, 101], ["GP", "PROTEIN", 113, 115], ["rEBOV", "TEST", 53, 58], ["rEBOV", "TEST", 96, 101]]], ["Cooperative binding of rEBOV-520 to the intact homologous EBOV GP increased steadily with increased concentrations of rEBOV-548 and up to \u223c5-fold higher than rEBOV-520 alone (Figure 2C), indicating that a higher dose of rEBOV-548 would be necessary to leverage strong cooperative effect in a two-antibody cocktail.", [["rEBOV-520", "CHEMICAL", 23, 32], ["rEBOV-548", "CHEMICAL", 118, 127], ["rEBOV-520", "CHEMICAL", 158, 167], ["rEBOV-548", "CHEMICAL", 220, 229], ["rEBOV-520", "CHEMICAL", 23, 32], ["rEBOV-548", "CHEMICAL", 118, 127], ["rEBOV-520", "CHEMICAL", 158, 167], ["rEBOV-548", "CHEMICAL", 220, 229], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 23, 32], ["EBOV GP", "ORGANISM", 58, 65], ["rEBOV-520", "SIMPLE_CHEMICAL", 158, 167], ["rEBOV-548", "SIMPLE_CHEMICAL", 220, 229], ["rEBOV", "PROTEIN", 23, 28], ["EBOV GP", "PROTEIN", 58, 65], ["rEBOV", "TEST", 118, 123], ["rEBOV", "TEST", 158, 163], ["a higher dose of rEBOV", "TREATMENT", 203, 225], ["a two-antibody cocktail", "TREATMENT", 290, 313]]], ["Binding of rEBOV-520 to the intact GP in the cocktail did not fully match the strong saturating binding of rEBOV-520 by itself to the proteolytically primed GPCL (Figure 2C).", [["rEBOV-520", "CHEMICAL", 11, 20], ["rEBOV-520", "CHEMICAL", 107, 116], ["rEBOV-520", "CHEMICAL", 11, 20], ["rEBOV-520", "CHEMICAL", 107, 116], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 11, 20], ["GP", "GENE_OR_GENE_PRODUCT", 35, 37], ["rEBOV-520", "SIMPLE_CHEMICAL", 107, 116], ["rEBOV", "PROTEIN", 11, 16], ["GP", "PROTEIN", 35, 37], ["rEBOV", "PROTEIN", 107, 112], ["proteolytically primed GPCL", "PROTEIN", 134, 161], ["rEBOV", "TEST", 11, 16]]], ["Therefore, binding of rEBOV-548 only partially enhanced accessibility of the base epitope on the intact GP for recognition by rEBOV-520, compared with the accessibility to the epitope on GPCL.mAbs in the Cocktail Cooperate, Enabling Enhanced GP Binding, Virus Neutralization, and In\u00a0Vivo Protection ::: ResultsWe next assessed whether cooperative binding conferred an enhanced neutralizing activity to the cocktail by using first the most antigenically divergent virus, SUDV. rEBOV-548 itself did not fully neutralize SUDV, and rEBOV-520 neutralized SUDV, but with modest potency (Figure 1B and S1A).", [["rEBOV-548", "CHEMICAL", 22, 31], ["rEBOV-520", "CHEMICAL", 126, 135], ["rEBOV-548", "CHEMICAL", 476, 485], ["SUDV", "CHEMICAL", 518, 522], ["rEBOV-520", "CHEMICAL", 528, 537], ["SUDV", "CHEMICAL", 550, 554], ["rEBOV-548", "CHEMICAL", 22, 31], ["rEBOV-548", "CHEMICAL", 476, 485], ["rEBOV-520", "CHEMICAL", 528, 537], ["rEBOV-548", "SIMPLE_CHEMICAL", 22, 31], ["GP", "GENE_OR_GENE_PRODUCT", 104, 106], ["GPCL", "GENE_OR_GENE_PRODUCT", 187, 191], ["SUDV", "SIMPLE_CHEMICAL", 518, 522], ["rEBOV-520", "SIMPLE_CHEMICAL", 528, 537], ["SUDV", "SIMPLE_CHEMICAL", 550, 554], ["rEBOV", "PROTEIN", 22, 27], ["GP", "PROTEIN", 104, 106], ["rEBOV", "PROTEIN", 126, 131], ["epitope", "PROTEIN", 176, 183], ["GPCL", "PROTEIN", 187, 191], ["mAbs", "PROTEIN", 192, 196], ["SUDV", "PROTEIN", 518, 522], ["S1A", "PROTEIN", 595, 598], ["SUDV", "SPECIES", 470, 474], ["rEBOV", "TEST", 22, 27], ["the base epitope", "PROBLEM", 73, 89], ["rEBOV", "TEST", 126, 131], ["the epitope on GPCL", "PROBLEM", 172, 191], ["cooperative binding", "PROBLEM", 335, 354], ["the cocktail", "TREATMENT", 402, 414], ["rEBOV", "TEST", 528, 533], ["base", "ANATOMY_MODIFIER", 77, 81], ["epitope", "OBSERVATION", 82, 89]]], ["Consistent with the observed increase in cooperative binding of the SUDV GP (Figure S2A), rEBOV-548 at a sub-neutralizing concentration potentiated the neutralizing activity of rEBOV-520 against chimeric virus displaying the SUDV GP by reducing the half-maximal inhibitory concentration (IC50) value by \u223c3-fold (Figure 2D).", [["rEBOV-548", "CHEMICAL", 90, 99], ["rEBOV-520", "CHEMICAL", 177, 186], ["rEBOV-548", "CHEMICAL", 90, 99], ["rEBOV-520", "CHEMICAL", 177, 186], ["SUDV GP", "GENE_OR_GENE_PRODUCT", 68, 75], ["Figure S2A", "GENE_OR_GENE_PRODUCT", 77, 87], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 90, 99], ["rEBOV-520", "SIMPLE_CHEMICAL", 177, 186], ["chimeric virus", "ORGANISM", 195, 209], ["SUDV GP", "PROTEIN", 68, 75], ["rEBOV", "PROTEIN", 90, 95], ["SUDV GP", "PROTEIN", 225, 232], ["SUDV", "SPECIES", 225, 229], ["rEBOV", "TEST", 90, 95], ["a sub-neutralizing concentration", "TREATMENT", 103, 135], ["rEBOV", "TEST", 177, 182], ["chimeric virus", "PROBLEM", 195, 209], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["cooperative binding", "OBSERVATION", 41, 60]]], ["Neutralization by the cocktail was synergistic, as determined by the Chou and Talalay method that estimates the combination index (CI) to define the effect of drug combination: additive effects (CI = 1), synergism (CI < 1), and antagonism (CI >1) (Chou, 2010).", [["Neutralization", "TREATMENT", 0, 14], ["CI", "TEST", 195, 197], ["synergism", "PROBLEM", 204, 213], ["CI", "TEST", 215, 217], ["antagonism", "TEST", 228, 238], ["CI", "TEST", 240, 242]]], ["We also demonstrated synergy in neutralization of the virus with the homologous EBOV GP using the cocktail (a 1:1 mixture of rEBOV-520 and rEBOV-548) (Figures S2B and S2C).", [["rEBOV-520 and rEBOV-548", "CHEMICAL", 125, 148], ["rEBOV-548", "CHEMICAL", 139, 148], ["EBOV", "ORGANISM", 80, 84], ["GP", "ORGANISM", 85, 87], ["rEBOV-520", "SIMPLE_CHEMICAL", 125, 134], ["EBOV GP", "PROTEIN", 80, 87], ["rEBOV", "PROTEIN", 125, 130], ["rEBOV", "PROTEIN", 139, 144], ["S2C", "PROTEIN", 167, 170], ["EBOV", "SPECIES", 80, 84], ["synergy", "PROBLEM", 21, 28], ["the virus", "PROBLEM", 50, 59], ["the cocktail", "TREATMENT", 94, 106], ["rEBOV", "TEST", 125, 130], ["rEBOV", "TEST", 139, 144], ["synergy", "OBSERVATION_MODIFIER", 21, 28], ["neutralization", "OBSERVATION", 32, 46]]], ["Together, these data supported our finding for cooperative binding of rEBOV-520 and rEBOV-548 to the GP.mAbs in the Cocktail Cooperate, Enabling Enhanced GP Binding, Virus Neutralization, and In\u00a0Vivo Protection ::: ResultsWe next tested whether rEBOV-548 potentiated protection by rEBOV-520 in the cocktail against SUDV in vivo by using a stringent Stat1-deficient (Stat1\u2212/\u2212) mouse challenge model that provides a uniform lethality (Raymond et al., 2011).", [["rEBOV-520", "CHEMICAL", 70, 79], ["rEBOV-548", "CHEMICAL", 84, 93], ["rEBOV-548", "CHEMICAL", 245, 254], ["rEBOV-520", "CHEMICAL", 281, 290], ["SUDV", "CHEMICAL", 315, 319], ["rEBOV-520", "CHEMICAL", 70, 79], ["rEBOV-548", "CHEMICAL", 84, 93], ["rEBOV-548", "CHEMICAL", 245, 254], ["rEBOV-520", "CHEMICAL", 281, 290], ["rEBOV-520", "SIMPLE_CHEMICAL", 70, 79], ["rEBOV-548", "SIMPLE_CHEMICAL", 84, 93], ["rEBOV-548", "SIMPLE_CHEMICAL", 245, 254], ["rEBOV-520", "SIMPLE_CHEMICAL", 281, 290], ["SUDV", "SIMPLE_CHEMICAL", 315, 319], ["Stat1", "GENE_OR_GENE_PRODUCT", 349, 354], ["Stat1\u2212", "GENE_OR_GENE_PRODUCT", 366, 372], ["mouse", "ORGANISM", 376, 381], ["rEBOV", "PROTEIN", 70, 75], ["rEBOV", "PROTEIN", 84, 89], ["GP.mAbs", "DNA", 101, 108], ["Stat1", "PROTEIN", 349, 354], ["mouse", "SPECIES", 376, 381], ["SUDV", "SPECIES", 315, 319], ["mouse", "SPECIES", 376, 381], ["rEBOV", "TEST", 70, 75], ["rEBOV", "TEST", 84, 89], ["Virus Neutralization", "TREATMENT", 166, 186], ["rEBOV", "TEST", 245, 250], ["a stringent Stat1-deficient (Stat1\u2212/\u2212) mouse challenge model", "TREATMENT", 337, 397]]], ["An irrelevant mAb DENV 2D22 (IgG1 isotype) specific to the dengue virus E protein (Fibriansah et al., 2015) was used as a control.", [["dengue", "DISEASE", 59, 65], ["IgG1", "GENE_OR_GENE_PRODUCT", 29, 33], ["dengue virus E", "ORGANISM", 59, 73], ["mAb DENV 2D22", "PROTEIN", 14, 27], ["IgG1 isotype", "PROTEIN", 29, 41], ["dengue virus E protein", "PROTEIN", 59, 81], ["dengue virus", "SPECIES", 59, 71], ["DENV", "SPECIES", 18, 22], ["dengue virus", "SPECIES", 59, 71], ["An irrelevant mAb DENV 2D22 (IgG1 isotype)", "TREATMENT", 0, 42], ["mAb DENV", "OBSERVATION", 14, 22]]], ["All SUDV-challenged mice that were treated with 10 mg/kg of rEBOV-548 mAb alone (which does not neutralize SUDV) on day 1 after infection succumbed to the disease by day 6 after infection, similarly to the animals in the control group.", [["SUDV", "CHEMICAL", 4, 8], ["rEBOV-548", "CHEMICAL", 60, 69], ["infection", "DISEASE", 128, 137], ["infection", "DISEASE", 178, 187], ["SUDV", "SIMPLE_CHEMICAL", 4, 8], ["mice", "ORGANISM", 20, 24], ["rEBOV-548 mAb", "SIMPLE_CHEMICAL", 60, 73], ["548 mAb", "PROTEIN", 66, 73], ["SUDV", "PROTEIN", 107, 111], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["rEBOV", "TREATMENT", 60, 65], ["infection", "PROBLEM", 128, 137], ["infection", "PROBLEM", 178, 187], ["infection", "OBSERVATION", 128, 137], ["infection", "OBSERVATION", 178, 187]]], ["Treatment with rEBOV-520 alone delayed mortality; however, only 10% of animals survived.", [["rEBOV-520", "CHEMICAL", 15, 24], ["rEBOV-520", "CHEMICAL", 15, 24], ["rEBOV-520", "SIMPLE_CHEMICAL", 15, 24], ["animals", "ORGANISM", 71, 78], ["rEBOV", "TREATMENT", 15, 20]]], ["Treatment with the cocktail (a 1:1 mixture of rEBOV-520 and rEBOV-548) conferred higher protection, with 50% of animals surviving and an associated p value = 0.01 (Mantel-Cox test) when compared with the treatment with rEBOV-520 alone (Figure 2E).", [["rEBOV-520", "CHEMICAL", 46, 55], ["rEBOV-548", "CHEMICAL", 60, 69], ["rEBOV-520", "CHEMICAL", 219, 228], ["rEBOV-520", "CHEMICAL", 46, 55], ["rEBOV-548", "CHEMICAL", 60, 69], ["rEBOV-520", "CHEMICAL", 219, 228], ["rEBOV-520", "SIMPLE_CHEMICAL", 46, 55], ["rEBOV-548", "SIMPLE_CHEMICAL", 60, 69], ["rEBOV-520", "SIMPLE_CHEMICAL", 219, 228], ["the cocktail", "TREATMENT", 15, 27], ["rEBOV", "TREATMENT", 46, 51], ["Mantel-Cox test", "TEST", 164, 179], ["rEBOV", "TREATMENT", 219, 224]]], ["These results showed that rEBOV-548 complemented the activity of rEBOV-520 against SUDV in vivo.", [["rEBOV-548", "CHEMICAL", 26, 35], ["rEBOV-520", "CHEMICAL", 65, 74], ["SUDV", "CHEMICAL", 83, 87], ["rEBOV-548", "CHEMICAL", 26, 35], ["rEBOV-520", "CHEMICAL", 65, 74], ["rEBOV-548", "SIMPLE_CHEMICAL", 26, 35], ["rEBOV-520", "SIMPLE_CHEMICAL", 65, 74], ["SUDV", "ORGANISM", 83, 87], ["SUDV", "SPECIES", 83, 87], ["rEBOV", "TEST", 26, 31], ["rEBOV", "TEST", 65, 70]]], ["It is unknown whether protection in this model can predict protection against SUDV in NHPs.mAbs in the Cocktail Cooperate, Enabling Enhanced GP Binding, Virus Neutralization, and In\u00a0Vivo Protection ::: ResultsUse of antibody cocktails is attractive because this approach avoids the high risk of virus escape by this RNA virus that is inherent in monotherapy approaches.", [["SUDV", "DISEASE", 78, 82], ["NHPs", "ORGANISM", 86, 90], ["Abs", "PROTEIN", 92, 95], ["SUDV", "SPECIES", 78, 82], ["Virus Neutralization", "TREATMENT", 153, 173], ["antibody cocktails", "TREATMENT", 216, 234], ["virus escape", "PROBLEM", 295, 307], ["this RNA virus", "PROBLEM", 311, 325], ["monotherapy approaches", "TREATMENT", 346, 368], ["virus", "OBSERVATION", 295, 300]]], ["We hypothesized that the cocktail of rEBOV-520 and rEBOV-548 counteracts the escape more efficiently than individual mAbs do because each mAb possesses independent neutralizing activity (EBOV and BDBV at least) and together they exhibit an enhanced activity.", [["rEBOV-520", "CHEMICAL", 37, 46], ["rEBOV-548", "CHEMICAL", 51, 60], ["rEBOV-520", "CHEMICAL", 37, 46], ["rEBOV-548", "CHEMICAL", 51, 60], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 37, 46], ["rEBOV-548", "SIMPLE_CHEMICAL", 51, 60], ["mAb", "GENE_OR_GENE_PRODUCT", 138, 141], ["EBOV", "ORGANISM", 187, 191], ["mAbs", "PROTEIN", 117, 121], ["mAb", "PROTEIN", 138, 141], ["EBOV", "SPECIES", 187, 191], ["rEBOV", "TEST", 37, 42], ["rEBOV", "TEST", 51, 56], ["individual mAbs", "TREATMENT", 106, 121], ["each mAb", "TREATMENT", 133, 141], ["enhanced activity", "OBSERVATION", 240, 257]]], ["We used high-throughput and quantitative real-time cell analysis assay (RTCA) that measures virus-induced cytopathic effect to screen for escape mutations in the presence of individual mAbs or the cocktail (Figures S2D and S2E).", [["cell", "ANATOMY", 51, 55], ["cell", "CELL", 51, 55], ["mAbs", "PROTEIN", 185, 189], ["S2E", "PROTEIN", 223, 226], ["quantitative real-time cell analysis assay", "TEST", 28, 70], ["measures virus", "PROBLEM", 83, 97], ["cytopathic effect", "PROBLEM", 106, 123], ["escape mutations", "PROBLEM", 138, 154], ["individual mAbs", "TREATMENT", 174, 189], ["the cocktail", "TREATMENT", 193, 205], ["cytopathic", "OBSERVATION_MODIFIER", 106, 116]]], ["Recombinant vesicular stomatitis viruses (rVSVs) displaying the EBOV GP (rVSV/EBOV GP) or SUDV GP (rVSV/SUDV GP) were incubated in the presence of increasing mAb concentrations, and we assessed neutralization in repeated passages in Vero cell monolayer cultures.", [["Vero cell monolayer cultures", "ANATOMY", 233, 261], ["vesicular stomatitis viruses", "DISEASE", 12, 40], ["Recombinant", "ORGANISM", 0, 11], ["vesicular stomatitis viruses", "ORGANISM", 12, 40], ["rVSVs", "ORGANISM", 42, 47], ["EBOV GP", "ORGANISM", 64, 71], ["rVSV/EBOV GP", "ORGANISM", 73, 85], ["SUDV GP", "ORGANISM", 90, 97], ["rVSV/SUDV GP", "ORGANISM", 99, 111], ["Vero cell monolayer cultures", "CELL", 233, 261], ["EBOV GP", "PROTEIN", 64, 71], ["rVSV", "PROTEIN", 73, 77], ["EBOV GP", "PROTEIN", 78, 85], ["SUDV GP", "PROTEIN", 90, 97], ["rVSV", "PROTEIN", 99, 103], ["SUDV GP", "PROTEIN", 104, 111], ["mAb", "PROTEIN", 158, 161], ["Vero cell monolayer cultures", "CELL_LINE", 233, 261], ["EBOV", "SPECIES", 64, 68], ["EBOV", "SPECIES", 78, 82], ["SUDV", "SPECIES", 90, 94], ["Recombinant vesicular stomatitis viruses", "PROBLEM", 0, 40], ["the EBOV GP", "TEST", 60, 71], ["rVSV", "TEST", 73, 77], ["EBOV GP", "TEST", 78, 85], ["SUDV GP", "TEST", 90, 97], ["increasing mAb concentrations", "PROBLEM", 147, 176], ["neutralization", "PROBLEM", 194, 208], ["repeated passages", "PROBLEM", 212, 229], ["Vero cell monolayer cultures", "TEST", 233, 261], ["vesicular stomatitis viruses", "OBSERVATION", 12, 40], ["increasing", "OBSERVATION_MODIFIER", 147, 157], ["mAb concentrations", "OBSERVATION", 158, 176], ["Vero cell monolayer", "OBSERVATION", 233, 252]]], ["Viruses escaping neutralization were assessed for susceptibility to neutralization by individual mAbs or the cocktail, and the genes encoding the GP were sequenced to confirm the presence of an escape mutation.", [["GP", "GENE_OR_GENE_PRODUCT", 146, 148], ["mAbs", "PROTEIN", 97, 101], ["GP", "PROTEIN", 146, 148], ["Viruses escaping neutralization", "PROBLEM", 0, 31], ["the cocktail", "TEST", 105, 117], ["an escape mutation", "PROBLEM", 191, 209], ["escape mutation", "OBSERVATION", 194, 209]]], ["Fifteen consecutive passages identified two rVSV/EBOV GP mutants that escaped neutralization by rEBOV-548 and one rVSV/SUDV GP mutant that escaped neutralization by rEBOV-520.", [["rEBOV-548", "CHEMICAL", 96, 105], ["rEBOV-520", "CHEMICAL", 165, 174], ["rVSV", "GENE_OR_GENE_PRODUCT", 44, 48], ["EBOV", "ORGANISM", 49, 53], ["GP", "GENE_OR_GENE_PRODUCT", 54, 56], ["rEBOV-548", "SIMPLE_CHEMICAL", 96, 105], ["rVSV", "ORGANISM", 114, 118], ["SUDV GP mutant", "ORGANISM", 119, 133], ["rEBOV-520", "SIMPLE_CHEMICAL", 165, 174], ["rVSV", "PROTEIN", 44, 48], ["EBOV GP mutants", "PROTEIN", 49, 64], ["rEBOV", "PROTEIN", 96, 101], ["rVSV", "PROTEIN", 114, 118], ["SUDV GP mutant", "PROTEIN", 119, 133], ["rEBOV", "PROTEIN", 165, 170], ["EBOV", "SPECIES", 49, 53], ["rEBOV-548", "SPECIES", 96, 105], ["Fifteen consecutive passages", "TREATMENT", 0, 28]]], ["Each of the mutants that we detected was selected in the presence of an individual mAb, and the mutations identified were within the predicted epitope for the respective mAb (Table S2).", [["mAb", "GENE_OR_GENE_PRODUCT", 83, 86], ["mAb", "PROTEIN", 83, 86], ["mAb", "PROTEIN", 170, 173], ["S2", "PROTEIN", 181, 183], ["an individual mAb", "TEST", 69, 86], ["the mutations", "PROBLEM", 92, 105], ["mAb", "OBSERVATION", 83, 86]]], ["Virus escape was not detected in passages in the presence of the cocktail, as confirmed by neutralization of the late passage viruses with individual mAbs rEBOV-520 or rEBOV-548.", [["rEBOV-520", "CHEMICAL", 155, 164], ["rEBOV-548", "CHEMICAL", 168, 177], ["Virus", "ORGANISM", 0, 5], ["rEBOV-548", "SIMPLE_CHEMICAL", 168, 177], ["mAbs", "PROTEIN", 150, 154], ["Virus escape", "PROBLEM", 0, 12], ["the cocktail", "TREATMENT", 61, 73], ["individual mAbs rEBOV", "TEST", 139, 160], ["not detected", "UNCERTAINTY", 17, 29]]], ["The rVSV/EBOV GP mutants that escaped neutralization by rEBOV-548 that we isolated were neutralized fully by rEBOV-520 alone and by the cocktail, showing that if one neutralizing mAb loses activity because of a virus variant with an escape mutation, the other neutralizing mAb in the cocktail maintained activity (Table S2).", [["rEBOV-548", "CHEMICAL", 56, 65], ["rEBOV-520", "CHEMICAL", 109, 118], ["rVSV", "GENE_OR_GENE_PRODUCT", 4, 8], ["EBOV GP", "ORGANISM", 9, 16], ["rEBOV-548", "SIMPLE_CHEMICAL", 56, 65], ["rEBOV-520", "SIMPLE_CHEMICAL", 109, 118], ["mAb", "GENE_OR_GENE_PRODUCT", 179, 182], ["rVSV", "PROTEIN", 4, 8], ["EBOV GP mutants", "PROTEIN", 9, 24], ["rEBOV", "PROTEIN", 56, 61], ["neutralizing mAb", "PROTEIN", 166, 182], ["neutralizing mAb", "PROTEIN", 260, 276], ["EBOV", "SPECIES", 9, 13], ["The rVSV", "TEST", 0, 8], ["neutralizing mAb", "TREATMENT", 166, 182], ["a virus variant", "PROBLEM", 209, 224], ["an escape mutation", "PROBLEM", 230, 248], ["neutralizing mAb", "TREATMENT", 260, 276], ["EBOV", "OBSERVATION", 9, 13], ["escape mutation", "OBSERVATION", 233, 248]]], ["These data strongly suggest that the use of this cocktail enhances the effective neutralizing potency of the mAbs and counteracts virus escape of the homologous EBOV.", [["EBOV", "ORGANISM", 161, 165], ["mAbs", "PROTEIN", 109, 113], ["EBOV", "SPECIES", 161, 165], ["this cocktail", "TREATMENT", 44, 57], ["the mAbs", "TREATMENT", 105, 113], ["the homologous EBOV", "TREATMENT", 146, 165]]], ["Although escape was not detected with the cocktail, the rEBOV-520 escape mutant we identified for rVSV/SUDV GP (N514Y, a conserved residue for EBOV, BDBV, and SUDV GP) was not fully neutralized by either mAb rEBOV-548 alone or by the cocktail, suggesting the possibility of escape by the heterologous SUDV.mAbs in the Cocktail Cooperate, Enabling Enhanced GP Binding, Virus Neutralization, and In\u00a0Vivo Protection ::: ResultsTherefore, cooperativity in GP binding by the cocktail could benefit therapeutic effectiveness by enhancing virus neutralization, enhancing in vivo protection, and reducing the risk of virus escape.The Cocktail mAbs Recognize Relatively Conserved Epitopes of Two Major Antigenic Sites of the GP ::: ResultsWe previously reported negative stain EM reconstructions of EBOV-520 in complex with the GP (Gilchuk et al., 2018).", [["rEBOV-548", "CHEMICAL", 208, 217], ["EBOV-520", "CHEMICAL", 790, 798], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 56, 65], ["rVSV", "GENE_OR_GENE_PRODUCT", 98, 102], ["SUDV GP", "ORGANISM", 103, 110], ["EBOV", "ORGANISM", 143, 147], ["BDBV", "GENE_OR_GENE_PRODUCT", 149, 153], ["SUDV GP", "GENE_OR_GENE_PRODUCT", 159, 166], ["SUDV", "GENE_OR_GENE_PRODUCT", 301, 305], ["GP", "GENE_OR_GENE_PRODUCT", 452, 454], ["EBOV", "ORGANISM", 790, 794], ["rEBOV", "PROTEIN", 56, 61], ["rVSV", "PROTEIN", 98, 102], ["SUDV GP", "PROTEIN", 103, 110], ["N514Y", "PROTEIN", 112, 117], ["BDBV", "PROTEIN", 149, 153], ["SUDV GP", "PROTEIN", 159, 166], ["mAb rEBOV", "PROTEIN", 204, 213], ["heterologous SUDV", "PROTEIN", 288, 305], ["mAbs", "PROTEIN", 306, 310], ["Cocktail mAbs", "PROTEIN", 626, 639], ["Conserved Epitopes", "PROTEIN", 661, 679], ["EBOV-520", "SPECIES", 790, 798], ["the rEBOV", "TEST", 52, 61], ["rVSV", "TEST", 98, 102], ["EBOV", "PROBLEM", 143, 147], ["BDBV", "TEST", 149, 153], ["the heterologous SUDV", "TREATMENT", 284, 305], ["the cocktail", "TREATMENT", 466, 478], ["enhancing virus neutralization", "TREATMENT", 522, 552], ["vivo protection", "TREATMENT", 567, 582], ["virus escape", "PROBLEM", 609, 621], ["The Cocktail mAbs", "TREATMENT", 622, 639], ["EBOV", "TEST", 790, 794], ["suggesting the possibility of", "UNCERTAINTY", 244, 273], ["escape", "OBSERVATION", 274, 280], ["virus escape", "OBSERVATION", 609, 621]]], ["The epitope of EBOV-548 has not yet been characterized.", [["EBOV-548", "CHEMICAL", 15, 23], ["EBOV", "ORGANISM", 15, 19], ["EBOV-548", "SPECIES", 15, 23]]], ["We performed negative stain EM studies by using complexes of rEBOV-548 Fab alone or a combination of both rEBOV-548 and rEBOV-520 Fabs with recombinant trimeric EBOV GP \u0394TM. rEBOV-548 recognized the glycan cap region and bound nearly perpendicular to the surface of the GP (Figure 3A), similar to the binding pose of c13C6, but also made interactions with the interior of the chalice within the outer domain of the glycan cap. c13C6, however, does not enhance rEBOV-520 binding, whereas rEBOV-548 does (data not shown).The Cocktail mAbs Recognize Relatively Conserved Epitopes of Two Major Antigenic Sites of the GP ::: ResultsTo define key contact residues of the epitope, we used alanine scanning mutagenesis of the GP and tested the binding of rEBOV-548 to individual members of a shotgun mutagenesis alanine mutation library of the EBOV GP displayed in cells.", [["surface", "ANATOMY", 255, 262], ["cells", "ANATOMY", 857, 862], ["rEBOV-548", "CHEMICAL", 61, 70], ["rEBOV-548", "CHEMICAL", 174, 183], ["rEBOV-520", "CHEMICAL", 460, 469], ["alanine", "CHEMICAL", 682, 689], ["rEBOV-548", "CHEMICAL", 747, 756], ["alanine", "CHEMICAL", 804, 811], ["rEBOV-548", "CHEMICAL", 174, 183], ["alanine", "CHEMICAL", 682, 689], ["rEBOV-548", "CHEMICAL", 747, 756], ["alanine", "CHEMICAL", 804, 811], ["rEBOV-548 Fab", "SIMPLE_CHEMICAL", 61, 74], ["Fabs", "GENE_OR_GENE_PRODUCT", 130, 134], ["EBOV", "ORGANISM", 161, 165], ["surface", "CELLULAR_COMPONENT", 255, 262], ["c13C6", "GENE_OR_GENE_PRODUCT", 317, 322], ["c13C6", "GENE_OR_GENE_PRODUCT", 427, 432], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 460, 469], ["alanine", "AMINO_ACID", 682, 689], ["alanine", "AMINO_ACID", 804, 811], ["EBOV", "ORGANISM", 836, 840], ["cells", "CELL", 857, 862], ["rEBOV", "PROTEIN", 61, 66], ["548 Fab", "PROTEIN", 67, 74], ["rEBOV", "PROTEIN", 106, 111], ["rEBOV", "PROTEIN", 120, 125], ["Fabs", "PROTEIN", 130, 134], ["recombinant trimeric EBOV GP \u0394TM", "PROTEIN", 140, 172], ["rEBOV", "PROTEIN", 174, 179], ["glycan cap region", "PROTEIN", 199, 216], ["GP", "PROTEIN", 270, 272], ["Figure 3A", "PROTEIN", 274, 283], ["c13C6", "PROTEIN", 317, 322], ["chalice", "PROTEIN", 376, 383], ["outer domain", "PROTEIN", 395, 407], ["glycan cap", "PROTEIN", 415, 425], ["c13C6", "PROTEIN", 427, 432], ["rEBOV", "PROTEIN", 460, 465], ["rEBOV", "PROTEIN", 487, 492], ["Cocktail mAbs", "PROTEIN", 523, 536], ["Conserved Epitopes", "PROTEIN", 558, 576], ["GP", "PROTEIN", 718, 720], ["rEBOV", "PROTEIN", 747, 752], ["EBOV GP", "PROTEIN", 836, 843], ["rEBOV", "TEST", 120, 125], ["rEBOV", "TEST", 174, 179], ["The Cocktail mAbs", "TREATMENT", 519, 536], ["alanine scanning mutagenesis", "TEST", 682, 710], ["a shotgun mutagenesis", "TEST", 782, 803], ["perpendicular", "OBSERVATION_MODIFIER", 234, 247], ["surface", "ANATOMY_MODIFIER", 255, 262], ["glycan cap", "OBSERVATION", 415, 425], ["contact residues", "OBSERVATION", 641, 657]]], ["We also generated antibody escape mutant EBOV viruses and determined their GP sequence.", [["EBOV", "ORGANISM", 41, 45], ["GP sequence", "DNA", 75, 86], ["EBOV viruses", "SPECIES", 41, 53], ["antibody escape mutant EBOV viruses", "PROBLEM", 18, 53], ["their GP sequence", "TEST", 69, 86]]], ["Mutations T240A, Y261A, R266A, T269A, T270A, I274A, and W275A reduced binding to the GP (Figure 3B), and escape mutation L273P reduced neutralizing potency.", [["W275A", "AMINO_ACID", 56, 61], ["GP (Figure 3B", "GENE_OR_GENE_PRODUCT", 85, 98], ["GP", "DNA", 85, 87], ["escape mutation", "PROBLEM", 105, 120], ["reduced neutralizing potency", "PROBLEM", 127, 155], ["neutralizing potency", "OBSERVATION", 135, 155]]], ["The key contact residues were positioned on the top of the glycan cap and within a region with relatively low sequence conservation.", [["glycan cap", "PROTEIN", 59, 69], ["relatively low sequence conservation", "TREATMENT", 95, 131], ["contact residues", "OBSERVATION", 8, 24], ["top", "OBSERVATION_MODIFIER", 48, 51], ["glycan cap", "OBSERVATION", 59, 69]]], ["However, five of seven contact residues were conserved among EBOV, BDBV, and SUDV GPs (EBOV GP residues Y261 and R266 are non-conserved) that explained broad reactivity of rEBOV-548.", [["rEBOV-548", "CHEMICAL", 172, 181], ["rEBOV-548", "CHEMICAL", 172, 181], ["EBOV", "ORGANISM", 61, 65], ["BDBV", "GENE_OR_GENE_PRODUCT", 67, 71], ["SUDV", "GENE_OR_GENE_PRODUCT", 77, 81], ["EBOV", "ORGANISM", 87, 91], ["rEBOV-548", "SIMPLE_CHEMICAL", 172, 181], ["BDBV", "PROTEIN", 67, 71], ["EBOV GP residues", "PROTEIN", 87, 103], ["R266", "PROTEIN", 113, 117], ["rEBOV", "PROTEIN", 172, 177], ["EBOV", "SPECIES", 61, 65], ["BDBV", "TEST", 67, 71], ["SUDV GPs", "TEST", 77, 85], ["EBOV GP residues", "TEST", 87, 103]]], ["Together, these studies identified a site of vulnerability for antibody recognition on the glycan cap that mediated cross-reactivity and cooperative binding in the cocktail of rEBOV-548 and rEBOV-520.The Cocktail mAbs Recognize Relatively Conserved Epitopes of Two Major Antigenic Sites of the GP ::: ResultsWe next defined the structural determinants of GP binding and reactivity breadth for rEBOV-520 by resolving the crystal structure of rEBOV-520 Fab in complex with EBOV GPCL to 3.46 \u0415 resolution (Table S3).", [["rEBOV-548", "CHEMICAL", 176, 185], ["rEBOV-520", "CHEMICAL", 190, 199], ["rEBOV-520", "CHEMICAL", 393, 402], ["rEBOV-520", "CHEMICAL", 190, 199], ["rEBOV-520", "CHEMICAL", 393, 402], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 176, 185], ["rEBOV-520", "CELL", 190, 199], ["rEBOV-520", "SIMPLE_CHEMICAL", 393, 402], ["EBOV", "ORGANISM", 471, 475], ["glycan cap", "PROTEIN", 91, 101], ["rEBOV", "PROTEIN", 176, 181], ["Cocktail mAbs", "PROTEIN", 204, 217], ["Conserved Epitopes", "PROTEIN", 239, 257], ["rEBOV", "PROTEIN", 393, 398], ["rEBOV", "PROTEIN", 441, 446], ["520 Fab", "PROTEIN", 447, 454], ["EBOV GPCL", "PROTEIN", 471, 480], ["these studies", "TEST", 10, 23], ["antibody recognition", "PROBLEM", 63, 83], ["the glycan cap", "TEST", 87, 101], ["rEBOV", "TEST", 190, 195], ["The Cocktail mAbs", "TREATMENT", 200, 217], ["GP binding", "PROBLEM", 355, 365], ["rEBOV", "TEST", 393, 398], ["EBOV GPCL", "TEST", 471, 480]]], ["The rEBOV-520 Fab bound to the base of each protomer of GPCL, and the constant domains were oriented upward from the viral membrane (Figure 3C).", [["membrane", "ANATOMY", 123, 131], ["rEBOV-520 Fab", "GENE_OR_GENE_PRODUCT", 4, 17], ["GPCL", "GENE_OR_GENE_PRODUCT", 56, 60], ["rEBOV", "PROTEIN", 4, 9], ["520 Fab", "PROTEIN", 10, 17], ["GPCL", "PROTEIN", 56, 60], ["The rEBOV", "TEST", 0, 9], ["the constant domains", "PROBLEM", 66, 86], ["base", "ANATOMY_MODIFIER", 31, 35], ["viral membrane", "OBSERVATION", 117, 131]]], ["The rEBOV-520 footprint includes relatively conserved regions including the internal fusion loop (IFL) stem of the GP2 subunit and the hydrophobic pocket formed by five residues of the GP1 subunit and termed previously the \u201c310\u201d pocket (Zhao et al., 2016, West et al., 2019).", [["rEBOV-520", "CHEMICAL", 4, 13], ["GP2", "GENE_OR_GENE_PRODUCT", 115, 118], ["GP1", "GENE_OR_GENE_PRODUCT", 185, 188], ["rEBOV-520 footprint", "DNA", 4, 23], ["internal fusion loop", "PROTEIN", 76, 96], ["IFL", "PROTEIN", 98, 101], ["GP2 subunit", "PROTEIN", 115, 126], ["hydrophobic pocket", "PROTEIN", 135, 153], ["GP1 subunit", "PROTEIN", 185, 196], ["The rEBOV", "TEST", 0, 9], ["the internal fusion loop (IFL) stem of the GP2 subunit", "TREATMENT", 72, 126], ["the hydrophobic pocket", "PROBLEM", 131, 153], ["the GP1 subunit", "TREATMENT", 181, 196], ["internal", "ANATOMY_MODIFIER", 76, 84], ["fusion loop", "OBSERVATION", 85, 96], ["hydrophobic pocket", "OBSERVATION", 135, 153]]], ["The footprint of rEBOV-520 is distinct from that of the previously described broad human base-specific mAb ADI-15878 (Murin et al., 2018, West et al., 2018) but is similar to the footprint of the potent human-base-specific mAb ADI-15946 (Figure 3D), which fully neutralizes EBOV and BDBV but not SUDV (Wec et al., 2017, West et al., 2019).", [["rEBOV-520", "CHEMICAL", 17, 26], ["ADI-15878", "CHEMICAL", 107, 116], ["ADI-15946", "CHEMICAL", 227, 236], ["rEBOV-520", "CHEMICAL", 17, 26], ["ADI-15946", "CHEMICAL", 227, 236], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 17, 26], ["human", "ORGANISM", 83, 88], ["human", "ORGANISM", 203, 208], ["EBOV", "ORGANISM", 274, 278], ["BDBV", "SIMPLE_CHEMICAL", 283, 287], ["rEBOV", "DNA", 17, 22], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 203, 208], ["EBOV", "SPECIES", 274, 278], ["BDBV", "SPECIES", 283, 287], ["specific mAb ADI", "TEST", 214, 230], ["footprint", "OBSERVATION_MODIFIER", 4, 13], ["base", "ANATOMY_MODIFIER", 209, 213]]], ["Both ADI-15946 and rEBOV-520 bound to the 310 pocket and IFL stem regions of the fusion loop, unlike human mAb ADI-15878, which binds to the hydrophobic loop end of the structure and bridges to a neighboring GP protomer (King et al., 2019).", [["ADI-15946", "CHEMICAL", 5, 14], ["rEBOV-520", "CHEMICAL", 19, 28], ["ADI-15878", "CHEMICAL", 111, 120], ["ADI-15946", "CHEMICAL", 5, 14], ["rEBOV-520", "CHEMICAL", 19, 28], ["ADI-15946", "SIMPLE_CHEMICAL", 5, 14], ["rEBOV-520", "SIMPLE_CHEMICAL", 19, 28], ["human", "ORGANISM", 101, 106], ["310 pocket", "PROTEIN", 42, 52], ["IFL stem regions", "PROTEIN", 57, 73], ["human mAb ADI-15878", "PROTEIN", 101, 120], ["hydrophobic loop end", "PROTEIN", 141, 161], ["GP protomer", "PROTEIN", 208, 219], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["Both ADI", "TEST", 0, 8], ["rEBOV", "TEST", 19, 24], ["the fusion loop", "TREATMENT", 77, 92], ["human mAb ADI", "TEST", 101, 114], ["IFL", "ANATOMY", 57, 60], ["stem", "ANATOMY_MODIFIER", 61, 65], ["fusion loop", "OBSERVATION", 81, 92], ["hydrophobic loop", "OBSERVATION", 141, 157]]], ["However, rEBOV-520 likely gained reactivity against SUDV by having a footprint slightly higher on the GP base than the ADI-15946, or a different angle of approach than that of ADI-15946, which was directed downward toward the viral membrane (Figure 3C), in contrast to ADI-15946, which is directed upward from the membrane (West et al., 2019).", [["membrane", "ANATOMY", 232, 240], ["membrane", "ANATOMY", 314, 322], ["rEBOV-520", "CHEMICAL", 9, 18], ["ADI-15946", "CHEMICAL", 119, 128], ["ADI-15946", "CHEMICAL", 176, 185], ["ADI-15946", "CHEMICAL", 269, 278], ["rEBOV-520", "CHEMICAL", 9, 18], ["ADI-15946", "CHEMICAL", 119, 128], ["ADI-15946", "CHEMICAL", 176, 185], ["ADI-15946", "CHEMICAL", 269, 278], ["rEBOV-520", "SIMPLE_CHEMICAL", 9, 18], ["SUDV", "SIMPLE_CHEMICAL", 52, 56], ["ADI-15946", "SIMPLE_CHEMICAL", 176, 185], ["membrane", "CELLULAR_COMPONENT", 314, 322], ["rEBOV", "PROTEIN", 9, 14], ["SUDV", "PROTEIN", 52, 56], ["rEBOV", "TEST", 9, 14], ["a footprint", "PROBLEM", 67, 78], ["ADI", "TEST", 176, 179], ["footprint", "OBSERVATION_MODIFIER", 69, 78], ["slightly", "OBSERVATION_MODIFIER", 79, 87], ["higher", "OBSERVATION_MODIFIER", 88, 94], ["viral membrane", "OBSERVATION", 226, 240], ["membrane", "ANATOMY_MODIFIER", 314, 322]]], ["This footprint allowed the mAb to avoid contact with the non-conserved EBOV GP residue N506 (R506 in SUDV GP) in the interface with rEBOV-520 (Figure 3D)\u2014a key contact residue for binding with complementarity determining region 3 of heavy chain (CDRH3) of ADI-15946 (West et al., 2019).", [["rEBOV-520", "CHEMICAL", 132, 141], ["ADI-15946", "CHEMICAL", 256, 265], ["ADI-15946", "CHEMICAL", 256, 265], ["mAb", "GENE_OR_GENE_PRODUCT", 27, 30], ["EBOV", "ORGANISM", 71, 75], ["mAb", "PROTEIN", 27, 30], ["R506", "PROTEIN", 93, 97], ["SUDV GP", "PROTEIN", 101, 108], ["rEBOV", "PROTEIN", 132, 137], ["complementarity determining region 3", "PROTEIN", 193, 229], ["heavy chain", "PROTEIN", 233, 244], ["CDRH3", "PROTEIN", 246, 251], ["the mAb", "TREATMENT", 23, 30], ["rEBOV", "TEST", 132, 137]]], ["Our findings highlighted the variability in epitopes of lead therapeutic candidate mAbs and identified rEBOV-520 as a distinct representative among the class of 310 pocket-targeting mAbs with an extended activity against SUDV.Cooperativity in the Two-Antibody Cocktail Is Mediated by Structural Remodeling of the GP Glycan Cap ::: ResultsAnalysis of the rEBOV-520 Fab-GPCL crystal structure identified 26 GPCL residues in the interface with rEBOV-520 Fab, 16 located in GP1 (amino acid [aa] 70\u201378, 104, 106, 107, 134, 136, 137, and 139) and ten located in GP2 (aa 510\u2013514, 516, 545\u2013547, and 549).", [["rEBOV-520", "CHEMICAL", 103, 112], ["amino acid", "CHEMICAL", 475, 485], ["amino acid", "CHEMICAL", 475, 485], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 103, 112], ["SUDV", "SIMPLE_CHEMICAL", 221, 225], ["Fab", "GENE_OR_GENE_PRODUCT", 451, 454], ["GP1", "GENE_OR_GENE_PRODUCT", 470, 473], ["amino acid", "AMINO_ACID", 475, 485], ["GP2", "GENE_OR_GENE_PRODUCT", 556, 559], ["epitopes", "PROTEIN", 44, 52], ["mAbs", "PROTEIN", 83, 87], ["rEBOV", "PROTEIN", 103, 108], ["310 pocket-targeting mAbs", "PROTEIN", 161, 186], ["SUDV", "PROTEIN", 221, 225], ["rEBOV", "DNA", 354, 359], ["GPCL residues", "PROTEIN", 405, 418], ["rEBOV", "PROTEIN", 441, 446], ["GP1", "PROTEIN", 470, 473], ["GP2", "PROTEIN", 556, 559], ["SUDV", "SPECIES", 221, 225], ["targeting mAbs", "TREATMENT", 172, 186], ["the rEBOV", "TEST", 350, 359], ["crystal structure", "TEST", 373, 390], ["GPCL residues", "PROBLEM", 405, 418], ["rEBOV", "TEST", 441, 446], ["Fab", "TEST", 451, 454], ["GP1", "TEST", 470, 473], ["amino acid", "TEST", 475, 485], ["aa", "TEST", 487, 489], ["GP2", "TEST", 556, 559], ["aa", "TEST", 561, 563], ["Remodeling", "OBSERVATION", 295, 305], ["GP2", "ANATOMY_MODIFIER", 556, 559]]], ["The 18-amino-acid-long CDRH3 interacted with a conformational epitope on the GP1-GP2 interface by making direct contacts with 13 GP1 (aa 70\u201378, 106, 107, 127, and 139) and 5 GP2 (aa 510\u2013514) residues that are relatively conserved among EBOV, BDBV, and SUDV (Figure S3A). rEBOV-520 bound to the 310 pocket of the GPCL formed by GP1 residues 70\u201378 (all contacted with CDRH3) and GP2 residues 510\u2013516 (four of seven contacted with CDRH3) that line the bottom part of the pocket (Figure 4A).", [["18-amino-acid", "CHEMICAL", 4, 17], ["rEBOV-520", "CHEMICAL", 271, 280], ["18-amino-acid", "CHEMICAL", 4, 17], ["rEBOV-520", "CHEMICAL", 271, 280], ["CDRH3", "GENE_OR_GENE_PRODUCT", 23, 28], ["GP2", "GENE_OR_GENE_PRODUCT", 81, 84], ["GP1", "GENE_OR_GENE_PRODUCT", 129, 132], ["GP2", "GENE_OR_GENE_PRODUCT", 174, 177], ["EBOV", "ORGANISM", 236, 240], ["Figure S3A", "GENE_OR_GENE_PRODUCT", 258, 268], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 271, 280], ["GPCL", "GENE_OR_GENE_PRODUCT", 312, 316], ["CDRH3", "GENE_OR_GENE_PRODUCT", 366, 371], ["CDRH3", "GENE_OR_GENE_PRODUCT", 428, 433], ["18-amino-acid-long CDRH3", "PROTEIN", 4, 28], ["conformational epitope", "PROTEIN", 47, 69], ["GP1", "PROTEIN", 77, 80], ["GP2", "PROTEIN", 81, 84], ["GP1", "PROTEIN", 129, 132], ["GP2", "PROTEIN", 174, 177], ["BDBV", "PROTEIN", 242, 246], ["SUDV", "PROTEIN", 252, 256], ["rEBOV", "PROTEIN", 271, 276], ["310 pocket", "PROTEIN", 294, 304], ["GPCL", "PROTEIN", 312, 316], ["GP1 residues 70\u201378", "PROTEIN", 327, 345], ["CDRH3", "PROTEIN", 366, 371], ["GP2", "PROTEIN", 377, 380], ["CDRH3", "PROTEIN", 428, 433], ["Figure 4A", "PROTEIN", 476, 485], ["EBOV", "SPECIES", 236, 240], ["EBOV", "TEST", 236, 240], ["BDBV", "TEST", 242, 246], ["GP1 residues", "TEST", 327, 339], ["GP2 residues", "TEST", 377, 389], ["bottom", "OBSERVATION_MODIFIER", 449, 455], ["pocket", "OBSERVATION_MODIFIER", 468, 474]]], ["In the unbound, full-length GP, the 310 pocket normally is occupied by the flexible descending \u03b217-\u03b218 loop of the glycan cap (GP1 residues 287\u2013291) that impedes access to the pocket.", [["GP1 residues 287\u2013291", "CHEMICAL", 127, 147], ["GP", "GENE_OR_GENE_PRODUCT", 28, 30], ["GP", "PROTEIN", 28, 30], ["310 pocket", "PROTEIN", 36, 46], ["\u03b217-\u03b218 loop", "PROTEIN", 95, 107], ["glycan cap", "PROTEIN", 115, 125], ["GP1 residues 287\u2013291", "PROTEIN", 127, 147], ["GP1 residues", "TEST", 127, 139], ["unbound", "OBSERVATION_MODIFIER", 7, 14], ["flexible", "ANATOMY_MODIFIER", 75, 83], ["descending", "ANATOMY_MODIFIER", 84, 94], ["glycan cap", "ANATOMY", 115, 125], ["pocket", "OBSERVATION_MODIFIER", 176, 182]]], ["Like ADI-15946 (West et al., 2019), rEBOV-520 either bound to a conformation of GP in which the \u03b217-\u03b218 loop is displaced, or actively displaced it from the pocket upon binding.", [["ADI-15946", "CHEMICAL", 5, 14], ["rEBOV-520", "CHEMICAL", 36, 45], ["ADI-15946", "CHEMICAL", 5, 14], ["rEBOV-520", "CHEMICAL", 36, 45], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 36, 45], ["GP", "PROTEIN", 80, 82], ["\u03b217", "PROTEIN", 96, 99], ["\u03b218 loop", "PROTEIN", 100, 108], ["rEBOV", "TEST", 36, 41], ["the \u03b217-\u03b218 loop", "TREATMENT", 92, 108], ["displaced", "OBSERVATION_MODIFIER", 112, 121], ["displaced", "OBSERVATION", 135, 144], ["pocket", "OBSERVATION_MODIFIER", 157, 163]]], ["The loop is not present in the GPCL, being removed by cleavage.", [["GPCL", "ANATOMY", 31, 35], ["GPCL", "GENE_OR_GENE_PRODUCT", 31, 35], ["GPCL", "PROTEIN", 31, 35], ["The loop", "TREATMENT", 0, 8], ["loop", "OBSERVATION", 4, 8], ["not present", "UNCERTAINTY", 12, 23]]], ["We used hydrogen-deuterium exchange mass spectrometry (HDX-MS) to compare deuterium labeling of peptides generated after digestion of the GP and GPCL with pepsin.", [["hydrogen-deuterium", "CHEMICAL", 8, 26], ["hydrogen", "CHEMICAL", 8, 16], ["deuterium", "CHEMICAL", 74, 83], ["GPCL", "SIMPLE_CHEMICAL", 145, 149], ["pepsin", "GENE_OR_GENE_PRODUCT", 155, 161], ["GP", "PROTEIN", 138, 140], ["GPCL", "PROTEIN", 145, 149], ["pepsin", "PROTEIN", 155, 161], ["hydrogen-deuterium exchange mass spectrometry", "TREATMENT", 8, 53], ["deuterium labeling of peptides", "PROBLEM", 74, 104], ["pepsin", "TREATMENT", 155, 161]]], ["Decrease in labeling of GP 310 pocket residues involved in the interface with CDRH3 confirmed limited accessibility of rEBOV-520 epitope in a structure of intact GP trimer (Figure 4A and S3B).", [["CDRH3", "GENE_OR_GENE_PRODUCT", 78, 83], ["CDRH3", "PROTEIN", 78, 83], ["rEBOV-520 epitope", "PROTEIN", 119, 136], ["GP trimer", "PROTEIN", 162, 171], ["Figure 4A", "PROTEIN", 173, 182], ["S3B", "PROTEIN", 187, 190], ["GP 310 pocket residues", "TREATMENT", 24, 46], ["rEBOV", "TEST", 119, 124], ["pocket residues", "OBSERVATION", 31, 46], ["intact", "OBSERVATION_MODIFIER", 155, 161], ["GP trimer", "OBSERVATION", 162, 171]]], ["Cleavage removes the glycan cap with the \u03b217-\u03b218 loop and exposes the pocket, which explained enhanced binding of rEBOV-520 to GPCL (Figure 1C) and enhanced neutralization potency of this mAb against virions bearing the GPCL compared with intact GP (Gilchuk et al., 2018).Cooperativity in the Two-Antibody Cocktail Is Mediated by Structural Remodeling of the GP Glycan Cap ::: ResultsPrevious work suggested that binding of the non-neutralizing macaque mAb FVM09 to the \u03b217-\u03b218 loop itself displaces the loop causing unmasking of the neutralizing epitopes for mAbs 2G4 and ADI-15946 on the GP base (Howell et al., 2017, West et al., 2019).", [["virions", "ANATOMY", 200, 207], ["\u03b217-\u03b218 loop", "CHEMICAL", 41, 53], ["rEBOV-520", "CHEMICAL", 114, 123], ["ADI-15946", "CHEMICAL", 573, 582], ["rEBOV-520", "CHEMICAL", 114, 123], ["ADI-15946", "CHEMICAL", 573, 582], ["rEBOV-520", "SIMPLE_CHEMICAL", 114, 123], ["GPCL", "SIMPLE_CHEMICAL", 127, 131], ["mAb", "GENE_OR_GENE_PRODUCT", 188, 191], ["GPCL", "CANCER", 220, 224], ["macaque", "ORGANISM", 445, 452], ["FVM09", "GENE_OR_GENE_PRODUCT", 457, 462], ["ADI-15946", "SIMPLE_CHEMICAL", 573, 582], ["\u03b217-\u03b218 loop", "PROTEIN", 41, 53], ["rEBOV", "PROTEIN", 114, 119], ["GPCL", "PROTEIN", 127, 131], ["mAb", "PROTEIN", 188, 191], ["GPCL", "PROTEIN", 220, 224], ["non-neutralizing macaque mAb FVM09", "PROTEIN", 428, 462], ["\u03b217", "PROTEIN", 470, 473], ["\u03b218 loop", "PROTEIN", 474, 482], ["neutralizing epitopes", "PROTEIN", 534, 555], ["mAbs 2G4", "PROTEIN", 560, 568], ["the glycan cap", "TREATMENT", 17, 31], ["the \u03b217-\u03b218 loop", "TREATMENT", 37, 53], ["rEBOV", "TEST", 114, 119], ["GPCL", "TEST", 127, 131], ["this mAb", "TREATMENT", 183, 191], ["the non-neutralizing macaque mAb", "TREATMENT", 424, 456], ["the neutralizing epitopes", "TREATMENT", 530, 555], ["mAbs", "TEST", 560, 564], ["ADI", "TEST", 573, 576], ["glycan", "OBSERVATION_MODIFIER", 21, 27], ["cap", "OBSERVATION_MODIFIER", 28, 31], ["pocket", "OBSERVATION_MODIFIER", 70, 76], ["Remodeling", "OBSERVATION", 341, 351]]], ["However, unlike with FVM09, whose binding was fully abolished by several alanine mutations in the \u03b217-\u03b218 loop (Howell et al., 2017), none of the alanine mutations within the \u03b217-\u03b218 loop reduced rEBOV-548 binding to the GP (data not shown).", [["alanine", "CHEMICAL", 73, 80], ["alanine", "CHEMICAL", 146, 153], ["rEBOV-548", "CHEMICAL", 196, 205], ["alanine", "CHEMICAL", 73, 80], ["alanine", "CHEMICAL", 146, 153], ["rEBOV-548", "CHEMICAL", 196, 205], ["FVM09", "GENE_OR_GENE_PRODUCT", 21, 26], ["alanine", "AMINO_ACID", 73, 80], ["alanine", "AMINO_ACID", 146, 153], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 196, 205], ["FVM09", "PROTEIN", 21, 26], ["\u03b217", "PROTEIN", 175, 178], ["\u03b218 loop", "PROTEIN", 179, 187], ["rEBOV", "PROTEIN", 196, 201], ["several alanine mutations", "TEST", 65, 90], ["the alanine mutations", "TEST", 142, 163]]], ["Rather, alanine substitutions in several residues of the \u03b217-\u03b218 loop, which are distal to the rEBOV-548 epitope in the upper portion of the glycan cap, increased rEBOV-520 binding by \u223c1.6- to 3-fold compared with binding to the wild-type GP (Figure 4B).", [["alanine", "CHEMICAL", 8, 15], ["rEBOV-520", "CHEMICAL", 163, 172], ["alanine", "CHEMICAL", 8, 15], ["alanine", "AMINO_ACID", 8, 15], ["\u03b217-\u03b218", "GENE_OR_GENE_PRODUCT", 57, 64], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 163, 172], ["\u03b217", "PROTEIN", 57, 60], ["\u03b218 loop", "PROTEIN", 61, 69], ["rEBOV-548 epitope", "PROTEIN", 95, 112], ["glycan cap", "PROTEIN", 141, 151], ["rEBOV", "PROTEIN", 163, 168], ["wild-type GP", "PROTEIN", 229, 241], ["alanine substitutions", "PROBLEM", 8, 29], ["increased rEBOV", "TEST", 153, 168], ["alanine substitutions", "OBSERVATION", 8, 29], ["several", "OBSERVATION_MODIFIER", 33, 40], ["residues", "OBSERVATION_MODIFIER", 41, 49], ["distal", "OBSERVATION_MODIFIER", 81, 87], ["upper", "ANATOMY_MODIFIER", 120, 125], ["portion", "ANATOMY_MODIFIER", 126, 133], ["glycan", "ANATOMY_MODIFIER", 141, 147], ["cap", "OBSERVATION_MODIFIER", 148, 151], ["increased", "OBSERVATION_MODIFIER", 153, 162]]], ["This suggested that rEBOV-548 does not bind to the \u03b217-\u03b218 loop, and binding to the loop itself is not required for cooperative enhancement of rEBOV-520 binding.Cooperativity in the Two-Antibody Cocktail Is Mediated by Structural Remodeling of the GP Glycan Cap ::: ResultsTo determine the structural determinants of cooperativity within the cocktail, we solved a cryogenic EM (cryo-EM) structure of rEBOV-520 and rEBOV-548 Fab in complex with EBOV GP with the glycan cap intact and mucin-like domain-deleted (\u0394Muc) at 4.1 \u00c5 resolution (Figure 5A; Table S4).", [["rEBOV-548", "CHEMICAL", 20, 29], ["rEBOV-520", "CHEMICAL", 143, 152], ["rEBOV-520", "CHEMICAL", 400, 409], ["rEBOV-548", "CHEMICAL", 20, 29], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 20, 29], ["\u03b217", "GENE_OR_GENE_PRODUCT", 51, 54], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 143, 152], ["rEBOV-520", "SIMPLE_CHEMICAL", 400, 409], ["rEBOV-548 Fab", "GENE_OR_GENE_PRODUCT", 414, 427], ["EBOV", "ORGANISM", 444, 448], ["mucin", "GENE_OR_GENE_PRODUCT", 483, 488], ["rEBOV", "PROTEIN", 20, 25], ["\u03b217", "PROTEIN", 51, 54], ["\u03b218 loop", "PROTEIN", 55, 63], ["rEBOV", "PROTEIN", 143, 148], ["rEBOV", "PROTEIN", 400, 405], ["rEBOV", "PROTEIN", 414, 419], ["548 Fab", "PROTEIN", 420, 427], ["EBOV GP", "PROTEIN", 444, 451], ["glycan cap", "PROTEIN", 461, 471], ["mucin", "PROTEIN", 483, 488], ["\u0394Muc", "PROTEIN", 510, 514], ["rEBOV", "TEST", 20, 25], ["rEBOV", "TEST", 400, 405], ["rEBOV", "TEST", 414, 419], ["the glycan cap", "TEST", 457, 471], ["mucin", "TEST", 483, 488], ["Remodeling", "OBSERVATION", 230, 240]]], ["To determine the contribution of rEBOV-548 to cooperativity, we also solved a cryo-EM structure of rEBOV-548 Fab alone in complex with EBOV GP \u0394Muc at 4.0 \u00c5 resolution (Figure S4; Table S4).", [["rEBOV-548", "CHEMICAL", 33, 42], ["rEBOV-548", "CHEMICAL", 99, 108], ["rEBOV-548", "CHEMICAL", 33, 42], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 33, 42], ["rEBOV-548 Fab", "GENE_OR_GENE_PRODUCT", 99, 112], ["EBOV", "ORGANISM", 135, 139], ["rEBOV", "PROTEIN", 33, 38], ["rEBOV", "PROTEIN", 99, 104], ["548 Fab", "PROTEIN", 105, 112], ["EBOV GP \u0394Muc", "PROTEIN", 135, 147], ["rEBOV", "TEST", 33, 38], ["rEBOV", "TEST", 99, 104]]], ["We were unable to solve the structure in the glycan cap region in the complex of GP-rEBOV-520 Fab alone by cryo-EM (data not shown), which is likely due to flexibility of the glycan cap.Cooperativity in the Two-Antibody Cocktail Is Mediated by Structural Remodeling of the GP Glycan Cap ::: ResultsUnlike the previously described mAb FVM09, our structure revealed that rEBOV-548 does not bind directly to the \u03b217- \u03b218 loop.", [["GP-rEBOV-520", "CHEMICAL", 81, 93], ["rEBOV-548", "CHEMICAL", 369, 378], ["rEBOV-548", "CHEMICAL", 369, 378], ["mAb", "GENE_OR_GENE_PRODUCT", 330, 333], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 369, 378], ["glycan cap region", "PROTEIN", 45, 62], ["GP", "PROTEIN", 81, 83], ["rEBOV", "PROTEIN", 84, 89], ["520 Fab", "PROTEIN", 90, 97], ["glycan cap", "PROTEIN", 175, 185], ["mAb FVM09", "PROTEIN", 330, 339], ["rEBOV", "PROTEIN", 369, 374], ["\u03b217- \u03b218 loop", "PROTEIN", 409, 422], ["the glycan cap", "PROBLEM", 171, 185], ["rEBOV", "TEST", 369, 374], ["glycan cap", "OBSERVATION", 45, 55], ["complex", "OBSERVATION_MODIFIER", 70, 77], ["likely due to", "UNCERTAINTY", 142, 155], ["glycan cap", "OBSERVATION", 175, 185], ["Remodeling", "OBSERVATION", 255, 265]]], ["Instead, the CDRH3 loop of rEBOV-548 directly interacted with the \u03b217 strand (residues 272\u2013275) of GP1, forming an extended beta sheet with the glycan cap, including highly conserved critical epitope residues I274 and W275 that were defined by loss of binding with alanine substitution and L273, for which mutation to proline resulted in loss of neutralizing activity. rEBOV-548, similarly to EBOV-442, inhibited glycan cap cleavage, which could be the molecular basis for neutralizing activity by these mAbs (Gilchuk et al., 2018).", [["rEBOV-548", "CHEMICAL", 27, 36], ["alanine", "CHEMICAL", 265, 272], ["L273", "CHEMICAL", 290, 294], ["proline", "CHEMICAL", 318, 325], ["loss of neutralizing activity", "DISEASE", 338, 367], ["rEBOV-548", "CHEMICAL", 369, 378], ["EBOV-442", "CHEMICAL", 393, 401], ["alanine", "CHEMICAL", 265, 272], ["proline", "CHEMICAL", 318, 325], ["rEBOV-548", "CHEMICAL", 369, 378], ["CDRH3", "GENE_OR_GENE_PRODUCT", 13, 18], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 27, 36], ["GP1", "GENE_OR_GENE_PRODUCT", 99, 102], ["alanine", "AMINO_ACID", 265, 272], ["L273", "AMINO_ACID", 290, 294], ["proline", "AMINO_ACID", 318, 325], ["EBOV-442", "ORGANISM", 393, 401], ["CDRH3 loop", "PROTEIN", 13, 23], ["rEBOV", "PROTEIN", 27, 32], ["\u03b217 strand", "DNA", 66, 76], ["GP1", "PROTEIN", 99, 102], ["beta sheet", "PROTEIN", 124, 134], ["glycan cap", "PROTEIN", 144, 154], ["epitope residues", "PROTEIN", 192, 208], ["I274", "PROTEIN", 209, 213], ["W275", "PROTEIN", 218, 222], ["mAbs", "PROTEIN", 504, 508], ["EBOV-442", "SPECIES", 393, 401], ["GP1", "TEST", 99, 102], ["the glycan cap", "TREATMENT", 140, 154], ["alanine substitution", "TREATMENT", 265, 285], ["mutation to proline", "PROBLEM", 306, 325], ["loss of neutralizing activity", "PROBLEM", 338, 367], ["rEBOV", "TEST", 369, 374], ["EBOV", "TEST", 393, 397], ["glycan cap cleavage", "PROBLEM", 413, 432], ["epitope residues", "OBSERVATION", 192, 208], ["neutralizing activity", "OBSERVATION", 346, 367]]], ["Two non-conserved GP1 residues Y261 and R266, whose mutation to alanine decreased binding of rEBOV-548 (Figure 3B), did not directly contact the rEBOV-548 paratope and were not within the cleavage site.", [["alanine", "CHEMICAL", 64, 71], ["rEBOV-548", "CHEMICAL", 93, 102], ["rEBOV-548", "CHEMICAL", 145, 154], ["alanine", "CHEMICAL", 64, 71], ["rEBOV-548", "CHEMICAL", 93, 102], ["rEBOV-548", "CHEMICAL", 145, 154], ["R266", "AMINO_ACID", 40, 44], ["alanine", "AMINO_ACID", 64, 71], ["GP1 residues", "PROTEIN", 18, 30], ["R266", "PROTEIN", 40, 44], ["rEBOV", "PROTEIN", 93, 98], ["rEBOV", "PROTEIN", 145, 150], ["alanine", "TEST", 64, 71], ["rEBOV", "TEST", 93, 98], ["GP1 residues", "OBSERVATION", 18, 30]]], ["In the SUDV GP, natural mutations Y261H and R266L affected rEBOV-548 activity in a similar way by lowering the EC50 for binding and reducing its neutralizing potency (Figures 1B, S1A, and S1B), suggesting destabilization of the epitope by these adjacent mutations.", [["rEBOV-548", "CHEMICAL", 59, 68], ["EC50", "CHEMICAL", 111, 115], ["R266L", "AMINO_ACID", 44, 49], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 59, 68], ["S1A", "GENE_OR_GENE_PRODUCT", 179, 182], ["S1B", "GENE_OR_GENE_PRODUCT", 188, 191], ["SUDV GP", "PROTEIN", 7, 14], ["rEBOV", "PROTEIN", 59, 64], ["S1A", "PROTEIN", 179, 182], ["S1B", "PROTEIN", 188, 191], ["natural mutations", "TEST", 16, 33], ["the epitope", "PROBLEM", 224, 235], ["these adjacent mutations", "PROBLEM", 239, 263], ["natural mutations", "OBSERVATION", 16, 33]]], ["In both rEBOV-548 Fab alone and rEBOV-520 + rEBOV-548 Fab bound states, the \u03b218-\u03b218\u2032 domain, C-terminal of the GP \u03b217-\u03b218 loop was displaced and structurally mimicked by the CDRH3 loop of rEBOV-548 (Figures 5B and S4).", [["rEBOV-548", "CHEMICAL", 188, 197], ["C", "CHEMICAL", 93, 94], ["rEBOV", "PROTEIN", 8, 13], ["548 Fab", "PROTEIN", 14, 21], ["rEBOV", "PROTEIN", 32, 37], ["rEBOV", "PROTEIN", 44, 49], ["\u03b218", "PROTEIN", 76, 79], ["\u03b218\u2032 domain", "PROTEIN", 80, 91], ["C-terminal", "PROTEIN", 93, 103], ["GP \u03b217-\u03b218 loop", "PROTEIN", 111, 126], ["CDRH3 loop", "PROTEIN", 174, 184], ["rEBOV", "PROTEIN", 188, 193], ["S4", "PROTEIN", 214, 216], ["rEBOV", "TEST", 32, 37], ["rEBOV", "TEST", 44, 49], ["Fab bound", "TEST", 54, 63], ["C", "TEST", 93, 94], ["the GP \u03b2", "TEST", 107, 115], ["rEBOV", "TEST", 188, 193], ["Figures", "TEST", 199, 206], ["terminal", "ANATOMY_MODIFIER", 95, 103]]], ["The rEBOV-548 LC contacted GP1 through hydrophobic interactions at the loop between \u03b11 and \u03b217 (residues 268 and 269) and through Q27L1 contacting residue D117, making a possible H-bond with the backbone of D117 (Figure 5C) that anchors the mAb to the inner chalice of the GP (Figure 5A).", [["inner chalice", "ANATOMY", 252, 265], ["rEBOV-548", "CHEMICAL", 4, 13], ["H", "CHEMICAL", 179, 180], ["GP1", "GENE_OR_GENE_PRODUCT", 27, 30], ["\u03b11", "GENE_OR_GENE_PRODUCT", 84, 86], ["D117", "AMINO_ACID", 155, 159], ["rEBOV", "PROTEIN", 4, 9], ["GP1", "PROTEIN", 27, 30], ["\u03b11", "PROTEIN", 84, 86], ["\u03b217", "PROTEIN", 91, 94], ["residues 268 and 269", "PROTEIN", 96, 116], ["Q27L1", "PROTEIN", 130, 135], ["D117", "PROTEIN", 207, 211], ["mAb", "PROTEIN", 241, 244], ["GP", "PROTEIN", 273, 275], ["Figure 5A", "PROTEIN", 277, 286], ["The rEBOV", "TEST", 0, 9], ["the backbone of D117 (Figure 5C", "TREATMENT", 191, 222], ["the mAb", "TREATMENT", 237, 244], ["loop", "ANATOMY_MODIFIER", 71, 75], ["inner", "ANATOMY_MODIFIER", 252, 257]]], ["We observed rEBOV-548-mediated destabilization and dissociation of the GP trimer (Figure S5A).", [["rEBOV-548", "CHEMICAL", 12, 21], ["rEBOV-548", "CHEMICAL", 12, 21], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 12, 21], ["GP trimer", "GENE_OR_GENE_PRODUCT", 71, 80], ["GP trimer", "PROTEIN", 71, 80], ["Figure S5A", "PROTEIN", 82, 92], ["rEBOV", "TEST", 12, 17]]], ["Such a dissociation was limited in the presence of the stalk-specific mAb ADI-16061 that was used to stabilize the GP for cryo-EM with rEBOV-548.", [["ADI-16061", "CHEMICAL", 74, 83], ["rEBOV-548", "CHEMICAL", 135, 144], ["ADI-16061", "CHEMICAL", 74, 83], ["rEBOV-548", "CHEMICAL", 135, 144], ["rEBOV-548", "SIMPLE_CHEMICAL", 135, 144], ["GP", "PROTEIN", 115, 117], ["a dissociation", "PROBLEM", 5, 19], ["rEBOV", "TEST", 135, 140]]], ["It is unclear whether this disruption seen with soluble GPs also occurs in membrane-anchored GPs or whether it contributes to the synergy.", [["membrane", "ANATOMY", 75, 83], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["this disruption", "PROBLEM", 22, 37], ["soluble GPs", "PROBLEM", 48, 59], ["the synergy", "PROBLEM", 126, 137], ["unclear whether", "UNCERTAINTY", 6, 21]]], ["Analysis of rEBOV-520 interactions in the structure of rEBOV-520 + rEBOV-548 bound to the GP showed that the rEBOV-520 CDRH3 loop makes additional contacts beyond the 310 pocket when the glycan cap is intact.", [["rEBOV-520", "CHEMICAL", 55, 64], ["rEBOV-548", "CHEMICAL", 67, 76], ["rEBOV-520", "CHEMICAL", 55, 64], ["rEBOV-548", "CHEMICAL", 67, 76], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 12, 21], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 67, 76], ["rEBOV", "PROTEIN", 12, 17], ["rEBOV-520 + rEBOV-548", "DNA", 55, 76], ["GP", "PROTEIN", 90, 92], ["rEBOV-520 CDRH3 loop", "DNA", 109, 129], ["310 pocket", "PROTEIN", 167, 177], ["glycan cap", "PROTEIN", 187, 197], ["rEBOV", "TEST", 12, 17], ["rEBOV", "TEST", 55, 60], ["rEBOV", "TEST", 67, 72], ["the GP", "TEST", 86, 92], ["the rEBOV", "TEST", 105, 114], ["CDRH3 loop", "TREATMENT", 119, 129], ["intact", "OBSERVATION", 201, 207]]], ["These contacts include Y108H3 with K510 in GP2, Y106H3 with T77 in GP1, and T104H3 with P250 in the base of the \u03b11 loop of GP1.", [["GP2", "GENE_OR_GENE_PRODUCT", 43, 46], ["GP1", "GENE_OR_GENE_PRODUCT", 67, 70], ["GP1", "GENE_OR_GENE_PRODUCT", 123, 126], ["K510", "PROTEIN", 35, 39], ["GP2", "PROTEIN", 43, 46], ["Y106H3", "PROTEIN", 48, 54], ["T77", "PROTEIN", 60, 63], ["GP1", "PROTEIN", 67, 70], ["T104H3", "PROTEIN", 76, 82], ["P250", "PROTEIN", 88, 92], ["\u03b11 loop", "PROTEIN", 112, 119], ["GP1", "PROTEIN", 123, 126], ["GP1", "TEST", 67, 70], ["T104H3", "TEST", 76, 82], ["base", "ANATOMY_MODIFIER", 100, 104], ["GP1", "ANATOMY_MODIFIER", 123, 126]]], ["The rEBOV-520 CDRH3 residue W100H3 bound to N512 in GP2, displacing the \u03b217-\u03b218 loop and mimicking the N512 interaction with W291GP1 of the \u03b217-\u03b218 loop in the unliganded structure (Figure 5D).", [["N512", "AMINO_ACID", 44, 48], ["GP2", "GENE_OR_GENE_PRODUCT", 52, 55], ["rEBOV", "PROTEIN", 4, 9], ["CDRH3", "PROTEIN", 14, 19], ["N512", "PROTEIN", 44, 48], ["GP2", "PROTEIN", 52, 55], ["\u03b217", "PROTEIN", 72, 75], ["\u03b218 loop", "PROTEIN", 76, 84], ["N512", "PROTEIN", 103, 107], ["W291GP1", "PROTEIN", 125, 132], ["\u03b217", "PROTEIN", 140, 143], ["\u03b218 loop", "PROTEIN", 144, 152], ["unliganded structure", "PROTEIN", 160, 180], ["The rEBOV", "TEST", 0, 9], ["CDRH3 residue", "TEST", 14, 27], ["GP2", "TEST", 52, 55]]], ["Residues T77, K510, and N512 were highly conserved among EBOV, BDBV, and SUDV GPs.", [["N512", "GENE_OR_GENE_PRODUCT", 24, 28], ["EBOV", "ORGANISM", 57, 61], ["EBOV", "SPECIES", 57, 61], ["BDBV", "SPECIES", 63, 67], ["SUDV", "SPECIES", 73, 77], ["Residues", "TEST", 0, 8], ["K510", "TEST", 14, 18], ["EBOV", "TEST", 57, 61], ["BDBV", "TEST", 63, 67], ["SUDV GPs", "PROBLEM", 73, 81]]], ["Of note, our previous study identified N512 as a key epitope residue for rEBOV-520, given that N512A mutation reduced binding to the GP (Gilchuk et al., 2018).", [["rEBOV-520", "CHEMICAL", 73, 82], ["N512", "GENE_OR_GENE_PRODUCT", 39, 43], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 73, 82], ["N512A", "GENE_OR_GENE_PRODUCT", 95, 100], ["N512", "PROTEIN", 39, 43], ["rEBOV", "PROTEIN", 73, 78], ["N512A", "PROTEIN", 95, 100], ["our previous study", "TEST", 9, 27], ["N512A mutation", "PROBLEM", 95, 109]]], ["Therefore, for efficient binding rEBOV-520 must overcome interference of the \u03b217-\u03b218 loop (at W291GP1) and \u03b11 helix (at P250GP1) contained in the glycan cap structure (Figure 5E).", [["rEBOV-520", "CHEMICAL", 33, 42], ["rEBOV-520", "CHEMICAL", 33, 42], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 33, 42], ["\u03b217-\u03b218", "GENE_OR_GENE_PRODUCT", 77, 84], ["\u03b11 helix", "GENE_OR_GENE_PRODUCT", 107, 115], ["rEBOV", "PROTEIN", 33, 38], ["\u03b217", "PROTEIN", 77, 80], ["\u03b218 loop", "PROTEIN", 81, 89], ["W291GP1", "PROTEIN", 94, 101], ["\u03b11 helix", "PROTEIN", 107, 115], ["P250GP1", "PROTEIN", 120, 127], ["glycan cap structure", "PROTEIN", 146, 166], ["the \u03b217-\u03b218 loop", "TREATMENT", 73, 89], ["glycan cap", "ANATOMY", 146, 156]]], ["When two Fabs of the cocktail bound to the GP, the \u03b218-\u03b218\u2032 region is displaced and the glycan cap pulled back, along with the \u03b217-\u03b218 loop, to allow efficient binding of rEBOV-520 (Figure 5F).", [["rEBOV-520", "CHEMICAL", 171, 180], ["rEBOV-520", "CHEMICAL", 171, 180], ["Fabs", "GENE_OR_GENE_PRODUCT", 9, 13], ["GP", "GENE_OR_GENE_PRODUCT", 43, 45], ["rEBOV-520", "SIMPLE_CHEMICAL", 171, 180], ["Fabs", "PROTEIN", 9, 13], ["GP", "PROTEIN", 43, 45], ["\u03b218-\u03b218\u2032 region", "DNA", 51, 66], ["glycan cap", "PROTEIN", 88, 98], ["\u03b217-\u03b218 loop", "PROTEIN", 127, 139], ["rEBOV", "PROTEIN", 171, 176], ["the glycan cap", "TREATMENT", 84, 98], ["rEBOV", "TEST", 171, 176], ["displaced", "OBSERVATION", 70, 79], ["glycan cap", "OBSERVATION", 88, 98]]], ["However, in a structure where rEBOV-548 bound to the GP alone, the glycan cap was not displaced to the degree it was when rEBOV-520 was bound but rather is reminiscent of the structure of unliganded GP.", [["rEBOV-548", "CHEMICAL", 30, 39], ["rEBOV-520", "CHEMICAL", 122, 131], ["rEBOV-548", "CHEMICAL", 30, 39], ["rEBOV-520", "CHEMICAL", 122, 131], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 30, 39], ["GP", "GENE_OR_GENE_PRODUCT", 53, 55], ["rEBOV-520", "SIMPLE_CHEMICAL", 122, 131], ["GP", "GENE_OR_GENE_PRODUCT", 199, 201], ["rEBOV", "PROTEIN", 30, 35], ["GP", "PROTEIN", 53, 55], ["glycan cap", "PROTEIN", 67, 77], ["rEBOV", "PROTEIN", 122, 127], ["unliganded GP", "PROTEIN", 188, 201], ["unliganded GP", "OBSERVATION", 188, 201]]], ["Although the \u03b218 and \u03b218\u2032 strands are displaced and replaced by rEBOV-548 CDRH3, the \u03b217-\u03b218 loop is largely intact and bound to the base of the IFL, blocking the 310 pocket (Figure S4).", [["\u03b218", "GENE_OR_GENE_PRODUCT", 13, 16], ["\u03b218\u2032", "GENE_OR_GENE_PRODUCT", 21, 25], ["IFL", "GENE_OR_GENE_PRODUCT", 145, 148], ["\u03b218 and \u03b218\u2032 strands", "DNA", 13, 33], ["rEBOV", "PROTEIN", 64, 69], ["CDRH3", "PROTEIN", 74, 79], ["\u03b217-\u03b218 loop", "DNA", 85, 97], ["IFL", "PROTEIN", 145, 148], ["310 pocket", "PROTEIN", 163, 173], ["rEBOV", "TEST", 64, 69], ["CDRH3", "TEST", 74, 79], ["displaced", "OBSERVATION_MODIFIER", 38, 47], ["largely", "OBSERVATION_MODIFIER", 101, 108], ["intact", "OBSERVATION", 109, 115], ["base", "ANATOMY_MODIFIER", 133, 137], ["IFL", "ANATOMY", 145, 148], ["pocket", "OBSERVATION_MODIFIER", 167, 173]]], ["Comparing solvent exclusion, the unliganded GP and the GP in a complex with rEBOV-548 alone appeared very similar, except for in the \u03b218-\u03b218\u2032 domain.", [["rEBOV-548", "CHEMICAL", 76, 85], ["rEBOV-548", "CHEMICAL", 76, 85], ["GP", "GENE_OR_GENE_PRODUCT", 44, 46], ["rEBOV-548", "SIMPLE_CHEMICAL", 76, 85], ["unliganded GP", "PROTEIN", 33, 46], ["GP", "PROTEIN", 55, 57], ["rEBOV", "PROTEIN", 76, 81], ["\u03b218", "PROTEIN", 133, 136], ["\u03b218\u2032 domain", "PROTEIN", 137, 148], ["rEBOV", "TEST", 76, 81], ["unliganded", "OBSERVATION_MODIFIER", 33, 43], ["GP", "OBSERVATION_MODIFIER", 44, 46], ["very", "OBSERVATION_MODIFIER", 101, 105], ["similar", "OBSERVATION", 106, 113]]], ["Most of the region where the rEBOV-520 CDR3 bound was still excluded and the \u03b11 helix was not displaced (Figure S5B), consistent with our observation that rEBOV-548 did not fully potentiate binding of rEBOV-520.", [["rEBOV-520", "CHEMICAL", 29, 38], ["rEBOV-548", "CHEMICAL", 155, 164], ["rEBOV-520", "CHEMICAL", 201, 210], ["rEBOV-548", "CHEMICAL", 155, 164], ["rEBOV-520", "CHEMICAL", 201, 210], ["\u03b11 helix", "GENE_OR_GENE_PRODUCT", 77, 85], ["rEBOV-548", "SIMPLE_CHEMICAL", 155, 164], ["rEBOV-520", "SIMPLE_CHEMICAL", 201, 210], ["rEBOV-520 CDR3", "DNA", 29, 43], ["\u03b11 helix", "PROTEIN", 77, 85], ["rEBOV", "PROTEIN", 201, 206], ["the rEBOV", "TEST", 25, 34], ["CDR3 bound", "PROBLEM", 39, 49], ["rEBOV", "TEST", 201, 206], ["not", "UNCERTAINTY", 90, 93], ["displaced", "OBSERVATION_MODIFIER", 94, 103], ["consistent with", "UNCERTAINTY", 118, 133]]], ["These data suggested that in the cocktail, rEBOV-520 alone was largely responsible for complete displacement of the \u03b217-\u03b218 loop as well as displacing the \u03b11 helix in the cocktail, whereas rEBOV-548 acted by displacement of the \u03b218-\u03b218\u2032 domain and the C-terminal portion of the \u03b217-\u03b218 loop, alleviating structural and kinetic restraints for efficient rEBOV-520 binding (Figure S6).Cooperativity in the Two-Antibody Cocktail Is Mediated by Structural Remodeling of the GP Glycan Cap ::: ResultsWe concluded that structural remodeling is the principal mechanism for the enhanced GP binding and ebolavirus neutralization by the cocktail of two cooperative, naturally occurring human mAbs rEBOV-548 and rEBOV-520 (Figures 5G, 5H, and S6; Video S1).Cooperativity in the Two-Antibody Cocktail Is Mediated by Structural Remodeling of the GP Glycan Cap ::: Results", [["rEBOV-520", "CHEMICAL", 43, 52], ["rEBOV-548", "CHEMICAL", 189, 198], ["rEBOV-520", "CHEMICAL", 352, 361], ["rEBOV-548", "CHEMICAL", 686, 695], ["rEBOV-520", "CHEMICAL", 700, 709], ["rEBOV-520", "CHEMICAL", 43, 52], ["C", "CHEMICAL", 252, 253], ["rEBOV-520", "CHEMICAL", 352, 361], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 43, 52], ["rEBOV-548", "GENE_OR_GENE_PRODUCT", 189, 198], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 352, 361], ["GP", "GENE_OR_GENE_PRODUCT", 578, 580], ["ebolavirus", "GENE_OR_GENE_PRODUCT", 593, 603], ["human", "ORGANISM", 675, 680], ["rEBOV-520", "GENE_OR_GENE_PRODUCT", 700, 709], ["Video S1", "GENE_OR_GENE_PRODUCT", 735, 743], ["rEBOV", "PROTEIN", 43, 48], ["\u03b217", "PROTEIN", 116, 119], ["\u03b218 loop", "PROTEIN", 120, 128], ["\u03b11 helix", "PROTEIN", 155, 163], ["rEBOV", "PROTEIN", 189, 194], ["\u03b218", "PROTEIN", 228, 231], ["\u03b218\u2032 domain", "PROTEIN", 232, 243], ["C-terminal portion", "PROTEIN", 252, 270], ["\u03b217-\u03b218 loop", "PROTEIN", 278, 290], ["rEBOV", "PROTEIN", 352, 357], ["S6", "PROTEIN", 378, 380], ["human mAbs", "PROTEIN", 675, 685], ["rEBOV", "PROTEIN", 686, 691], ["rEBOV", "PROTEIN", 700, 705], ["5H", "PROTEIN", 723, 725], ["S6", "PROTEIN", 731, 733], ["Video S1", "PROTEIN", 735, 743], ["human", "SPECIES", 675, 680], ["human", "SPECIES", 675, 680], ["structural and kinetic restraints", "TREATMENT", 304, 337], ["structural remodeling", "PROBLEM", 512, 533], ["the enhanced GP binding", "PROBLEM", 565, 588], ["ebolavirus neutralization", "TREATMENT", 593, 618], ["rEBOV", "TEST", 700, 705], ["Figures", "TEST", 711, 718], ["displacement", "OBSERVATION_MODIFIER", 96, 108], ["helix", "ANATOMY_MODIFIER", 158, 163], ["cocktail", "ANATOMY", 171, 179], ["displacement", "OBSERVATION_MODIFIER", 208, 220], ["terminal", "ANATOMY_MODIFIER", 254, 262], ["portion", "ANATOMY_MODIFIER", 263, 270], ["kinetic restraints", "OBSERVATION", 319, 337], ["Remodeling", "OBSERVATION", 451, 461], ["remodeling", "OBSERVATION", 523, 533], ["Remodeling", "OBSERVATION", 814, 824]]]], "PMC7508125": [["This has been lifted to an extent, following the historic call from the Prime Minister encouraging telephonic calls over personal visits to the doctor for minor ailments during the COVID-19 crisis.", [["minor ailments", "PROBLEM", 155, 169], ["the COVID", "TEST", 177, 186]]], ["This was subsequently followed by the issue of the telemedicine practice guidelines from the Ministry of Health and Family Welfare.[6] Similarly, in USA, regulatory guidelines have been relaxed allowing Medicare to reimburse telemedicine consultations, and the Drug Enforcement Administration to permit e-prescriptions even with controlled substances without prior in-person visits.[7] Despite what may seem to be a giant leap, it is important to ensure that these guidelines take a permanent shape and continue to facilitate the easy and fearless use of telemedicine \u2013 both from the practitioner's and patient's point of view.", [["patient", "ORGANISM", 603, 610], ["patient", "SPECIES", 603, 610], ["a permanent shape", "TREATMENT", 481, 498], ["giant", "OBSERVATION", 416, 421]]], ["Regulations regarding license to practice and e-prescribe also need to be redrawn in order to prevent cross practice across the borders.The technological barrierThe quantum leap in technology over the last two decades has made this barrier smaller and modest than before.", [["The technological barrier", "TREATMENT", 136, 161], ["quantum leap", "OBSERVATION", 165, 177], ["barrier smaller", "OBSERVATION_MODIFIER", 232, 247], ["modest", "OBSERVATION_MODIFIER", 252, 258]]], ["If the experience from the doctors all over the nation in the last two months is any indication, it is heartening to note that technological jargon is hardly an issue for most practitioners and patients, who are already well equipped to use a smartphone for a variety of purposes such as social networking, banking, online shopping etc. Despite that, access to the internet and technological illiteracy does remain an issue in our country and will have to be addressed in the future if we truly aim to reach the remotest of areas.The financial barrierEven though the technology and internet has become cheaper than before, the financial part of the consultation still remains a grey area.", [["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202]]], ["This is an important barrier which must be looked at and clearly defined for telemedicine to be universally accepted.The ethical barrierOne of the biggest question marks on the fidelity of telemedicine remains its ethical aspect.", [["The ethical barrierOne", "TREATMENT", 117, 139], ["biggest", "OBSERVATION_MODIFIER", 147, 154]]], ["The internet remains a largely uncontrolled and unregulated universe with substantial loopholes detected from time to time.", [["substantial loopholes", "PROBLEM", 74, 95], ["largely", "OBSERVATION_MODIFIER", 23, 30], ["uncontrolled", "OBSERVATION", 31, 43], ["substantial", "OBSERVATION_MODIFIER", 74, 85], ["loopholes", "OBSERVATION", 86, 95]]], ["How patient confidentiality and data can be secured from malware and phishing attacks also remains a significant concern.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["phishing attacks", "PROBLEM", 69, 85]]], ["Secure portals need to be developed, which need to replace the commonplace apps being used at present.The scientific barrierOne of the deepest concerns from the old school practitioners remains the scientific accuracy of the examination being performed over the internet.", [["Secure portals", "TREATMENT", 0, 14], ["the commonplace apps", "TREATMENT", 59, 79], ["the examination", "TEST", 221, 236]]], ["From an ophthalmological point of view, even a simple assessment such as visual acuity or colour vision still remains unreliable and unproven on any internet-based platform.", [["a simple assessment", "TEST", 45, 64], ["visual acuity", "TEST", 73, 86], ["colour vision", "TEST", 90, 103]]], ["The present study,[8] we hope, will pave the path for many large, unbiased, randomised controlled trials proving and disproving every technological assistant in place, so that over time, we can finally have reliable tools we can use with confidence.The scientific barrierTo conclude, telemedicine is not just an interesting, but gradually becoming essential tool for all ophthalmologists.", [["The present study", "TEST", 0, 17], ["randomised controlled trials", "TREATMENT", 76, 104], ["The scientific barrier", "TREATMENT", 249, 271], ["large", "OBSERVATION_MODIFIER", 59, 64]]], ["The COVID-19 pandemic, in its devastating wake, has provided us with a unique opportunity to permanently strengthen the infrastructure of this technology.", [["The COVID", "TEST", 0, 9], ["devastating", "OBSERVATION_MODIFIER", 30, 41]]]], "PMC7267426": [["The coronavirus disease 2019 (COVID\u201019) viral pandemic has continued to challenge scientists and physicians attempting to understand the breadth of clinical manifestations and potential severity.", [["coronavirus disease", "DISEASE", 4, 23], ["viral pandemic", "DISEASE", 40, 54], ["coronavirus", "ORGANISM", 4, 15], ["The coronavirus disease", "PROBLEM", 0, 23], ["viral pandemic", "PROBLEM", 40, 54], ["coronavirus disease", "OBSERVATION", 4, 23]]], ["Not restricted to the respiratory tract, it appears to affect many organ systems other than the lungs.", [["respiratory tract", "ANATOMY", 22, 39], ["organ systems", "ANATOMY", 67, 80], ["lungs", "ANATOMY", 96, 101], ["respiratory tract", "ORGANISM_SUBDIVISION", 22, 39], ["organ", "ORGAN", 67, 72], ["lungs", "ORGAN", 96, 101], ["respiratory tract", "ANATOMY", 22, 39], ["lungs", "ANATOMY", 96, 101]]], ["Dermatologists have been on the watch for skin manifestations.", [["skin", "ANATOMY", 42, 46], ["skin", "ORGAN", 42, 46], ["skin manifestations", "PROBLEM", 42, 61], ["skin", "ANATOMY", 42, 46], ["manifestations", "OBSERVATION", 47, 61]]], ["Early on, various skin eruptions were reported, but none were considered specific, and some represented a viral exanthema.", [["skin", "ANATOMY", 18, 22], ["exanthema", "DISEASE", 112, 121], ["skin", "ORGAN", 18, 22], ["various skin eruptions", "PROBLEM", 10, 32], ["a viral exanthema", "PROBLEM", 104, 121], ["various", "OBSERVATION_MODIFIER", 10, 17], ["skin", "ANATOMY", 18, 22], ["eruptions", "OBSERVATION", 23, 32], ["viral", "OBSERVATION_MODIFIER", 106, 111], ["exanthema", "OBSERVATION", 112, 121]]], ["Somewhat unexpected has been the emerging numbers of chilblain\u2010like lesions as shown in the six cases presented in this issue,1a newer and possibly more unique challenge for dermatologists.", [["chilblain\u2010like lesions", "ANATOMY", 53, 75], ["chilblain\u2010like lesions", "CANCER", 53, 75], ["chilblain\u2010like lesions", "PROBLEM", 53, 75], ["lesions", "OBSERVATION", 68, 75]]], ["Are these vascular lesions directly related to the virus?", [["vascular lesions", "ANATOMY", 10, 26], ["vascular lesions", "PATHOLOGICAL_FORMATION", 10, 26], ["these vascular lesions", "PROBLEM", 4, 26], ["the virus", "PROBLEM", 47, 56], ["vascular", "ANATOMY", 10, 18], ["lesions", "OBSERVATION", 19, 26], ["virus", "OBSERVATION", 51, 56]]], ["Unfortunately, given the lockout, face\u2010to\u2010face evaluations and testing for the virus have been limited, hence the lack of biopsies and thorough vascular and coagulopathy workups.", [["vascular", "ANATOMY", 144, 152], ["coagulopathy", "DISEASE", 157, 169], ["biopsies", "CANCER", 122, 130], ["vascular", "MULTI-TISSUE_STRUCTURE", 144, 152], ["the lockout, face\u2010to\u2010face evaluations", "TEST", 21, 58], ["testing", "TEST", 63, 70], ["the virus", "PROBLEM", 75, 84], ["biopsies", "TEST", 122, 130], ["thorough vascular and coagulopathy workups", "TEST", 135, 177], ["vascular", "ANATOMY", 144, 152], ["coagulopathy", "OBSERVATION", 157, 169]]], ["None of the chilblain\u2010like lesions shown in the six patients presented1had a biopsy.", [["chilblain\u2010like lesions", "ANATOMY", 12, 34], ["chilblain\u2010like lesions", "CANCER", 12, 34], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["the chilblain\u2010like lesions", "PROBLEM", 8, 34], ["a biopsy", "TEST", 75, 83], ["lesions", "OBSERVATION", 27, 34]]], ["However, based on the clinical presentation of the lesions, they are vascular in nature and are most likely related to perniosis or microthrombi, which could include an antiphospholipid syndrome with a lupus anticoagulant2or others to be determined.", [["lesions", "ANATOMY", 51, 58], ["vascular", "ANATOMY", 69, 77], ["microthrombi", "ANATOMY", 132, 144], ["perniosis", "DISEASE", 119, 128], ["microthrombi", "DISEASE", 132, 144], ["antiphospholipid syndrome", "DISEASE", 169, 194], ["lupus", "DISEASE", 202, 207], ["lesions", "PATHOLOGICAL_FORMATION", 51, 58], ["vascular", "MULTI-TISSUE_STRUCTURE", 69, 77], ["the lesions", "PROBLEM", 47, 58], ["perniosis", "PROBLEM", 119, 128], ["microthrombi", "PROBLEM", 132, 144], ["an antiphospholipid syndrome", "PROBLEM", 166, 194], ["a lupus anticoagulant2or others", "TREATMENT", 200, 231], ["lesions", "OBSERVATION", 51, 58], ["vascular", "ANATOMY", 69, 77], ["most likely related to", "UNCERTAINTY", 96, 118], ["perniosis", "OBSERVATION", 119, 128], ["microthrombi", "OBSERVATION", 132, 144], ["antiphospholipid syndrome", "OBSERVATION", 169, 194], ["lupus", "OBSERVATION", 202, 207]]]], "PMC4383489": [["IntroductionDengue is an acute, systemic viral infection and a public health problem in the tropical world [1].", [["IntroductionDengue", "DISEASE", 0, 18], ["viral infection", "DISEASE", 41, 56], ["an acute, systemic viral infection", "PROBLEM", 22, 56], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["systemic", "OBSERVATION_MODIFIER", 32, 40], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56]]], ["The etiological agents of dengue are any of the four dengue viruses (DENV-1-4).", [["dengue", "DISEASE", 26, 32], ["dengue", "DISEASE", 53, 59], ["dengue viruses", "ORGANISM", 53, 67], ["DENV-1-4", "ORGANISM", 69, 77], ["dengue", "SPECIES", 26, 32], ["dengue viruses", "SPECIES", 53, 67], ["dengue", "PROBLEM", 26, 32], ["the four dengue viruses", "PROBLEM", 44, 67], ["DENV", "TEST", 69, 73]]], ["In endemic countries it is common for all four DENV serotypes to co-circulate.", [["DENV", "SPECIES", 47, 51]]], ["Late-stage trials of a dengue vaccine with intermediate efficacy have recently been reported, offering hope of a public health intervention [2, 3].IntroductionThe World Health Organisation (WHO) has a stated goal of reducing global dengue mortality by 50% by 2020 [1].", [["dengue", "DISEASE", 23, 29], ["dengue", "DISEASE", 232, 238], ["dengue", "SPECIES", 23, 29], ["dengue", "SPECIES", 232, 238], ["a dengue vaccine", "TREATMENT", 21, 37], ["a public health intervention", "TREATMENT", 111, 139], ["stage trials", "OBSERVATION_MODIFIER", 5, 17]]], ["Improvements in case diagnosis and management will be central to achieving this aim.", [["management", "TREATMENT", 35, 45]]], ["Significant loss of intravascular plasma volume leading to hypovolemic shock (dengue shock syndrome (DSS)), usually between the 4th-6th day of illness, is the commonest life-threatening complication of dengue [1, 4].", [["intravascular", "ANATOMY", 20, 33], ["plasma", "ANATOMY", 34, 40], ["hypovolemic shock", "DISEASE", 59, 76], ["dengue shock syndrome", "DISEASE", 78, 99], ["DSS", "DISEASE", 101, 104], ["illness", "DISEASE", 143, 150], ["dengue", "DISEASE", 202, 208], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 33], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["Significant loss of intravascular plasma volume", "PROBLEM", 0, 47], ["hypovolemic shock", "PROBLEM", 59, 76], ["dengue shock syndrome", "PROBLEM", 78, 99], ["illness", "PROBLEM", 143, 150], ["loss", "OBSERVATION_MODIFIER", 12, 16], ["intravascular plasma volume", "OBSERVATION", 20, 47], ["hypovolemic shock", "OBSERVATION", 59, 76], ["shock syndrome", "OBSERVATION", 85, 99]]], ["It\u2019s widely held that the case-incidence of DSS can be reduced via careful monitoring and the judicious use of parenteral fluids to maintain an adequate intravascular volume [1].", [["intravascular", "ANATOMY", 153, 166], ["DSS", "DISEASE", 44, 47], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 153, 166], ["DSS", "TREATMENT", 44, 47], ["careful monitoring", "TEST", 67, 85], ["parenteral fluids", "TREATMENT", 111, 128]]], ["Ideally, this case management approach is enabled because the attending physician had made an early diagnosis and thus alerted clinicians, nurses and family caregivers to the signs and symptoms suggestive of clinical worsening.", [["the signs and symptoms", "PROBLEM", 171, 193], ["clinical worsening", "PROBLEM", 208, 226]]], ["Additional benefits of an early diagnosis include support to community level public health interventions and improvements in the sensitivity of case surveillance systems and disease burden estimates.", [["community level public health interventions", "TREATMENT", 61, 104], ["case surveillance systems", "TEST", 144, 169], ["disease burden estimates", "PROBLEM", 174, 198]]], ["Furthermore, it is likely that the therapeutic window of opportunity for a dengue antiviral drug lies in the first 48\u201372 hours of illness [5].", [["dengue", "DISEASE", 75, 81], ["illness", "DISEASE", 130, 137], ["dengue", "SPECIES", 75, 81], ["a dengue antiviral drug", "TREATMENT", 73, 96]]], ["Thus, programmatic use of therapeutic interventions in the future will likely go hand in hand with strategies for early diagnosis.IntroductionYet there are numerous challenges for busy primary care clinicians in making a diagnosis of dengue in the first few days of illness.", [["hand", "ANATOMY", 81, 85], ["hand", "ANATOMY", 89, 93], ["dengue", "DISEASE", 234, 240], ["hand", "ORGANISM_SUBDIVISION", 81, 85], ["hand", "ORGANISM_SUBDIVISION", 89, 93], ["dengue", "SPECIES", 234, 240], ["therapeutic interventions", "TREATMENT", 26, 51], ["dengue", "PROBLEM", 234, 240], ["illness", "PROBLEM", 266, 273]]], ["Rapid lateral flow tests, based on the detection of the viral NS1 antigen, are available in some settings and can provide a confirmatory diagnosis [6\u20138].", [["NS1 antigen", "GENE_OR_GENE_PRODUCT", 62, 73], ["viral NS1 antigen", "PROTEIN", 56, 73], ["Rapid lateral flow tests", "TEST", 0, 24], ["the detection", "TEST", 35, 48], ["the viral NS1 antigen", "TEST", 52, 73]]], ["The diagnostic performance of the WHO dengue case definition, which relies on non-specific signs and symptoms that overlap with other infectious diseases, is unknown in the first few days of illness [1].", [["dengue", "DISEASE", 38, 44], ["infectious diseases", "DISEASE", 134, 153], ["non-specific signs and symptoms", "PROBLEM", 78, 109], ["other infectious diseases", "PROBLEM", 128, 153]]], ["Potts et al concluded that more prospective studies were needed to construct a valid and generalizable algorithm to guide the differential diagnosis of dengue in endemic countries [9].", [["dengue", "DISEASE", 152, 158], ["more prospective studies", "TEST", 27, 51], ["generalizable algorithm", "TEST", 89, 112], ["dengue", "PROBLEM", 152, 158]]], ["To this end, several prospective studies have described the creation of classifiers for the diagnosis of dengue [10\u201312].", [["dengue", "DISEASE", 105, 111], ["several prospective studies", "TEST", 13, 40], ["dengue", "PROBLEM", 105, 111]]], ["However none of these studies have exclusively focused on pediatric fever cases presenting to primary care facilities with short illness histories, a very common scenario in dengue endemic settings.", [["fever", "DISEASE", 68, 73], ["dengue", "DISEASE", 174, 180], ["these studies", "TEST", 16, 29], ["short illness histories", "PROBLEM", 123, 146]]], ["Against this backdrop, the purpose of the current study was to prospectively derive a dengue diagnostic algorithm from routinely collected clinical and laboratory findings in pediatric patients with <72 hours of illness history and compare this approach against the diagnostic performance of a leading NS1 rapid test (BioRad NS1 Ag STRIP) in the same patients.", [["dengue", "DISEASE", 86, 92], ["illness", "DISEASE", 212, 219], ["patients", "ORGANISM", 185, 193], ["NS1", "ORGANISM", 302, 305], ["patients", "ORGANISM", 351, 359], ["NS1", "PROTEIN", 302, 305], ["BioRad NS1 Ag STRIP", "PROTEIN", 318, 337], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 351, 359], ["the current study", "TEST", 38, 55], ["a dengue diagnostic algorithm", "TEST", 84, 113], ["a leading NS1 rapid test", "TEST", 292, 316], ["BioRad NS1 Ag STRIP", "TREATMENT", 318, 337]]], ["The results provide pragmatic methods to enhance the early diagnosis of dengue in primary care settings.Human research ethics ::: Materials and MethodsThe study protocol was approved by the Hospital for Tropical Diseases scientific and ethical committee and the Oxford University Tropical Research Ethical Committee (OXTREC 35\u201310).", [["dengue", "DISEASE", 72, 78], ["Human", "ORGANISM", 104, 109], ["Human", "SPECIES", 104, 109], ["dengue", "SPECIES", 72, 78], ["Methods", "TREATMENT", 144, 151], ["The study protocol", "TEST", 151, 169]]], ["The accompanying parent/guardian of each child provided written informed consent.Patient enrolment ::: Materials and MethodsRecruitment occurred in the public sector outpatient departments of Children\u2019s Hospital No. 1 (HCMC), Children\u2019s Hospital No. 2 (HCMC), The Hospital for Tropical Diseases (HCMC), Tien Giang Provincial Hospital, Dong Nai Children\u2019s Hospital, Binh Duong Provincial Hospital and Long An Provincial Hospital.", [["Tropical Diseases", "DISEASE", 277, 294], ["HCMC", "DISEASE", 296, 300], ["child", "ORGANISM", 41, 46], ["Patient", "SPECIES", 81, 88], ["Children", "SPECIES", 226, 234], ["Tropical Diseases", "PROBLEM", 277, 294], ["Diseases", "OBSERVATION", 286, 294]]], ["A patient presenting to one of the study sites was eligible for enrolment if they met the following inclusion criteria\u2014a) fever at presentation (or history of fever) and less than 72 hours of symptom history, b) in the attending physicians opinion dengue was a possible diagnosis, c) 1\u201315 years of age inclusive, d) accompanying family member or guardian had a mobile phone and e) written informed consent for the child to participate was provided by the parent/guardian.", [["fever", "DISEASE", 122, 127], ["fever", "DISEASE", 159, 164], ["dengue", "DISEASE", 248, 254], ["patient", "ORGANISM", 2, 9], ["patient", "SPECIES", 2, 9], ["the study sites", "TEST", 31, 46], ["fever", "PROBLEM", 122, 127], ["fever", "PROBLEM", 159, 164]]], ["Patients were excluded if- a) the attending physician believed they were unlikely to be able to attend follow-up or b) the attending physician believed another (non-dengue) diagnosis was more likely.", [["dengue", "DISEASE", 165, 171], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["more likely", "UNCERTAINTY", 187, 198]]], ["Patient enrolment occurred consecutively during normal clinical hours on weekdays without restriction.", [["Patient", "SPECIES", 0, 7]]], ["All patients were enrolled into the study before the attending physician received the results of any routine laboratory tests.Clinical and laboratory investigations on the day of enrolment ::: Materials and MethodsAt the time of enrolment, information on the patient\u2019s age, sex, illness history, presenting signs and symptoms were recorded in a case report form.", [["illness", "DISEASE", 279, 286], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 259, 266], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 259, 266], ["the study", "TEST", 32, 41], ["any routine laboratory tests", "TEST", 97, 125], ["laboratory investigations", "TEST", 139, 164], ["Methods", "TREATMENT", 207, 214], ["symptoms", "PROBLEM", 317, 325]]], ["The definitions used to support standardized data capture are shown in S1 Table.", [["standardized data capture", "TEST", 32, 57]]], ["Blood samples were drawn for routine hematology, biochemistry and NS1 rapid test.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["NS1", "PROTEIN", 66, 69], ["Blood samples", "TEST", 0, 13], ["routine hematology", "TEST", 29, 47], ["biochemistry", "TEST", 49, 61], ["NS1 rapid test", "TEST", 66, 80]]], ["All NS1 rapid tests (NS1 Ag STRIP, BioRad) were performed on the same day of patient enrolment by one of two trained laboratory technicians at the Hospital for Tropical Diseases.", [["Ag", "CHEMICAL", 25, 27], ["patient", "ORGANISM", 77, 84], ["NS1", "PROTEIN", 4, 7], ["NS1 Ag STRIP", "PROTEIN", 21, 33], ["patient", "SPECIES", 77, 84], ["All NS1 rapid tests", "TEST", 0, 19], ["NS1 Ag STRIP", "TEST", 21, 33], ["Tropical Diseases", "PROBLEM", 160, 177], ["Diseases", "OBSERVATION", 169, 177]]], ["Routine hematology results, but not biochemistry or NS1 rapid test results, were made available to the attending physician, who decided on the management approach, i.e. hospitalization or ambulatory follow-up.Patient follow-up ::: Materials and MethodsA 2nd blood sample for the purposes of serology was collected around the time of defervescence from all patients that were hospitalized anytime during their acute illness.", [["blood sample", "ANATOMY", 258, 270], ["blood", "ORGANISM_SUBSTANCE", 258, 263], ["patients", "ORGANISM", 356, 364], ["NS1", "PROTEIN", 52, 55], ["Patient", "SPECIES", 209, 216], ["patients", "SPECIES", 356, 364], ["NS1 rapid test", "TEST", 52, 66], ["MethodsA", "TEST", 245, 253], ["blood sample", "TEST", 258, 270], ["serology", "TEST", 291, 299], ["their acute illness", "PROBLEM", 403, 422]]], ["If the patient was managed solely on an ambulatory basis for the duration of their illness, then a 2nd early convalescence blood sample for the purposes of serology was collected only from a randomly selected 10% of this patient population.", [["blood sample", "ANATOMY", 123, 135], ["patient", "ORGANISM", 7, 14], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["patient", "ORGANISM", 221, 228], ["patient", "SPECIES", 7, 14], ["patient", "SPECIES", 221, 228], ["blood sample", "TEST", 123, 135], ["serology", "TEST", 156, 164], ["this patient population", "TREATMENT", 216, 239]]], ["All clinical and laboratory data were stored in an ICH-GCP compliant, clinical data management platform called \u201cCLIRES\u201d.", [["ICH", "DISEASE", 51, 54], ["laboratory data", "TEST", 17, 32], ["an ICH", "PROBLEM", 48, 54]]], ["Demographic and clinical data were double entered.", [["clinical data", "TEST", 16, 29]]], ["Electronic data files containing hematological results were uploaded directly to CLIRES.", [["Electronic data files", "TEST", 0, 21]]], ["Independent study monitoring was performed by the Clinical Trials Unit of the Oxford University Clinical Research Unit which examined adherence to the trial procedures, data collection and recording and compliance with ICH-GCP.Dengue diagnostics and case definitions ::: Materials and MethodsThe gold standard diagnostic result was a composite derived from three tests; RT-PCR, IgM serology and NS1 detection by ELISA.", [["ICH", "DISEASE", 219, 222], ["Dengue", "DISEASE", 227, 233], ["NS1", "GENE_OR_GENE_PRODUCT", 395, 398], ["NS1", "PROTEIN", 395, 398], ["Independent study monitoring", "TEST", 0, 28], ["the trial procedures", "TREATMENT", 147, 167], ["data collection", "TEST", 169, 184], ["ICH", "PROBLEM", 219, 222], ["GCP", "PROBLEM", 223, 226], ["three tests", "TEST", 357, 368], ["RT-PCR", "TEST", 370, 376], ["IgM serology", "TEST", 378, 390], ["NS1 detection", "TEST", 395, 408], ["ELISA", "TEST", 412, 417]]], ["First, all enrolment plasma samples were tested with a validated, quantitative RT-PCR assay to detect DENV RNA [13].", [["plasma samples", "ANATOMY", 21, 35], ["plasma samples", "ORGANISM_SUBSTANCE", 21, 35], ["DENV RNA", "RNA", 102, 110], ["DENV", "SPECIES", 102, 106], ["all enrolment plasma samples", "TEST", 7, 35], ["quantitative RT-PCR assay", "TEST", 66, 91], ["DENV RNA", "PROBLEM", 102, 110]]], ["Next, any enrolment plasma samples that were negative in the RT-PCR assay were tested using the Platelia Dengue NS1 Ag ELISA assay (BioRad) and scored according to the manufacturer's instructions.", [["plasma samples", "ANATOMY", 20, 34], ["Ag", "CHEMICAL", 116, 118], ["plasma samples", "ORGANISM_SUBSTANCE", 20, 34], ["Platelia Dengue NS1", "SPECIES", 96, 115], ["any enrolment plasma samples", "TEST", 6, 34], ["the RT-PCR assay", "TEST", 57, 73]]], ["Samples with equivalent results were repeated and if still equivocal they were scored as negative.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["Next, IgM ELISA serology (Panbio, Brisbane, Australia) was performed according to the manufacturer's instructions for patients who had paired plasma samples (enrolment and early convalescence) and who were negative in both the DENV RT-PCR assay and Platelia Dengue NS1 ELISA.", [["plasma samples", "ANATOMY", 142, 156], ["patients", "ORGANISM", 118, 126], ["plasma samples", "ORGANISM_SUBSTANCE", 142, 156], ["IgM", "PROTEIN", 6, 9], ["NS1", "PROTEIN", 265, 268], ["patients", "SPECIES", 118, 126], ["DENV", "SPECIES", 227, 231], ["Platelia Dengue NS1", "SPECIES", 249, 268], ["IgM ELISA serology", "TEST", 6, 24], ["paired plasma samples", "PROBLEM", 135, 156], ["the DENV RT", "TEST", 223, 234], ["PCR assay", "TEST", 235, 244]]], ["Any patient who was\u2014a) DENV RT-PCR positive, b) NS1 ELISA positive, or c) had DENV IgM seroconversion in paired plasma samples, was classified as a laboratory-confirmed dengue case.", [["plasma samples", "ANATOMY", 112, 126], ["dengue", "DISEASE", 169, 175], ["patient", "ORGANISM", 4, 11], ["DENV", "ORGANISM", 23, 27], ["NS1", "ORGANISM", 48, 51], ["DENV", "ORGANISM", 78, 82], ["IgM", "GENE_OR_GENE_PRODUCT", 83, 86], ["plasma samples", "ORGANISM_SUBSTANCE", 112, 126], ["NS1", "PROTEIN", 48, 51], ["IgM", "PROTEIN", 83, 86], ["patient", "SPECIES", 4, 11], ["DENV", "SPECIES", 78, 82], ["DENV RT-PCR", "TEST", 23, 34], ["b) NS1 ELISA", "TEST", 45, 57], ["DENV IgM seroconversion", "PROBLEM", 78, 101], ["paired plasma samples", "TEST", 105, 126]]], ["IgM seroconversion was defined as a change in the MAC ELISA test result from negative to positive in paired plasma samples with the 2nd sample collected 6 or more days after illness onset and >2 days after the 1st sample.Dengue diagnostics and case definitions ::: Materials and MethodsAny patient who was DENV RT-PCR negative, NS1 ELISA negative and did not IgM seroconvert in paired plasma samples was classified as \u201cnot dengue\u201d.", [["plasma samples", "ANATOMY", 108, 122], ["plasma samples", "ANATOMY", 385, 399], ["illness", "DISEASE", 174, 181], ["Dengue", "DISEASE", 221, 227], ["dengue", "DISEASE", 423, 429], ["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["plasma samples", "ORGANISM_SUBSTANCE", 108, 122], ["patient", "ORGANISM", 290, 297], ["NS1", "ORGANISM", 328, 331], ["IgM", "GENE_OR_GENE_PRODUCT", 359, 362], ["plasma samples", "ORGANISM_SUBSTANCE", 385, 399], ["IgM", "PROTEIN", 0, 3], ["NS1", "PROTEIN", 328, 331], ["IgM", "PROTEIN", 359, 362], ["patient", "SPECIES", 290, 297], ["DENV", "SPECIES", 306, 310], ["IgM seroconversion", "PROBLEM", 0, 18], ["the MAC ELISA test", "TEST", 46, 64], ["the 2nd sample", "TEST", 128, 142], ["illness onset", "PROBLEM", 174, 187], ["the 1st sample", "TEST", 206, 220], ["Methods", "TREATMENT", 279, 286], ["DENV RT-PCR", "TEST", 306, 317], ["NS1 ELISA", "TEST", 328, 337], ["IgM", "TEST", 359, 362], ["paired plasma samples", "TEST", 378, 399]]], ["Any patient who was DENV RT-PCR negative and NS1 ELISA negative at the time of enrolment, but did not have paired samples available for serology, was classified as a \u201cpresumptive not-dengue\u201d case.", [["samples", "ANATOMY", 114, 121], ["dengue", "DISEASE", 183, 189], ["patient", "ORGANISM", 4, 11], ["NS1", "ORGANISM", 45, 48], ["NS1", "PROTEIN", 45, 48], ["patient", "SPECIES", 4, 11], ["DENV", "SPECIES", 20, 24], ["DENV RT-PCR", "TEST", 20, 31], ["NS1 ELISA", "TEST", 45, 54], ["serology", "TEST", 136, 144]]], ["For analysis, data from \u201cnot dengue\u201d and \u201cpresumptive not-dengue\u201d cases were pooled.Enrichment of NS1 ::: Materials and MethodsPlasma samples were enriched for proteins with molecular weight >100kDa using Amicon filtration units (Millipore).", [["Plasma samples", "ANATOMY", 127, 141], ["dengue", "DISEASE", 29, 35], ["dengue", "DISEASE", 58, 64], ["NS1", "ORGANISM", 98, 101], ["Plasma samples", "ORGANISM_SUBSTANCE", 127, 141], ["NS1", "PROTEIN", 98, 101], ["analysis", "TEST", 4, 12], ["MethodsPlasma samples", "TEST", 120, 141], ["proteins", "TEST", 160, 168], ["molecular weight", "TEST", 174, 190], ["Amicon filtration units", "TREATMENT", 205, 228]]], ["Briefly, 200\u03bcl of plasma was concentrated to ~30\u03bcl and then tested in the Platelia NS1 ELISA.", [["plasma", "ANATOMY", 18, 24], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["NS1", "PROTEIN", 83, 86]]], ["All concentrated samples were tested in parallel with an aliquot of the original plasma samples and the filtrate (containing proteins with molecular weight <100kDa).Statistical methods ::: Materials and MethodsLogistic regression was used for the development of the diagnostic algorithm.", [["samples", "ANATOMY", 17, 24], ["plasma samples", "ANATOMY", 81, 95], ["plasma samples", "ORGANISM_SUBSTANCE", 81, 95], ["All concentrated samples", "TEST", 0, 24], ["the filtrate", "TEST", 100, 112], ["molecular weight", "TEST", 139, 155], ["MethodsLogistic regression", "TREATMENT", 203, 229], ["the diagnostic algorithm", "TEST", 262, 286]]], ["A detailed assessment of the model assumptions of linearity and additivity was performed (S1 Text).", [["A detailed assessment", "TEST", 0, 21]]], ["The model was then simplified using step-wise backwards selection using Akaike\u2019s Information Criterion (AIC) and stability selection [14].", [["step-wise backwards selection", "TREATMENT", 36, 65]]], ["The performance of the model was assessed with respect to discrimination (receiver operating characteristic curves (ROCs) and area under the ROC curve (AUC)), calibration (calibration plots and calibration intercepts and slopes), and standard accuracy criteria of binary diagnostic tests (sensitivity, specificity, negative and positive predictive values).", [["the ROC curve", "TEST", 137, 150], ["AUC", "TEST", 152, 155], ["calibration (calibration plots", "TEST", 159, 189], ["calibration intercepts", "TEST", 194, 216], ["binary diagnostic tests", "TEST", 264, 287], ["specificity", "TEST", 302, 313]]], ["We selected the cut-off point to classify a patient as dengue positive at a predicted risk of dengue of \u226533.3%, corresponding to assuming that the \u201ccost\u201d of missing a true dengue patient is twice as large as the cost of a false-positive [17].", [["dengue", "DISEASE", 55, 61], ["dengue", "DISEASE", 94, 100], ["dengue", "DISEASE", 172, 178], ["patient", "ORGANISM", 44, 51], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 179, 186], ["dengue", "SPECIES", 55, 61], ["dengue", "SPECIES", 94, 100], ["dengue positive", "PROBLEM", 55, 70]]], ["To avoid over-optimistic estimates of model accuracy and performance due to model derivation and evaluation on the same dataset, all accuracy measures were corrected for optimism by validation.", [["model derivation", "TEST", 76, 92], ["evaluation", "TEST", 97, 107]]], ["Validation was performed for the whole model development process including variable selection.", [["Validation", "TEST", 0, 10], ["the whole model development process", "TREATMENT", 29, 64]]], ["Two validation schemes were employed to mimic external validation:Statistical methods ::: Materials and MethodsThe final logistic model was also presented as a nomogram for direct clinical use.", [["Methods", "TREATMENT", 104, 111], ["a nomogram", "TEST", 158, 168]]], ["All statistical analyses were performed using the statistical software R v3.1.1 (R foundation for statistical computing, Vienna, Austria) and its companion packages c060 version 0.2\u20133 (for stability selection), randomForest version 4.6\u20137 (for random forest) and rpart version 4.1\u20138 (for CART).Study population ::: Results5729 children with fever of less than 72 hours were enrolled at one of the seven clinical study sites in southern Vietnam between October 2010 and December 2012.", [["fever", "DISEASE", 340, 345], ["children", "ORGANISM", 326, 334], ["children", "SPECIES", 326, 334], ["All statistical analyses", "TEST", 0, 24], ["randomForest version", "TEST", 211, 231], ["rpart version", "TEST", 262, 275], ["fever", "PROBLEM", 340, 345]]], ["A summary of the patient screening, enrolment and diagnostic outcomes is shown in S1 Fig A total of 5707 patients were included in the analyses.", [["patient", "ORGANISM", 17, 24], ["patients", "ORGANISM", 105, 113], ["patient", "SPECIES", 17, 24], ["patients", "SPECIES", 105, 113], ["the patient screening", "TEST", 13, 34]]], ["1692 (29.6%) participants had laboratory-confirmed dengue.", [["dengue", "DISEASE", 51, 57], ["participants", "ORGANISM", 13, 25], ["participants", "SPECIES", 13, 25], ["dengue", "PROBLEM", 51, 57]]], ["The baseline characteristics of the dengue and non-dengue cases are shown in Table 1.", [["dengue", "DISEASE", 36, 42], ["non-dengue", "DISEASE", 47, 57], ["the dengue and non-dengue cases", "PROBLEM", 32, 63]]], ["Notably, dengue cases were older than non-dengue cases.", [["dengue", "DISEASE", 9, 15], ["non-dengue", "DISEASE", 38, 48], ["dengue", "SPECIES", 9, 15], ["dengue cases", "PROBLEM", 9, 21]]], ["All four DENV serotypes were detected; DENV-1 was the commonest serotype, followed by DENV-4, -2 and -3.Diagnostic accuracy of the NS1 Ag Strip test and association with viremia ::: ResultsEnrolment plasma samples (n = 5707) were tested for the presence of NS1 by NS1 Ag Strip test in a blinded, real-time fashion.", [["plasma samples", "ANATOMY", 199, 213], ["viremia", "DISEASE", 170, 177], ["Ag", "CHEMICAL", 135, 137], ["Ag", "CHEMICAL", 268, 270], ["DENV", "ORGANISM", 9, 13], ["DENV-1", "ORGANISM", 39, 45], ["DENV-4", "ORGANISM", 86, 92], ["-3", "GENE_OR_GENE_PRODUCT", 101, 103], ["NS1", "ORGANISM", 131, 134], ["plasma samples", "ORGANISM_SUBSTANCE", 199, 213], ["NS1", "GENE_OR_GENE_PRODUCT", 257, 260], ["NS1", "PROTEIN", 131, 134], ["Ag", "PROTEIN", 135, 137], ["NS1", "PROTEIN", 257, 260], ["NS1 Ag", "PROTEIN", 264, 270], ["DENV-1", "SPECIES", 39, 45], ["DENV", "SPECIES", 9, 13], ["DENV-1", "SPECIES", 39, 45], ["DENV-4", "SPECIES", 86, 92], ["All four DENV serotypes", "PROBLEM", 0, 23], ["DENV", "PROBLEM", 39, 43], ["DENV", "TEST", 86, 90], ["Diagnostic accuracy", "TEST", 104, 123], ["the NS1 Ag Strip test", "TEST", 127, 148], ["viremia", "PROBLEM", 170, 177], ["Enrolment plasma samples", "TEST", 189, 213], ["NS1", "PROBLEM", 257, 260], ["NS1 Ag Strip test", "TEST", 264, 281], ["four", "OBSERVATION_MODIFIER", 4, 8], ["DENV", "OBSERVATION_MODIFIER", 9, 13], ["serotypes", "OBSERVATION", 14, 23], ["viremia", "OBSERVATION", 170, 177]]], ["Against the composite gold-standard reference diagnostic result, the NS1 Ag Strip test had a sensitivity of 70.4% (95%CI: 68.2\u201372.6%), specificity of 99.2% (95%CI: 98.9\u201399.5%), positive predictive value (PPV) of 97.4% (95%CI: 96.3\u201398.2%), and negative predictive value (NPV) of 88.9% (95%CI: 87.9\u201389.8%) for the diagnosis of dengue (Table 2).", [["dengue", "DISEASE", 325, 331], ["Ag", "CHEMICAL", 73, 75], ["NS1", "ORGANISM", 69, 72], ["NS1", "PROTEIN", 69, 72], ["Ag", "PROTEIN", 73, 75], ["dengue", "SPECIES", 325, 331], ["the NS1 Ag Strip test", "TEST", 65, 86], ["a sensitivity", "TEST", 91, 104], ["CI", "TEST", 118, 120], ["specificity", "TEST", 135, 146], ["CI", "TEST", 160, 162], ["PPV", "TEST", 204, 207], ["CI", "TEST", 222, 224], ["NPV", "TEST", 270, 273], ["CI", "TEST", 288, 290], ["dengue", "PROBLEM", 325, 331]]], ["There was a striking difference in diagnostic performance by serotype, with NS1 detection being less sensitive in DENV-2 infections irrespective of the serological response (primary vs secondary)(S2 Table).", [["infections", "DISEASE", 121, 131], ["NS1", "GENE_OR_GENE_PRODUCT", 76, 79], ["DENV-2", "ORGANISM", 114, 120], ["NS1", "PROTEIN", 76, 79], ["DENV-2", "SPECIES", 114, 120], ["serotype", "PROBLEM", 61, 69], ["NS1 detection", "TEST", 76, 89], ["DENV", "PROBLEM", 114, 118], ["2 infections", "PROBLEM", 119, 131], ["the serological response", "PROBLEM", 148, 172], ["striking", "OBSERVATION_MODIFIER", 12, 20], ["difference", "OBSERVATION_MODIFIER", 21, 31], ["DENV", "OBSERVATION", 114, 118]]], ["The detection of NS1 was strongly associated with the concentration of DENV RNA in the same plasma sample; the odds of NS1 detection increased by 1.8 (95%CI: 1.6\u20131.9) for each 10-fold higher DENV RNA concentration (Table 2).", [["plasma sample", "ANATOMY", 92, 105], ["NS1", "GENE_OR_GENE_PRODUCT", 17, 20], ["plasma", "ORGANISM_SUBSTANCE", 92, 98], ["NS1", "GENE_OR_GENE_PRODUCT", 119, 122], ["NS1", "PROTEIN", 17, 20], ["DENV RNA", "RNA", 71, 79], ["NS1", "PROTEIN", 119, 122], ["DENV RNA", "RNA", 191, 199], ["DENV", "SPECIES", 71, 75], ["DENV", "SPECIES", 191, 195], ["NS1", "PROBLEM", 17, 20], ["DENV RNA", "PROBLEM", 71, 79], ["NS1 detection", "TEST", 119, 132], ["CI", "TEST", 154, 156], ["NS1", "OBSERVATION", 17, 20], ["DENV", "OBSERVATION", 71, 75]]], ["These data define the strengths and weaknesses of NS1 rapid testing; it is highly specific but is compromised by suboptimal sensitivity, especially for DENV-2 cases.Manipulation of plasma specimens to improve NS1 detection ::: ResultsVolume enrichment of the plasma molecular weight fraction containing multimeric NS1 (>100,000kDa) was performed on plasma samples from 21 viremic dengue cases enrolled in this study.", [["plasma specimens", "ANATOMY", 181, 197], ["plasma", "ANATOMY", 259, 265], ["plasma samples", "ANATOMY", 349, 363], ["dengue", "DISEASE", 380, 386], ["NS1", "GENE_OR_GENE_PRODUCT", 50, 53], ["DENV-2", "ORGANISM", 152, 158], ["plasma specimens", "ORGANISM_SUBSTANCE", 181, 197], ["NS1", "GENE_OR_GENE_PRODUCT", 209, 212], ["plasma", "ORGANISM_SUBSTANCE", 259, 265], ["NS1", "GENE_OR_GENE_PRODUCT", 314, 317], ["plasma samples", "ORGANISM_SUBSTANCE", 349, 363], ["NS1", "PROTEIN", 50, 53], ["NS1", "PROTEIN", 209, 212], ["multimeric NS1", "PROTEIN", 303, 317], ["NS1 rapid testing", "TEST", 50, 67], ["DENV", "PROBLEM", 152, 156], ["plasma specimens", "TEST", 181, 197], ["NS1 detection", "TEST", 209, 222], ["the plasma molecular weight fraction", "TEST", 255, 291], ["multimeric NS1", "TEST", 303, 317], ["plasma samples", "TEST", 349, 363], ["this study", "TEST", 405, 415], ["multimeric NS1", "OBSERVATION", 303, 317]]], ["However, despite 5-10-fold concentration of plasma, this processing failed to materially improve the diagnostic yield, with only 1 of 11 samples changing their status from negative (original sample) to positive (concentrated sample) in the Platelia NS1 ELISA (S3 Table).The Early Dengue Classifier; A diagnostic rule based on clinical and simple laboratory features ::: ResultsMultivariate logistic regression analyses of clinical, demographic and laboratory data from 5707 patients were performed to generate a practical dengue diagnostic classifier that could replace or augment NS1-based diagnosis in the first 72 hours of illness.", [["plasma", "ANATOMY", 44, 50], ["samples", "ANATOMY", 137, 144], ["sample", "ANATOMY", 191, 197], ["sample", "ANATOMY", 225, 231], ["Dengue", "DISEASE", 280, 286], ["dengue", "DISEASE", 522, 528], ["plasma", "ORGANISM_SUBSTANCE", 44, 50], ["patients", "ORGANISM", 474, 482], ["NS1", "ORGANISM", 581, 584], ["NS1", "PROTEIN", 249, 252], ["NS1", "PROTEIN", 581, 584], ["patients", "SPECIES", 474, 482], ["dengue", "SPECIES", 522, 528], ["plasma", "TREATMENT", 44, 50], ["laboratory data", "TEST", 448, 463], ["illness", "PROBLEM", 626, 633]]], ["The most parsimonious model, derived from stability selection, used the patient\u2019s age, white cell count and platelet count at the time of enrolment to classify dengue from non-dengue cases (Table 3).", [["white cell", "ANATOMY", 87, 97], ["platelet", "ANATOMY", 108, 116], ["dengue", "DISEASE", 160, 166], ["non-dengue", "DISEASE", 172, 182], ["patient", "ORGANISM", 72, 79], ["white cell", "CELL", 87, 97], ["platelet", "CELL", 108, 116], ["patient", "SPECIES", 72, 79], ["white cell count", "TEST", 87, 103], ["platelet count", "TEST", 108, 122]]], ["Alternative approaches to feature selection yielded models with only slightly higher performance but relied on many more (more than ten) variables (S4 Table).", [["slightly higher performance", "PROBLEM", 69, 96]]], ["The most parsimonious model, herein called the Early Dengue Classifier (EDC), had a sensitivity of 74.8% (95%CI: 73.0\u201376.8%), specificity of 76.3% (95%CI: 75.2\u201377.6%), positive predictive value of 57.1% (95%CI: 56.2\u201359.0%), and negative predictive value of 87.8% (95%CI: 86.8\u201388.5%) for correctly classifying dengue cases in the entire dataset at the pre-defined cut-off of 33.3%.", [["Dengue", "DISEASE", 53, 59], ["dengue", "DISEASE", 309, 315], ["dengue", "SPECIES", 309, 315], ["a sensitivity", "TEST", 82, 95], ["CI", "TEST", 109, 111], ["specificity", "TEST", 126, 137], ["CI", "TEST", 151, 153], ["CI", "TEST", 207, 209], ["CI", "TEST", 267, 269]]], ["Of note, this pre-defined cut-off reflecting clinical priorities was very close to the cut-off corresponding to the point on the ROC curve closest to the upper left corner (perfect model), which was 34.2% (Fig 1A).", [["left corner", "ANATOMY", 160, 171], ["the ROC curve", "TEST", 125, 138], ["upper", "ANATOMY_MODIFIER", 154, 159], ["left", "ANATOMY_MODIFIER", 160, 164], ["corner", "ANATOMY_MODIFIER", 165, 171]]], ["The area under the ROC curve (AUC) was 0.829 (Fig 1B) and the predicted risk of dengue agreed well with the observed risk (Fig 1C).", [["dengue", "DISEASE", 80, 86], ["dengue", "SPECIES", 80, 86], ["the ROC curve", "TEST", 15, 28], ["AUC", "TEST", 30, 33], ["dengue", "PROBLEM", 80, 86], ["dengue", "OBSERVATION", 80, 86]]], ["The EDC had sensitivity of 72.9% (95% CI: 69.6\u201376.6%) for DENV1, 74.7% (95%CI: 71.0\u201379.7%) for DENV2, 68.4% (95%CI: 59.2\u201374.5%) for DENV3 and 78.2% (95%CI: 75.5\u201383.3%) for DENV4 infection.", [["infection", "DISEASE", 178, 187], ["DENV2", "ORGANISM", 95, 100], ["DENV4", "GENE_OR_GENE_PRODUCT", 172, 177], ["DENV2", "SPECIES", 95, 100], ["sensitivity", "TEST", 12, 23], ["CI", "TEST", 38, 40], ["DENV1", "TEST", 58, 63], ["CI", "TEST", 75, 77], ["DENV2", "TEST", 95, 100], ["CI", "TEST", 112, 114], ["DENV3", "TEST", 132, 137], ["CI", "TEST", 152, 154], ["DENV4 infection", "PROBLEM", 172, 187], ["infection", "OBSERVATION", 178, 187]]], ["The overall performance characteristics of the EDC under temporal, leave-one-site-out validation or seasonality (rainy versus dry season), are summarized in S5 Table.", [["validation", "PROBLEM", 86, 96], ["seasonality", "PROBLEM", 100, 111]]], ["These results suggest that, in settings where NS1 rapid tests are not routinely available, the EDC could assist primary care physicians in dengue diagnosis.The Early Dengue Classifier; A diagnostic rule based on clinical and simple laboratory features ::: ResultsIn settings where NS1 rapid tests are routinely used, the EDC can be combined with the NS1 rapid test as a composite test (classified as positive when either NS1 rapid test or EDC are positive, and classified as negative when both NS1 rapid test and EDC are negative).", [["dengue", "DISEASE", 139, 145], ["Dengue", "DISEASE", 166, 172], ["NS1", "GENE_OR_GENE_PRODUCT", 46, 49], ["NS1", "ORGANISM", 281, 284], ["EDC", "SIMPLE_CHEMICAL", 321, 324], ["NS1", "GENE_OR_GENE_PRODUCT", 350, 353], ["NS1", "GENE_OR_GENE_PRODUCT", 421, 424], ["NS1", "ORGANISM", 494, 497], ["NS1", "PROTEIN", 46, 49], ["NS1", "PROTEIN", 281, 284], ["NS1", "PROTEIN", 350, 353], ["NS1", "PROTEIN", 421, 424], ["NS1", "PROTEIN", 494, 497], ["NS1 rapid tests", "TEST", 46, 61], ["NS1 rapid tests", "TEST", 281, 296], ["the NS1 rapid test", "TEST", 346, 364], ["a composite test", "TEST", 368, 384], ["NS1 rapid test", "TEST", 421, 435], ["NS1 rapid test", "TEST", 494, 508], ["EDC", "TEST", 513, 516]]], ["This composite test had sensitivity of 91.6% (95%CI: 90.4\u201392.9%) while the specificity was 75.7% (95%CI: 74.5\u201377.0%).", [["This composite test", "TEST", 0, 19], ["sensitivity", "TEST", 24, 35], ["CI", "TEST", 49, 51], ["the specificity", "TEST", 71, 86], ["CI", "TEST", 101, 103]]], ["Corresponding positive and negative predictive values were 61.7% (95%CI: 60.6\u201363.1%) and 95.5% (95%CI: 94.9\u201396.1%).", [["CI", "TEST", 69, 71], ["CI", "TEST", 99, 101]]], ["If a higher specificity was desired, a higher cut-off value of the EDC could be used for the combined test instead, e.g. a cut-off of 50% would lead to a sensitivity of 86.0% (95%CI: 84.5\u201387.6%) and specificity of 89.6% (95%CI: 88.7\u201390.5%).", [["EDC", "SIMPLE_CHEMICAL", 67, 70], ["the combined test", "TEST", 89, 106], ["a sensitivity", "TEST", 152, 165], ["CI", "TEST", 179, 181], ["specificity", "TEST", 199, 210], ["CI", "TEST", 224, 226]]], ["These results imply that the EDC is useful in settings with and without NS1 rapid testing.User-friendly applications of the Early Dengue Classifier ::: Results", [["EDC", "CHEMICAL", 29, 32], ["Dengue", "DISEASE", 130, 136], ["EDC", "SIMPLE_CHEMICAL", 29, 32], ["NS1", "GENE_OR_GENE_PRODUCT", 72, 75], ["NS1", "PROTEIN", 72, 75], ["NS1 rapid testing", "TEST", 72, 89]]]], "PMC7454798": [["Study Design and Participants ::: METHODSWe performed a retrospective, longitudinal study of adult patients age > 18 at our 3 academic, tertiary care centers from March 1 through May 24, 2020.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["longitudinal study", "TEST", 71, 89]]], ["Inclusion criteria were patients who tested positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) via nasopharyngeal swab, and had a neurovascular event requiring intensive care unit admission for neuro-intensive care and/or neurosurgical consultation.", [["nasopharyngeal swab", "ANATOMY", 122, 141], ["neurovascular", "ANATOMY", 153, 166], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 64, 102], ["patients", "ORGANISM", 24, 32], ["nasopharyngeal swab", "ORGAN", 122, 141], ["patients", "SPECIES", 24, 32], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 57, 116], ["Severe Acute Respiratory Syndrome", "PROBLEM", 57, 90], ["Coronavirus", "TEST", 91, 102], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["nasopharyngeal swab", "TEST", 122, 141], ["a neurovascular event", "PROBLEM", 151, 172], ["neurosurgical consultation", "TEST", 245, 271], ["Severe", "OBSERVATION_MODIFIER", 57, 63], ["Acute", "OBSERVATION_MODIFIER", 64, 69], ["Respiratory Syndrome", "OBSERVATION", 70, 90], ["nasopharyngeal swab", "ANATOMY", 122, 141], ["neurovascular", "ANATOMY", 153, 166]]], ["Institutional Review Board approval was obtained, and individual patient consent was not required.Data Collection ::: METHODSUsing hospital and department datasets, we collected relevant demographic (eg, age and sex), clinical (eg, comorbidities), laboratory (eg, D-dimer), radiological, and outcomes data (eg, death and disposition) from electronic medical records.", [["death", "DISEASE", 311, 316], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72]]], ["Neurovascular events were classified according to etiology, including acute ischemic stroke (eg, LVO), cerebral venous sinus thrombosis (CVST), and intracranial hemorrhage (eg, intraparenchymal, subarachnoid, and subdural).", [["Neurovascular", "ANATOMY", 0, 13], ["cerebral venous sinus", "ANATOMY", 103, 124], ["intracranial", "ANATOMY", 148, 160], ["intraparenchymal", "ANATOMY", 177, 193], ["subarachnoid", "ANATOMY", 195, 207], ["subdural", "ANATOMY", 213, 221], ["acute ischemic stroke", "DISEASE", 70, 91], ["LVO", "DISEASE", 97, 100], ["cerebral venous sinus thrombosis", "DISEASE", 103, 135], ["CVST", "DISEASE", 137, 141], ["intracranial hemorrhage", "DISEASE", 148, 171], ["cerebral venous sinus", "MULTI-TISSUE_STRUCTURE", 103, 124], ["Neurovascular events", "PROBLEM", 0, 20], ["acute ischemic stroke", "PROBLEM", 70, 91], ["cerebral venous sinus thrombosis", "PROBLEM", 103, 135], ["CVST", "PROBLEM", 137, 141], ["intracranial hemorrhage (eg, intraparenchymal, subarachnoid, and subdural)", "PROBLEM", 148, 222], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["ischemic", "OBSERVATION_MODIFIER", 76, 84], ["stroke", "OBSERVATION", 85, 91], ["cerebral", "ANATOMY", 103, 111], ["venous sinus", "ANATOMY", 112, 124], ["thrombosis", "OBSERVATION", 125, 135], ["intracranial", "ANATOMY", 148, 160], ["hemorrhage", "OBSERVATION", 161, 171], ["intraparenchymal", "ANATOMY_MODIFIER", 177, 193], ["subarachnoid", "ANATOMY_MODIFIER", 195, 207], ["subdural", "ANATOMY_MODIFIER", 213, 221]]], ["Hospital events included intubation, Acute Respiratory Distress Syndrome (ARDS), venous thromboembolism (VTE), and intervention (eg, mechanical thrombectomy and craniotomy).", [["venous", "ANATOMY", 81, 87], ["Acute Respiratory Distress Syndrome", "DISEASE", 37, 72], ["ARDS", "DISEASE", 74, 78], ["venous thromboembolism", "DISEASE", 81, 103], ["VTE", "DISEASE", 105, 108], ["venous", "MULTI-TISSUE_STRUCTURE", 81, 87], ["intubation", "TREATMENT", 25, 35], ["Acute Respiratory Distress Syndrome", "PROBLEM", 37, 72], ["ARDS)", "PROBLEM", 74, 79], ["venous thromboembolism", "PROBLEM", 81, 103], ["VTE", "PROBLEM", 105, 108], ["intervention (eg", "TREATMENT", 115, 131], ["mechanical thrombectomy", "TREATMENT", 133, 156], ["craniotomy", "TREATMENT", 161, 171], ["Acute", "OBSERVATION_MODIFIER", 37, 42], ["Respiratory Distress", "OBSERVATION", 43, 63], ["venous", "ANATOMY", 81, 87], ["thromboembolism", "OBSERVATION", 88, 103], ["thrombectomy", "OBSERVATION", 144, 156], ["craniotomy", "OBSERVATION", 161, 171]]], ["Data were reviewed by a team that included faculty neuro-intensivists, neuro-interventionalists, neurosurgeons, and a neuroradiologist.RESULTSWe identified 26 patients in our health system meeting inclusion criteria (Table 1).", [["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167]]], ["In our cohort, 7/26 (27%) were younger than age 50, 12/26 died (46%), and among deaths, 10/12 (83%) were age 50 or older.", [["deaths", "DISEASE", 80, 86]]], ["The most frequent presenting neurovascular event (see Figure 1) was acute ischemic stroke in 17/26 patients (65%), of whom 15 had a LVO and 2 had a small-vessel occlusion (SVO).", [["neurovascular", "ANATOMY", 29, 42], ["small-vessel", "ANATOMY", 148, 160], ["ischemic stroke", "DISEASE", 74, 89], ["LVO", "DISEASE", 132, 135], ["SVO", "DISEASE", 172, 175], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 29, 42], ["patients", "ORGANISM", 99, 107], ["vessel", "MULTI-TISSUE_STRUCTURE", 154, 160], ["patients", "SPECIES", 99, 107], ["acute ischemic stroke", "PROBLEM", 68, 89], ["a LVO", "TEST", 130, 135], ["a small-vessel occlusion", "PROBLEM", 146, 170], ["neurovascular", "ANATOMY", 29, 42], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["ischemic", "OBSERVATION_MODIFIER", 74, 82], ["stroke", "OBSERVATION", 83, 89], ["small", "OBSERVATION_MODIFIER", 148, 153], ["vessel", "ANATOMY", 154, 160], ["occlusion", "OBSERVATION", 161, 170]]], ["Among LVO patients, 13 were older than age 50 and/or had risk factors for stroke (13/15, 87%), 8 died (8/15, 53%), 7 survived with a favorable outcome (median Glasgow Coma Scale [GCS] score, 13), and 3 had hemorrhagic conversion (3/15, 20%).", [["LVO", "DISEASE", 6, 9], ["stroke", "DISEASE", 74, 80], ["Coma", "DISEASE", 167, 171], ["hemorrhagic", "DISEASE", 206, 217], ["LVO", "CANCER", 6, 9], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["stroke", "PROBLEM", 74, 80], ["GCS] score", "TEST", 179, 189], ["hemorrhagic conversion", "PROBLEM", 206, 228], ["hemorrhagic", "OBSERVATION_MODIFIER", 206, 217]]], ["Five LVO patients developed ARDS (5/15, 33%), all of whom died.", [["LVO", "DISEASE", 5, 8], ["ARDS", "DISEASE", 28, 32], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["ARDS", "PROBLEM", 28, 32], ["ARDS", "OBSERVATION", 28, 32]]], ["A total of 9 LVO patients underwent mechanical thrombectomy (9/15, 60%), of whom 5 died (5/9, 56%), and 4 survived with a good outcome (median GCS, 13.5).", [["LVO", "DISEASE", 13, 16], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["mechanical thrombectomy", "TREATMENT", 36, 59], ["median GCS", "TEST", 136, 146], ["mechanical thrombectomy", "OBSERVATION", 36, 59]]], ["Two LVO patients underwent a decompressive craniectomy, including one for hemorrhagic conversion after thrombectomy (Figure 2), and another for malignant cerebral edema without prior thrombectomy (the patient later developed an unexplained acute subdural hematoma (SDH) 2 wk postoperatively).RESULTSA total 7 of the 26 patients had an initial hemorrhagic event on presentation (7/26, 27%), including SDH (3/26) and hypertensive intraparenchymal hemorrhage (1/27).", [["malignant cerebral edema", "ANATOMY", 144, 168], ["subdural", "ANATOMY", 246, 254], ["intraparenchymal", "ANATOMY", 428, 444], ["LVO", "DISEASE", 4, 7], ["hemorrhagic", "DISEASE", 74, 85], ["cerebral edema", "DISEASE", 154, 168], ["acute subdural hematoma", "DISEASE", 240, 263], ["SDH", "DISEASE", 265, 268], ["hemorrhagic", "DISEASE", 343, 354], ["SDH", "DISEASE", 400, 403], ["hypertensive", "DISEASE", 415, 427], ["intraparenchymal hemorrhage", "DISEASE", 428, 455], ["patients", "ORGANISM", 8, 16], ["cerebral edema", "PATHOLOGICAL_FORMATION", 154, 168], ["patient", "ORGANISM", 201, 208], ["subdural hematoma", "PATHOLOGICAL_FORMATION", 246, 263], ["patients", "ORGANISM", 319, 327], ["patients", "SPECIES", 8, 16], ["patient", "SPECIES", 201, 208], ["patients", "SPECIES", 319, 327], ["a decompressive craniectomy", "TREATMENT", 27, 54], ["hemorrhagic conversion", "PROBLEM", 74, 96], ["thrombectomy", "TREATMENT", 103, 115], ["malignant cerebral edema", "PROBLEM", 144, 168], ["prior thrombectomy", "TREATMENT", 177, 195], ["an unexplained acute subdural hematoma", "PROBLEM", 225, 263], ["an initial hemorrhagic event", "PROBLEM", 332, 360], ["SDH", "PROBLEM", 400, 403], ["hypertensive intraparenchymal hemorrhage", "PROBLEM", 415, 455], ["decompressive", "OBSERVATION_MODIFIER", 29, 42], ["craniectomy", "OBSERVATION", 43, 54], ["thrombectomy", "OBSERVATION", 103, 115], ["malignant", "OBSERVATION_MODIFIER", 144, 153], ["cerebral", "ANATOMY", 154, 162], ["edema", "OBSERVATION", 163, 168], ["without", "UNCERTAINTY", 169, 176], ["thrombectomy", "OBSERVATION", 183, 195], ["unexplained", "OBSERVATION_MODIFIER", 228, 239], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["subdural", "ANATOMY", 246, 254], ["hematoma", "OBSERVATION", 255, 263], ["hemorrhagic", "OBSERVATION", 343, 354], ["SDH", "OBSERVATION", 400, 403], ["hypertensive", "OBSERVATION_MODIFIER", 415, 427], ["intraparenchymal", "ANATOMY_MODIFIER", 428, 444], ["hemorrhage", "OBSERVATION", 445, 455]]], ["In addition, 1 patient had aneurysmal subarachnoid hemorrhage, who died after developing severe vasospasm and COVID-19-related ARDS, another had apoplexy from a known and previously stable pituitary adenoma, and a third had a hemorrhagic cerebellar metastasis with previously unknown metastatic disease in the brain.RESULTSOne postpartum woman developed extensive CVST of multiple deep and superficial veins (Figure 3), but recovered with anticoagulation.", [["subarachnoid", "ANATOMY", 38, 50], ["pituitary adenoma", "ANATOMY", 189, 206], ["cerebellar", "ANATOMY", 238, 248], ["brain", "ANATOMY", 310, 315], ["superficial veins", "ANATOMY", 390, 407], ["aneurysmal subarachnoid hemorrhage", "DISEASE", 27, 61], ["vasospasm", "DISEASE", 96, 105], ["COVID-19", "CHEMICAL", 110, 118], ["ARDS", "DISEASE", 127, 131], ["apoplexy", "DISEASE", 145, 153], ["pituitary adenoma", "DISEASE", 189, 206], ["hemorrhagic", "DISEASE", 226, 237], ["patient", "ORGANISM", 15, 22], ["pituitary adenoma", "CANCER", 189, 206], ["cerebellar", "ORGAN", 238, 248], ["metastatic disease", "CANCER", 284, 302], ["brain", "ORGAN", 310, 315], ["woman", "ORGANISM", 338, 343], ["superficial veins", "MULTI-TISSUE_STRUCTURE", 390, 407], ["patient", "SPECIES", 15, 22], ["woman", "SPECIES", 338, 343], ["aneurysmal subarachnoid hemorrhage", "PROBLEM", 27, 61], ["severe vasospasm", "PROBLEM", 89, 105], ["COVID", "TEST", 110, 115], ["ARDS", "PROBLEM", 127, 131], ["apoplexy", "PROBLEM", 145, 153], ["a known and previously stable pituitary adenoma", "PROBLEM", 159, 206], ["a hemorrhagic cerebellar metastasis", "PROBLEM", 224, 259], ["previously unknown metastatic disease in the brain", "PROBLEM", 265, 315], ["extensive CVST of multiple deep and superficial veins", "PROBLEM", 354, 407], ["anticoagulation", "TREATMENT", 439, 454], ["aneurysmal", "OBSERVATION_MODIFIER", 27, 37], ["subarachnoid", "ANATOMY", 38, 50], ["hemorrhage", "OBSERVATION", 51, 61], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["vasospasm", "OBSERVATION", 96, 105], ["ARDS", "OBSERVATION", 127, 131], ["stable", "OBSERVATION_MODIFIER", 182, 188], ["pituitary", "ANATOMY", 189, 198], ["adenoma", "OBSERVATION", 199, 206], ["hemorrhagic", "OBSERVATION_MODIFIER", 226, 237], ["cerebellar", "ANATOMY", 238, 248], ["metastasis", "OBSERVATION", 249, 259], ["metastatic", "OBSERVATION", 284, 294], ["brain", "ANATOMY", 310, 315], ["extensive", "OBSERVATION_MODIFIER", 354, 363], ["CVST", "OBSERVATION", 364, 368], ["multiple", "OBSERVATION_MODIFIER", 372, 380], ["deep", "ANATOMY_MODIFIER", 381, 385], ["superficial veins", "ANATOMY", 390, 407]]], ["Another had a spontaneous vertebral artery dissection, without resulting ischemia or hemorrhage, and was discharged neurologically intact.", [["vertebral artery", "ANATOMY", 26, 42], ["vertebral artery dissection", "DISEASE", 26, 53], ["ischemia", "DISEASE", 73, 81], ["hemorrhage", "DISEASE", 85, 95], ["vertebral artery", "MULTI-TISSUE_STRUCTURE", 26, 42], ["a spontaneous vertebral artery dissection", "PROBLEM", 12, 53], ["resulting ischemia", "PROBLEM", 63, 81], ["hemorrhage", "PROBLEM", 85, 95], ["spontaneous", "OBSERVATION_MODIFIER", 14, 25], ["vertebral artery", "ANATOMY", 26, 42], ["dissection", "OBSERVATION", 43, 53], ["without", "UNCERTAINTY", 55, 62], ["ischemia", "OBSERVATION", 73, 81], ["hemorrhage", "OBSERVATION", 85, 95], ["intact", "OBSERVATION", 131, 137]]], ["Two patients had subcortical SVOs.RESULTSDuring hospitalization (median 9 d), 14 patients required intubation (14/26, 54%) and 8 developed ARDS (8/26, 31%), of whom 7 died (7/8, 88%).", [["subcortical SVOs", "ANATOMY", 17, 33], ["subcortical SVOs", "DISEASE", 17, 33], ["ARDS", "DISEASE", 139, 143], ["patients", "ORGANISM", 4, 12], ["subcortical SVOs", "CANCER", 17, 33], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 81, 89], ["subcortical SVOs", "PROBLEM", 17, 33], ["intubation", "TREATMENT", 99, 109], ["ARDS", "PROBLEM", 139, 143], ["subcortical", "ANATOMY_MODIFIER", 17, 28], ["SVOs", "ANATOMY", 29, 33], ["ARDS", "OBSERVATION", 139, 143]]], ["Two patients had venous thromboembolic events (2/26, 7.7%).", [["venous", "ANATOMY", 17, 23], ["venous thromboembolic events", "DISEASE", 17, 45], ["patients", "ORGANISM", 4, 12], ["venous", "MULTI-TISSUE_STRUCTURE", 17, 23], ["patients", "SPECIES", 4, 12], ["venous thromboembolic events", "PROBLEM", 17, 45], ["venous", "ANATOMY", 17, 23], ["thromboembolic", "OBSERVATION", 24, 38]]], ["Mortalities had a substantially higher D-dimer on admission (mean 20 963 ng/mL) than those ultimately discharged (3172 ng/mL) (see Figure 4).", [["D-dimer", "GENE_OR_GENE_PRODUCT", 39, 46]]], ["Ferritin was also noted to be elevated (mean 922 ng/mL overall).", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ferritin", "PROTEIN", 0, 8], ["Ferritin", "TEST", 0, 8], ["elevated", "PROBLEM", 30, 38]]], ["Mortalities had a lower GCS on admission (median 7) than survivors, whose median GCS was 14 on presentation and at discharge.DISCUSSIONOur data supports the growing body of evidence that manifestations of COVID-19 may include neurologically devastating ischemic events.2,6,7 In particular, we found that the high mortality among COVID-19 patients with LVOs (8/15, 53%) was true even among those receiving mechanical thrombectomy (5/9, 56%), similar to a prior report of COVID-19 patients,6 and substantially greater than the generally cited rate of 15% prior to the pandemic.8 Although most patients in our series were older than age 50, we found that several younger patients presented with a LVO of unexplained etiology, consistent with prior reports.1DISCUSSIONA subset of our patients (27%), however, presented with hemorrhage rather than ischemia\u2014and among the LVO patients, 4 later developed intracranial hemorrhage\u2014suggesting that COVID-19 might, in some cases, predispose to hemorrhagic complications.", [["LVOs", "ANATOMY", 352, 356], ["intracranial", "ANATOMY", 898, 910], ["GCS", "DISEASE", 24, 27], ["GCS", "DISEASE", 81, 84], ["COVID-19", "CHEMICAL", 205, 213], ["2,6,7", "CHEMICAL", 269, 274], ["LVOs", "DISEASE", 352, 356], ["LVO", "DISEASE", 694, 697], ["hemorrhage", "DISEASE", 820, 830], ["LVO", "DISEASE", 866, 869], ["intracranial hemorrhage", "DISEASE", 898, 921], ["COVID-19", "CHEMICAL", 938, 946], ["hemorrhagic", "DISEASE", 983, 994], ["COVID-19", "CHEMICAL", 205, 213], ["2,6,7", "SIMPLE_CHEMICAL", 269, 274], ["patients", "ORGANISM", 338, 346], ["LVOs", "CANCER", 352, 356], ["patients", "ORGANISM", 479, 487], ["patients", "ORGANISM", 591, 599], ["patients", "ORGANISM", 668, 676], ["patients", "ORGANISM", 780, 788], ["patients", "ORGANISM", 870, 878], ["patients", "SPECIES", 338, 346], ["patients", "SPECIES", 479, 487], ["patients", "SPECIES", 591, 599], ["patients", "SPECIES", 668, 676], ["patients", "SPECIES", 780, 788], ["patients", "SPECIES", 870, 878], ["a lower GCS", "PROBLEM", 16, 27], ["whose median GCS", "TEST", 68, 84], ["COVID", "TEST", 205, 210], ["neurologically devastating ischemic events", "PROBLEM", 226, 268], ["COVID", "TEST", 329, 334], ["LVOs", "TEST", 352, 356], ["mechanical thrombectomy", "TREATMENT", 405, 428], ["COVID", "TEST", 470, 475], ["the pandemic", "PROBLEM", 562, 574], ["hemorrhage", "PROBLEM", 820, 830], ["intracranial hemorrhage", "PROBLEM", 898, 921], ["COVID", "TEST", 938, 943], ["hemorrhagic complications", "PROBLEM", 983, 1008], ["thrombectomy", "OBSERVATION", 416, 428], ["consistent with", "UNCERTAINTY", 723, 738], ["hemorrhage", "OBSERVATION", 820, 830], ["intracranial", "ANATOMY", 898, 910], ["hemorrhage", "OBSERVATION", 911, 921], ["hemorrhagic", "OBSERVATION_MODIFIER", 983, 994], ["complications", "OBSERVATION", 995, 1008]]], ["Although data are very limited, one study of COVID-19 patients reported 11 cases of ischemic strokes (5 LVOs), 1 CVST, and 1 cerebral hemorrhage\u2014similar to the variety in our cohort\u2014suggesting that COVID-19 may be associated with a spectrum of cerebrovascular pathology.7 The authors also reported an analogously high mortality rate among these 13 patients (38.5%).7 In another case series that included COVID-19 patients with 12 LVOs and 2 CVSTs, overall mortality was comparable (42.8%), and a similar proportion of patients developed hemorrhagic conversion requiring craniectomy.6DISCUSSIONIn addition to the initial neurological ictus, COVID-19 sequelae of other organ systems likely contributed to the high mortality.", [["cerebral", "ANATOMY", 125, 133], ["cerebrovascular", "ANATOMY", 244, 259], ["neurological", "ANATOMY", 620, 632], ["organ", "ANATOMY", 667, 672], ["ischemic strokes", "DISEASE", 84, 100], ["LVOs", "DISEASE", 104, 108], ["CVST", "DISEASE", 113, 117], ["COVID-19", "CHEMICAL", 198, 206], ["LVOs", "DISEASE", 430, 434], ["CVSTs", "DISEASE", 441, 446], ["hemorrhagic", "DISEASE", 537, 548], ["neurological ictus", "DISEASE", 620, 638], ["COVID-19", "CHEMICAL", 198, 206], ["patients", "ORGANISM", 54, 62], ["cerebral", "ORGAN", 125, 133], ["COVID-19", "GENE_OR_GENE_PRODUCT", 198, 206], ["cerebrovascular", "ANATOMICAL_SYSTEM", 244, 259], ["patients", "ORGANISM", 348, 356], ["patients", "ORGANISM", 413, 421], ["patients", "ORGANISM", 518, 526], ["organ", "ORGAN", 667, 672], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 348, 356], ["patients", "SPECIES", 413, 421], ["patients", "SPECIES", 518, 526], ["one study", "TEST", 32, 41], ["COVID", "TEST", 45, 50], ["ischemic strokes", "PROBLEM", 84, 100], ["1 CVST", "PROBLEM", 111, 117], ["1 cerebral hemorrhage\u2014similar", "PROBLEM", 123, 152], ["COVID", "TEST", 198, 203], ["cerebrovascular pathology", "PROBLEM", 244, 269], ["COVID", "TEST", 404, 409], ["hemorrhagic conversion", "PROBLEM", 537, 559], ["craniectomy", "TREATMENT", 570, 581], ["the initial neurological ictus", "PROBLEM", 608, 638], ["COVID", "TEST", 640, 645], ["other organ systems", "PROBLEM", 661, 680], ["the high mortality", "PROBLEM", 703, 721], ["ischemic", "OBSERVATION_MODIFIER", 84, 92], ["strokes", "OBSERVATION", 93, 100], ["cerebral", "ANATOMY", 125, 133], ["hemorrhage\u2014similar", "OBSERVATION", 134, 152], ["variety", "OBSERVATION_MODIFIER", 160, 167], ["cerebrovascular", "ANATOMY", 244, 259], ["pathology", "OBSERVATION", 260, 269], ["hemorrhagic", "OBSERVATION_MODIFIER", 537, 548], ["conversion", "OBSERVATION", 549, 559], ["craniectomy", "OBSERVATION", 570, 581]]], ["In particular, ARDS had a 88% case fatality rate in our series and was invariably fatal among LVO patients.", [["ARDS", "DISEASE", 15, 19], ["LVO", "DISEASE", 94, 97], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["ARDS", "PROBLEM", 15, 19], ["ARDS", "OBSERVATION", 15, 19]]], ["However, although the overall mortality rate in our cohort was high, there appeared to be a dichotomous presentation and outcome\u2014either a poor initial condition with fulminant disease (worse than expected from neurological event alone) or a favorable presentation followed by recovery.", [["neurological", "ANATOMY", 210, 222], ["fulminant disease", "DISEASE", 166, 183], ["the overall mortality rate", "TEST", 18, 44], ["a dichotomous presentation", "PROBLEM", 90, 116], ["a poor initial condition", "PROBLEM", 136, 160], ["fulminant disease", "PROBLEM", 166, 183], ["dichotomous", "OBSERVATION", 92, 103], ["fulminant", "OBSERVATION_MODIFIER", 166, 175], ["disease", "OBSERVATION", 176, 183]]], ["In effect, prognosis likely depends on the initial neurological condition and development of other COVID-19-related complications.DISCUSSIONCerebrovascular events in COVID-19 may be related to a coagulopathic, pro-inflammatory state that results in a cytokine release storm and thrombogenic, vascular endothelial dysfunction, as well as vasculitis,5,9-12 similar to phenomena observed in previous coronavirus outbreaks including Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome.4,13-15 It is possible that vascular endothelial injury, angiotensin-converting enzyme 2 (ACE2) receptor downregulation,16 and a systemic coagulopathic state may lead to a spectrum of neurovascular complications of COVID-19, including hemorrhage, ischemia, venous thrombosis, and arterial dissection (Figure 5).", [["neurological", "ANATOMY", 51, 63], ["complications.DISCUSSIONCerebrovascular", "ANATOMY", 116, 155], ["vascular endothelial", "ANATOMY", 292, 312], ["vascular endothelial", "ANATOMY", 528, 548], ["neurovascular", "ANATOMY", 684, 697], ["venous", "ANATOMY", 757, 763], ["arterial", "ANATOMY", 780, 788], ["COVID-19", "CHEMICAL", 166, 174], ["endothelial dysfunction", "DISEASE", 301, 324], ["vasculitis", "DISEASE", 337, 347], ["coronavirus", "DISEASE", 397, 408], ["Acute Respiratory Syndrome", "DISEASE", 436, 462], ["Middle East Respiratory Syndrome", "DISEASE", 467, 499], ["4,13-15", "CHEMICAL", 500, 507], ["angiotensin", "CHEMICAL", 557, 568], ["COVID", "DISEASE", 715, 720], ["hemorrhage", "DISEASE", 735, 745], ["ischemia", "DISEASE", 747, 755], ["venous thrombosis", "DISEASE", 757, 774], ["COVID-19", "CHEMICAL", 166, 174], ["COVID-19", "GENE_OR_GENE_PRODUCT", 166, 174], ["vascular endothelial", "TISSUE", 292, 312], ["4,13-15", "SIMPLE_CHEMICAL", 500, 507], ["vascular endothelial", "TISSUE", 528, 548], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 557, 588], ["ACE2", "GENE_OR_GENE_PRODUCT", 590, 594], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 684, 697], ["venous", "MULTI-TISSUE_STRUCTURE", 757, 763], ["arterial", "MULTI-TISSUE_STRUCTURE", 780, 788], ["cytokine", "PROTEIN", 251, 259], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 557, 604], ["the initial neurological condition", "PROBLEM", 39, 73], ["other COVID", "PROBLEM", 93, 104], ["complications.DISCUSSIONCerebrovascular events", "PROBLEM", 116, 162], ["COVID", "TEST", 166, 171], ["a coagulopathic, pro-inflammatory state", "PROBLEM", 193, 232], ["a cytokine release storm", "TREATMENT", 249, 273], ["thrombogenic, vascular endothelial dysfunction", "PROBLEM", 278, 324], ["vasculitis", "PROBLEM", 337, 347], ["phenomena", "PROBLEM", 366, 375], ["previous coronavirus outbreaks", "PROBLEM", 388, 418], ["Severe Acute Respiratory Syndrome", "PROBLEM", 429, 462], ["Middle East Respiratory Syndrome", "PROBLEM", 467, 499], ["vascular endothelial injury", "PROBLEM", 528, 555], ["angiotensin", "TEST", 557, 568], ["converting enzyme", "TEST", 569, 586], ["ACE2", "TEST", 590, 594], ["receptor downregulation", "TEST", 596, 619], ["a systemic coagulopathic state", "PROBLEM", 627, 657], ["neurovascular complications", "PROBLEM", 684, 711], ["COVID", "TEST", 715, 720], ["hemorrhage", "PROBLEM", 735, 745], ["ischemia", "PROBLEM", 747, 755], ["venous thrombosis", "PROBLEM", 757, 774], ["arterial dissection", "PROBLEM", 780, 799], ["coagulopathic", "OBSERVATION", 195, 208], ["thrombogenic", "OBSERVATION", 278, 290], ["vascular endothelial dysfunction", "OBSERVATION", 292, 324], ["vasculitis", "OBSERVATION", 337, 347], ["coronavirus outbreaks", "OBSERVATION", 397, 418], ["Severe", "OBSERVATION_MODIFIER", 429, 435], ["Acute", "OBSERVATION_MODIFIER", 436, 441], ["Respiratory Syndrome", "OBSERVATION", 442, 462], ["Middle", "ANATOMY_MODIFIER", 467, 473], ["Respiratory Syndrome", "OBSERVATION", 479, 499], ["possible", "UNCERTAINTY", 514, 522], ["vascular endothelial", "ANATOMY", 528, 548], ["injury", "OBSERVATION", 549, 555], ["systemic", "OBSERVATION_MODIFIER", 629, 637], ["coagulopathic", "OBSERVATION", 638, 651], ["neurovascular", "ANATOMY", 684, 697], ["complications", "OBSERVATION", 698, 711], ["hemorrhage", "OBSERVATION", 735, 745], ["ischemia", "OBSERVATION", 747, 755], ["venous", "ANATOMY", 757, 763], ["thrombosis", "OBSERVATION", 764, 774], ["arterial", "ANATOMY", 780, 788], ["dissection", "OBSERVATION", 789, 799]]], ["This may explain not only the observation of strokes (in otherwise healthy patients without risk factors for stroke), but also the high rate of hemorrhagic conversion, as well as hemorrhage from otherwise stable lesions (eg, aneurysm and pituitary adenoma).", [["lesions", "ANATOMY", 212, 219], ["aneurysm", "ANATOMY", 225, 233], ["pituitary adenoma", "ANATOMY", 238, 255], ["strokes", "DISEASE", 45, 52], ["stroke", "DISEASE", 109, 115], ["hemorrhagic", "DISEASE", 144, 155], ["hemorrhage", "DISEASE", 179, 189], ["aneurysm", "DISEASE", 225, 233], ["pituitary adenoma", "DISEASE", 238, 255], ["patients", "ORGANISM", 75, 83], ["lesions", "PATHOLOGICAL_FORMATION", 212, 219], ["aneurysm", "PATHOLOGICAL_FORMATION", 225, 233], ["pituitary adenoma", "CANCER", 238, 255], ["patients", "SPECIES", 75, 83], ["strokes", "PROBLEM", 45, 52], ["stroke", "PROBLEM", 109, 115], ["hemorrhagic conversion", "PROBLEM", 144, 166], ["hemorrhage", "PROBLEM", 179, 189], ["otherwise stable lesions (eg", "PROBLEM", 195, 223], ["aneurysm", "PROBLEM", 225, 233], ["pituitary adenoma", "PROBLEM", 238, 255], ["strokes", "OBSERVATION", 45, 52], ["hemorrhagic", "OBSERVATION_MODIFIER", 144, 155], ["conversion", "OBSERVATION", 156, 166], ["hemorrhage", "OBSERVATION", 179, 189], ["otherwise", "OBSERVATION_MODIFIER", 195, 204], ["stable", "OBSERVATION_MODIFIER", 205, 211], ["lesions", "OBSERVATION", 212, 219], ["aneurysm", "OBSERVATION", 225, 233], ["pituitary adenoma", "OBSERVATION", 238, 255]]], ["Notably, our finding of high D-dimer levels, previously reported among COVID-19 patients,9 may suggest a consumptive coagulopathy similar to Disseminated Intravascular Coagulation.12 Elevated D-dimer may also indicate greater disease severity,9 and might be a potential marker of prognosis, as levels were substantially higher among mortalities than survivors.Disclosures ::: CONCLUSIONThe authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.", [["Intravascular", "ANATOMY", 154, 167], ["coagulopathy", "DISEASE", 117, 129], ["Disseminated Intravascular Coagulation", "DISEASE", 141, 179], ["D-dimer", "GENE_OR_GENE_PRODUCT", 29, 36], ["patients", "ORGANISM", 80, 88], ["D-dimer", "GENE_OR_GENE_PRODUCT", 192, 199], ["D-dimer", "PROTEIN", 29, 36], ["Elevated D-dimer", "PROTEIN", 183, 199], ["patients", "SPECIES", 80, 88], ["high D-dimer levels", "PROBLEM", 24, 43], ["COVID", "TEST", 71, 76], ["a consumptive coagulopathy", "PROBLEM", 103, 129], ["Disseminated Intravascular Coagulation", "PROBLEM", 141, 179], ["Elevated D-dimer", "PROBLEM", 183, 199], ["greater disease severity", "PROBLEM", 218, 242], ["devices", "TREATMENT", 488, 495], ["high D-dimer", "OBSERVATION_MODIFIER", 24, 36], ["consumptive", "OBSERVATION_MODIFIER", 105, 116], ["coagulopathy", "OBSERVATION", 117, 129], ["Disseminated", "OBSERVATION_MODIFIER", 141, 153], ["Intravascular Coagulation", "OBSERVATION", 154, 179], ["Elevated", "OBSERVATION_MODIFIER", 183, 191], ["D-dimer", "OBSERVATION_MODIFIER", 192, 199], ["may also indicate", "UNCERTAINTY", 200, 217], ["greater", "OBSERVATION_MODIFIER", 218, 225], ["disease", "OBSERVATION", 226, 233]]]]}